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Abstract 
 
von Willebrand disease (VWD) is the most common autosomal congenital bleeding disorder in 
humans results from either quantitative deficiencies in the level of plasma glycoprotein von 
Willebrand factor (VWF)  (type 1 and type 3) or qualitative deficiencies ( type 2). Type 1 VWD 
the commonest VWD variant is characterized by mucocutaneous bleeding and a partial 
quantitative deficiency of plasma VWF. Previous analysis of an EU VWD1 family cohort 
undertook mutation scanning and sequencing of the VWF gene in 150 index cases (IC), but 
failed to detect mutations in ~33% IC. Single nucleotide polymorphisms (SNP) within primer 
annealing sites leading to lack of mutant allele amplification or insensitivity of mutation 
scanning methods may explain this failure. In this study, VWF 18 IC were re-analysed where 
phenotype suggested that mutations may have been missed using newly designed primers free 
of SNP underneath their annealing sites and direct sequencing. 
 
Mutational analysis of 18IC led to the identification of heterozygous mutations in four families; 
missense mutations c.6811T>G; p.W2271G (in compound heterozygosity with 
c.2811G>A;p.R854Q) and c.3469T>C;p.C1157R (in compound heterozygosity with 
c.1614del;p.S539Lfs*38), silent mutation c.4146G>T;p.L1382= and splice mutation 
c.1432+1G>T (in compound heterozygosity with c.2446C>T;p.R816W).  
 
p.W2271G, p.C1927R and p.C1157R mutations affect fully conserved residues, predicted to be 
damaging by in silico analysis, p.L1382= predicted to alter splicing exonic enhancer (ESE) and 
c.1432+1G>T predicted to produce a null allele. These identified mutations appeared to be 
segregated with disease phenotype. Mutations were missed due to insensitivity of mutation 
analysis method (c.6811T>G) and SNP within primer annealing sites (c.3469T>C and 
c.1432+1G>T). In addition to the mutations identified, in vitro expression of two previously 
identified changes was also undertaken (the two mutations were c.2771G>A;p.R924Q and 
c.5779T>C;p.C1927R and were found in one IC).   
 
In vitro expression data indicates that missense mutations p.C1157R, p.C1927R and p.W2271G 
located in D3 and D4 assemblies resulted in in significantly reduced secretion of VWF levels 
with significantly increased intracellular retention, abnormal intracellular storage and abnormal 
multimers, but p.R924Q showed normal expression. Also, reduced secretion in p.W2271G and 
p.C1927R appeared to be due to dominant-negative mechanism. p.L1382= revealed a 
significant defect of secreted VWF which may be due to its impact on mRNA translation rate. 
Silent change may contribute to VWF deficiency through alteration protein folding or 
II 
 
destroying splicing regulatory elements (SRE) that mediates exon skipping resulting in 
truncated protein. The expression of p.S539Lfs*38 resulted to significant defect of secreted 
VWF due to nonsense mediated decay (NMD). Results raised from in vitro expression found to 
be correlated with phenotypes observed in patients with identified mutations. This study has 
provided insight into the pathogenicity of type 1 VWD. 
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1. Introduction 
 
1.1. Epidemiology and clinical features of von Willebrand disease 
von Willebrand disease (VWD) has been identified as the most common autosomal congenital 
bleeding disorder in humans in the last two decades, with prevalence rates ranging between 
0.1% and 1.3% in the population according to many epidemiological studies. VWD affects both 
genders, and occurrence across ethnic groups is approximately equal frequencies (Miller et al., 
1987, Rodeghiero et al., 1987, Ruggeri and Zimmerman, 1987, Werner et al., 1993, Sadler et 
al., 2000, Bowman et al., 2010, Flood et al., 2011, Ghosh and Shetty, 2011). 
Gene alterations lead to qualitative and quantitative abnormalities in the von Willebrand factor 
(VWF) protein in the plasma, and these result in VWD. The disease presents as excess 
mucocutaneous bleeding, which can be mild to severe depending on the VWD type, in the form 
of easy bruising, menorrhagia, epistaxis and bleeding post-surgery or trauma (Sadler et al., 
2006). 
Based on clinical characteristics and laboratory findings, VWD is classified into three primary 
types: type 1 VWD; type 2 VWD, which is further divided into four secondary subtypes (2A, 
2B, 2M and 2N); and type 3 VWD (Sadler, 1994, Sadler et al., 2006). 
1.2. History of von Willebrand disease 
In 1926, a Finnish physician named Dr. Erik von Willebrand described the first case of VWD in 
several members of families from Föglo in the Finnish Aland Islands. These individuals 
presented with significant mucocutaneous bleeding, including easy bruising, menorrhagia and 
epistaxis. Initially, von Willebrand thought that the bleeding was due to abnormal platelet 
function, and he described it as “pseudohaemophilia” (von Willebrand, 1926, Ginsburg and 
Bowie, 1992). In 1950, a reduction in the level of plasma coagulation factor VIII (FVIII) in 
mucocutaneous bleeding was observed (Graham, 1959, Sadler, 1998). Larrieu and Soulier then 
found low levels of FVIII and prolonged bleeding times in pseudohemophilia patients, and they 
proposed the name von Willebrand disease for this condition (Alexander and Goldstein, 1953, 
Larrieu and Soulier, 1953). In 1963, Salzman demonstrated in vitro a decreased adhesiveness of 
platelets to glass from the blood of patients with VWD.  He found that this was normalized with 
normal plasma (Salzman, 1963, Larrieu et al., 1968, Meyer and Larrieu, 1970). During the 
1960s, cases of VWD reported from several countries indicated that the disease was distributed 
worldwide, and it was defined as an autosomal heritable haemorrhagic disease characterized by 
a prolonged bleeding time, decreased activity of FVIII, decreased platelet adhesion and a 
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progressive increase of FVIII activity after the infusion of plasma and FVIII concentrate 
(Nilsson and Holmberg, 1979). Most cases of types 1, 2A and entirally all 2B and 2M are 
inherited as autosomal dominant while types 2N and 3 are inherited as autosomal recessive 
disorders. Many studies suggested that the impaired haemostasis in VWD was due to the lack of 
a certain plasma protein called VWF. When this factor was infused, it corrected the prolonged 
bleeding time and increased the level of FVIII. At the Congress of the International Society of 
Haematology in Rome in 1958 it was asserted that a previously unknown factor in blood had 
been discovered (Blomback, 1958, Blomback et al., 1964). Then in 1970, through the use of 
newly developed immunoassays and laboratory techniques, VWF, the carrier of FVIII, was 
detected, isolated and identified as the cause of VWD. At that time, it was recognized as being 
distinct from blood coagulation FVIII (Weiss et al., 1973, Ruggeri and Zimmerman, 1980). In 
1971, Zimmerman developed an immunologic technique using a polyclonal antibody against 
VWF and FVIII to distinguish between VWD and haemophilia A (Zimmerman et al., 1971), 
and in 1985, the VWF was cloned by several groups in the United States (Ginsburg et al., 1985, 
Sadler, 1998). VWF is a large multimeric plasma glycoprotein with a high molecular weight 
that plays an important role in primary haemostasis. Zimmerman et al (1986) detected the VWF 
multimers after electrophoresis of purified VWF in 5% of polyacrylamide gels (Zimmerman et 
al., 1986). Mancuso et al (1989) reported the genomic structure of VWF in 1989 (Mancuso et 
al., 1989), and in 2001, A disintegrin-like and metalloprotease domain (reprolysin type) with 
thrombospondin type 1 motifs (ADAMTS13) that cleaves multimeric VWF was discovered 
(Fujikawa et al., 2001). 
 
1.3. The molecular biology of von Willebrand factor 
1.3.1. The VWF gene 
Many studies showed that the large multimeric VWF is encoded by a large gene located at the 
tip of the short arm of chromosome 12 at 12p13.3 (Ginsburg et al., 1985, Verweij et al., 1985). 
VWF consists of 52 exons that extend over approximately 178 kb of DNA (Figure 1.1A). The 
VWF exons vary in size between 40 base pairs (bp), the smallest being exon 50, and 1,400 bp, 
the largest being exon 28 (Mancuso et al., 1989), while the introns range in size from 97 bp to 
almost 19,900 bp. The length of encoded VWF mRNA is 9 kb.  
Two factors have, to date, made the analysis of the VWF gene both demanding and complicated. 
One factor is the large size of the VWF gene. The other is the presence of an unprocessed partial 
pseudogene copy that is located on chromosome 22. This pseudogene is highly similar to the 
VWF gene and corresponds to exons between 23 and 34 with slight sequence variation, 
estimated at 3%, from the chromosome 12 locus (Figure 1.1A). So, during polymerase chain 
reaction (PCR), care must be taken to ensure that the amplification is for the true VWF sequence 
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and not for the sequence of the VWF pseudogene (VWFP) (Mancuso et al., 1991, Laffan et al., 
2004). Moreover, the presence of single nucleotide polymorphisms (SNP) within primer 
sequence annealing sites could mask heterozygous genetic defects and could lead to missing 
mutation. 
1.3.2. The VWF protein 
The primary translation pre-pro-VWF product consists of 2813 amino acids (AA) with a 22 AA 
signal peptide, a 741 AA large pro-peptide (VWFpp) and a 2050 AA mature VWF molecule 
that starts with residue 764 and ends with residue 2813. These are secreted as mature VWF 
multimers formed from single VWF subunits that contain all the binding sites that are needed to 
perform its function (Figure 1.1C) (Titani et al., 1986). The first VWF exon contains 250 base 
pairs and is non-coding. The next 15 exons of VWF encode the pro-peptide of VWF, while the 
mature multimers of VWF are encoded by exons 18-52 (Mercier et al., 1991). The VWF pro-
peptide and mature VWF subunit contain four types of repeating domains found in two to five 
copies, and each is arranged from the amino to the carboxyl ends in the following order: D1-D2-
D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (Figure.1.1A) (Shelton-Inloes et al., 1986). These 
domains are essential for the different functions of VWF, including platelet adhesion and 
aggregation in addition to other binding functions with other proteins, such as GpIbα, FVIII and 
collagen. Domains from D' to CK comprise the mature VWF, while the VWF pro-peptide 
consists of D1 and D2 domains. A significant amount of cysteine is present in VWF, which 
accounts for 243 of 2813 AA in the pro-VWF product (8.3%). It has been found that all VWF 
domains contain abundant amounts of cysteine except the three A domains, which have only six 
cysteines and are considered to be cysteine poor regions. The secreted protein has cysteine 
residue linked monomers held together by intra-and inter- subunit disulfide bonds to form 
multimers (Marti et al., 1987, Dong et al., 1994, Sadler, 2009). Also, in the updated annotation 
of VWF structure, no new cysteines have been identified, but 8 cysteines now lie in gaps 
between domains and in domains boundaries. These include 8 cysteine residues found between 
D1-D2, D2-D3, D3-A1, A3-D4 (D4N) and between D4 and C1 (Figure 1.1B) (Zhou et al., 
2012). 
In order to assign the whole VWF sequence and due to the presence of gaps between VWF 
domains, the structure was updated and re-annotated to cover these gaps that contain cysteine 
residues. Based on sequence repeats, homologies and number of cysteine residues, additional 
modules were added to D domains and VWF expression at acidic pH mimicking the conditions 
that occur in the Golgi followed by examination using electron microscopy. The updated 
structure consists of three A domains, six C domains, five D domains and a terminal CK 
domain, while B domains are eliminated. D domains consist of modules that include cysteine 8  
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Figure 1.1: Schematic representation of the VWF protein and encoding exons. A): Shows the original functional domains of VWF, exons encoded 
by each domain and the size of the entire VWF (178 kb). VWF consists of several repeated domains A, B, C and D. B): Shows the VWF protein updated 
and re-annotated functional domains. The revised domains consist of four D assembly domains, three A domains and six C domains where B domains 
are eliminated.  Additional multiple modules include cysteine 8 (C8) domains, trypsin-inhibitor-like (TIL) domains and E repeats that follow each TIL 
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domain. The D4N module which contains eight cysteines is found between A3 and VWD4 domains. The Arg-Gly-Asp (RGD) sequence is found within 
C4 domain. Vertical lines represent boundaries of domain assemblies. C): Shows the 2813 amino acids of pre-pro-VWF, of which the first 22 AA 
comprise the signal peptide (SP), the following 741 AA comprise the pro-peptide (VWFpp) which consists of  D1 and D2 domains and disulphide 
isomerase-like sites (CGLC) and the final 2050 AA represent the mature VWF. D): Represents mutation distribution and location in each domain that 
have been identified in VWD types 1, 2 and 3. Mutations were found in all domains in type 1 and 3, while type 2 VWD varies based on the subtype 
(Wagner et al., 1987, Mancuso et al., 1989, Ruggeri, 2001, Goodeve, 2010, Zhou et al., 2012). 
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(C8) domains, trypsin-inhibitor-like (TIL) domains that contain five highly conserved disulfide 
bonds and E repeats follow each TIL domain. D domain assemblies 1-3 are subdivided into 
multiple modules; VWD, C8, TIL and E in each, while VWD4 is similar but lacks segment E 
and has an additional D4N module which makes a bridge between A3 and VWD4 by a 
disulphide bond. D' is a small domain containing only TIL and E modules (Figure 1.1B). The 
VWC4 domain carries the VWF RGD motif (Zhou et al., 2012). This updated structure enables 
identification of additional disulfides bonds in the additional modules. 
1.4. Biosynthesis of VWF 
The synthesis of VWF has been studied extensively, and it has been found that VWF is 
synthesised exclusively in two types of cell: endothelial cells and megakaryocytes. VWF from 
both sites has the same structure, and the processing of VWF at these sites seems to be similar. 
Many studies have examined the processing of VWF, in terms of assembly, secretion and 
expression, and found that it is complex (Jaffe et al., 1974, Nachman et al., 1977). VWF forms 
high molecular weight multimers and is packaged in secretary vesicles: Weibel-Palade bodies 
(WPB) in endothelial cells and alpha-granules in megakaryocytes (Wagner et al., 1982, Sporn et 
al., 1985). VWF is released from Weibel-Palade bodies to the circulation either basally or 
following stimulation (Giblin et al., 2008). In order to explore the effect of mutant VWF on its 
synthesis, storage and secretion, blood outgrowth endothelial cells (BOEC) were isolated from 
peripheral blood of type 1 and 2 VWD patients followed by measuring the level of released 
VWF and mRNA before and after stimulation. As a result, the level of released VWF was found 
to be decreased in patients with type 1 VWD and type 2M VWD which reflects the defect in 
VWF synthesis while synthesis and secretion were normal in patients with type 2A 
accompanied with functional defects (Starke et al., 2013a). 
1.4.1. Dimerisation 
VWF processing, namely glycosylation and dimerization, takes place in the endoplasmic 
reticulum (ER), while multimerisation occurs in the Golgi apparatus (GA). Pre-pro VWF 
undergoes an extensive series of intracellular and post-translational modifications to regulate its 
synthesis, prior to release and exit of VWF from the ER (Figure 1.2). Initially, the released 
mRNA is translated to synthesize a VWF product of 2813 AA (pre-pro-VWF polypeptide), 
which includes a 22 AA signal peptide, a large pro-peptide of 741 AA and a mature VWF 
subunit of 2050 AA that is released from the original molecule during intracellular biosynthesis. 
This primary product is translocated from the ribosome into the endoplasmic reticulum, where 
signal peptidase cleaves and removes the signal peptide domain, converting it into the pro-VWF 
monomer (Figure 1.2). After removal of the signal peptide, the pro-VWF monomer is folded  
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Figure 1.2: Schematic representation showing the intracellular synthesis of HMW-VWF. Initially, VWF is synthesised as a pre-pro-VWF product 
of 2813 AA. This product is translocated into the ER where SP is removed forming the pro-VWF which subsequently forms C-terminal dimers. The 
pro-VWF dimers exit from the ER to the Golgi complex and trans-Golgi network (TGN) where pro-VWF forming head to head bridges followed by 
cleavage of VWFpp by Furin occurs. In the Golgi and TGN, dimers form a bridge of disulphide bonds between each other which leads to the assembly 
of HMW-VWF multimers. Both VWFpp and mature VWF multimers are released to Weibel-Palade bodies in either endothelial cells or platelet α-
granules (Rehemtulla and Kaufman, 1992, Rosenberg et al., 2002, Michaux et al., 2006, Sadler, 2009). 
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and disulfide bonds are formed between the adjacent VWF monomers via cysteine knot (CK) or 
their carboxyl terminal regions  domains at residues p.C2671 to p.C2813, forming tail-to-tail 
dimers (Mayadas and Wagner, 1992, Katsumi et al., 2000, Sadler, 2009). The D4-CK domains 
are cysteine rich and the last 151 amino acids of the mature VWF subunit following the C6 
domain (from the updated domain structure) seem to be essential to the completion of the 
process of dimerisation. They are involved in tail-to-tail dimerisation and are needed to achieve 
efficient dimerisation. However, in vitro expression studies showed that dimerisation fails when 
using recombinant VWF that lacks some of these 151 AA, degrading in the ER (Marti et al., 
1987, Voorberg et al., 1991, Schneppenheim et al., 1996, Yadegeri et al., 2013). 
 
These sequences within the CK domain may play a role in retaining the monomers in the ER 
until they are either degraded or dimerised. Furthermore, there is some evidence that the last 90 
AA in the CK domain play a role in the dimerisation of VWF due to their similarity to the CK 
superfamily of proteins, which have a high tendency to dimerise, usually by forming disulfide 
bonds (McDonald and Hendrickson, 1993, Desseyn et al., 1997). In vitro expression studies 
using mutated recombinant VWF have been conducted to study the effect of several mutations in 
the CK domains in VWF dimerisation. Several mutations in the carboxyl terminal region, 
including p.C2362F, p.C2773R, p.C2739Y and p.A2801D, have been identified and found to 
disrupt VWF dimerisation and cause defective formation. The p.C2773R mutation that was 
identified through the carboxyl terminal domains has been found to impair dimerisation in 
addition to causing abnormal HMW multimers (Schneppenheim et al., 1996, Hommais et al., 
2006b, Tjernberg et al., 2006).  The large pro-peptide VWF is also not needed for dimerisation 
because expression of a mutated recombinant mature VWF with the pro-peptide deleted results 
in normal secretion of a dimeric VWF, which indicates that VWFpp is not needed for 
dimerisation or for the exit of the VWF protein from the ER but is required for multimerisation 
(Verweij et al., 1987, Wise et al., 1988, Haberichter et al., 2000). 
 
1.4.2. Glycosylation of VWF in ER 
Glycosylation is defined as the addition of high-mannose carbohydrate side chains glycans to 
VWF in order to facilitate and regulate the release of VWF from the ER to the GA. After the 
removal of the signal peptide and prior to tail-to-tail dimerisation, the pro-VWF is also 
extensively modified and glycosylated in the ER. The VWF post-translational glycosylation is 
found to have an effect on VWF structure and function. It is essential for dimerisation, regulates 
folding and preserves protein structure, and is required for release of VWF from ER to GA 
(Kornfeld and Kornfeld, 1985, Wagner et al., 1986, Lenting et al., 2010). Moreover, it protects 
VWF from intracellular destruction and degradation which prolongs the protein half-life. In 
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addition, it has an effect on circulating VWF survival. Individuals with blood group O who lack 
glycosyl-transferase encoded by the ABO gene that protects VWF from clearance have lower 
plasma levels of VWF compared to those with AB blood group who have transferase-enzyme. It 
was suggested that the absence of ABO glycosyl-transferase influences the cleavage 
susceptibility of VWF by ADAMTS13 and contributes to reduced levels of plasma VWF in 
individuals who lack this allele (Bowen, 2003). There are several glycosylation carbohydrate 
sites, which are located on VWF, and these glycans account for almost 20% of the total mass of 
the VWF (McKinnon et al., 2010). Glycosylation is divided into two types; N-linked 
glycosylation where glycans are added to asparagine residues on VWF present in the Asn-X-
Ser/Thr/Cys sequence (X indicates any amino acid) and O-linked glycosylation where glycans 
are added to either serine or threonine residues in VWF (Lenting et al., 2010). There are sixteen 
N-linked glycosylation sites, twelve of which are located in mature VWF and the remainder in 
VWF pro-peptide (Titani et al., 1986, McKinnon et al., 2010). The distribution of these side 
chains is not equal along the VWF protein. There is a large gap in the central region, and most 
of these sites are located on either the amino or carboxyl terminal ends of each VWF subunit 
(Titani et al., 1986, McKinnon et al., 2010). N-linked glycans are distributed between VWF 
residues 856-2791 and O-linked glycans distributed between VWF residues1247-2299 (Lenting 
et al., 2010). Furthermore, the ABO blood group oligosaccharides are present on plasma VWF 
as a part of the N-linked glycosylation oligosaccharides (Matsui et al., 1992). An in vitro 
expression study performed by Wanger et al.1986 reported that glycosylation is needed to 
achieve proper dimerisation and multimerisation. They found that adding tunicamycin to the 
endothelial cells in the culture medium in order to inhibit the N-linked glycosylation resulted in 
an accumulation of pro-VWF in the ER and impaired dimerisation (Wagner et al., 1986). These 
findings suggest that dimerisation occurs after glycosylation. Moreover, an experimental study 
that mutated the VWF N- linked glycosylation binding sites followed by transfection in human 
embryonic kidney (HEK293T) cells found reduced VWF secretion and prevention of VWF 
dimer formation and multimer assembly (McKinnon et al., 2010). There are twelve O-linked 
glycosylation sites, ten of which are located in mature VWF, where sialyalated T-antigen was 
reported to account for 70-90% and ABH antigen found to account for approximately 1% of 
glycosylation sites. It has been proposed that O-linked glycans influence VWF survival by an 
unknown mechanism that may be due to cleavage susceptibility by ADAMTS13. Until now the 
role of O-glycans on VWF function is still poorly understood, but Gallinaro et al (2008) showed 
a strong influence of ABO blood group on VWF clearance where the half-life of VWF in group 
O individuals is shorter (10 hr) compared to non-group O (26 hr). (Gallinaro et al., 2008). 
However, knowledge of O-glycan addition has improved our understanding about the exact 
effect of glycosylation on VWF function (van Schooten et al., 2007, Canis et al., 2010, McGrath 
et al., 2010). 
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1.4.3. Folding of VWF in the ER 
Apart from glycosylation and dimerisation, proper folding of VWF is required to release pro-
VWF from the ER to the Golgi. In the ER, proteins are checked for proper folding and 
misfolded proteins are selected and destroyed by the proteasome complex (Hampton, 2002). 
Many mutations that may affect the secretion of VWF or the destruction of misfolded protein in 
the ER have been identified in patients with VWD. p.C1157F and p.C1234W mutants were 
found to cause intracellular retention and abnormal multimerisation (Hommais et al., 2006a). It 
has been proposed that the p.C1149R mutation identified in families diagnosed with type 1 
VWD caused intracellular retention and decreased secretion (Bodo et al., 2001a, Eikenboom et 
al., 2009). Impaired processing of VWF in the ER during intracellular biosynthesis may 
contribute to the symptoms observed in patients with VWD. 
1.4.4. VWF multimerisation 
Following the translation of mRNA, signal peptide cleavage, initial glycosylation and tail-to-tail 
dimerisation in the ER, multimerisation, further glycosylation and proteolytic cleavage of 
VWFpp dimer also takes place in the Golgi apparatus. The pro-VWF dimers are transported 
from the ER to the Golgi complex and polymerise to build large chains of VWF linked by 
additional disulfide bonds. The D1 and D2 assemblies that represent the VWF pro-peptide 
contain two CGLC sequences. p.C159-G-L-C162 and p.C521-G-L-C524 residues are found in 
each domain with vicinal cysteine motifs, which resemble the active sites of the protein 
disulfide isomerase (PDI) enzymes which catalyse the formation of intracellular disulfide bonds 
during VWF synthesis and secretion in the ER. These isomerase-like enzymes enhance and 
promote pro-VWF association and the formation of head-to-head multimers through 
intermolecular disulfide bonding between adjacent D3 domains near to the amino-termini of the 
pro-VWF dimers (Sadler, 2009). This association results in the production of multimers of more 
than 20 million daltons in size (Figure 1.2).  Also, prior to multimerisation when the pro-VWF 
dimers are released from the ER into the Golgi, galactose and sialic acid are added to form 
secondary carbohydrate complexes (Mayadas and Wagner, 1992, Rehemtulla and Kaufman, 
1992, Ruggeri, 1999, Rosenberg et al., 2002). The results of various studies suggest that 
VWFpp plays a critical role in VWF biosynthesis, particularly during protein multimerisation. 
A study conducted by Mayadas and Wanger (1989) indicated that the pro-peptide is needed to 
regulate multimerisation of the dimers expressed either as full length VWF or as independent 
expression of pro-peptide and mature VWF (Mayadas and Wagner, 1989). Following head-to-
head multimerisation through the D3 domains of the dimers, proteolytic removal of the 741AA 
of VWFpp occurs in the Golgi network. Either a membrane associated calcium-dependent 
endoprotease enzyme or paired basic amino acid cleaving enzyme (Furin) catalyses cleavage of 
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the VWFpp at position p.R763-S764 to produce two fragments: mature multimers of 2050 AA 
plus the VWF pro-peptide consisting of 741 AA (Figure 1.2) (Mayadas and Wagner, 1992). 
Intracellularly and before secretion, the cleaved VWF pro-peptide remains non-covalently 
linked with the mature VWF-multimers within two storage sites; endothelial WPB and platelet 
alpha granules. However, both proteins are dissociated when secreted from the cell into the 
plasma (van de Ven et al., 1990, Bosshart et al., 1994, Sadler, 2009). Many laboratories have 
used the ratio of secreted VWFpp/VWF:Ag and FVIII/VWF:Ag to evaluate synthesis and 
measure the rate of VWF clearance. Increased pro-peptide to antigen ratios suggest a clearance 
defect (Haberichter et al., 2006, Haberichter et al., 2008, Sztukowska et al., 2008, Eikenboom et 
al., 2013b). The stored VWF is regularly secreted at the site of vascular injury to promote 
platelet adhesion, aggregation and response to inflammation. 
1.5. Functional domains of VWF  
The pre-pro-VWF consists of various homologous domains, including signal peptide (SP), three 
A domains, six C domains and four D assemblies, with the partial D' assembly (Figure 1.1A and 
B) (Ginsburg et al., 1985, Mancuso et al., 1989, Zhou et al., 2012). During intracellular 
processing, the SP and VWFpp, which consist of D1 and D2 assemblies, are removed, leaving 
the mature VWF, which is responsible for the major function of VWF required during vascular 
injury. Mature VWF has various binding functions due to the presence of different domains 
(Figure 1.1A and B). VWF exists as various sizes of multimers with variable molecular weights 
of VWF, but the most active forms of VWF have the highest molecular weight multimers 
(HMW) due to the presence of higher numbers of active binding sites for platelet GpIb. These 
support the functional domains and the capacity to bind sub-endothelium and platelets (Sadler, 
1998). These domains are key to VWF carrying out its functions, which include binding with 
various proteins, such as collagen and FVIII in addition to platelets and any genetic defects 
within these domains may alter the function (Ruggeri, 1999).  
1.6. Storage and function of von Willebrand factor 
1.6.1. Platelet plug formation 
High molecular weight (HMW) VWF multimers, which hemostatically are the most effective 
forms, are synthesized and stored in various tissues. Some VWF stored in the WPB in 
endothelial cells and in platelet granules, but approximately 10% of endothelial VWF stored. 
The mature form of VWF is secreted directly into the circulating plasma or sub-endothelial 
matrix (Ruggeri, 2001). One of the most important functions of VWF is to interact with platelets 
in order to bring about adhesion and subsequent aggregation upon vascular injury. At sites of 
vascular injury, VWF promotes and mediates the interaction between exposed sites of sub-
endothelium and the platelet membrane via the platelet glycoproteins and thereby supports 
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adhesion and platelet aggregation. Following blood vessel (BV) injury and under high shear 
stress conditions, conformational changes of VWF occur facilitating VWF-platelet binding and 
thereby platelet adhesion and aggregation.  
Within mature VWF, two domains, A1 and A3, are responsible for binding with collagen 
(Figure 1.1A). A3 is the major binding site for type I and III collagen, which also binds to A1, 
while type VI collagen is involved in binding with A1 domain only. Flood et al (2012), reported 
mutations located in the A1 domain associated with bleeding characterized by a selective 
reduction in the binding to type VI collagen but not types I and III such as p.R1399H, p.S1387I 
and p.Q1402P. The exposed immobilised VWF which binds via its A3 domain to exposed 
collagen of the BV wall. Binding of VWF to exposed collagen results in a shape change, 
exposing the VWF A1 domain, this interacts with the platelet glycoprotein GpIbα (Figure 1.3). 
The interaction between VWF and platelet receptor GpIbα is the only interaction that occurs in 
unactivated platelet. This interaction between immobilised VWF and GpIbα is required for the 
initiation of platelet adhesion and further aggregation (Savage et al., 1996, Nichols et al., 2008b, 
Reininger, 2008).  
Following initial interaction between VWF A1 domain with GPIbα, further activation of platelet 
surface complex receptors, such as GPIbβ and GPIbIX engage VWF and collagen and thereby 
result in adhesion (Kenny et al., 2002).  Following the initial adhesion of VWF and platelets, 
other domains of VWF bind to other platelet receptors and platelet aggregation subsequently 
result in thrombus formation. GpIbα complex binding induces the platelet surface expression of 
the GPIIb/IIIa ( integrin αIIbẞ3) platelet receptor, which rapidly binds with high affinity to the 
circulating VWF RGDS (Arg-Gly-Asp-Ser) sequence that is located within the C-terminal end 
of the C4 domain at position 1744 to 1746. The GPIIb/IIIa  receptor also binds to fibrinogen to 
further enable platelet-platelet interactions.  Platelet binding with circulating immobilised VWF 
results in platelet aggregation and initiation of the coagulation pathway (Figure 1.3) and 
formation of a platelet plug through activation of thrombin, converting fibrinogen to insoluble 
fibrin strands. (Weiss et al., 1991, Beacham et al., 1992, Reininger, 2008). 
1.6.2. Binding with FVIII 
One of the most important functions of VWF is to carry FVIII and protect it from degradation 
caused by proteolytic proteins in the plasma and thereby prolong the survival of FVIII and 
localize it to the site of vascular injury (Rodeghiero, 2002, Keeney et al., 2008) (Figure 1.1A).  
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Figure 1.3 Diagram showing the role of VWF in platelet aggregation and clot formation. Following blood vessel injury, VWF which adheres to 
sub-endothelial collagen is released. Platelets passing to the site of endothelial damage bind to VWF via platelet GpIb receptors resulting in the 
adhesion of platelets to the damaged sites. The primary binding of platelets to exposed VWF induces the activation of platelet GpIIb/IIIa receptors 
which enables VWF to form a bridge between adjacent platelets leading to platelet aggregation and thrombus formation.  (Ruggeri, 1999, Nichols et al., 
2008b, Reininger, 2008). Also, Platelets bind to fibrinogen via GpIIb/IIIa receptors, thus lead to clot formation. 
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HMW-VWF is not essential for this function (Zimmerman and Ruggeri, 1987, Ruggeri, 1999). 
The D' and D3 domains are the regions responsible for the binding of VWF to FVIII, and 
missense mutations that occur in this region can impair this binding and cause type 2N VWD 
(Nishino et al., 1989, Mazurier et al., 2001, Sadler et al., 2006). Also, many mutations located in 
the D3 region may result in type 2A(IIE) VWD (Hommais et al., 2006a, Schneppenheim et al., 
2010).Many studies have shown that the half- life of FVIII in the presence of normal quantities 
of VWF is significantly higher than when less than normal amounts are present or in its 
absence. In vitro studies have shown that the half-life of FVIII in the absence of VWF is 
significantly lower (2.5 hr) than when VWF levels are normal (8-12 hr) (Cattaneo et al., 1994, 
Noe, 1996). The binding domain D'-D3, which is located within the first 272 amino acid 
residues of the mature subunit, was identified as the binding site of VWF for factor VIII (Vlot et 
al., 1996). 
1.7. Cleavage of HMW multimers 
HMW-VWF is cleaved by the ADAMTS13 enzyme which cuts VWF multimers into smaller 
fragments reducing platelet aggregation and clot formation. The cleavage site of VWF is located 
within the A2 domain at residues p.Y1605-M1606 (Figure 1.1A) (Zheng et al., 2001). Some 
mutations in this domain result in type 2A VWD due to either impaired multimer assembly or 
due to increased susceptibility of VWF to cleavage by ADAMTS13 which can impair secretion 
(IIA group I) or enhance proteolysis (IIA group II) (Zimmerman et al., 1986, Lyons et al., 
1992). Also, the p.Y1584C mutation in this domain results in increased susceptibility of VWF 
to cleavage and mild intracellular retention in type 1 VWD patients (Bowen, 2004). 
In contrast, mutations in the ADAMTS13 gene results in reduce quantity in circulation alter the 
binding of ADAMTS13 to VWF and lead to accumulation of HMW-VWF, induce platelet 
aggregation and lead to thrombotic thrombocytic purpura (TTP) and thereby microvascular 
thrombus formation (Moake et al., 1986, Levy et al., 2001). 
1.8. Diagnosis of von Willebrand disease 
Three main pillars must be taken into consideration when diagnosing type 1 VWD: a personal 
history of significant and multiple bleeding symptoms, a positive family history and a low level 
of VWF in the plasma. Since VWD is a highly heterogeneous bleeding disease, diagnosis is 
complicated and these pillars together contribute to the accurate diagnosis of VWD. The 
bleeding symptoms apparent in VWD patients vary, even within the same family, and usually 
depend on the severity of the disease as well as the VWD type or subtype.  Some patients only 
bleed when there is a haemostatic challenge. Individuals diagnosed with type 1 VWD may have 
no bleeding symptoms, whilst those with type 3 VWD may have a severe bleeding tendency. 
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Moreover, the presence of mild bleeding symptoms in healthy individuals may complicate the 
diagnosis and lead to a false positive diagnosis. However, using a bleeding score (BS) to 
evaluate bleeding may help and support the accuracy of diagnosis. Also, accurate diagnosis and 
classification of VWD is important in order that the disease can be managed correctly via 
treatment of bleeding or preventive therapy. 
1.8.1. Clinical diagnosis of von Willebrand disease 
Clinical diagnosis plays an essential role in the accurate diagnosis of VWD and aims to avoid 
misdiagnosis as well as false-positive diagnosis. In the past, many studies were performed to 
evaluate bleeding symptoms among patients with different types of VWD, but there were no 
clear guidelines for evaluating the bleeding in those patients (Silwer, 1973, Federici, 2004). The 
history of mucocutaneous bleeding symptoms throughout a patient’s life should be used as an 
initial clinical evaluation tool for a patient who is suspected as having VWD as well as looking 
at the patient’s family history in terms of a bleeding disorder. 
International multicenter studies have now established a BS, which is based on a quantitative 
analysis of the number and severity of mucocutaneous bleeding symptoms. The purpose of the 
BS is to provide a measure of the bleeding symptoms in VWD cases and to compare the 
relationship between both clinical and laboratory findings and thereby verify the accuracy of 
diagnosis (Tosetto et al., 2006, Tosetto et al., 2007, Bowman et al., 2008). The BS also helps to 
predict the occurrence of future bleeding in some circumstances, especially during tooth 
extraction or surgery, and it helps to identify patients who need preventive therapy (Tosetto et 
al., 2007). The final BS is derived by summing all haemorrhagic symptoms based on their 
severity and ranged from 0 to 3 where 0 represents the absence of bleeding even after particular 
procedures, such as dental or surgical, through 1, 2 and 3 for varying degrees of bleeding to 
more than 3, which indicates the presence of significant bleeding that requires medical 
intervention. This particular score is highly sensitive and used to evaluate the severity of 
bleeding in response to haemostatic challenges. A BS score higher than three is considered 
abnormal (Eikenboom et al., 2006, Tosetto et al., 2006, Tosetto et al., 2007, Bowman et al., 
2008). The BS is reached through the clinician filling in a simple questionnaire to evaluate 
patients bleeding symptoms. The initial questionnaire used to assess the severity of bleeding 
was time consuming for both physicians and patients, so this questionnaire has been modified 
and certain details that had little direct effect on the score have been removed (Bowman et al., 
2008, Rodeghiero et al., 2010). Tosetto et al. reported that the BS was significantly higher in 
index cases and affected family members when compared to both unaffected family members 
and controls (Tosetto et al., 2006). Recently, BS was revised for diagnosis of bleeding disorder 
in children to distinguish between children with and without a bleeding disorder. Children 
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usually have less exposure to bleeding challenges but have specific bleeding symptoms such as 
umbilical stump bleeding. circumcision and cephalohematoma that are not present in adults 
(Montgomery, 2005). The bleeding symptoms are scored from 0 (no abnormal bleeding 
symptoms) to 3 (severe bleeding) (Rodeghiero et al., 2010, O'Brien, 2012). 
1.8.2. Laboratory diagnosis of VWD 
The diagnosis of VWD does not depend on one particular test but on various assays to evaluate 
the levels, structure and function of VWF. According to Laffan et al.’s (2004) guidelines on the 
diagnosis of VWD,  laboratory tests are categorized into screening tests for the initial 
assessment, specific tests to confirm the presence of VWD and more advanced tests to 
distinguish between particular types and subtypes of VWD and to identify genetic defects 
(Laffan et al., 2004). Due to variability in bleeding symptoms among VWD patients, laboratory 
tests play an essential role in the diagnosis and classification of VWD. Some physiological and 
pathological factors, such as stress, age, infection and pregnancy may influence the level of 
VWF, causing it to fluctuate. Hence, these investigations should be repeated at least two times 
with concordant results under different conditions especially in patients suspected of having 
type 1 VWD, to avoid any false results. 
1.8.2.1. Screening tests for diagnosing VWD  
A group of laboratory tests are used for the initial evaluation and diagnosis of bleeding and 
haemorrhagic disorders, which may include bleeding time, platelet count, activated partial 
thromboplatsin time (APTT) and prothrombin time (PT) (Sadler et al., 2000, Laffan et al., 
2004). These results vary depending on the type of VWD and its severity. Skin bleeding time 
(BT) evaluates the ability of blood to form blood clots to stop bleeding via making small 
incision in skin. It was not considered a suitable screening test for primary haemostasis but 
should be considered in specific circumstances in the investigation of patients with bleeding 
disorders if other tests have not demonstrated a defect. The clinical utility of BT is limited due 
to its low sensitivity, low specificity, invasive and poorly reproducibility as it is prolonged in 
some platelet disorders, this test is now rarely used and has been replaced by the more sensitive 
platelet function closure time assay (PFA-100 and PFA-200), which however is not very 
sensitive in type 1 VWD (Tosetto et al., 2007). This test tends to be normal in patients with type 
2N VWD but may be abnormal in patients with the other types of VWD (Schlammadinger et 
al., 2000). Thrombocytopenia is generally observed only in type 2B VWD and in some variants 
of type 2A such as p.R1374H, while the platelet count remains within the normal range in 
patients with other types of VWD. Prothrombin time is within normal limits in all types of 
VWD, while APTT is usually normal or mildly abnormal but variably prolonged in patients 
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with type 3 VWD and severe type 2N due to decreases in the level of circulating FVIII. These 
two tests are generally used as screening tests to detect the level and activity of coagulation 
factors, such as FVIII, FIX and FVII, and to diagnose haemophilia, and they are still used 
widely to diagnose any suspicion of a bleeding disorder. The detection of APTT within the 
normal range should not exclude VWD nor prevent any follow-up diagnosis (Sadler et al., 
2000). 
1.8.2.2. Specific laboratory studies 
These tests are used to confirm a VWD diagnosis and to screen for VWD. The following assays 
evaluate the level and function of VWF:  
 
1.8.2.2.1. VWF antigen assay (VWF:Ag) 
This test measures the proportion of VWF protein (VWF:Ag) in the plasma and is considered to 
be one of the most important confirmatory tests of VWD. The levels of VWF in the plasma can 
increase or decrease in the same individual depending on several factors. Its levels increase after 
stress, infections, in pregnancy and with age, while levels are lower among the blood group O 
population. VWF levels are invariably decreased in type 1 VWD and absent or below the 
detection limit in type 3, while low or normal levels can be observed in type 2 VWD variants 
(Sadler et al., 2000). Levels of VWF are evaluated in the laboratory using immunological 
methods, such as latex immunoassay (LIA) and enzyme linked immunosorbant assay (ELISA) 
(Favaloro, 2001, Laffan et al., 2004, Castaman et al., 2010b). The normal level is approximately 
48-167 IU/dL. Reference ranges are based on an average from a pool of blood samples with 
different blood groups. 
1.8.2.2.2. VWF ristocetin co-factor activity (VWF:RCo) 
VWF ristocetin co-factor activity (VWF:RCo) is a standard test that can be used to evaluate 
VWF function due to its ability to associate and interact with the GpIbα after the addition of the 
antibiotic ristocetin via platelet agglutination methods (Castaman et al., 2003, Laffan et al., 
2004). Addition of ristocetin stimulates binding of VWF to platelets. Results are based on the 
presence of normal multimeric structures. Results with reduced values indicate a loss of HMW 
multimers. In type 1 VWD, VWF:RCo and VWF:Ag levels are reduced equally and the ratio 
between VWF:RCo/VWF:Ag is approximately normal, while in types 2A and 2M the ratio of 
VWF:RCo to VWF:Ag is significantly decreased and values of VWF:Ag and VWF:RCo below 
the detection limit in type 3 (Sadler et al., 2000, Lethagen, 2007). The normal range is 
approximately 47-194 IU/dL.  
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1.8.2.2.3. FVIII activity (FVIII:C) 
This test investigates the activity of FVIII in plasma. This is measured by either a clotting assay 
based on the APTT test using factor VIII deficient plasma or by a chromogenic assay (Laffan et 
al., 2004). The level of FVIII in plasma is directly proportional to the level of VWF because the 
half-life of FVIII is dependent on the level of VWF. Therefore, FVIII is significantly reduced or 
absent in type 3 VWD due to a severe lack of VWF, and is generally < 10 IU/dL or may even be 
undetectable on rare occasions. FVIII coagulant activity (FVIII:C) is also reduced in type 2N 
due to poor binding by VWF, and variable activity has been reported in other types of VWD 
based on the levels of VWF in the plasma (Table 1.2) (Sadler et al., 2000). The normal range is 
approximately 57-198 IU/dL. 
1.8.3. Laboratory tests for VWD classification 
Additional laboratory methods are widely available to facilitate the identification, classification 
and subtyping of VWD types and subtypes. They include the following assays: 
1.8.3.1. VWF multimeric analysis 
When VWD has been diagnosed, VWF multimeric analysis is used to determine the presence or 
absence of HMW-VWF multimers and to identify any abnormalities in multimer structure. 
Thus, the disease type can be classified. In this discriminating test, patient plasma is 
electrophoresed through 1 to 1.5% medium resolution agarose gels. A normal pattern of HMW 
multimers, including low, intermediate and high molecular weights, is found in type 1 VWD, 
while a mildly abnormal structure is observed in a small proportion in this type, and an absence 
of multimers is observed in type 3 VWD. Also, HMW multimers are generally normal in types 
2N and 2M VWD in contrast with types 2A and 2B VWD, in which they may be completely or 
partially absent. This test is useful for the sub-typing of type 2A and identification of type 2M 
VWD (Laffan et al., 2004, Schneppenheim and Budde, 2005). Technically, this test is difficult 
to perform, and good quality multimer analysis can only be produced in a limited number of 
laboratories. 
1.8.3.2. Ristocetin-induced platelet aggregation (RIPA) 
The ristocetin-induced platelet aggregation (RIPA) screening test at a low dose of ristocetin is 
used to distinguish between type 2B and other VWD variants (Frontroth et al., 2010). The RIPA 
evaluates the strength of VWF interaction with platelets after ristocetin in variable 
concentrations (~0.5-1.3 mg/ml) has been added to platelet-rich plasma samples. Aggregation is 
observed in type 2B VWD with the lowest concentration of ristocetin (~0.5 mg/ml), but 
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aggregation reduced in other types compared to normal plasma. Also, aggregation at this 
concentration is absent in other VWD types and normal individuals (Laffan et al., 2004). 
However, this test is used exclusively to identify type 2B and is not sensitive enough for the 
diagnosis and subtyping of other VWD variants.   
1.8.3.3. VWF:FVIII binding assay (VWF:FVIIIB) 
This is an ELISA based assay particularly used to evaluate the binding affinity of VWF for 
FVIII. VWF with endogenous FVIII is captured onto an ELISA plate, followed by removal of 
endogenous FVIII using a high concentration solution of calcium chloride. Next, recombinant 
FVIII is added, and binds to the immobilized VWF. Then, ELISA or a chromogenic assay are 
used in turn to quantify VWF:Ag and bound exogenous FVIII. A markedly decreased affinity is 
reported in type 2N.  This lower affinity distinguishes type 2N VWD from mild to moderate 
forms of haemophilia A (Sadler et al., 2000, Laffan et al., 2004, Caron et al., 2009). 
1.8.3.4. VWF-collagen binding assay (VWF:CB) 
This ELISA based technique investigates and evaluates the binding affinity of VWF to collagen. 
This assay depends upon the presence or absence of VWF with a HMW multimer structure 
much as does the VWF:RCo assay, where strong binding is achieved with HMW VWF 
(Neugebauer et al., 2002). The presence of mutations within VWF in the A3 domain may also 
affect the binding affinity of VWF to collagen (Ribba et al., 2001). The normal range of this 
assay is very similar to those for the VWF:Ag and VWF:RCo assays (66-226 IU/dL). 
1.8.3.5. The ratio of VWF pro-peptide to mature VWF (VWFpp/VWF:Ag) 
This test investigates the ratio of the VWF pro-peptide (VWFpp) to VWF:Ag in patients with 
type 1 VWD in order to evaluate the survival of VWF in the plasma. These two proteins are 
found dissociated and circulating independently in the plasma. The half-life of VWFpp, which 
circulates as a homodimer, is 2-3 hours, while mature VWF has a half-life of 8-12 hours 
(Borchiellini et al., 1996, Haberichter et al., 2006). The normal ratio of pro-peptide to mature 
VWF is expected to be one. This ratio is increased in individuals with mutations which lead to 
reduced survival or increased clearance of VWF such as p.R1205H. This is possibly due to 
normal VWF secretion and normal levels of pro-peptide but reduced levels of mature VWF due 
to an increased rate of clearance (Haberichter et al., 2008). This ratio may help in the 
identification of a number of patients with type 1 VWD having mutations enhanced VWF 
clearance that results in short half-life (Eikenboom et al., 2013a). 
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1.8.3.6. Molecular analysis of VWF gene 
VWF analysis can be performed in order to help diagnose and classify VWD. Some mutations in 
VWF are specific to particular VWD subtypes. Moreover, the detection of genetic defects, 
including missense mutations, deletions and insertions can make the molecular mechanism of 
VWD easier to comprehend and can help clarify VWD pathogenesis as well as facilitate the 
diagnosis and subtyping of VWD cases (Laffan et al., 2004). The presence of missense 
mutations associated with type 2 VWD in particular VWF domains has given rise to 
recommendations to analyse specific regions. It is better to start with these domains but a 
further search in other domains may be required (Keeney et al., 2008). The first of these being 
exons 17-27 in type 2N and exon 28 in type 2A, 2B and 2M and exons 1-52 in type 3. 
Mutations that are found in type 1 are mostly missense and located throughout VWF (Cumming 
et al., 2006, Goodeve et al., 2007, James et al., 2007). All exons should be sequenced when 
there were no mutations identified or dosage analysis can be applied to detect large deletion or 
duplication within VWF. 
1.8.3.7 Factors that make diagnosis of type 1 VWD difficult 
The diagnosis of VWD is based on the presence of low levels of VWF in the patient’s plasma in 
addition to the presence of bleeding symptoms in patients and family members. The diagnosis 
of VWD is difficult due to various physiological and environmental reasons. Firstly, a slightly 
low level of VWF is often found in blood group O individuals, who may be difficult to 
distinguish from patients who have classic type 1 VWD. Also, incomplete penetrance of VWF 
mutations in different families and variable expressivity in the same family result in variable 
levels of VWF (Tosetto et al., 2007). Furthermore, low levels of VWF are often associated with 
the presence of mild bleeding disorders, but this does not necessarily indicate VWD and can 
lead to false positive diagnosis (Sadler, 2007). Levels of VWF increase spontaneously in 
response to stress, infections, pregnancy, and exercise and also with age, which may hide the 
true level of VWF, lead to less bleeding and thereby cause misdiagnosis of VWD. Finally, the 
reduced sensitivity of tests used to diagnose type 1 VWD and variability in bleeding symptoms 
make the diagnosis difficult because of variable expressivity and mutation penetrance. However 
it may contributes to difficulties of properly differentiation between patients with mild type 1 
VWD and healthy individuals who have VWF levels close to the lower end of normal range 
(Eikenboom et al., 2006). 
1.9. Classification of von Willebrand disease 
Various classifications of VWD have been reported based upon the VWF phenotypic analysis 
and the severity of the bleeding among VWD patients and the initial classifications were 
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complex (Holmberg and Nilsson, 1972, Ruggeri and Zimmerman, 1987). In 1972, Holmberg 
and Nilsson categorized the disorder into two main groups, one with normal VWF antigen 
plasma concentration and another with structurally abnormal VWF antigen. This was done 
using the crossed immuneelectrophoresis technique (Holmberg and Nilsson, 1972). In 1987, 
when the molecular structure and function of VWF was known, Ruggeri et al (1987) offered a 
definitive classification of the disease based upon the structural and functional abnormalities of 
VWF. This classification was mainly based on the VWF multimer patterns in order to 
distinguish various types of VWD using agarose gel electrophoresis. Limited phenotype data 
provided minimal information about the molecular mechanisms that lead to various types of 
VWD. Moreover, this categorization led to the emergence of many disease subtypes that 
clinicians found difficult to use for diagnosis and treatment of VWD patients (Ruggeri and 
Zimmerman, 1987, Schneppenheim et al., 2001b). 
Thus, in 1994, a simplified, easier to use phenotypic classification based on the clinical and 
laboratory characteristics of VWD, including its molecular aspects, was proposed by Sadler. 
This was accepted by the International Society on Thrombosis and Haemostasis Scientific and 
Standardisation Committee on von Willebrand Factor (ISTH SSC on VWF). Accordingly, 
VWD is currently classified into three main, or primary, types based on laboratory findings and 
family data. These three types are: partial quantitative deficiency (type 1), qualitative deficiency 
(type 2) and total quantitative deficiency (type 3). Type 2 VWD is further subdivided into four 
sub, or secondary, types: 2A, 2B, 2M and 2N, depends upon the pathophysiological mechanism. 
In certain circumstances, tertiary information that includes the name of the place that indicates a 
remarkable phenotype such as a “Vicenza” mutation or a VWF multimer pattern that in turn 
indicates that a particular disease mechanism, such as 2A (IIC) or (IIE) can be used (Sadler et 
al., 2006). 
The previous classification restricted VWD to VWF mutations, implying that mutations within 
the gene were the predominant cause of VWD. In 2006, with increased knowledge of the 
pathophysiology of VWD, VWD classification was reviewed, re-evaluated and progressed by 
the ISTH SSC on VWF to incorporate new ideas on the disease (Sadler et al., 2006). Two 
amendments to the 1994 classification were introduced. Firstly, that VWD is not only caused by 
VWF mutations due to many patients having shown no identified mutation and it thus being a 
possibility that other genetic defects contribute to the disease phenotype. Secondly, that normal 
quantity and quality of plasma VWF can be observed in type 1 VWD patients who presumably 
bleed despite the presence of a mutation in VWF. This may due to the incomplete penetrance 
and variable expressivity of some VWF mutations (Sadler et al., 2006). Moreover, recent studies 
on type 1 VWD identified patients with slight multimer abnormalities that do not impede VWF 
function (Goodeve et al., 2007, James et al., 2007). This new version of the classification aimed 
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to facilitate and enable procedures for diagnosis and treatment to provide the best care for VWD 
patients. 
1.9.1. Type 3 VWD 
Type 3 VWD is the rarest of all the VWD types and accounts for less than 5% of all VWD cases 
with a very low frequency amongst the population, there being only 0.5 case per one million 
individuals in Scandinavian countries (Mannucci et al., 1984). However, in communities where 
consanguineous partnerships are common such as Iran, Arabic and Indian population, the 
frequency can be as high as 6 cases per million people (Sadler et al., 2000, Ghosh and Shetty, 
2011). This type is most prevalent within Middle Eastern populations, especially the Arab and 
Iranian population, while it is least prevalent within Southern European populations (Weiss et 
al., 1982, Berliner et al., 1986, Lak et al., 2000). Type 3 VWD is the most clinically severe form 
of VWD and is characterised by undetectable VWF in the plasma and platelets as well as a 
secondary reduction in the level of FVIII, leading to the impairment of both primary and 
secondary haemostasis. It is inherited as an autosomal recessive trait. Patients with homozygous 
or compound heterozygous forms usually present with severe haemorrhagic symptoms, 
including epistaxis, bleeding following surgical procedures, menorrhagia, and mucocutaneous 
and arthropathic bleeding, at an early stage in their lives due to a severe reduction in FVIII 
(Nichols and Ginsburg, 1997, Federici, 2004), while heterozygous relatives occasionally present 
with mild haemorrhagic symptoms. A large number of mutations responsible for this type have 
been reported as being distributed throughout the whole VWF locus, including the coding and 
non-coding (splice sites) sequences (Figure 1.1D). These mutations are highly variable among 
various populations and mostly impair VWF production and cause a null allele phenotype. The 
genetic abnormalities associated with type 3 VWD include nonsense, large deletion, splice site, 
small deletion and small insertion, all of which result in frameshift. These mutations account for 
almost 80% of mutations, while missense mutations account for the remaining 20% (Zhang et 
al., 1994, Baronciani et al., 2003, Bowman et al., 2013). The large deletions involve the removal 
of one or more exons of VWF sequence and are mainly associated with type 3 VWD.  
Expression studies have shown that large deletions may impair VWF multimerisation and cause 
a reduction in VWF secretion. Deletions in type 3 are usually out of frame which causes a 
truncated protein to be made which is degraded through nonsense mediated decay. A study 
conducted by Allen et al. reported that a number of type 3 missense mutations cause 
intracellular retention of VWF because mutations disrupt VWF multimerisation and thus affect 
VWF folding (Allen et al., 2000b). Moreover, gene conversion between VWF and VWFP, where 
the pseudogene sequence introduces a null mutation, is considered to be a mechanism 
associated with type 3 VWD (Gupta et al., 2008, Sutherland et al., 2009b).  
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1.9.2. Type 2 von Willebrand disease 
Type 2 VWD represents the qualitative defects of VWF that affect its function. Up to 25% of all 
VWD patients have type 2 VWD. According to the most recent classification, type 2 VWD is 
subdivided based on the structural and functional defects that alter the binding of VWF to FVIII 
or to platelets or collagen and therefore alter platelet adhesion. Various types of mutations, 
nearly all missense and others such as in-frame deletions and insertions, are associated with the 
disease phenotype in the majority of patients. 
1.9.2.1. Type 2A VWD  
This is the commonest variant of type 2 VWD, being found in almost 75% of all type 2 VWD 
patients and is mostly inherited as autosomal dominant although some variants are inherited as 
autosomal recessive (Schneppenheim et al., 2010). Type 2A is a qualitative defect that affects 
the function of VWF due to an absence or a reduction in HMW-VWF multimers. This impairs 
VWF binding to the platelet binding site on GpIbα. Patients with this type usually present mild 
to moderate bleeding symptoms with normal or reduced levels of VWF:Ag and FVIII:C activity 
and an abnormal functional assay as a significantly decreased level of VWF:RCo is observed in 
addition to reduced VWF:RCo/VWF:Ag ratio (Nichols and Ginsburg, 1997, Meyer et al., 2001, 
Schneppenheim and Budde, 2005). The majority of mutations that contribute to this variant are 
missense, and are mainly (82%) located in the A1 and A2 domains of VWF encoded by exon 
28, although few mutations have also been identified in the D3 domain in type 2A(IIE) (Meyer 
et al., 1997, Schneppenheim et al., 2010). About 8% of mutations are found in the pro-peptide 
domains and a further 8% of mutations are found in the C-terminal domains (Figure 1.1D). 
(Hilbert et al., 1995, Meyer et al., 1997, Sadler et al., 2006). These mutations lead to the 
emergence of the disease and cause structural and functional changes to the VWF through two 
main mechanisms. Firstly, they impair the assembly of large VWF multimers, causing the 
secretion of small or intermediate multimers, which reduce the binding to platelets or other 
receptors (Zimmerman et al., 1986, Lyons et al., 1992). More than 70 mutations have been 
identified, of which 64 of 70 are missense in various VWF domains impairing normal VWF 
multimer assembly and secretion, leading to less HMW (VWF) multimers in plasma and 
platelets (http://www.vwf.group.shef.ac.uk/ accessed November, 2012) (Hampshire and 
Goodeve, 2011). Many studies have identified various types of mutations mostly are missense 
and rarely small deletion, large deletion and insertion in different domains that impair or prevent 
VWF multimerisation, alter intracellular transportation can lead to intracellular retention of 
VWF. Homozygous or compound heterozygous mutations that occur in the pro-peptide D2 
domain encoded by exons 11-17 impair multimer assembly in the ER due to abnormal 
formation of disulphide bonds and prevent multimerisation and intracellular transport, thereby 
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producing small multimers or dimers and the presence of a fine smear around the central bands 
that lack the ability to react with platelets. This is inherited as autosomal recessive, and was 
originally named type 2A(IIC) VWD (Ruggeri et al., 1982, Batlle et al., 1986, Schneppenheim 
et al., 1995). Other types of heterozygous mutations located in the CK domain can impair the 
assembly of dimers in the ER and prevent the dimerisation of pro VWF. These mutations lead to 
the secretion of small multimers that lack normal function in addition to absence of triplet 
satellite bands normally results from ADAMTS13 cleavage. This multimer pattern was initially 
referred to as VWD type 2A(IID) which exhibit dominant inheritance (Kinoshita et al., 1984, 
Schneppenheim et al., 1996, Budde, 2008).  The 2A(IIE) phenotype is characterized by the lack 
of large VWF multimers. This subtype is inherited as autosomal dominant and often caused by 
heterozygous mutations leading to loss or gain of cysteine residues in the D3 domain that can 
impair multimerisation and further multimer assembly due to interfering with the formation of 
disulfide bonds in the Golgi and secretion of oligomers only. These mutations produce smeary 
multimer patterns characterized by absence of the outer proteolytic bands (Zimmerman et al., 
1986, Meyer et al., 2001, Schneppenheim et al., 2001b, Schneppenheim et al., 2010). 
The second mechanism is characterised by impaired VWF assembly and secretion in addition to 
increased sensitivity of VWF to the cleaving protease represented by ADAMTS13, which is 
caused by mutations located in the A2 domain. Mutations in the A2 domain can lead to 
increased proteolysis by ADAMTS13 and impair multimer assembly due to abnormal folding 
caused by mutation (Sadler et al., 2006, Nichols et al., 2008b). These mutations markedly 
interfere with VWF folding and make the p.Y1605-M1606 bond in the A2 domain accessible to 
the cleaving protease. Based on this mechanism, this pattern has been divided into two mutation 
groups. The hallmark of group I, which has an effect on the A2 domain folding, is the presence 
of mutations that enhance proteolysis and mainly impair multimer assembly and impair 
intracellular transport or secretion, whereas group II mutations have normal multimerisation and 
secretion of VWF, but multimer destruction can occur in plasma due to enhanced susceptibility 
of HMW-VWF to cleavage that results from extracellular proteolysis by ADAMTS13 following 
secretion (Zimmerman et al., 1986, Lyons et al., 1992). Jacobi et al (2012) have reported several 
mutations identified in type 2A patients that do not fit into either group I or II categories. These 
mutations result from complex mechanisms that include intracellular retention and degradation 
of VWF, loss of  WPB formation and regulated storage which is associated with severe reduced 
secretion and abnormal multimer assembly in mutations involve cysteine residues (Jacobi et al., 
2012).  
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1.9.2.2. Type 2B VWD  
This is the rarest subtype accounting for less than 5% of all VWD cases and is characterized by 
an increased affinity of VWF for the platelet GpIbα binding site, which may be associated with 
reduced HMW multimers in the plasma as a result of increased cleavage by ADAMTS13 
(Keeney and Cumming, 2001, Sadler et al., 2006).  This type is inherited mostly as autosomal 
dominant with a few cases being recessively inherited but not confirmed by mutation analysis 
(Donner et al., 1987). Mutations responsible for this type cause conformational changes that 
render the GPIbα receptor exposed and enable VWF to bind to platelet GpIbα spontaneously 
(Sadler et al., 2006). The majority of the mutations that are responsible are missense mutations 
that are located within or adjacent to the VWF A1 domain (Figure 1.1D) (Sadler et al., 2006, 
Goodeve, 2010). These mutations stabilise the A1 domain bound conformation and thereby 
enhance the binding of VWF to the platelets (Randi et al., 1991, Huizinga et al., 2002). 
Although many studies have reported that almost 25 missense and one duplication mutations are 
associated with type 2B VWD, four mutations are considered to be the most common 
(http://www.vwf.group.shef.ac.uk/ accessed November 2012). Frequent variants are located 
within the A1 domain and are responsible for almost 90% of this form of VWD (Ginsburg and 
Sadler, 1993, Nichols and Ginsburg, 1997, Meyer et al., 2001). 
1.9.2.3. Type 2M VWD  
Type 2M VWD is dominantly inherited, and bleeding symptoms vary from mild to severe 
(Nitu-Whalley et al., 2000, Sadler et al., 2006). This subtype is caused by mutations that alter 
the binding of VWF to platelet or to the subendothelium, which has an essentially normal range 
of HMW multimers. (Meyer et al., 2001, Schneppenheim et al., 2001b, Sadler et al., 2006). The 
function of VWF in this subtype is indicated by a significant decrease in VWF:RCo levels in 
companion with VWF:Ag. Impaired binding of VWF to platelets decreases the cleavage of 
VWF by ADAMTS13 and prevents degradation of the VWF subunits, resulting in the 
preservation of the HMW multimers but loss of HMW-VWF is relatively observed  (Mancuso 
et al., 1996, Budde, 2008). Most of the detected mutations that alter platelet binding and are 
responsible for type 2M VWD are missense or in-frame deletions located in the A1 domain 
encoded by exon 28 (Figure 1.1D) (Rabinowitz et al., 1992, Meyer et al., 2001). Moreover, 
mutations found in the A3 domain may cause type 2M VWD by reducing the binding of VWF 
to collagen and thereby reducing platelet adhesion. They include p.L1696R, p.S1731T, 
p.W1745C, p.S1783A, p.H1786D and p.P1824H (Ribba et al., 2001, Flood et al., 2012, 
Legendre et al., 2013). 
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1.9.2.4. Type 2N VWD 
Type 2N VWD, which is recessively inherited, was initially described as the 'Normandy' type of 
VWD because the first patient with this subtype was born in this area of France. Type 2N is 
characterised by the markedly reduced binding affinity of VWF to pro-coagulant FVIII and 
reduced FVIII levels in the plasma along with normal or mildly reduced levels of the VWF:Ag 
and VWF:RCo (Mazurier et al., 1990b, Mazurier et al., 2001). Multimers are often normal, but 
some patients with type 2N have multimer defects, which can include ultra-high MWM or an 
absence of HMW multimers (Jorieux et al., 1998, Allen et al., 2000a). Type 2N VWD is 
clinically similar to mild haemophilia A, which can lead to misdiagnosis. Patients usually 
present with musculoskeletal bleeding symptoms due to decreased levels of FVIII (Mazurier, 
1992). However, a differential test measuring the binding of FVIII to VWF (VWF:FVIIIB), is 
currently used to distinguish between these disorders and also to identify type 2N VWD. Type 
2N is the result of mutations located in the FVIII binding site of VWF. These lie between 
Ser764 and Arg1225 residues and cover the domain D' and part of D3 domain (exons 18-27), 
which impair VWF binding to FVIII and subsequently is classified as type 2A (Figure 1.1D) 
(Nishino et al., 1989, Mazurier et al., 1990a, Sadler et al., 2006). Three genetic mechanisms are 
involved in this subtype: homozygosity, which is less common and involves both alleles having 
the same 2N missense mutation; compound heterozygosity, where two different 2N missense 
mutations are found one on each allele; and compound heterozygosity, where in addition to a 
2N missense mutation on one allele there is a null mutation of the second (Mazurier et al., 2001, 
Schneppenheim and Budde, 2005). To date, almost 28 missense mutations have been reported 
as the genetic cause of type 2N VWD, and it has been found that almost 90% of the cases of this 
subtype result from three variants: p.R816W, p.T791M and p.R854Q (Mazurier and Meyer, 
1996, Mazurier and Hilbert, 2005). The latter one, p.R854Q, is the most prevalent, occurring in 
the heterozygous form in 1% of the Caucasians population. In vitro expression studies have 
shown that this mutation, when found in the homozygous form, causes the least severe type 2N 
(Nishino et al., 1996, Castaman et al., 2010a). p.R854Q frequently occurs in the heterozygous 
form, and it can be co-inherited with other mutations, resulting in mixed or dual type 2N/other 
VWD types. Several mutations in the VWF D' domain have been identified in type 2N VWD 
patients, an example of them p.C788Y and p.C858F, These alterations, which induce 
conformational changes in the D' domain, reduce the binding of FVIII to VWF in addition to 
impairing normal VWF multimerisation and secretion (Jorieux et al., 2000) 
1.9.3. Type 1 VWD 
Type 1 VWD is the most common form of VWD with 70-80% of all patients diagnosed with 
VWD having type 1. It is characterised by a partial quantitative deficiency of VWF in the 
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plasma, and patients usually present with mild to moderate mucocutaneous bleeding symptoms 
including easy bruising, epistaxis, prolonged bleeding following surgery and dental extraction 
or cleaning, menorrhagia and postpartum bleeding. Musculoskeletal bleeding also occurs when 
FVIII is reduced secondary to reduced VWF. Bleeding symptoms are mostly associated with 
low levels of VWF and are observed more in adult females than males and children due to 
increased rates of exposure to haemostatic challenges. Menorrhagia is the most common 
bleeding symptom among women, while bruising and epistaxis are observed more in children 
(James and Lillicrap, 2006). 
Type 1 VWD is mostly inherited as an autosomal dominant trait with reduced penetrance and 
variable expressivity, which complicates diagnosis, and more rarely inherited as autosomal 
recessive (Nichols and Ginsburg, 1997, Keeney and Cumming, 2001, Cumming et al., 2006, 
Goodeve et al., 2007). Reduced/incomplete penetrance of type 1 VWD mutations means that an 
individual with a known mutation within VWF does not display any phenotypic symptoms of 
disease, whereas the variable expressivity of a mutation means that individuals with a known 
mutation can express vastly different phenotypes. These could potentially be due to other 
polymorphisms or mutations that are inherited alongside them, meaning that both mutations 
would have to be present in order to result in a disease phenotype and that if only one is present, 
an individual does not present with bleeding symptoms. One of the changes in the updated 
VWD classification is the inclusion of type 1 VWD patients who have slightly decreased 
HMWM, which does not affect the relatively normal function of VWF levels (Sadler et al., 
2006).  
1.9.3.1. Type 1 VWD mutational cohort studies 
Since 2000, three early multicentre studies have carried out analysis of groups of patients and 
their families diagnosed with type 1 VWD. These three studies were the MCMDM-1VWD 
study (Molecular and Clinical Markers for the Diagnosis and Management of type 1 von 
Willebrand Disease), which was conducted within the European Union, the UKHCDO study 
(United Kingdom Haemophilia Centre Doctor's Organisation), which was conducted in the UK, 
and the Canadian study (Cumming et al., 2006, Goodeve et al., 2007, James et al., 2007). Also, 
Swedish and American studies have been conducted and analysed group of patients diagnosed 
with type 1 VWD (Lanke et al., 2005, Flood et al., 2011). The genetic linkage between VWF 
and type 1 VWD was investigated in 31 Swedish families diagnosed with type 1 VWD 
according to ISTH criteria. As a result, genetic co-segregation to VWF was observed high in 
87% of families because families who were non informative excluded from the study (Lanke et 
al., 2005). The aim of these studies was to improve our understanding of the molecular basis 
and pathogenesis of type 1 VWD. These three extensive studies recruited 305 IC from a number 
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of families who were historically diagnosed with type 1 VWD in addition to a large number of 
healthy controls. The outcome of these three studies was similar, with the highest proportion of 
identified mutations, 62-70%, being missense mutations, while other types of mutations, such as 
splice sequence mutations, transcription regulatory mutations, small deletions, insertions and 
nonsense mutations were also identified in lower proportions ranging from 2 to 16%. Almost 
40% of families recruited in these studies were linked to VWF (Eikenboom et al., 2006). The 
majority of these mutations are located in the A1, A2 and D3 domains. The level of VWF was 
lower on average when a mutation was detected. However, to date, although these three studies 
failed to detect mutation in 35-40% of cases, they have identified almost 150 in total different 
mutations in the VWF gene as the main cause of VWD in 60-65% of IC  and the online locus-
specific database for von Willebrand disease (http://www.vwf.group.shef.ac.uk/) holds details 
of these mutations (Hampshire and Goodeve, 2011). Moreover, these studies reported that more 
than one candidate mutation was identified in 15-20% of cases (Cumming et al., 2006, Goodeve 
et al., 2007, James et al., 2007). These genetic abnormalities may alter the expression, 
processing and function of VWF.  
1.9.3.1.1. The European Union study on type 1 VWD 
The EU study (MCMDM-1VWD) which was co-ordinated from Sheffield, was designed with 
the aim of increasing knowledge about molecular mechanisms and the pathogenesis of type 1 
VWD. It initially recruited a total of 154 IC with affected and unaffected family members from 
fourteen VWD treatment medical centres in nine European countries. Later, four IC were 
eliminated from the study; two because the multimers were not detected due to a very low level 
of VWF, one due to insufficient plasma sample and one because the DNA sample was 
insufficient for mutational analysis (Goodeve et al., 2007). A total of 150 IC who were 
historically diagnosed with type 1 VWD and their families, 278 affected members (AFM) and 
312 unaffected members (UFM) plus 1166 healthy control (HC) samples were included in this 
study. The healthy controls’ samples were analysed along with the VWD patients’ samples in 
order to help understand the molecular basis of VWD. Every family recruited for this study 
contained one IC, as many affected and unaffected members as possible and a minimum of two 
generations. Extensive phenotypic and genotypic studies were performed. During recruitment, 
several coagulation tests were performed on all members of all the families and HC individuals 
to determine the individual phenotypes. In addition, to evaluate the severity of the bleeding, all 
family members were assessed using a detailed bleeding score questionnaire. Most of the 
patients had at least one bleeding symptom, while almost 80% presented with more than one 
symptom. Few individuals classified as UFM showed bleeding symptoms at recruitment 
(Tosetto et al., 2006). To assess the linkage between VWF and clinical and phenotypic data in 
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the recruited families, three different short tandem repeat markers were used to detect linkage 
between VWD and VWF. The GTn  repeat marker, which is located within the promoter region, 
and the TCTAn repeat (STR III) and TCTAn repeat (STR II), which are both located within 
intron 40, were used (Eikenboom et al., 2006). Within this study, VWD was linked to VWF in 
70% of cases; of which complete co-segregation was achieved in 40% of IC and 30% was not 
linked to VWF plus 30% was non-informative. 
Extensive amplification and sequencing of the entire coding region of VWF (exons 2-52) and 
the closely flanking intronic regions in addition to 2 kb of the 5' regulatory region was 
performed for mutational analysis in most IC. This cohort was analysed using various 
mutational scanning techniques including single-stranded conformation polymorphism (SSCP), 
conformation sensitive gel electrophoresis (CSGE), denaturing high-performance liquid 
chromatography (dHPLC) and direct DNA sequencing, which was used following screening to 
identify all mutations (Goodeve et al., 2007). As a result, 124 mutations were identified in 105 
(70%) of the IC, 34% (54) of which were novel mutations. These identified mutations were 
mainly missense (80%), although others, including splice, nonsense/insertion and promoter, 
were found to a lesser degree. The mutations identified were located throughout VWF, most of 
them within the A domains. Almost 50% of IC showed incomplete penetrance. 10 to 15% of 
mutations resulted in null alleles, and more than one mutation was detected in 15% of IC. The 
most frequent candidate mutations identified were p.Y1584C and p.R1205H (Goodeve et al., 
2007). 
The analysed IC were divided into three groups based on the multimer pattern and the presence 
or absence of mutations. Group 1 represented the 57 IC (38%) who had abnormal multimers, a 
very low level of VWF:Ag with median ranges between 10 and 19 IU/dL and the median BS 
was 10. Abnormal multimers do not fit with the standard criteria for type 1 VWD diagnosis, 
however, these ‘atypical’ individuals were studied to ensure no mutations within the cohort 
were overlooked. The abnormal multimers showed as either a relative loss of high 
molecular weight VWF multimers, or abnormal satellite bands (Sadler 1994, Goodeve et al. 
2007). The reduction of VWF levels was more in IC with more than one mutation compared to 
those with only one mutation. Mutations were found in 54/57 and the remaining 3 IC showed no 
mutation although having abnormal multimers, with one candidate mutation being reported in 
45 IC and the remaining IC showing more than one candidate mutation. Complete co-
segregation was seen in almost 60% of cases (Goodeve et al., 2007). Group 2 represented the 51 
IC (34%) with normal multimers and identified mutations. Also, the IC in this group had 
moderate levels of VWF:Ag, ranging between 26 and 70 IU/dL and median BS was 8. 44 IC 
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each had one mutation identified, while two or more mutations were identified in 7 IC. 
Complete co-segregation was observed in 41% of cases (Goodeve et al., 2007).  
The third group is the questionable group, and more research is needed due to the absence of 
mutations amongst the IC representing this group. Although the patients did bleed, the 
MCMDM-1VWD study failed to detect genetic alterations in 42 IC (28%) of the investigated 
150 IC although the median BS was similar to other groups (median BS=8). These IC had 
normal multimers but no identified mutation even though the median level of VWF:Ag was 49 
IU/dL, higher than levels in groups 1 and 2 but below the normal range ( NR=50-200 IU/dL). 
Out of the 42 cases, eleven children aged 6-18 years showed no significant bleeding despite four 
of them having a reduced level of VWF. In contrast, out of the 31 cases that bled, 23 presented 
with a low level of VWF, 13 of which were not linked to VWF. Complete co-segregation was 
observed in only 19% of this group and incomplete co-segregation was observed in 45% of 
cases. Blood group O was predominant amongst this group and accounted for almost 76% of IC, 
while 63% of complete segregating IC and 89% of incomplete co-segregating IC had blood 
group O (Goodeve et al., 2007). 
1.9.3.1.2. Reasons for failure to detect mutations 
Although these three studies provided details about the molecular and genetic basic of type 1 
VWD, they failed to detect the genetic alterations or mutations involved in VWD in 30-40% of 
VWD cases (Cumming et al., 2006, Goodeve et al., 2007, James et al., 2007). The failure of 
these studies to determine the cause of these genetic defects can be explained by the following: 
1.9.3.1.2.1. Missed mutations 
 Mutations may have been missed in some families in the EU study that showed complete co-
segregation. Several mutation analysis methods, including SSCP, CSGE, DHPLC and direct 
DNA sequencing, were used to sequence VWF exonic regions (Goodeve et al., 2007). However, 
these methods can lack sensitivity and thus may have missed mutations (Markoof et al., 1998, 
Whittock et al., 1999, Eng et al., 2001). Furthermore, mutations may have also been missed due 
to human error. Re-evaluation of patients within this group using direct sequencing could 
identify new mutations.  
The VWF gene is a highly polymorphic gene, and mutations may be missed due to the presence 
of SNP located within sites of primer annealing that can lead to poor or mono-allelic 
amplification of the mutant allele. SNP within the primer sequence could mask a heterozygous 
genetic defect, and this could cause a mutation to be missed (Eikenboom et al., 1994, Thomas et 
al., 2006b, Hampshire et al., 2010). The primers used in the EU study were designed prior to the 
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availability of the complete VWF sequence using the limited knowledge of the sequence 
available in 2000. This limited knowledge lacked information on SNP that impact on molecular 
analysis (Goodeve et al., 2007). After re-designing primers free of SNP within their sequence, 
Thomas et al. (2006) and Hampshire et al. (2010) identified mutations in patients with type 1 
and type 2 VWD whose previous mutation analysis was negative. Thus, reviewing the design of 
primers for SNP on a regular basis is recommended. 
1.9.3.1.2.2. Misdiagnosis of type 1 VWD 
Many environmental and genetic factors make the diagnosis of type 1 VWD difficult, and this 
may lead to misdiagnosis or false positive diagnoses of VWD, leading to an unexpected link to 
VWF. Furthermore, many studies have shown that other bleeding disorders may impair the 
function of VWF and result in bleeding symptoms similar to those of VWD (Cumming et al., 
2006, Eikenboom et al., 2006). During the EU study, Daly et al. reported a novel genetic defect 
in P2RY12 (c.520A>G; p.K174E) in a patient who was initially diagnosed with mild type 1 
VWD and were found to have a locus heterogeneity that may contribute to bleeding symptoms 
(Daly et al., 2009). In this instance the mutation in P2RY12 is likely to explain the bleeding 
symptoms and hence this IC is likely to have a platelet defect disorder rather than type 1 VWD. 
1.9.3.1.2.3. Heterozygous copy number variation (CNV) 
It has been proposed that large deletions and duplications of VWF may be causative mutations 
in type 1 VWD; however, these mutations can be missed when present as large scale 
heterozygous deletions or duplications of either single or multiple exons within VWF. 
Heterozygous deletions of VWF  in type 1 VWD  were not detected using standard DNA 
sequencing/ mutation scanning techniques due to the presence of the wild-type allele, standard 
sequencing and scanning methods do not quantify exons present and so detection of 
heterozygous deletions is difficult. However, Sutherland et al (2009) detected a deletion 
involving exons 4-5 that was homozygous in type 3 individuals and heterozygous in type 1 
individuals. This deletion was initially detected in homozygous type 3 individuals due to exons 
4 and 5 failing to amplify during PCR analysis in 7 patients, leading to the detection of a 
deletion of exons 4-5. The deletion and breakpoints was confirmed using a PCR primer walking 
technique. A multiplex PCR was then designed around the breakpoints, to be able to screen 
patients that were homozygous and heterozygous for the deletion. This multiplex assay was 
used to screen 34 individuals in the UKHCDO type 1 VWD study for a heterozygous deletion 
of exon 4-5 and it was confirmed in 2 individuals, suggesting that heterozygous deletions may 
contribute to type 1 VWD (Sutherland et al., 2009a). Therefore, newly developed techniques 
capable of finding these alterations, such as multiplex ligation-dependent probe amplification 
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(MLPA), have been recommended (Sellner and Taylor, 2004, Cumming et al., 2006). Moreover, 
Cartwright et al (2013) reported that copy number variation (CNV) may contribute to type 1 
VWD pathogenesis in the EU study. Large deletions of exons 4-5 (3 IC) and of exon 3, 32-34 
and 33-34 were identified each in 1 IC, none of which had been previously identified in the EU 
study (Cartwright et al., 2013). MLPA could therefore be implemented as an initial screen for 
all types of VWD mutational analysis (Yadegari et al., 2011). 
1.9.3.1.2.4. Other genetic loci may contribute to VWD 
The presence of mutations or genetic alterations outside of VWF other than the ABO blood 
group locus could be a possible cause of VWD and may influence the survival of VWF in the 
plasma by increasing the rate of protein clearance (Casana et al., 2001, Eikenboom et al., 2006, 
James et al., 2007). ABO groups can affect VWF levels due to the different complexities of 
carbohydrate structures present on VWF between individuals with different blood group. ABO 
blood group system is based on A,B or H antigens on red blood cells and other carbohydrate 
structures. N-linked and O-linked carbohydrates can have A, B or H carbohydrates which are 
added during dimerisation, multimerisation and maturation of VWF in the ER and Golgi (Canis 
et al. 2010, Canis et al. 2012). ABO codes for a glycosyltransferase, which adds N-acetyl 
galactosamine to galactose of the H carbohydrate in A blood group; another galactose is added 
to the galactose of H antigen for blood group B and in people with O blood group nothing is 
added and the H antigen carbohydrate structure is unchanged. This is because there is a 
nucleotide deletion in ABO, which introduces a stop codon and leads to loss of function of the 
glycosyltransferase enzyme. 
 
Smith et al. in the Cohorts for Heart and Aging Research Genome Epidemiology (CHARGE) 
study reported seven different candidate genes outside of VWF that demonstrate significant 
statistical associations with VWF:Ag levels in the plasma either through impaired gene 
expression or biosynthesis or by increasing the rate of VWF clearance. Syntaxin binding protein 
5 (STXBP5) and syntaxin 2 (STX2) proteins associated with exocytosis and vesicular trafficking, 
while other genes such as stabilin-2 (STAB2), C-type lectin domain family, member M 
(CLEC4M) and scavenger receptor class A, member 5 (SCARA5) were significantly associated 
with level of VWF possibility due to increased VWF clearance (Smith et al., 2010, Rydz et al., 
2013). Table 1.1 lists various genes that can influence the level of VWF in the plasma.
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                             Table 1.1 Genes shown to be associated with variation in the level of VWF and their location adapted from Smith et al 2010. 
Protein function Encoded protein Located on 
chromosome 
Gene 
Regulates exocytosis and neurotransmitter Syntaxin-binding 
protein 5 
6 STXBP5 
Mediates uptake of ferritin- bound iron Ferritin receptor Ferritin receptor 8 SCARA5 
Express transferase enzymes with different glycosyltransferase properties, adding 
either N-acetyl galactosamine to the H antigen to convert to the A antigen or adding 
galactose to the H antigen converting it to into the B antigen. A mutation in the 
ABO gene can stop glycosyltransferase activity and prevent addition of a sugar 
group, leaving the H antigen (O blood group) 
ABO protein 9 ABO 
Transmembrane receptor protein which has been shown to have a number of 
functions in angiogenesis, lymphocyte homing, cell adhesion and receptor 
scavenging 
Stabilin-2 12 STAB2 
Syntaxins have been shown to function in the targeting and fusion of intracellular 
transport vesicles and in epithelial morphogenesis 
Syntaxin-2 12 STX2 
Not known Tandem C2 domains 
nuclear protein 
14 TC2N 
Involved in the innate immune system response and recognition of bacteria and 
viruses 
C-type lectin domain 
family 4, member M 
19 CLEC4M 
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The Genetic Analysis of Idiopathic Thrombophilia (GAIT) study was a genome-wide linkage 
analysis on chromosomal loci that may influence the levels of VWF among 21 thrombophilic 
Spanish families. As a result, this study confirmed the presence of potential genetic loci 
additional to the ABO locus on chromosomes 1, 2, 5, 6 and 22 that influence VWF levels and 
may influence the risk of thromboembolic disease. This study interestingly indicated that the 
ABO locus has the major influence on circulating VWF levels, while VWF alone has only a 
limited influence (Souto et al., 2003).  In addition to studies on humans, experimental studies 
performed to investigate VWF and potential other genetic loci in mice because the mouse model 
of VWD shows similar levels of VWF with incomplete penetrance and variable expressivity 
compared to humans. A number of studies were conducted in order to analyse the genotype and 
phenotype and to explain the variability in circulating VWF. These studies were able to identify 
a number of loci when cross breeding with specific mouse strains (Table  
1.2). 
 
Table 1.2 List of studies conducted on mice demonstrated VWF variability 
Comments  Reference 
Identification of one locus termed as modifier of VWF1, Mvwf1 by 
cross breeding of RIIIS/J and CASA/Rk strains. This locus was 
accounted for 65% of the variability of circulating VWF levels. The 
modification effect in Mvwf1 was suggested to be due to a mutation in  
B4galnt2 which can influence  VWF glycosylation 
(Mohlke et al., 1996, 
Mohlke et al., 1999) 
 
 
Identification of another locus within VWF on chromosome 6 termed  
Mvwf2 which was able to explain 16% of VWF level variability. This 
point mutation was found to impair VWF secretion and synthesis 
(Lemmerhirt et al., 
2007) 
Mvwf5 modifier which was found to impair binding of cis-regulatory 
elements in its promoter  
(Shavit et al., 2009). 
An additional two loci; Mvwf3  and Mvwf4 were identified and found 
to influence VWF levels when co-inherited with Mvwf2. Mouse Mvwf4 
was mapped to chromosome 13 and shared homology with a human 
genetic locus located at chromosome 5 and 6 
(Lemmerhirt et al., 
2007). 
Mvwf6 showed homology to human genetic locus 12q 13.2 and Mvwf7 
modifiers from cross breeding C57BL/6J and WSB/EiJ mice strains 
which may regulate the level of VWF 
(Shavit et al., 2009)  
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FUT3 (fucosyltransferase 3) encodes fucosyltransferase that required for adding the fucose to 
polysaccharides during Synthesis of Lewis antigen. FUT3 encodes for the fucosyltransferase 
that adds fucose to the precursor molecule (Lewis antigen) where its absence may increases the 
rate of VWF clearance. Mutations found in FUT3 were associated with a 10%  reduction in the 
level of VWF (Hickson et al., 2009a). Individuals with Lewis negative genotype showed low 
levels of VWF compared to Lewis positive genotype while the level of VWF is higher in 
homozygous individuals carry Se allele than heterozygous ones (O'Donnell et al., 2002b, Cakir 
et al., 2004). Moreover, Stockley et al (2012) identified mutations in platelet G-protein coupled 
receptor (GPCR) genes which are co-inherited in patients with type 1 VWD recruited through 
the EU study and were found to be associated with the bleeding phenotype. The presence of 
mutation outside the VWF may lead to reduction of VWF level and can explain the disease 
phenotype observed in IC who showed no mutation in this study. 
1.9.3.1.2.5. Single nucleotide polymorphism within VWF 
Most SNP within VWF have no effect on the level of VWF, but two recent studies (Campos et 
al., 2011, Zabaneh et al., 2011) have shown that SNP located within VWF regions that encode 
the D' and D3 domains, the amino terminal domains of mature VWF may be strongly associated 
with levels of VWF either through an influence on clearance or on biosynthesis. In order to 
identify genetic variants associated with VWF levels in healthy individuals, the gene-centric 
Illumina Human Cardio Vascular Disease (CVD) BedChip was used. As a result, 48 SNP were 
identified in four genes; ABO, VWF, ESR1and NRG1. A combined effect of five ABO SNP and 
2 VWF SNP located in exon 18 (c.2365A>G; p.T789A) and intron 20 (c.2685+498A>G) on the 
levels of VWF has been found. The ABO polymorphisms were found to be responsible for about 
15% and VWF polymorphisms for an additional 2% of the variance of the VWF levels (Zabaneh 
et al., 2011). Also, Campos et al, (2011) have reported a significant association between VWF 
levels and 18 VWF SNP, of which 16 were intronic and 2 were silent exonic polymorphisms 
located in exons 18 (c.2385T>C; p.T795=) and 22 (c.2880G>A; p.R960=) which are within the 
D' and D3 domains (Campos et al., 2011). 
1.9.3.2. Type 1 VWD mutation mechanisms 
Mutations affect the level of VWF in various ways. Recent studies have reported a large number 
of mutations located within different domains that affect the level of VWF in patients diagnosed 
with type 1 VWD (Figure 1.1D) (Goodeve et al., 2007, James et al., 2007). Mutations can cause 
type 1 VWD through a number of mechanisms, including: reduced VWF secretion, an increased 
rate of VWF clearance (decreased survival) and slightly increased susceptibility to the 
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proteolytic cleavage enzyme ADAMTS13 (Haberichter et al., 2006, Sadler et al., 2006, 
Goodeve, 2010).  
1.9.3.2.1. Reduced secretion and intracellular retention of VWF 
Reduced secretion of VWF is considered to be the most common mechanism causing type 1 
VWD. The mutations that affect gene expression may impair and disrupt the intracellular 
transport of VWF to the plasma thereby leading to a low level of VWF, causing an inherited 
dominant type 1 VWD. The EU study identified a number of missense mutations responsible for 
the pathogenicity in patients with type 1 VWD (Goodeve et al., 2007). An in vitro expression 
study conducted by Eikenboom et al (2009) was performed to examine the pathogenicity of 14 
missense mutations detected in patients diagnosed with type 1 VWD. Interestingly, seven 
homozygous missense mutations (p.G160W, p.N1661I, p.L2207P, p.C2257S, p.C2304Y, 
p.G2441C, and p.C2477Y) showed a severe deficiency of VWF in the plasma due to 
intracellular retention, aberrant multimer patterns indicating loss of HMW multimers and 
impaired secretion (Eikenboom et al., 2009). Moreover, expression study indicated that four 
heterozygous mutations (p.2287W, p.R2464C, p.G2518S and p.Q2520P) caused a mild 
reduction in secreted VWF. Normal secretion was reported for three benign missense mutations 
(p.G19R, p.P2063S and p.R2313H) (Eikenboom et al., 2009). 
1.9.3.2.2. Clearance of VWF in plasma 
Haberichter et al. (2006), (2008) reported that increased clearance of VWF in the plasma is an 
important mechanism in the pathogenesis of type 1 VWD. They used the ratio of VWFpp 
/VWF:Ag in patients with type 1 VWD to evaluate the survival of VWF in the plasma and 
found an increased ratio among patients with type 1 VWD with certain missense mutations and 
an increased clearance phenotype after the administration of  1-desamino-8-D-arginine 
vasopressin (DDAVP-desmopressin) (Haberichter et al., 2006, Haberichter et al., 2008). These 
findings suggest that an increase in the rate of clearance may be the cause of the low level of 
VWF in the plasma of affected cases. The most common type of mutation that represents the 
clearance phenotype is the Vicenza mutation (p.R1205H). According to EU and Canadian 
studies, this was the second most frequent mutation found in the index cases (IC), affecting 
almost 6% of them. When patients with this mutation were compared with healthy control 
individuals, the average half-life of VWF was significantly reduced (<2 hr), clearance after 
DDAVP infusion was greatly increased, there were lower levels of VWF in the plasma, and 
multimer structure was abnormal but more subtle than observed in type 2A VWD in some 
individuals (Casonato et al., 2002, Sadler et al., 2006, Goodeve et al., 2007, James et al., 2007, 
Budde et al., 2008a). The Vicenza subtype (p.R1205H) was previously classified as type 2M 
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VWD but is currently classified as type 1 VWD (Sadler et al., 2006). In vitro expression studies 
using rVWF have shown that normal secretion is achieved, indicating that the abnormal level is 
not due to a synthesis defect (Casonato et al., 2002). Other missense mutations, such as 
p.C1130F, p.W1144G and p.C1149R in the D3 domain and p.S2179F and p.C2671Y in the D4 
and CK domains, have been associated with this phenotype and have been shown to cause 
accelerated clearance and low levels of plasma VWF post desmopressin infusion but to a lesser 
degree than the Vicenza mutation (Gavazova et al., 2002, Schooten et al., 2005, Haberichter et 
al., 2006). As a result of these studies, it appears that an increased rate of clearance is 
responsible for 5-15% of type 1 VWD cases. 
1.9.3.2.3. Increased susceptibility to proteolytic cleavage 
The most common mutation identified by these three cohort studies was the p.Y1584C variant, 
which was found in 10-25% of the IC of type 1 and < 2% of healthy individuals (Cumming et 
al., 2006, Goodeve et al., 2007, James et al., 2007). This mutation is associated with a low level 
of VWF, ranging between 25 and 40 IU/dL. It slightly increases the susceptibility of VWF to 
the proteolytic enzyme ADAMTS13 and also increases intracellular retention in affected 
individuals. Their defects result in impaired binding of VWF to the platelet receptors, thereby 
reducing platelet plug formation (O'Brien et al., 2003, Bowen and Collins, 2004, James et al., 
2006, Sadler et al., 2006). Furthermore, this mutation can cause a slight reduction in survival or 
increased clearance though to a much lesser degree than the Vicenza mutation. It is located 
within the A2 domain and has phenotypic penetrance of approximately 70% (O'Brien et al., 
2003). The presence of p.Y1584C in individuals with blood group O contributes to slightly 
increased clearance and susceptibility to ADAMTS13 cleavage (Davies et al., 2007, Davies et 
al., 2008). 
1.10. Environmental and genetic factors affect level of VWF 
Although type 1 VWD is the most common of the three VWD types, it is the most complicated 
to diagnose. The level of VWF may be affected by environmental as well as genetic factors. 
VWF levels and half-life were found to increase with age at a rate of about 10 IU/dL per decade 
(Kadir et al., 1999, Nossent et al., 2006). Also, VWF levels increase in response to infection, 
malignancy, stress, in pregnancy and estrogen treatment, while levels are significantly less in 
individuals with blood group O compared with individuals with other blood groups, with 
clearance being accelerated in the blood group O population (Gill et al., 1987, Shima et al., 
1995, Kadir et al., 1999, Laffan et al., 2004, Franchini et al., 2007). A study conducted by Gill 
et al. (1987) showed that the average levels of VWF in individuals with blood group O were 25-
35 % lower than the average levels in individuals with blood groups A, B and AB . The highest 
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mean level of plasma VWF was observed in individuals with blood group AB (123.3 IU/dL), 
but levels were lower in individuals with blood group A (116.9 IU/dL)) and B (105.9 IU/dL) 
respectively, while the lowest level of VWF was observed in individuals with blood group O 
(74.8 IU/dL). Also, individuals who have the AO genotype have a lower level of VWF when 
compared to those with the AA genotype (Shima et al., 1995, O'Donnell et al., 2002a). 
Moreover, Souto et al. (2000) reported that the level of VWF in AO and BO genotypes, where 
there is one O allele, was significantly lower than in AA, BB and AB genotypes, where there 
are no O alleles. The average level of VWF in individuals with one O allele (AO) was 2-5% 
lower than the average level in individuals with no O allele, that is the (AA) genotype (Souto et 
al., 2000). Various transferase enzymes specificities are encoded by ABO glycosyl-transferase 
alleles. Due to disruption of the allele by a single base pair deletion in individuals with blood 
group O, the enzyme is non-functional. The presence of sugar groups that are added in 
individuals with blood group A and B protects VWF from clearance and the clearance of VWF 
is more rapid due to their absence in blood group O (Castaman et al., 2009). The absence of 
ABO glycosyl-transferase thus increases the cleavage susceptibility of VWF by ADAMTS13 
and contributes to its increased rate of clearance (Bowen, 2003, Davies et al., 2008). It has been 
shown that the half-life of VWF is influenced by blood group, which influences the rate of 
clearance of circulating VWF rather than its rates of synthesis and secretion. Nossent et al 
(2006) reported that the half-life of mature circulating VWF in individuals with blood group O 
(10 hr) is 2 hr lower compared to non-O (12 hr), while VWFpp was not influenced by blood 
groups because it does not carry ABO antigen (Nossent et al., 2006). Davies et al (2007) 
showed that the rate of VWF clearance in blood group O individuals who carry the p.Y1584C 
mutation is higher than those with blood group A who have the same mutation (Davies et al., 
2007, Davies et al., 2008). 
1.11. Aim of study 
The EU study carried out mutational analysis on a group of patients who were historically 
diagnosed with type 1 von Willebrand disease along with a large number of HC. This cohort 
study has used various mutation analysis techniques with variable sensitivities. However, this 
study failed to detect mutations in almost 30% of IC (Goodeve et al., 2007).  
The hypothesis being tested in the present study was that mutations in VWF have been missed in 
a proportion of type 1 VWD patients who have been analysed previously due to the insensitivity 
of mutation scanning methods used or due to the presence of single nucleotide polymorphisms 
(SNP) within primer annealing sites leading to lack of mutant allele amplification.  
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One of the initial aims of this study was to revise and screen all primers used during the EU 
study for the presence of SNP within primer sequences in addition to designing and optimising 
new primers when SNP were found to reside under historical primers.  
The second aim was to re-analyse and re-sequence all 52 VWF exons in addition to 
approximately 50 bp into each end of each intron in 18 candidate index cases historically 
diagnosed as having type 1 VWD where point mutations were likely to have been missed either 
due to there being a SNP within primer binding sequences or to insensitivity of the mutation 
analysis previously undertaken. 
A third aim was to perform in silico analysis to examine the predicted pathogenicity of any 
candidate type 1 and non-type 1 VWD mutations identified. In the case on non-type 1 VWD 
mutations, this was from a historical VWD diagnosis whereby the family (P9F18) was re-
classified as a potential type 3 case. In silico analysis of the mutations was used to determine the 
effect of the mutations prior to in vitro analysis. The final aim was to transfect the mutagenized 
plasmid bearing recombinant mutant VWF cDNA (rVWF) into HEK293T mammalian cells and 
to perform in vitro expression of both newly detected and other selected mutations in order to 
determine the effect of any new candidate mutations on VWF structure and function. 
Overall, this study aimed to increase knowledge about molecular mechanisms and the 
pathogenesis of type 1 VWD and to determine the mechanism by which candidate mutations 
exert an effect on VWF synthesis and secretion (Figure 1.4) 
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In silico analysis of VWF primers for presence of SNP 
 
New primers designed free of SNP, primer optimization 
 
VWF mutational analysis using PCR and direct sequencing 
 
Identify mutation(s) 
 
Determine inheritance in affected family 
 
In silico analysis to predict pathogenicity 
 
Mutagenesis to obtain recombinant mutant VWF (rVWF) 
 
Preparation of mutagenized plasmid 
 
Transfection of WT and mutagenized plasmids into HEK293T cells 
 
Confocal analysis of intracellular VWF 
 
Intracellular and extracellular expressed VWF and multimer analysis 
 
Data analysis 
Figure 1.4 Flow chart showing the aim and plan of the study 
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2. Materials and methods 
 
2.1. Materials 
2.1.1. Patient population and samples 
The MCMDM-1VWD study included 154 families who were selected from fourteen 
haemophilia centres in nine European countries and who were historically diagnosed with type 
1 VWD and their families, 278 AFM, 312 UFM and 1166 HC (Goodeve et al., 2007). All these 
cases were diagnosed as type 1 VWD by standard criteria and guidelines created by ISTH-SSC 
on VWF (Sadler et al., 2006).  Among all, VWF mutation was not identified in 42 index cases 
(IC). All individuals were recruited following informal consent. 
Clinical and laboratory data as well as genotypic data on all IC were available. The clinical data 
included bleeding score (Tosetto et al., 2006), while laboratory data included test results for 
VWF antigen (VWF:Ag), FVIII coagulant activity (FVIII:C), ristocetin cofactor activity 
(VWF:RCo), platelet function assay (PFA-100 using ADP and epinephrine), ristocetin-induced 
platelet aggregation (RIPA), VWF-FVIII binding assay (VWF:FVIIIB), the ratio of VWF pro-
peptide (VWFpp) to mature VWF (VWFpp/VWF:Ag) and VWF multimer pattern. Any 
VWF:Ag and VWF:RCo of 3 or less was listed as 3 IU/dL for mathematical purposes. In 
addition, genetically determined ABO blood group and platelet count results were included. 
Genomic DNA was extracted from citrated whole blood for all family members and stored at -
20°C. Stored genomic DNA from the 18 IC and HC as well was utilised to search for mutations 
in the VWF gene. DNA samples for IC and HC had already been extracted from whole blood 
during the EU study were used in this study (Goodeve et al., 2007). HC samples were used for 
two purposes; first to optimise the amplification conditions for VWF exons. Second, they were 
analysed and sequenced alongside IC to compare their traces. Samples were obtained following 
informed consent.  
Eighteen index cases (18 IC) out of 77 IC who were diagnosed as having type 1 VWD within 
the European Union study (MCMDM-1VWD) were selected for the study. IC selected for the 
current study either had no mutation detected (n=13) or had a VWF mutation detected that was 
insufficient to explain the patient's phenotype (n=5). Moreover, these selected cases had low 
levels of VWF and presented with significant bleeding. 
2.1.2. Chemicals, reagents, kits and enzymes 
Chemicals and reagents were supplied from various sources. They were used for DNA 
amplification, DNA electrophoresis, PCR product purification DNA sequencing, mutagenesis, 
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transfection and enzyme linked Immunosorbent assay (ELISA). PCR Master MixReddyMix® 
was purchased from Fisher Scientific (Loughborough, UK) while thin walled thermo-tube strips 
and domed cap strips were purchased from ABgene Ltd (Surrey, UK). The ExoSAP-IT kit was 
supplied by USB Corporation (Ohio, USA) while the agarose gel extraction kit, QIAprep Spin 
Miniprep Kit, QIAGEN
®
 Plasmid Maxi Kits were purchased from QIAGEN Ltd. (Crawley, 
UK). The transfection reagents Lipofectamine LTX reagent was purchased from Invitrogen by 
Life Technologies (USA). The 5× passive lysis buffer (5× PLB) and Dual-Luciferase
®
 Reporter 
Assay System were both from Promega Ltd. (USA). The QuickChange® Lightning site-directed 
mutagenesis kit was purchased from Agilent Technologies; Stratagene (USA). The antibodies 
used for ELISA were purchased from Enzyme Research (Swansea, UK), while standard 
VWF:Ag calibrator was purchased from Siemens Healthcare GmbH (Marburg, Germany). 
2.1.3. Primers 
PCR primer sequences were supplied by Eurofins MWG (Ebersberg, Germany). A number of 
oligonucleotide primers had already been prepared in previous studies while others were 
redesigned and supplied lyophilized and were re-constituted with deionized water (dH2O) 
according to supplier's instructions to prepare a concentration of 100 pmol/µl (Eurofins MWG, 
Ebersberg, Germany). A 1 in 10 dilution was prepared with dH2O to form a working stock 
solution for each primer to be used for PCR. 
2.2. Methods 
2.2.1. PCR primer design and SNP check 
In this study, a set of primers were used to PCR amplify VWF essential regions including all 52 
exons and closely flanking intronic regions in addition to 1.4 kb of intron 1. Some of these 
primers had previously been designed for the historical MCMDM-1VWD study and other 
previous studies. All of these primers were revised and screened for the presence of possible 
SNP within primer sequences in order to avoid amplification errors. Primers that showed no 
SNP underneath their annealing sites were utilised in VWF amplification, but primers which 
were found to have SNP within their sequences were re-designed. Because VWF is highly 
polymorphic and due to the presence of VWFP (pseudogene) which is similar to a large portion 
of VWF, care must be taken when designing the primers. Presence of SNP within primer 
sequences may lead to lack of amplification, while design of primers for exons 23-34 without 
including sequence mismatches with VWFP will cause amplification of the pseudogene in 
addition to the target gene. Therefore, designed primers did not include SNP underneath their 
annealing sites and included sequence mismatches with VWFP. Prior to publication of the full 
human gene sequence, this was not always possible due to lack of intron sequence. Also 
43 
 
designed primers were 50bp at least away from the target exon in order to amplify the exon and 
intronic flanking regions to include any splice-site defects.  
Primers were checked for the presence of SNP underneath their annealing sites by two methods; 
first, a manual search to identify SNP within primer sequence through comparison with the 
genomic sequence ENSG00000110799 (HGNC symbol:VWF), accessed using the Ensembl 
genome browser (www.ensembl.org/index, last accessed May 2010). The VWF sequence was 
obtained from the National Center for Biotechnology information (NCBI). The nucleotide 
accession number was NC_000012.11 and protein accession number was NP_000543.2. 
Second, SNP were checked and identified within primer sequences by using the Manchester 
SNP check tool (http//ngrl.manchester.ac.uk/SNPCheckv2/snpcheck.htm, last accessed 
November 2010). In this way, the primer pair sequences were entered and checked for the 
presence of SNP in PCR primer binding sites. 
All primers used either forward or reverse were attached to M13 tails except for primers used in 
long PCR and for DNA sequencing. M13 primers are universal primers used to facilitate DNA 
sequencing where single forward and single reverse primers are used to sequence target DNA. 
The sequence of M13 forward and reverse primers are listed in appendix 1. 
Primers that had SNP within their sequences were re-designed by using online Primer3 software 
(www.bioinformatics.org.sms2, accessed May 2010). When designing primers, many criteria 
were taken into account. All primers were between 18-25 bases in length, had GC content 
between 45-60%, had no repeat of >3 of a single base, and avoided complementarities between 
forward and reverse primers. In addition to designing forward and reverse primers, Primer 3 
calculated GC%, melting temperature (Tm), length of each primer and product size.  
 Due to the constraint of the small number of possible positions to design primers for the 
pseudogene region, it was not always possible to design primers following all of these criteria. 
Primers used to amplify VWF exons 23-34 where VWF and VWFP are highly similar (97%), 
were designed manually to include sequence mismatches between gene and pseudogene at the 3' 
end (Mancuso et al, 1989; Mancuso et al, 1991). This was achieved by aligning VWF sequence 
against VWFP sequence using Clustal multiple sequence aligment available on the website 
(http://www.clustal.org/ last accessed January 2011). Occasionally, mismatches were introduced 
to confer maximum VWF specificity and to de-stabilise binding to VWFP. 
2.2.2. Polymerase chain reaction (PCR) amplification of VWF 
Essential regions of VWF and closely flanking intronic regions that required re-sequencing were 
amplified by performing PCR. PCR is a quick technique used to amplify a particular DNA 
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region to generate large quantities of target DNA with known sequence and length for a variety 
of applications. The PCR reaction takes place in a thermal cycler consisting of cycles of 
repeated heating and cooling providing suitable temperatures required for the reaction. 
2.2.2.1. Conventional PCR 
PCR is commonly performed in small reaction tubes with a buffered mixture containing forward 
and reverse oligonucleotide primers with sequence complementary to the target DNA, genomic 
DNA, Taq polymerase and deoxynucleoside triphosphate (dNTP). Three essential steps are 
required to achieve amplification; denaturating of the double stranded DNA, annealing of the 
primers to their template single stranded DNA and elongation of annealed primers in the 
presence of dNTP and Taq polymerase to generate a new DNA complementary to the target 
DNA. Some primer pairs used in this study required optimisation of conditions. These 
conditions included annealing temperature, number of cycles and MgCl2 concentration. After 
completing the optimization, primers were used to amplify VWF.   
2.2.2.2. DNA amplification of VWF 
Every exon of VWF was amplified individually. The procedure was performed according to the 
standard method. The PCR mixtures used are shown in Appendix Table 2. Twenty seven µl of 
PCR master mix (ReddyMix) resulting in a final concentration of 1.5 mM MgCl2 was mixed 
with 0.6 µl (10pmol/µl) of forward and reverse primers, 1.2 µl of dH2O and 0.6 µl of genomic 
DNA (100ng/µl) results in a final reaction volume of 30 µl. The 100 pmol/µl stock primers were 
diluted with deionized water to prepare a concentration of 10 pmol/µl. The PCR ReddyMix 
master mix contained:1.25 units of thermoprime plus DNA polymerase, 75 mM Tris-HCl (pH 
8.8 at 25°C), 20 mM (NH4)2 SO4, 1.5 mM MgCl2, 0.2 mM each of dATP, dCTP, dGTP and 
dTTP and and red dye for electrophoresis. PCR contained 1.5 mM MgCl2 unless specified. 
All reactions were undertaken in 0.2 ml Eppendorf tubes and PCR reactions were performed 
using a GeneAMP 9700 thermocycler (Applied Biosystems, Singapore). The thermal cycling 
steps to amplify VWF were programmed as shown in Appendix Table 3. The conventional PCR 
temperature cycling conditions used were; initial denaturation step at 94°C for 7 min, followed 
by amplification over 35 cycles starting with denaturation at 94°C for 1 min, primer annealing 
for 1 min at n°C based on primer Tm, extension at 72°C for 1 min and a final extension step for 
7 min at 72°C (Appendix Table 3). The primer sequence, annealing temperatures, MgCl2 
concentration and cycles for previously designed primers are listed in Appendix Table 4. 
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2.2.2.3. Long-range PCR 
In order to amplify exon 28, intron 1 and exon 1 which are each 1.4kb in size, long range PCR 
(LR-PCR) amplification was used. LR-PCR is similar to the standard method except that the 
Phusion Taq polymerase has a high 5'-3' polymerase activity in addition to 3'-5' proofreading 
ability was used. Exon 28 and its intronic flanking regions were amplified in a 50µl reaction 
containing 10µl HF buffer, 1µl mM dNTP, 2.5 µl (10 pmol/µl) of each primer, 0.5µl of phusion 
Taq polymerase and 31.5µl dH2O. Two µl of template DNA (100ng/µl) was added to the 
reaction. The LR-PCR temperature cycling conditions used were; initial denaturation step at 
98°C for 30 sec, followed by amplification for 32 cycles starting with denaturation at 98°C for 
10 sec, primer annealing at 67°C for 30 sec based on primer Tm, extension at 72°C for 2 min 
and a final extension step for 10 min at 72°C. The LR-PCR reaction was performed using a 
GeneAMP 9700 thermocycler. Primers used to sequence the long range PCR exon 28 region are 
listed in Appendix Table 5. The estimated Tm was calculated using the Finnzymes online tool 
at: (http://www.finnzymes.fi/tm_determination.html, last accessed June 2011). The exon-intron 
1 single amplicons was amplified using OneTaq Hot Start Master Mix in a 100 µl reaction 
containing 50µl OneTaq Hot Start 2X master mix with standard buffer, 2µl (10 pm/µl) of each 
primer, 42µl of dH2O and 4 µl of 100ng/µl of DNA samples. The primer sequence, annealing 
temperatures, MgCl2 concentration and cycles for exon-intron 1 are listed in Appendix Table 6. 
The thermocycling conditions used were similar to the routine PCR where initial denaturation 
was at 94°C for 30 sec, followed by amplification over 30 cycles starting with denaturation at 
94°C for 30 sec, primer annealing at 58°C for the exon- intron 1 region for 55 sec or based on 
primer Tm, extension at 68°C for 1 min per kb and a final extension step for 5 min at 68°C. 
2.2.2.4. Agarose gel electrophoresis 
DNA amplification using specific primers was followed by agarose gel electrophoresis. To 
ensure that successful DNA amplification had been achieved and to determine the size of PCR 
products, agarose gel electrophoresis was employed. Electrophoresis on agarose gel is a 
standard method used to separate, identify and purify DNA fragments. DNA products are 
separated in the gel according to their size: smaller DNA fragments migrate faster through the 
gel and larger DNA fragments migrate slower. The location of nucleic acids within the gel was 
determined directly by staining with a low concentration of the intercalating dye Ethidium 
Bromide (EB) (3,8-diamino-5ethyl-6 phenylphennanthridinium bromide). To detect VWF 
integrity, DNA was electrophoresed on 0.7% to 2% agarose gel stained with EB based on the 
expected size of the DNA fragments that were compared with a size marker. The agarose gel 
was prepared by dissolving appropriate amounts of agarose powder in appropriate volumes of 
1x Tris-Borate EDTA (TBE) buffer (8.9 mM Boric acid, 8.9mM Tris base, 0.2 mM EDTA pH 
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8.3). The suspension was heated in the microwave until the agarose completely dissolved and 
left until the solution had cooled to approximately 60°C.  This was followed by adding EB to a 
final concentration of 10mg/ml into the agarose. The gel was left to solidify for almost one 
hour. Prior to electrophoresis, the gel was placed into the electrophoresis apparatus and overlaid 
with 1x TBE buffer. Five µl of each sample alongside DNA hyperladder (Bioline) with known 
size bands was mixed with 2µl loading dye containing bromophenol blue unless a PCR master 
mix already containing loading dye was used. It was loaded carefully in the gel wells. The 
power supply at a constant 100 volts was connected for 35-55 min so that the DNA migrated 
towards the anode. After completion of the electrophoresis, the gel was placed on the UV 
transilluminator (Bio-Rad laboratories Ltd, Hertfordshire, UK) at 302 nm and photographed to 
detect the quality and the size of DNA using a gel documentation system (ChemiDoc EQ 
camera Bio-Rad). 
Various DNA standard size markers with different sizes were used in this study based on the 
DNA fragments that were electrophoresed. DNA size was evaluated by comparing with a 
standard size hyperladder. Hyperladders supplied by Bioline that contained fragments between 
25 bp and 10 kbp were used. Hyperladder IV was the marker used generally in this study and 
included 9 regularly spaced fragments, ranging between 100 bp and 1000 bp (Appendix 7). 
Each band was an exact multiple of 100bp. 
2.2.3. PCR product purification 
There are various techniques used for DNA purification based on the requirement of the 
procedure. In this study, ExoSAP-IT (USB products, Ohio, USA) was used to purify PCR 
products prior to DNA sequencing. ExoSAP-IT is a quick method used for fast and efficient 
clean-up of PCR products prior to DNA sequencing. This method was used to remove unwanted 
primers and dNTP from PCR products. ExoSAP-IT reagent contains two different hydrolytic 
enzymes, exonuclease I which removes residual single-stranded primers and any extraneous 
single-strand DNA produced in the PCR and shrimp alkaline phosphatase which removes the 
remaining dNTP from the PCR mixture. PCR product purification was undertaken using a 1:10 
dilution of ExoSAP-IT reagent. Thus, 6µl of PCR product, 4µl of dH2O and 4µl of 1:10 
ExoSAP-IT were mixed together in a PCR tube and followed by centrifugation at 700 g using 
an ALC microcentrifuge PK120 (Thermo Electron Corporation, France). This mixture was put 
in a thermocycler and incubated for 30 min at 37°C followed by enzyme inactivation at 80°C 
for a further 15 min.  
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2.2.4. DNA sequencing analysis 
After completion of purification, samples were sent for automated DNA sequencing to the Core 
Genomic Facility at the School of Medicine, University of Sheffield. Direct DNA sequencing 
was used as a method for identification of sequence variants in VWF amplified fragments. Each 
successfully amplified fragment was directly sequenced in both directions using the BigDye 
terminator v3.1 (Applied Biosystems, Foster City, USA) on an ABI PRISM 3730 DNA analyser 
(Applied Biosystems, Japan). The output sequence was analysed using the Staden sequence 
analysis package (Staden, 1979, Staden, 1984) and FinchTV v1.4 software (Geospiza inc., 
Seattle, USA). 
2.2.4.1. Principle of DNA sequencing 
The process of determining the order of the nucleotide bases along a DNA strand is called DNA 
sequencing. This technique was developed in 1977 by Fredrick Sanger and is known as Sanger 
sequencing or the chain termination method (Sanger et al., 1977). This technique is similar to 
PCR and utilizes fluorescent 2’-3’-dideoxynucleotide triphosphate (ddNTP), molecules that 
differ from dNTP in having a hydrogen atom at carbon-3 rather than an OH group. These 
molecules terminate the DNA chain elongation because they cannot form a phosphodiester bond 
with the next deoxynucleotide during DNA elongation. In this technique, the amplified product 
from the PCR (DNA template) is added to a reaction tube containing Taq DNA polymerase, a 
primer that can hybridise at the desired location on a single strand of the DNA (as opposed to 
both strands in PCR), and all four nucleotide bases (A, T, C, G). In addition, small amounts of 
four fluorescently- labeled ddNTP (almost 1% of the dNTP concentration) A, T, C, G are added 
to the mixture. After the first deoxynucleotide is added to the growing complementary 
sequence, DNA polymerase moves along the template and continues to add bases. The strand 
synthesis reaction continues until a dideoxynucleotide is added, blocking further elongation 
(termination). After 45 cycles of the reaction, the resulting mixture will contain a series of 
fragments of different lengths depending on how many bases have been added to the chain 
before one ddNTP was attached and blocked further elongation. These fragments with various 
sizes are separated by capillary electrophoresis. A smaller fragment migrates faster, so the DNA 
molecules are separated according to their size. The fluorescent signal released from the labeled 
end of ddNTP during electrophoresis is detected and recorded by a charge coupled device 
(CCD). Each ddNTP has its own colour, so the order of the bases in the sequenced fragment can 
be detected. The 5' terminal base (ddNTP) of the shortest fragment that moves the fastest is the 
first base detected and larger products follow, thus the sequence can be read base by base. 
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2.2.4.2. Sequence analysis 
2.2.4.2.1. Staden sequence analysis 
In order to detect sequence variation and putative mutations or polymorphisms, the sequencing 
traces for VWF were checked and analysed using the Staden software package (Staden, 1979, 
Staden, 1984). Staden subtracts two traces from each other to show where these traces are 
similar or differ, indicated by peaks or troughs on the 'trace dif ' display. This program was used 
to analyse the released sequence data and align it with the wild-type VWF.  
The reference sequence used in this study was ENSG00000110799 VWF. Sequences of IC and 
HC were imported into a blank Staden database (VWF sequence) as DNA reference sequence 
derived and saved from Ensembl website (http://www.ensembl.org/index.html). A blank 
database was created by importing the VWF reference sequence. The Ensembl sequence used 
was marked up with reported SNP and exons and introns were highlighted. A blank database 
was created first, and then IC and HC sequences were imported for each analysis. Two software 
files were selected from the Staden package. Pregap4 software was utilised to add the ab1 files 
of IC and HC to the blank database, while GAP4 was utilized in order to edit the sequence of 
VWF. Ab1 files of IC, HC (forward and reverse) and the copy of blank database files were 
added and run using pregap4 to allow all traces to be aligned to the reference sequence in the 
blank database. Forward and reverse control traces were selected as the reference sequence to be 
compared with traces of IC. This step was created each time when processing a single exon. To 
analyse the generated sequence, GAP4 software was used. It compares the traces of the gene 
sequence against traces of the control sequence and the reference traces. Next, GAP4 subtracts 
one trace from another to generate new traces that show the differences in the form of 
highlighted peaks or troughs. Every VWF exon sequence was analysed and evaluated 
individually.  
2.2.5. Prediction of the effect of amino acid substitutions on protein function 
To evaluate the possible pathogenicity underlying identified sequence variations, in silico 
prediction tools were used. Three different online tools were used to overcome weakness or 
defect in any of the tools (Houdayer et al., 2008). The amino acid substitution online tools used 
are listed below: 
Sorting Intolerant From Tolerant (SIFT) predicts whether an amino acid substitution affects 
protein function based on sequence homology and the physical properties of amino acids: 
http://sift.jcvi.org/. 
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Polymorphism Phenotyping (PolyPhen) tool predicts the possible effects of an amino acid 
replacement on the structure and function of a human protein using straightforward physical and 
comparative considerations: http://genetics.bwh.harvard.edu/pph/. 
Align Grantham Variation Grantham Deviation (GVGD) predicts where missense substitutions 
in proteins of interest fall in a spectrum from enriched deleterious to enriched neutral: 
http://agvgd.iarc.fr/. Tools were accessed December 2010. 
2.2.6. In silico splice-site prediction 
mRNA splicing is defined as a process that allows removal of introns and joins exons together 
post- transcription in order to form mature mRNA. It has been suggested that the presence of 
genetic alterations located either within intronic sequence surrounding the splice site junction or 
exonic regions including missense, nonsense and silent mutations can potentially affect the 
splicing mechanisms (Cartegni et al., 2002, Zatkova et al., 2004). In an attempt to predict the 
potential effects of VWF alteration on splicing mechanisms, several different online in silico 
splice site prediction tools were used to overcome weaknesses and shortcomings in any of them. 
Also these tools were used to evaluate the pathogenicity of potential splice site modifications. 
These online tools included MaxEntScan: scorsplice (MES) 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html, Splice site prediction by 
neural network (http://fruitfly.org:9005/seq_tools/splice.html), NetGene2 splice prediction 
(http://www.cbs.dtu.dk/services/NetGene2/) and Human Splice Finder (HSF) 
(http://www.umd.be/HSF/). All these tools were accessed between December 2010 and May 
2013. 
2.2.7. In silico prediction of exonic splice enhancers and silencers 
In order to predict the effect of exonic mutation on exonic splice enhancer (ESE), exonic splice 
silencer (ESS) and the possibility of creating a new splice sites, three bioinformatics online in 
silico prediction tools were used.  
They include several online tools such as exonic splice enhancer (ESE) 
(http://www.umd.be/HSF/), Human Splice Finder (HSF) (http://www.umd.be/HSF/), and 
RESCUE-ESE (http://www.umd.be/HSF/). All tools were accessed between December 2010 
and May 2013. 
2.2.8. Multiple sequence alignment (Evolutionary Conservation) 
To evaluate the amino acid sequence evolutionary conservation, the affected amino acid 
sequence of the VWF was aligned against orthologues. The purpose of this analysis was to 
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predict the possible impact of altered sequence on the VWF protein structure. It was undertaken 
through aligning different species and compares their protein sequence homology. Therefore, 
various species were selected to align and compare. The protein sequences for all species were 
created using FASTA format (blastp: http://blast.ncbi.nlm.nih.gov, last accessed January 2012). 
Multalin online tools for multiple sequence alignment were used to compare selected sequence 
homology (http://multalin.toulouse.inra.fr/multalin/, last accessed January 2012). 
2.2.9. Model structure of the protein 
To generate a model structure and show the model, 1SQ0 (VWF A1 domain) Protein Data Bank 
(PDB) file for crystal structure and PYMOL were used respectively. PYMOL is a programme 
used to visualize nucleic acids and proteins in graphic forms. 
2.2.10. Graphical codon usage analysis 
The graphical codon usage analyser (GCUA) tool which compares the frequency of use of two 
different triplet codons encoding the same amino acid was used (Nakamura et al., 2000). Codon 
usage data was collected from group of genes in thousand individuals. 
2.2.11. Nomenclature and numbering of VWF sequence 
Sequence variants were identified and numbered according to the recommendations and 
guidelines issued by both the International Society on Thrombosis and Haemostasis Scientific 
and Standardisation SubCommittee (ISTH-SSC) on VWF (Goodeve et al., 2011)  as well as the 
Human Genome Variation Society (HGVS) (den Dunnen and Antonarakis, 2001). The name of 
VWF was utilised according to the guidelines of Human Genome Organization (HUGO) gene 
nomenclature committee (HGNC) which uses italicised Latin symbols for genes to distinguish 
them from proteins. 
The first nucleotide (adenine) of the initiator methionine translation codon (ATG) at the 
beginning of exon 2 of VWF sequence was used as the protein start site and given the number 
+1. The numbering of exonic nucleotides started from this point while the previous nucleotide 
was numbered as -1. The numbering of the intronic regions started from the closest exonic 
nucleotide and was given a number prefixed with either a sign + or – depending on the sequence 
direction either 5' or 3'. The one letter code was used to denote amino acids. The sequence of 
VWF amino acids were numbered from the first translation initiation codon (methionine) as 
amino acid number 1 (Goodeve et al., 2001, Goodeve et al., 2011). The nucleotide alterations 
were prefixed with a letter (c.), while the protein substitutions were prefixed with a letter (p.). 
Moreover, in the presence of insertions or deletions, the number of involved nucleotides 
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followed the symbol ins or del respectively. The presence of * sign represents mutation that 
create stop codon (e.g p.A123*). The symbol fs* followed by number indicates a frameshift 
mutation causes creation of a stop codon after number of codons downstream of the mutation 
(e.g p.A123Cfs*20). 
2.2.12. Generation of VWF mutant plasmids 
Site-directed mutagenesis (SDM) was performed in order to create a specific nucleotide 
alteration in the recombinant vector that contained the wild-type human VWF cDNA. SDM is a 
quick, simple, efficient and accurate mutagenesis technique used to mutate vectors either small 
or large. SDM is based on PCR thermal cycling using a set of mutagenic primers, both of which 
contain the desired nucleotide change. Each primer was complementary to opposite strands of 
the plasmid to create the change in the wild-type plasmid. It also used a PfuUltra high fidelity 
DNA polymerase (Agilent Technologies, UK Ltd) which permits extension of the primer 
without strand displacement (Figure 2.1).  
2.2.12.1. VWF expression plasmid 
The pcDNA3.1/Hygro (-) expression plasmid (Life Technologies Ltd, Paisley, UK) (5.6 kb) 
containing full-length wild type human VWF cDNA (8.6 kb) was kindly provided by Prof. 
Reinhard Schneppenheim, Germany (Figure 2.2). The full length VWF cDNA originated from 
the VWF-PMT2 plasmid which was transferred to a pcDNA3.1/Hygro (-) expression plasmid. 
The VWF cDNA was introduced into the plasmid using two restriction enzymes, EcoRI and 
NotI. It produces almost 14 kb pcDNA3.1VWF plasmid (Schneppenheim et al., 2001a). This 
plasmid was used for expression of VWF in the HEK293T cell line. 
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Figure 2.1 Site directed mutagenesis (SDM) method. A) The DNA plasmid contains the WT 
cDNA that is denatured using thermal cycling. B) A set of mutagenic primers containing the 
desired nucleotide change anneal to the plasmid and are extended using high fidelity PfuUltr -
based DNA polymerase to introduce the desired change. C) As some intact parental DNA 
plasmid has not been mutagenized, Dpn I digests parental methylated and hemimethylated DNA 
but not the mutagenized sequence. D) Subsequently the mutated plasmids are transformed into 
ultracompetent E.coli cells for nick repair (adapted from QuikChange® Lighting Site-directed 
Mutagenesis kit, instruction manual). 
2.2.12.1.2. Structure of pcDNA3.1/Hygro (-) 
The VWF cDNA (8.6kb) was previously cloned into pcDNA3.1/Hygro (-) plasmid that is 5.6 kb 
in size. The pcDNA3.1 plasmid is designed to enable a high level of protein expression when 
transfected into mammalian cell line, either transiently or stably. Specifically, the plasmid 
backbone has a number of features enable high level protein expression in mammalian cell line 
(Figure 2.2), the presence of the human cytomegalovirus (P cMV) promoter driving high level 
expression of the VWF cDNA gene sequence inserted into multiple cloning site. The presence 
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of T7 promoter/priming site allows insertion of the gene of interest and facilitates cloning. The 
hygromycin resistance gene is used as a selection antibiotic to create stably transfected cell line, 
driven by the SV40 promoter/origin (SV40 ori) of replication. The SV40 promoter/ origin of 
replication is also used to drive expression of transfected plasmid in cells which contain the 
SV40 large T antigen. The bovine growth hormone polyadenylation (BGH pA) and SV40 early 
polyadenylation (SV40 pA) sites allow for correct transcription, translation and polyadenylation 
processing of plasmid mRNA insert sequence. The polyadenylation site used is determined by 
whether the mammalian cell lines used for transfection contain the SV40 large T antigen. Also, 
the phage origin (f1ori) enables production of a single-stranded copy of DNA. Finally, the 
presence of ampicillin resistance gene (β-lactamase) allows for the positive selection of E.coli 
bacteria (Amp R) containing plasmid after transformation of mutagenised VWF cDNA in order 
to determine the presence or absence of a mutation after small scale mini-preparation and 
extraction of plasmid DNA. During bacterial transformation the pUC origin (pUC ori) allows 
for replication of the plasmid in E.coli. 
 
  
Figure 2.2 Map of pcDNA 3.1/Hygro used as expression vector 
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2.2.12.2. Transformation into NM554 E.coli competent cells 
Competent cells are defined as bacterial cells that have the ability to uptake extracellular naked 
plasmid DNA from the surrounding media. The aim was to transfer plasmid containing full-
length wild-type human VWF cDNA into E.coli NM554 competent cells. The purpose was to 
produce a large quantity of plasmid DNA containing full sequence of wild-type VWF cDNA in 
order to firstly ensure that the appropriate wild-type sequence was present within the plasmid 
and also to use the wild-type plasmid as a template during mutagenesis and to prepare it for 
transfection. Transformation of plasmid DNA into competent cells was carried out based on 
heat shock treatment. The NM554 competent cells kept frozen at -80 °C were thawed on ice for 
a few minutes prior to adding 100 µl of cells to a pre-chilled 14 ml polypropylene round-bottom 
reaction tube (Becton Dickinson Labware, Franklin Lakes, NJ. USA). Five µl of the 
recombinant plasmid was added and mixed gently with 100 µl NM554 competent cells. At the 
same time, 100 µl of competent cells only were added to another reaction tube to be used as a 
negative control. This was followed by incubating the reaction tubes on ice for 10 min. Then, 
they were heat shocked at 42°C in a water bath for 90 sec in order to enable membrane pores to 
be opened. The reaction tubes were kept immediately on ice for 2 min before addition of 100 µl 
of LB-broth alone without ampicillin (Merck KGaA, Darmstadt, Germany) to each tube and 
immediately incubated at 37 °C for 20 min with shaking at 200 rpm. 2.5% of LB broth (0.5% 
yeast extract, 1% tryptone and 1% NaCl) was prepared by dissolving 10 g of LB with 400 ml 
deionized water and autoclaved for one hour. Samples were plated onto LB-agar plates 
containing 50 mg/ml ampicillin and one plate was included without E.coli plating as a negative 
control. Ampicillin was prepared by dissolving 0.84 g of sodium bicarbonate and 0.5 g of 
ampicillin trihydrate (Sigma)   into 10 ml of deionized water to prepare a solution of 1 M. The 
mixture was filtered through non-pyrogeneic syringe filter (Pall Corporation, Life Science, MI. 
USA), aliquoted in 1 ml tube and then stored at -20°C. 3.5% LB-agar was prepared by 
dissolving 11.1g LB-agar (Merck KGaA, Darmstadt, Germany) (0.5%  yeast extract, 1%  
tryptone, 2% of agar and 1% NaCl) in 300 ml deionized water and autoclaving at 121°C for one 
hr. Following plating, plates were incubated inverted overnight at 37°C. After overnight 
incubation, plates were checked for the presence of colonies which were inoculated into LB-
broth for plasmid DNA purification (Section 2.2.12.5). 
2.2.12.3. Mutagenic primer design 
The mutagenic oligonucleotide primers used in this study were designed individually based on 
the desired mutation. Eight pairs of primers were designed to introduce the respective mutation 
into the plasmid containing wild type VWF cDNA (Appendix Table 8). According to the 
manufacturer's recommendations, both of the forward and reverse mutagenic primers must 
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contain the desired nucleotide change, primers should be in length between 25-45 bases with ≥ 
78°C melting temperature, they should have a GC content as minimum 40% and terminate with 
G or C bases. Primers were designed online using QuikChange primer design program at: 
www.aglient.com/genomics/qcpd (Accessed May, 2011). All designed primers were supplied 
lyophilized and were re-constituted with deionized water according to supplier's instructions to 
prepare a concentration of 100 pmol/µl. The optimised concentration of each oligonucleotide 
designed primer to be used during mutagenesis was 125 ng according to the mutagenesis 
protocol. The following equation was used in order to convert nanograms to picomoles:  X 
pmoles of oligo = ng of oligo x 1000/ 330 x No of bases in the oligonucleotide primer.  
The purpose of this technique was to introduce the respective mutation into the VWF construct 
to be expressed in the human embryonic kidney (HEK) 293T cells (LGC Standards, Middlesex, 
UK) and eventually to evaluate the level and structure of released VWF protein. Plasmids 
containing the desired mutations were created using QuikChange® Lightning site-directed 
mutagenesis kit (Agilent Technologies; Stratagene, USA). Mutagenesis was performed on the 
wild-type plasmid pcDNA 3.1 containing the full-length cDNA sequence for human VWF. 
Eight mutagenic primers used to introduce mismatches to wild-type are listed in Appendix 8.  
Site-directed mutagenesis based on PCR was carried out in 50 µl reactions containing 5µl of 
reaction buffer, 1 µl of (125) ng of each forward and reverse oligonucleotide primer, 1 µl of 
dNTP mix and 1.5 µl of Quik solution reagent. A series of quantities of dsDNA template 10, 25, 
50 and 100 ng were added to separate reactions in order to optimise the colony number 
following transformation. This was followed by adding 1 µl of QuikChange Lightning enzyme. 
ddH2O was added to the reaction to reach a final volume of 50 µl.  
A control mutagenesis reaction using pWhitescript mutagenesis plasmid was run alongside the 
sample reaction to evaluate the mutagenesis efficiency as indicated in table 2.1. The thermal 
PCR temperature cycling conditions used for both sample and control reactions were; initial 
denaturation step at 95°C for 2 min, followed by amplification over 18 cycles starting with 
denaturation at 95°C for 20 sec, primer annealing at 60°C for 10 sec, extension at 68°C for 7 
min (30 sec/kb) and a final extension step for 5 min at 68°C. The mutagenesis PCR reaction was 
performed using a GeneAMP 9700 thermocycler. The PCR reaction was followed by adding 2 
µl of Dpn I restriction enzyme directly to each reaction mixture and gently mixing using a 
pipette. Dpn I digests parental methylated and hemimethylated template DNA. The reaction 
mixture was immediately incubated at 37 °C in a water bath for 5 min to allow digestion of 
parental DNA. The treated PCR product were stored at -20 °C or used immediately for bacterial 
transformation. 
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Table 2.1 Preparation of the pWhitescript mutagenesis control reaction 
Component Volume 
10x reaction buffer 5 µl 
25 ng of pWhitescript 4.5 kb control plasmid (5 ng/µl) 5 µl 
125 ng of oligonucleotide control primer 1 (100 ng/µl) 1.25 µl 
125 ng of oligonucleotide control primer 2 (100 ng/µl) 1.25 µl 
dNTP mix 1 µl 
QuikSolution reagent 1.5 µl 
QuikChange lightning enzyme 1 µl 
ddH2O to bring the final reaction volume to 50 µl 34 µl 
 
2.2.12.4. Transformation of XL10-Gold ultracompetent cells 
The purpose of this reaction was to transform mutated plasmid (either sample and/or control 
reactions) following mutagenesis into highly efficient competent cells for nick repair. It was 
performed following mutagenesis and Dpn I digestion. The frozen XL10-Gold ultracompetent 
cells were gently thawed for 5 min on ice before addition of 45 µl of cells to a prechilled 14-ml 
BD Falcon polypropylene round-bottom tube. 2 µl of ẞ-mecraptoethanol (ẞ-ME) was mixed 
gently with the ultracompetent cells and incubated on ice for 2 min. ẞ-ME has been shown to 
increase transformation efficiency. This was followed by adding 2 µl of Dpn I-treated plasmid 
DNA from sample plasmid and pWhitescript control plasmid into the mixture. Also 1 µl of 0.01 
ng/µl pUC18 control plasmid was added to another 45 µl XL10-Gold competent cells to 
determine the transformation efficiency of the competent cells. They were mixed gently and 
incubated on ice for 30 min before heat shocking in a water bath at 42 °C for 30 sec. Samples 
were kept on ice for 2 min immediately after heat shock and 500 µl of preheated NZY broth (10 
g of NZ amine (casein hydrolysate), 5 g of NaCl and 5 g of yeast extract) at 42 °C in water bath 
was added into each reaction tube followed by incubating the tubes for one hr at 37 °C with 
shaking at 200 rpm. NZY broth (Fisher Scientific, USA) was prepared by dissolving 8.8 g of 
NZY powder in 400 ml deionised water and autoclaved at 121 °C for one hr. After the 
incubation period, 250 µl of each transformed sample was plated onto LB-agar plates containing 
50 mg/ml ampicillin for mutagenesis samples. Plates were prepared by adding a 15 ml of LB-
ampicillin agar to each plate. Also 10 µl of the pWhitescript mutagenesis control and 2.5 µl of 
pUC18 transformation control were plated onto LB-ampicillin agar plates containing 80µl/ml of 
5-bromo-4-chloro-3-indolyl-ẞ-D-galactopyranoside (X-gal) and 20 mM isopropyl-1-thio-ẞ-D-
galactopyranoside (IPTG).  
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Mutagenesis (pWhitescript) and transformation (pUC18) control plasmids were used to evaluate 
the mutagenesis and transformation efficiency respectively and also to ensure the synthesis of 
sufficient mutant DNA in the reaction. Plates for mutagenesis and pUC18 controls for blue-
white colour screening were prepared by dissolving 4 µg of X-gal in 200 µl of IPTG. This 
mixture was added to 50 ml of LB-agar and 100 µl of 50 mg/ml of ampicillin (15 ml/plate). The 
IPTG was prepared by dissolving 0.476 g of IPTG in 100 ml deionised water. Following 
plating, transformation plates were incubated inverted at 37 °C for > 16 hr. After overnight 
incubation, plates were checked for the presence of colonies and selected colonies were isolated 
for plasmid DNA purification.  
The efficiency of mutagenesis of the pWhitescript control plasmid and of transformation of the 
pUC18 control plasmid were evaluated by calculating the percentage of blue colonies from the 
transformation of pWhitescript and pUC18 control plasmids on agar plates containing IPTG and 
X-gal using this formula: 
Number of blue colony forming units (cfu) / total number of colony forming units (cfu) X100 
2.2.12.5. Purification of plasmid DNA using mini-prep 
This test was performed to produce a small quantity of plasmid DNA in order to sequence the 
fragment of VWF cDNA that had the respective mutation to ensure the achievement of 
mutagenesis. It was carried out using the QIAprep Spin mini-prep kit protocol (QIAGEN Ltd, 
Crawley, UK). Four colonies from the transformed plates were picked and each was inoculated 
into 10 ml of LB-broth containing 50 mg/ml of ampicillin. It was followed by overnight 
incubation at 37 °C with shaking at 200 rpm. After overnight incubation, 1.5 ml of culture was 
transferred into an Eppendorf tube and centrifuged at 13,000 g for 3 min using an accuSpin
TM 
Micro centrifuge (Fisher Scientific, Osterode, Germany). The supernatant was aspirated and this 
step was repeated twice more. The cell pellet was resuspended in 250 µl of suspension buffer P1 
that contained RNase A and LyseBlue reagent. Following the addition of 250 µl of P2 buffer; 
the tubes were gently inverted and mixed several times until the solution turned blue. It was left 
for 5 min before adding 350 µl of neutralisation buffer N3 and tubes were also gently mixed by 
inversion several times until the solution became cloudy. Following centrifugation at 13,000 g 
for 10 min, the supernatant was applied to the QIAprep spin column. The column was 
centrifuged for one min at 13,000 g and the flow-through was discarded before washing the 
column with 0.5 ml PB buffer. Again, the column was centrifuged at 13,000 g for one min and 
the flow-through was discarded before adding 0.75 ml of the PE buffer that had 80 % ethanol to 
the column and centrifuged at 13,000 g for one min twice to remove the residual wash buffer. 
After discarding the flow-through, the QIAprep column was transferred into a clean 1.5 ml 
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Eppendorf tube for DNA elution by adding 50 µl of EB buffer to the column. The samples were 
kept at room temperature for one min to increase DNA yield followed by centrifugation for one 
min at 13,000 g. The plasmid DNA was submitted for DNA sequencing analysis to check for 
the occurrence of the desired mutation within the plasmid.  
2.2.12.5.1 DNA sequence alignment 
The released sequencing data (FASTA sequence) for VWF cDNA expression plasmid was 
aligned to the VWF cDNA reference sequence (Gene ID: ENSG00000110799) using NCBI 
BLAST software: http://blast.ncbi.nlm.nih.gov/Blast.cgi, last accessed, May 2011). This 
analysis was aim to detect any nucleotide(s) variation present in the expressed plasmid 
compared to the reference sequence pre and post mutagenesis and also to confirm the presence 
of desired nucleotide change. Also, all identified variants found in the wild-type expressed 
plasmid were checked for their effect on VWF structure and function using VWF database at:  
(www.ragtimedesign.com/vwf/polymorphism, last accessed May 2011). 
2.2.12.6. Preparation of glycerol stock 
The remaining quantity of cell culture used during mini-prep was used to make a long-term 
glycerol stock of bacterial cells to be used for maxi-prep or further plasmid DNA purification. A 
glycerol stock was prepared by adding 1.7 ml of the culture media into a fresh 2 ml screw-cap 
tube. It was centrifuged at 13,000 g for 3 min. After removing the supernatant, another 1.7 ml of 
cell suspension was added to the tube twice followed by centrifugation at 13,000 g for 3 min. 
The supernatant was aspirated and the cell pellet was resuspended in 200 µl of cell suspension, 
before adding another 1.1 ml of cell suspension to the tube. Finally, 0.3 ml of 80% glycerol was 
gently added to the tube containing the cell suspension before storing the glycerol stock at -80 
°C. 
2.2.12.7. Measurement of plasmid DNA concentration using the NanoDrop 
spectrophotometer 
Nucleic acid and protein present in plasmid DNA preparations were quantified using a 
spectrophotometer and absorbance at 260 nm and 280 nm respectively. The plasmid DNA 
concentration was measured in the NanoDrop®- ND-1000 (Thermo Fisher Scientific, Inc., 
Wilmington), with readings taken at 260 nm and 280 nm. A sample volume of 1μl was used for 
the NanoDrop® after applying deionised water as a blank. The sample was pipetted onto the 
lower measurement pedestal. The sampling arm was closed and measurement was initiated 
using software on the PC. The average of three readings was taken as ng/µl. The ratio of A260/ 
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A280 should be between 1.6-1.8. A Ratio of 1.8 indicates the presence of pure DNA while a ratio 
below this range indicates the presence of impurities or protein contamination. The presence of 
organic solvents such as ethanol may lead to a lower ratio. Moreover the ratio of A260/ A230 
should be considered. A ratio of > 2 is indicative of pure DNA while a ratio below this value is 
indicative of protein or phenol contamination. 
2.2.12.8. Purification of large scale plasmid DNA using maxi-prep 
To produce a large quantity of plasmid DNA either wild type or mutant required during 
transfection experiments, large-scale plasmid DNA purification was carried out using the 
QIAgen maxi-prep purification kit (QIAGEN Ltd, Crawley, UK). A small quantity of cells from 
a glycerol stock was inoculated a large flask containing 250 ml of LB-broth and 50 mg/ml 
penicillin and was incubated in an orbital shaker at 37 °C overnight. After overnight incubation, 
the cell suspension was transferred in a Beckman 250 ml tube (Beckman, USA) and bacterial 
cells were harvested by centrifugation at 5000 g at 4 °C for 8 min using a Beckman J2-21M/E 
centrifuge with JA-14 rotor. The supernatant was carefully decanted and the cell pellets were 
resuspended in 10 ml of buffer P1 containing RNase A and LyseBlue reagents followed by 
pipetting up and down until no cell clumps remained. Ten ml of lysis solution P2 was added and 
the tube gently inverted several times until the solution colour turned blue and became viscous. 
After 5 min incubation, 10 ml of neutralising pre-chilled buffer P3 was added and the tube was 
inverted gently several times until the suspension became a white precipitate. It was followed by 
incubation on ice for 20 min, then centrifuged at 14,000 g for 30 min at 4 °C using the JA-14 
rotor. The supernatant containing the lysate was carefully transferred to a fresh Beckman tube 
and again centrifuged at 14,000 g for 15 min at 4 °C. During centrifugation, a QIAGEN-tip 500 
was equilibrated by applying 10 ml of QBT buffer and the column was allowed to empty by 
gravitonal flow. The supernatant containing the plasmid DNA was transferred to the 
equilibrated QIAGEN-tip and allowed to enter the resin layer by gravity flow. In order to 
remove all contaminants, the QIAGEN-tip was washed twice using 30 ml QC buffer. After 
washing, the QIAGEN column was placed into a Beckman 40 ml tube before elution. Plasmid 
DNA was eluted from the resin by addition of 15 ml QF elution buffer. The DNA was 
precipitated by adding 10.5 ml of room-temperature isopropanol to the eluted DNA followed by 
inversion and centrifugation at 12,000 g for 30 min at 4 °C using a JA-20 rotor. The supernatant 
was carefully discarded before the pellet was washed with 5 ml 70% ethanol. The solution was 
again centrifuged at 12,000 g (JA-20) for 10 min at 4 °C. Without disturbing the pellet, the 
supernatant was carefully discarded and the pellet was air-dried by allowing standing for 10 min 
at room temperature to remove excess ethanol. The DNA pellet was resuspended with 0.5-1 ml 
(based on pellet size) of sterile dH2O. The concentration of plasmid DNA was measured using 
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NanoDrop as previously described in section 2.2.12.7. The plasmid DNA was submitted to 
sequencing to check the entire cDNA sequence for either the wild-type or to ensure the presence 
of the desired mutation only and no other nucleotide changes were found within the mutant 
plasmid. The entire VWF cDNA was sequenced using the 18 primers listed in Appendix 9. 
These primers were designed and supplied lyophilised and were re-constituted with deionised 
water according to supplier's instructions to prepare a concentration of 100 pmol/µl. The 
plasmid DNA was stored either at -20 or 2-6 °C.  
2.2.13. In vitro expression of VWF mutants 
In vitro expression helped to determine the mechanism by which identified mutations lead to the 
disease phenotype in the affected families from the MCMDM-1VWD cohort study. This was 
achieved by using transient transfection of mutant VWF plasmid in parallel with wild-type VWF 
plasmid in order to mimic the homozygous and heterozygous states. The transient transfection 
was conducted in human embryonic kidney cell line (HEK) 293T cells. 
 2.2.13.1. Culture of HEK293T cells 
The cells were maintained in Dulbecco's modified Eagle's medium (DMEM + GlutaMAX) 
(Gibco Life Technology Ltd). 10% of heat inactivated foetal bovine serum (FBS) (Gibco Life 
Technology Ltd) was added to the medium to prepare full medium. GlutaMAX media was used 
to increase cell performance, minimize ammonia toxicity and also to increase the stability of 
media. Cells were split frequently for subcultures using 10% trypsin and phosphate buffered 
saline (PBS) (Life Technologies Ltd) and reached the desired confluence (70-90%) in almost 3 
days when grown in 80 cm³ flasks. Trypsin (10%) was prepared by adding 5 ml of trypsin-
EDTA (PAA Laboratory Ltd, Germany) into 45 ml of PBS. HEK293T cells were incubated at 
37°C with 5% CO2 and 95% air in a humidified condition. Cells were split in an aseptic hood 
when they reached the desired confluency or when the colour of the medium changed from red 
to orange. The HEK293T cells were selected to be used for transient transfection of wild-type 
and mutant VWF because they do not express endogenous VWF. 
2.2.13.2. Cell thawing 
The HEK293T cells were removed from liquid nitrogen and cells were thawed on ice before 
being transferred into a Falcon tube and centrifuged for 5 min at 2000 g (Centaur 2, England). 
The supernatant was carefully discarded before re-suspending the pellet with 5 ml of full 
medium, followed by an additional spin at 2000 g for 5 min. Again the supernatant was 
discarded and the pellet was resuspended in 6 ml of full medium and then the mixture was 
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transferred to a flask containing 9 ml of full media. Cells were incubated at 37°C/5% CO2 until 
they reached the required confluency. 
2.2.13.3. Passaging HEK293T cells 
All cell culture media including DMEM, PBS and trypsin were put into 37°C water bath for 
approximately 15 min prior to splitting the cells. Bottles were cleaned before being placed in the 
hood along with a pipette gun, pipettes and a waste jug. After checking the tissue culture flask 
for the presence of any infection, the old media was aspirated off the cells. This was followed 
by gently adding 10 ml of PBS to the flask and tilting to allow the media to wash over the cells 
without disturbing them. The PBS was aspirated before 2 ml of 10% trypsin-EDTA was added 
to the cells making sure that the cells were lightly covered by trypsin and incubated for 
approximately 5 min at 37
o
C until the cells started to float and could easily be dislodged from 
the flask with light tapping.  6 ml of full media was added and pipetted up and down to make 
sure to collect all the cells from the bottom of the flask. One ml of the trypsinised medium was 
added into a new T75 cm
2
 flask containing 14 ml of full media followed by incubation at 37 
°C/5% CO2. 
2.2.13.4. Cell counting 
HEK293T cells were counted and adjusted manually to 1.5x10
6 
in each plate using a 
haemocytometer (AC6000 Modified Fuchs Rosenthal Counting Chamber). Prior to counting, 
the cell suspension was trypsinised, centrifuged at 2000 g (Centaur 2, England) and followed by 
discarding the supernatant and adding of 6 ml of prewarmed full medium to the pellet. Prior to 
use, the haemocytometer and cover-slip were cleaned gently with ethanol. This was followed by 
adding 20 µl of cell suspension into the edge of the coverslip of one side to cover the counting 
area under the coverslip. Cells within the 4x4 (16 small squares) within one major square of the 
counting grid were counted using x10 objective on an inverted phase contrast microscope 
(Zeiss, Germany). The obtained number was multiplied by 10 which represent the number of 
cells per µl. Finally, the volume of cells required to be added to 8 ml of full media in one plate 
was determined by dividing 1.5x10
6   
/number of cells/µl. 
2.2.13.5. Transient transfection and in vitro expression using Lipofectamine LTX 
Lipofectamine™ LTX reagent (Invitrogen, UK) was used to transiently introduce full length 
wild-type and mutant plasmid DNA into HEK293T cell. Lipofectamine ™ LTX reagent is a 
highly efficient transfection reagent which is an animal-origin free formulation for the 
transfection of plasmid DNA into HEK293 cells with low cytotoxicity. Lipofectamine creates a 
complex with the plasmid DNA and forms a positively charged DNA-Lipofectamine complex 
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which binds with the cell surface membrane carrying a negative charge. The discrepancy in 
charges between the cell membrane and DNA-Lipofectamine complexes facilitates the entry of 
DNA into the cells by endocytosis.  
The transient transfection of wild-type and mutant VWF constructs was undertaken in 10 cm³ 
dishes using a plasmid concentration of 6µg in total. One day prior to transfection, a total of 
1.5x10
6  
cells were plated into 10 cm³ petri dishes containing 8 ml of complete media and cells. 
Cells were incubated for 24 hr at 37 °C/5% CO2 until they reached approximately 50-80% 
confluency on the day of transfection. 24 hr following incubation of seeded cells, a master mix 
containing 50 µl of Lipofectamine, 2 µl of renilla (500 ng/µl), 6 µl of plasmid DNA (prepared 
from working concentration of 1000 ng/µl) was prepared and diluted with 1.2 ml of DMEM 
reduced serum media (Table 2.2). The transfection efficiency was assessed by transfecting cells 
with a Renilla luciferase plasmid (Promega, UK, Ltd; Southampton, UK). The expression level 
of transfection data was normalised to correct for transfection efficiency of the cells using 
Renilla. Also, Renilla was used to evaluate whether the expressed VWF quantity was a true 
reflection exactly of what was happening in the cells. The Renilla plasmid expresses a 
fluorescent protein which can be measured using luminometry. The mixture was allowed to 
stand in the hood at room temperature for 30 min then added drop-wise with gentle swirling into 
each dish. This was followed by incubating cells for 48 hr at 37 °C/5% CO2 to allow expression 
of VWF. Moreover, to mimic the in vivo state of patients with these mutations, co-transfection 
of each mutation expressed in the study was carried out using three different co-transfection 
states (Figure 2.3). The first state was conducted to mimic the wild-type-homozygous state 
using only wild-type plasmid while in the second state, only mutant plasmid was transfected in 
order to mimic the mutant homozygous state. In the third state, a mixture of 50% wild-type and 
50% of mutant plasmid was transfected in order to mimic the heterozygous state of the mutation 
(Table 2.2). For each experiment, transfection was undertaken in triplicate and repeated three 
times using a total of 6µg of plasmid DNA. 
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Table 2.2 Summary of transfection method  
Reagent Wild-type 
VWF homozygous 
Mutant-VWF 
homozygous  
Mutant and wild-type-
VWF heterozygous  
Volume of plating 
medium 
8 ml 8 ml 8 ml 
Cells per dish 1.5x10
6   
 1.5x10
6   
 1.5x10
6   
 
Lipofectamine 
LTX reagent 
50 µl 50 µl 50 µl 
Plasmid DNA 
(1000 ng/µl) 
6  µl of WT plasmid 6 µl of mutant plasmid 3   µl of WT+ 3 µl of mutant 
plasmid 
Renilla (500 ng/µl) 2   µl 2   µl 2   µl 
Dilution media 
(Reduced serum) 
1.2 ml 1.2 ml 1.2 ml 
 
 
 
 
Figure 2.3: A schematic representation of the co-transfection protocol. A) Represents the 
transfection of wild type vector only to mimic the WT homozygous state. B) Represents the 
transfection of mutant vector alone to mimic the mutant homozygous state. C) In order to mimic 
the heterozygous state, a mixture of both wild type and mutant vectors was transfected. 
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2.2.13.5.1. Inhibition of proteosome activity of transfected HEK293T cells 
Inhibition of the proteosome activity of transfected cells was undertaken for mutants showed 
low levels of expressed VWF. The severe reduction of expressed VWF was thought to be due 
degradation of mutant protein by proteosome complex. However, the obtained results following 
proteosome inhibition were compared to those results from normal transfection. Transfection 
was undertaken in 6 well plates using at cell density of 250,000 cells/ well in 2 ml of DMEM, 
plasmid concentration of 2.5 µg/ml in total, Renilla concentration of 1.5 µg/ml and 10 µl of 
Lipofectamine LTX. The transfection was similar to the normal transfection except for adding 
the inhibition solution 45 hr prior to harvesting. Each transfected well contain 2180 µl in total 
and the working concentration of proteosome inhibitor to be added was 25 µM. 5.3 µl of the 
inhibitor solution of 10 mM stock solution was added to each well three hr prior to harvesting. 
The cells were collected 48 hr post transfection for wild-type, homozygous and heterozygous 
states as previously described. The secreted and lysate VWF was measured using ELISA. 
2.2.13.6. Collection of cell culture supernatant and cell lysate 
Forty-eight hr post transfection; one ml of the supernatant media was collected from each plate 
and transferred to an Eppendorf tube while the remaining medium was collected into a fresh 
Falcon tube and stored at -20 °C for multimer analysis. This was followed by washing the cells 
attached to the plate with 2 ml of PBS buffer; media was allowed to wash gently over the cells 
without disturbing them. After removal of the PBS buffer from the plate, adherent cells were 
directly lysed using one ml of 1:5 diluted passive lysis 5X buffer (Promega, USA). This buffer 
was formulated to promote rapid lysis of cultured cells without the need for scraping adherent 
cells. Upon addition of the lysis buffer plates were rotated on a shaker at room temperature for 
15 min at 100 rpm, and then one ml of lysates was transferred into an Eppendorf tube and kept 
at -20 °C for ELISA analysis. The cell lysates were centrifuged at 13,000 g for 10 min prior to 
ELISA assay to remove any cellular debris. 
2.2.14. Measurement of expressed VWF using ELISA 
Following transfection, the expressed VWF protein from the HEK293T transfected cells either 
in the supernatant or cell lysate was measured using a sandwich ELISA method. 
2.2.14.1. Principle of ELISA 
ELISA assay is used to measure the concentration of VWF. The coated polyclonal antibodies to 
VWF bound to solid phase are bound to VWF found in samples and reference plasma forming 
anti VWF-VWF complex and the remaining binding sites are blocked to block unbound sites to 
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avoid false positive results. The secondary detecting conjugated antibodies to VWF are added 
forming a sandwich complex with anti VWF-VWF (Figure 2.4). The peroxidase substrate O-
Phenylenediamine (OPD) is added to the reaction to determine the activity of peroxidase. 
Peroxidase which is conjugated with the secondary antibody catalyses the reaction with OPD 
(colourless) via producing a soluble yellow product diaminophenazine (DAP) that can be 
measured and read spectrophotometrically at an optical density (OD) of 490 nm. The colour 
intensity produced was proportional to the concentration of VWF present (Figure 2.4).  
2.2.14.2. ELISA Procedure 
The capture antibody (Enzyme Research, Swansea, UK) was diluted 1/100 with coating buffer 
(50 mM carbonate coating buffer, pH 9.6) and 100 µl was added to each well of a 96 plate and 
incubated at 4 °C overnight. Coating buffer was prepared by dissolving 1.59 g of sodium 
carbonate (Na2CO3) and 2.93 g of sodium bicarbonate (NaHCO3) in deionized water with the 
volume made up to one litre to produce a solution of 50 mM carbonate and pH was adjusted to 
9.6. 24 hr after incubation, the coating antibody was discarded followed by adding 150 µl of 
blocking buffer to each well and incubated for one hr at room temperature in a wet box. 
Blocking buffer was prepared by dissolving 2 g of bovine serum albumin (BSA) (Sigm-RIA 
grade) in 200 ml of PBS to give a final concentration of 1% at pH of 7.4. This was followed by 
washing wells three times with wash buffer (PBS-Tween 0.1% v/v). Next, 100 µl of 
supernatants,  lysates and VWF standard calibrator samples was added to the wells followed by 
incubation at room temperature for 90 min. In order to produce a standard curve, a 12 serial 
dilutions of standard calibrator (Siemens Healthcare GmbH, Marburg, Germany) starting from 
1/5 down to 1/10240 was prepared in duplicate (Figure 2.5). Calibrator was diluted in HBS-
BSA-T20 (100mM HEPES, 100mM NaCl, 1% w/v BSA, 0.1% v/v Tween-20, pH 7.2). After 
washing three times, 100 µl of 1/100 diluted detection antibody (Enzyme Research, Swansea, 
UK) diluted in HBS-BSA-T20 was applied to every well and incubated for 90 min at RT in 
humid box. The plate was washed three times followed by adding 100 µl of OPD substrate 
buffer (27 mM Citric acid, 97 mM Na2HPO4, pH 5.0) containing 6% hydrogen peroxide (H2O2) 
to each well to produce a coloured reaction. After the colour changed to yellow in a period 
between 5-10 minutes, the reaction was stopped by adding 100 µl of 2.5M sulphuric acid to all 
wells. The micro plate was read at wavelength of 490 nm using Varioskan Flash plate reader 
(Thermo Fisher Scientific, Loughborough, UK).  
Moreover, to measure the luciferase activity and to determine the Renilla plasmid expression, 
the plate reader was also used at 490 nm. It was done by mixing 10 µl lysate samples of WT, 
homozygous and heterozygous with 25 µl of (1:50) dual-luciferase reporter in ELISA plate 
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(Promega, WI, USA). The plate was read at a wavelength of 490 nm using Varioskan Flash 
plate reader. 
 
Figure 2.4 Diagram showing the principle of the ELISA technique. A) A 96 well micro-
plate was used in ELISA method. B) Purified capture antibody to VWF was bound to the well 
and the remaining binding sites on the wells were blocked using bovine serum albumin. C) The 
plate was washed, and then supernatants, cell lysates and reference plasma samples were 
applied to the micro well. D)  VWF antigen present in samples binds to coated antibodies. E) 
After washing, detecting-enzyme conjugate antibody is applied to enable forming a sandwich 
complex between the coating and detection antibodies. F) Colorless peroxidase substrate is 
added. After a fixed time, the colour of substrate is changed to yellow in proportion to the 
concentration of VWF antigen. G) The plate is read using plate reader at an optical density of 
490 nm. 
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Figure 2.5 Summary of double serial dilution to create a series of solutions starting from 
1:5 down to 1:10240 using VWF standard calibrator to produce a standard curve. Firstly, 
a 1:5 dilution was prepared by adding 60 µl of stock reference plasma into 240 µl HBS-BSA-
T20 sample diluent. Sample was mixed thoroughly then 150 µl of 1:5 dilution was transferred 
into the second tube to produce 1:10 dilution. This process was repeated until a dilution of 
1:10240 was reached. Blank contains sample diluent only. 
2.2.14.3. ELISA data analysis 
All results from the plate reader appeared as an optical density (OD). In order to calculate the 
level of expressed VWF:Ag from transfected HEK293T cells, a standard curve was produced 
using a standard control pooled plasma containing VWF with known concentration. The 
concentration of VWF in cell lysates and supernatants was calculated using the standard curve 
plotted between the known concentrations of each diluted reference plasma against its 
corresponding OD. The concentration of expressed VWF:Ag was measured and converted to 
international units per decilitre (IU/dL). Also, the expression level of transfection data was 
normalised to correct for transfection efficiency of the cells using Renilla expression. The VWF 
concentration was divided by Renilla expression to give a ratio, from which mutants were then 
compared to wild type expression. The mean values and standard deviation of wild-type, 
homozygous and heterozygous mutations including supernatants and lysates were calculated for 
all three experiments. Finally, the levels of VWF either homozygous or heterozygous were 
expressed as a percentage compared to the expressed level of wild-type. 
2.2.15. Statistical analysis 
Data including mean values, standard deviation and bar chart were analysed and prepared using 
Microsoft Excel 2010 (Microsoft Software, USA) and GraphPad Prism version 5 (GraphPad 
Software, San Diego, CA). Comparison of mean values was carried out using One-way 
ANOVA. Results were considered statistically significant at P < 0.05. 
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2.2.16. Multimer analysis 
Multimer analysis of wild-type-VWF and VWF mutants expressed in vitro was performed by 
Prof. Ulrich Budde (Hamburg, Germany). VWF multimer analysis was undertaken on cell 
supernatants and size separated on medium resolution 1.6% sodium dodecyl sulphate (SDS) 
agarose gel (Budde et al., 2008b). 
2.2.17. Immunofluorescence analysis 
Wild-type and mutant VWF constructs were transiently transfected into HEK293 cells in order 
to determine the intracellular storage of VWF within pseudo WPB. Transfected cells were 
seeded in 6 well plates
 
on glass coverslips at a cell density of 150,000 cells/ well in 2 ml of 
DMEM with10% FBS 24 hr prior to transfection. Transfection was undertaken using a plasmid 
concentration of 2.5 µg/ml in total. On the day of transfection, 2.5 µg of wild-type and mutant 
plasmids were diluted in 2 ml of DMEM reduced serum media in wild-type, homozygous and 
heterozygous states. 10 µl of Lipofectamine LTX was added to the mixture. Following 30 min 
incubation at room temperature, 2 ml of the mixture was added drop-wise into each well. The 
plate was incubated at 37 °C/5% CO2 for 48 hr to allow VWF expression. 
2.2.17.1. Immunofluorescence staining 
Forty eight hr post transfection, transfected cells were stained with immunofluorescent 
antibodies. Cell media was aspirated from each well followed by three wash steps with 1 ml 
PBS for 5 min each to ensure removal of all remaining media. After washing, 1 ml of BD 
cytofix solution buffer (Biosciences, San Diego, USA) was added and incubated for 20 min to 
fix cells into coverslip. After 3 washes with 1 ml of PBS, 1 ml of PBS/1%TritonX-100 was 
added to each well in order to permeabilise the cells followed by incubation for 10 min and 
washing 3 times with PBS. In order to block non-specific sites, one ml of 1% bovine serum 
albumen BSA-PBS solution was added followed by incubation for 20 min. After 3 washes with 
1 ml PBS, 1.5 ml of 1:500 primary antibodies was added to each well. Primary antibody 
solution was prepared by diluting 3 µl of anti-VWF rabbit primary antibody (DakoCytomation, 
Glostrup, Denmark) and 3µl of mouse anti-α-tubulin primary antibody (Sigma-Aldrich, UK) to 
1.5 ml of 1% BSA-PBS. Cells were incubated in a wet box at 4 °C overnight. After incubation, 
primary antibodies were aspirated followed by washing 3 times with 1 ml of PBS for 15 min 
each. This was followed by adding 1.5 ml of 1:500 secondary antibody solutions which was 
prepared by diluting 3 µl of anti-rabbit Alexa Fluor 488 VWF green secondary antibody and 3µl 
of anti-mouse Alexa Fluor 555 of α-tubulin red secondary antibody (Invitrogen, USA) to 1.5 ml 
of 1% BSA-PBS. After one hr incubation in the dark, the secondary antibody solution was 
aspirated followed by 3 washes for 15 min each with 1 ml PBS and two washes with 1 ml dH2O 
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for 5 min each. dH2O was aspirated and coverslips were left to air-dry for 10 min. Coverslips 
were removed from the well and placed over 25 µl of mounting media on a microscope slide. 
After 15 min incubation at RT in the dark, the edges of the coverslips were sealed with nail 
varnish to prevent drying out of the cell sample. The cells were analysed on Zeiss LSM 510 
Meta confocal laser microscope using Apochromat 40X/ 1.2 water UV-VIS-NIP objective. 
Also, to determine the localisation of VWF within WPB-like organelles, a similar protocol was 
undertaken using VWF and the ER marker protein disulfide-isomerase (PDI). In this 
experiment, mouse anti-PDI primary antibody (Abcam, UK) was used to stain cells instead of 
mouse anti-α-tubulin primary antibody in addition to anti-VWF rabbit primary antibody. Cells 
were analysed on Zeiss LSM 510 Meta confocal laser microscope using Apochromat 63X/ 1.4 
oil Ph3 UV-VIS-NIP objective using transmitted light with phase contrast. 
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3. Sequence re-analysis of VWF in the EU-MCMDM-1VWD study 
3.1. Introduction 
The EU study (MCMDM-1VWD) carried out mutational analysis on a group of IC who were 
historically diagnosed with type 1 VWD. This study successfully identified mutations in almost 
70% of IC using various techniques with variable sensitivity. However this cohort analysis 
failed to determine the genetic variants associated with VWD in the remaining 30% of cases 
(Goodeve et al., 2007). The failure of this study to identify the genetic cause in these IC may be 
due to several reasons. The mutational analysis of VWF was performed using various techniques 
including CSGE, SSCP, DHPLC and direct sequencing which had variable sensitivity ranging 
between 75% and 100% and may have caused mutations to be missed. Also, mutations may 
have also been missed due to human error. Moreover, it is known that VWF is a highly 
polymorphic gene, and the presence of SNP within primer annealing sites can lead to mono 
allelic amplification that could mask a heterozygous genetic variant and this could cause a 
mutation to be missed (Thomas et al., 2006a, Hampshire et al., 2010). This part of the study 
aimed to re-analyse and re-sequence all 52 exons of VWF in IC where point mutations were 
likely to have been missed either due to there being a SNP within primer binding sites or due to 
insensitivity of the mutation analysis previously undertaken. 
The EU study failed to detect mutations in 42 IC who had normal multimers. The median level 
of VWF:Ag in these IC was 49 IU/dL and the IC presented with an average BS of 8. Blood 
group O accounted for almost 76% of IC and complete co-segregation of VWF with VWD was 
observed in only 19% of this group. Hence the recruitment criteria was based on a historical 
diagnosis of VWD, possibly not phenotypic, VWF:Ag was used over RCo activity because of 
the SNP polymorphism that can have a severe effect on activity if present and hence interfere 
with the assay and skew any results. 
IC selected for the current study either had no mutation detected or had a VWF mutation 
detected that was not sufficient to explain the patient’s phenotype. Eighteen IC diagnosed with 
type 1 VWD who had no mutation identified or in whom a mutation was found but did not 
explain the disease phenotype, had a low level of VWF:Ag less than the lower end of the 
normal range or presented with bleeding, and showed co-segregation between VWD and VWF  
within the EU study were selected (Figure 3.1). Out of 18 IC included in this study, two families 
had been excluded from the original study due to a markedly low levels of VWF (P9F18) and 
insufficient DNA sample (P10F5) (Goodeve et al., 2007). The selection criteria involved IC 
with VWF:Ag levels less than 50 IU/dL or with BS > 3. Out of 18 IC, 5 (28%) already had a 
previously identified mutation(s) with a low level of VWF:Ag and the remaining cases showed  
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Figure 3.1 Flow chart shows the selection criteria for the VWD IC recruited in this study
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Table 3.1: Phenotypic data for 18 ICs 
Index Case Bleeding  
score 
VWF:Ag 
IU/dL 
VWF:RCo 
IU/dL 
 
FVIII:C 
IU/dL 
VWF:FVIIIB pp/Ag VWF:CB 
IU/dL 
RCo/Ag Multimer 
structure 
ABO blood 
group 
genotype 
Previously 
identified 
mutation 
P1F2II:1 19 43 38 57 Normal 1.1 58 0.88 Normal O/O  
P2F13I:3 6 27 29 66 Normal 2.9 34 1.07 Normal O/O  
P4F5I:1 13 16 15 25 Normal 7.0 11 0.94 Normal O/O  
P4F7II:1 9 51 57 45 Normal 1.4 68 1.12 Normal O/O  
P5F1II:3 2 37 32 28 Het 1.8 43 0.86 Normal O/A p.R854Q 
P6F4II:1 10 57 35 74 Normal 0.9 33 0.61 Normal O/O  
P6F9II:1 15 44 42 44 Normal 2.0 74 0.95 Normal O/O  
P7F8I:2 3 38 39 107 Normal 2.2 46 1.03 Normal O/O  
P8F2II:2 6 26 40 75 Normal 2.4 43 1.54 Normal O/A2 p.Q2544X 
P8F3I:2 8 61 50 125 Normal 1.4 25 0.82 Normal ®NA  
P8F5II:1 4 49 56 78 Normal 1.5 50 1.14 Normal O/O  
     P9F14II:2 18 3 3 7 Normal 8.5 1 1 Abnormal O/A p.[R924Q;C1
927R] 
c.1533+1G>T 
P9F18I:1 9 3 3 3 *NI 0.0 0.7 1 Abnormal O/O p.S539fs 
P10F5II:2 4 48 41 84 Normal 0.0 63 0.85 Normal O/O  
P10F7II:1 12 55 42 88 Normal 1.8 56 0.76 Normal O/O  
P10F8II:1 10 49 52 14 2N 1.3 57 1.06 Normal O/O p.R816W 
P10F9II:3 9 46 53 80 Normal 2.0 64 1.15 Normal O/O  
P12F5II:1 13 39 42 57 Normal 1.7 58 1.08 Normal O/O  
Normal range -3-3 48-167 47-194 57-198 Normal 1-1.5 66-226 0.6-1.62 Normal -  
*Not interpretable, ®Not available, (Ag ) antigen, RCo (ristocetin cofactor),  FVIII:C (factor VIII coagulant activity), pp (pro-peptide), CB (collagen 
binding), Het (Heterozygous), 2N (type 2N VWD) 
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no mutation (Table 3.1). Fourteen IC (78%) had VWF:Ag levels less than 50 IU/dL and the 
other four had a level slightly higher than the lower normal range (51-61 IU/dL), but had high 
BS ranging between 8-12 (Table 3.1). Complete co-segregation was observed in 6 (33%) IC and 
blood group O/O genotype was predominant and found in 14 IC (78%), two IC were O/A, one 
IC was O/A2 while ABO genotype was not available in one IC (Table 3.1). Therefore, 
amplification and re-sequencing of VWF in 18 IC who showed no mutation during the EU study 
using primers that showed no SNP within their sequences and direct DNA sequencing to 
sequence all VWF  52 exons and closely flanking intronic regions contributed in identifying 
mutations in several IC which were missed in the previous study.  
3.2. Primer design and SNP screen 
For the purpose of designing VWF primers and ensuring no SNP within primer sequences, an 
extensive in silico analysis was performed using tools described in section 2.2.1. Avoidance of 
the presence of SNP underneath the annealing site of primers was undertaken throughout this 
study to prevent the possibility of an amplification error that could hide the presence of 
heterozygous mutation(s). All 52 pairs of primers used in the EU study were screened for the 
presence of SNP within primer sequences. Out of these, 32 primer pairs showed no SNP and 
were used to amplify VWF in the 18 IC (Appendix Table 4), while SNP were found in 16 
primers including those for exons 8, 12, 14, 15, 18, 20 and 36 (Appendix Table 10). SNP within 
primer sequences were identified by using the Manchester SNP Check tool 
(http//ngrl.manchester.ac.uk/SNPCheckv2/snpcheck.htm, last accessed November 2010) and a 
manual check by eye through comparison with the genomic VWF sequence reference (Section 
2.2.1). Twenty primer pairs were re-designed to amplify the VWF exons and closely flanking 
intronic regions, out of which 12 primers were within the VWFP region (exons 23-34) whilst the 
remaining were redesigned for amplification of exons 1, 8, 12, 14, 15, 18, 20 and 36. Nine 
primers were redesigned due to the presence of both together SNP within the primer binding 
sequence and because primer nucleotides were too close to the target exon, eight primers were 
re-designed due to only the presence of SNP within primer sequences and three were redesigned 
due to either an amplification problem or a primer sequence error (Appendix 10). Primers 
outside of the VWFP region were designed using Primer3 online software (Section 2.2.1) and 
primers for amplification of exons with overlap to VWFP were designed manually with 
mismatch to the pseudogene. During primer design, it was ensured that the last nucleotide 
within the primer sequence was approximately 50 nucleotides from the target exon sequence 
with no SNP in the primer sequence and mismatches introduced between gene and pseudogene 
were included to de-stabilize binding to VWFP and to confer maximum specificity of VWF as 
described in section 2.2.1, but due to the constraints of the small number of possible positions to 
75 
 
design primers in the pseudogene region, it was not always possible to design primers following 
these criteria (Figure 3.2). Mismatches between gene and pseudogene were introduced into 
primers in the pseudogene region as seen in figure 3.2. Mismatches were introduced to reverse 
primers of exons 26, 33 and 34 and to both forward and reverse primers of exon 28 in order to 
ensure maximum VWF specificity and to de-stabilise binding to VWFP. Appendices 11 and 12 
show the re-designed primers in the study including primer sequences, introduced mismatches, 
GC content, annealing temperature and product size. 
TAGATGCTCTTCCACGTCTCTCCAGATCTCAACTGGGTGTTCCTTGGAGT 
TAGATGCTCTTCCACGTCTCTCCAGATCTCAACTGGGTGTTCCTTGGAGT 
************************************************** 
 
CTCTGAATCATTCAGCTTTTAAGTGACTTAAGGATCCACCGT-GAGACAG 
TTCTGAATCATTCAGCTTTTAAGTGACTTAAGGATCCACCGTTAAGACAG 
*****************************************  ****** 
 
GGTGTCCAGCCGCAGTCAGTACTGACTTGGTGTGATCTGTTCTCCATCCT 
GGTGTCGAGCCGCAGTCAGTACTGACTTGGCGTGATCTGTTCTCCATCCT 
****** *********************** ******************* 
 
CAGGGGATGCCTTGGGCTTTGCTGTGCGACACTTGACTTCAGAAATGCAT 
CAGGGGATGCCTTGGGCTTTGCTGTGCGATACTTGACTTCAGAAATGCAT 
***************************** ******************** 
 
GGTGCCAGGCCGGGAGCCTCGAAGGCGGTGGTCATCCTGGTCACGGATGT 
GGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTCACGGACGT 
******************** ************************** ** 
 
CTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGTA 
CTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGTA 
************************************************** 
 
AGAATCTGGTGTACAGTCCTCAATTCAGGAGAGCGAGACTTCAGAAATGA 
AGAATCTGGTGTACAGTCCTCAATTCAGGAGAGCGAGACTTCAGAAATGA 
************************************************** 
TAGAGGATTAAAAGTGGCCTGGGGTTACTTTTGGATGTTGTGGCTGATAT 
TAGAGGATTAAAAGTGGGCTGGGGTTACTTTTGGATGTTGTGGCTGATAT 
***************** ******************************** 
 
Figure 3.2 Alignments between VWF and VWFP and mismatch locations (exon 31) 
This figure shows the process of designing primers by including mismatches between the gene 
and pseudogene. Nucleotides in bold red the exonic region. Nucleotides of the pseudogene are 
highlighted in yellow while black nucleotides represent true VWF. Presence of asterisks 
represents the matches between the gene and pseudogene while the absence of asterisks 
represents mismatches sites between them. Nucleotides highlighted in turquoise represent 
forward and reverse primers used to amplify exon 31, the attached nucleotide highlighted in 
violet represents the mismatches between VWF and VWFP within primer sequence, blue arrows 
refer to forward and reverse primers. Nucleotides highlighted in red represent reported SNP. 
The forward primer was not 50 nucleotides from the exonic region due to presence of SNP 
within the mismatched area. 
F 
 
 
 
 
 
 
 
R 
R 
R 
 
76 
 
3.3. PCR optimisation 
Initially, all newly re-designed primers were used to amplify VWF exons using standard PCR 
conditions. These conditions included denaturation at 94 °C for one min, annealing at 60 °C for 
one min, extension at 72 °C for one min for 35 cycles using a 1.5 mM concentration of MgCl2. 
The purpose of that was to minimise time required for PCR optimisation and also for the 
simplicity of amplification. Moreover, to save the quantity of IC DNA samples, 3 DNA control 
samples collected from the BTS were used to optimise the PCR reaction for the newly designed 
VWF primers.  
With the initial conditions, most exons (13 exons out of 19) did not require any further 
optimisation and showed ideal amplification at the standard PCR conditions with the exception 
of primers for exons 15, 26, 27, 28, 32 and 33 which required further specific optimisation. PCR 
optimisation was performed by changing the annealing temperature, number of cycles or MgCl2 
concentration in order to alter the specificity of the reaction. 
3.3.1. Specific exon optimisation 
The six exons required further PCR optimisation due to either the appearance of non-specific 
bands or failure of amplification during initial PCR optimisation are listed in Appendix Table 
11 and 12. The exon 15 reaction was optimised at annealing temperature of 55°C for 32 cycles, 
the optimal amplification of exon 26 was established at annealing temperature of 60°C and 32 
cycles, the optimal amplification of exon 27 was established at annealing temperature of 
60°C/1.5 mM MgCl2 and 35 cycles (Figure 3.3), exon 32 was optimised at annealing 
temperature of 56 °C for 35 cycles (Figure 3.4) and the optimal amplification conditions of exon 
33 was achieved at annealing temperature of 61°C with 2.5 mM MgCl2 for 35 cycles (Appendix 
Table 11 and 12). 
3.3.1.1 Exon 28 
During the MCMDM-1VWD study, exon 28 was amplified using 1 amplicons and conventional 
PCR to cover the entire 1.4 kb sequences followed by sequencing the entire exon 28 using 4 
overlapping amplicons (Appendix 5). Although exon 28 is a large exon of 1.4 kb in size, its 
amplification was initially optimised using conventional PCR conditions. The calculated 
melting temperature was 59°C. However, when performing PCR using the calculated Tm, at 
initial annealing temperature (60°C) and at 64°C, the PCR reaction for exon 28 failed to amplify 
at these annealing temperatures. Following these failures, the annealing temperature was further 
lowered to 55, 53, 52 and 50°C and combined with a range of MgCl2 concentrations (1.5, 2, 2.5, 
3, and 4 mM) at each temperature. However, the PCR reaction still failed to amplify. Following 
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persistent failure, a long PCR reaction was designed as described in Section 2.2.2.3. The 
calculated melting temperature for the exon 28 primers according to the Phusion polymerase 
manufacturer’s instructions was 67°C. When performing long PCR using this calculated melting 
temperature, a strong and clear amplification product could be observed on the agarose gel 
(Figure 3.5). Therefore, the optimal amplification conditions for primers of exon 28 were 
achieved at 67°C/32 cycles using long range PCR conditions. 
3.4. Confirmation of VWF amplification 
As mentioned previously there is high sequence similarity (97%) between VWF and VWFP.  To 
ensure that the amplification was for the VWF rather than the VWFP, the generated amplicons of 
control samples were analysed using DNA sequencing. Mismatched sites and sequence 
differences between VWF and VWFP were compared in the generated sequences from all 
amplicons of this region. As a result, all amplifications were for VWF and none of the amplicon 
sequences corresponded to the pseudogene (Figure 3.6). 
 
Figure 3.3 Amplification of exon 27 on a 1% agarose gel. A) amplification at 60°C and 1.5 
mM MgCl2 faint bands are shown, B) strong amplification at 62°C/2.5 mM MgCl2. M; 
hyperladder IV, 1-3 BTS  control samples; B negative control. Arrow indicates amplicons size. 
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Figure 3.4 Amplification of exon 32 on a 1% agarose gel. A) Failure of amplification at 
60°C, B) Amplification at 56°C and 1.5 mM MgCl2. M; hyperladder IV, 1-3 BTS control 
samples; B negative control. Arrow indicates amplicons size. 
 
Figure 3.5 Amplification of exon 28 on a 1% agarose gel. Long range PCR amplicon at 67°C. 
M; hyperladder I, 1-3 BTS control samples; B negative control. Arrow indicates the size of 
amplicon. 
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Figure 3.6 Chromatogram of part of VWF exon 32 indicating mismatch sites between 
VWF and VWFP. Nucleotides marked with red arrows represent differences between VWF 
VWFP. Mismatched sites are highlighted in red. 
3.5. VWF amplification and sequencing 
During the original study conducted by MCMDM-1VWD, 30% of IC showed no mutation. Out 
of those, 18 families were re-analysed who presented with low level of VWF, had significant 
bleeding and no mutation identified or a mutation did not account for phenotype. Throughout 
the study, the newly designed primers and previously used primers that showed no SNP 
underneath their annealing sites were successfully amplified and sequenced for 52 VWF exons 
covering exonic and flanking regions for all IC listed in table 3.1 to detect any possible missed 
candidate mutations located within the entire VWF exonic and flanking regions.  
3.6. Identified VWF mutations and polymorphisms 
Initially, only the IC from each family was screened and when a candidate mutation was 
identified in any IC, it was analysed in all remaining family members including affected and 
unaffected members in order to determine the inheritance of the mutation. Analysis of the 
sequencing results revealed no new SNP, but four mutations, out of which 3 novel were 
identified in four index cases in exons 26, 28, 39 and intron 12. Three of these IC already had a 
mutation previously identified that was insufficient to explain their phenotype. The newly 
detected candidate mutations can be categorised into three groups, missense changes were 
identified in exons 26 and 39, a silent change was present in exon 28 and a splice-site mutation 
was located in intron 12 (Table 3.2). None of these newly novel identified mutations have been 
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detected prior to this study. However, many previously reported polymorphisms were identified. 
All previously reported SNP that were identified in this study are summarised in Appendix 13. 
Table 3.2 List of candidate missed and previously candidate mutations identified in this 
study 
IC Location Nucleotide 
change 
Amino acid change Previously identified 
candidate mutation 
P5F1II:3 Exon 39 c.6811T>G p.W2271G p.R854Q (2N) 
P9F18I:1 Exon 26 c.3469T>C p.C1157R p.S539Lfs*38 
P10F5II:2 Exon 28 c.4146G>T p.L1382= Nil 
P10F8II:1 Intron 12 c.1432+1G>T Splice change leading 
to exon skipping 
p.R816W (2N) 
 
3.6.1. Mutation result in family P5F1 
During analysis of DNA sample of P5F1II:3 IC, 22 nucleotide changes were detected. These 
changes included twenty known heterozygous polymorphisms (Table 3.3), 2 of which were 
shown to have an effect on protein sequence (Section 1.9.3.1.2.5) and two candidate mutations. 
The candidate mutations included one novel missense mutation detected in exon 39 and a 
previously reported missense change c.2811G>A predicted to result in p.R854Q that impairs 
VWF binding to FVIII in one IC. The novel heterozygous point mutation was identified in the 
exonic region located at nucleotide position 6811 where T was replaced by G (c.6811T>G) as 
shown in figure 3.7. This mutation has not been reported previously and was found only in one 
IC (P5F1II:3). This novel missense mutation resulted in a substitution of the amino acid 
tryptophan located at position 2271 of the VWF protein with a glycine (p.W2271G). 
Tryptophan is one of the largest amino acids while glycine is the smallest of the 20 amino acids 
(Figure 3.8). However, tryptophan and glycine amino acids also differ in other properties. 
Subsequently, sequence analysis for this fragment was performed for all family members that 
comprised the IC, two AFM and one UFM. By using bi-directional DNA sequencing, the 
candidate mutation in addition to the IC was detected in both AFM (I:2 and II:2), while the 
UFM (II:6) showed normal sequence (Figure 3.9). 
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Table 3.3: List of 20 known heterozygous SNP in IC P5F1II:3 
SNP reference 
number 
Nucleotide 
change 
Amino acid 
change 
Effect on protein 
expression 
SNP location 
Exon/Intron 
rs2286608 c.1-64C>T  No Intron 1 
rs1800378 c.1451A>G p.H484R No Exon 13 
rs7312411 c.1548T>C p.Y516= No Exon 14 
rs1063856 c.2365A>G p.T789A Yes* Exon 18 
rs1063857 c.2385T>C p.Y795= YesƗ Exon 18 
rs216321 c.2555A>G p.Q852R No Exon 20 
rs1800380 c.2880G>A p.R960= No Exon 22 
rs34877178 c.2968-53G>A  No Intron 22 
rs3858686 c.2968-125C>T  No Intron 22 
rs56121649 c.3109-90G>C  No Intron 23 
rs56068059 c.3109-128G>T  No Intron 23 
rs6127535 c.5049A>C p.A1683= No Exon 28 
rs17491334 c.6064-71C>T  No Intron 35 
rs177702 c.6799-14C>T  No Intron 38 
rs10849371 c.6846A>G p.T2282= No Exon 39 
rs55867239 c.6977-22C>T  No  Intron 40 
rs216867 c.7239T>C p.T2413= No  Exon 42 
rs2270239 c.7549-59A>C  No  Intron 44 
rs11063962 c.7771-13C>T  No  Intron 46 
rs7976955 c.8442+204C>T  No  3' untranslated 
region 
*Associated with alteration in VWF levels and in perfect linkage disequilibrium with SNP, Ɨ 
associated with alteration in VWF levels in CHARGE study (Smith et al., 2010). 
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Figure 3.7 Heterozygous c.6811T>G point mutation in P5F1 
A and B show the bidirectional sequencing of the heterozygous c.6811T>G mutation in exon 
39, C and D show bidirectional sequencing of the wild type control. E shows the alignment of 
human cDNA to the exon 39 predicted amino acid sequence. The red arrows indicate the 
affected nucleotide (T) and amino acid (tryptophan). The TGG codon encoding tryptophan has 
been substituted to GGG that encodes glycine. 
 
A           B  
Figure 3.8 Chemical structures of amino acids A (tryptophan) and B (glycine). Source: 
www.wikimedia.org. 
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Figure 3.9 Sequence analysis results of family P5F1II:3. The candidate mutation c.6811T>G 
is marked by a red arrow. This mutation found in the IC and the AFM was absent from the 
UFM. 
3.6.1.1. Linkage and mutation analysis in family P5F1 
To assess the linkage between VWF and clinical and phenotypic data in recruited families, the 
MCMDM-1VWD study had previously performed linkage analysis (Eikenboom et al., 2006). 
Three different linkage analysis markers were applied to detect linkage between VWD and 
VWF. The GT(n)  repeat marker is located within the promoter region, while the TCTA(n) repeat 
(STR III) and TCTA(n) repeat (STR II) both are located within intron 40 (Figure 3.10). P5F1II:3 
was a small family consisting of four members, including three patients and one UFM. 
Therefore, it was not possible to establish definitive linkage between VWD and VWF in this 
family (Eikenboom et al., 2006). The p.R854Q mutation which affects VWF binding to FVIII 
was found in the two children P5F1II:3 (IC) and P5F1II:2 (AFM) and was likely to have 
originated in their father (Not tested). The presence of this mutation (p.R854Q) likely explains 
the low level of FVIII in the children who carry this mutation and the normal level of FVIII in 
the mother who does not carry the p.R854Q mutation (Figure 3.10). The level of VWF:Ag was 
markedly decreased in the IC and AFM who carried p.W2271G, ranging from 37-38 IU/dL, 
VWF:RCo ranging between 32-43 IU/dL , while the level of FVIII:C was reduced in the IC (28 
IU/dL) and the AFM child P5F1II2 (34 IU/dL) and normal in the mother P5F1I2 (85 IU/dL) 
who lack the p.R854Q mutation. BS was normal in all except AFM P5F1I2 probably due to low 
age (Table 3.4). However, this family showed reduced phenotypic data and O/A blood group 
genotype. Linkage analysis results indicated that the IC and AFM (II:2) who carry p.R854Q 
shared a haplotype [191]-[159]-[174] (GT repeat, STRIII and STRII) indicated by the green 
allele which originated from the father, while the haplotype [189]-[151]-[174] (black allele) 
associated with p.W2271G was found in all AFM and the IC. The latter markers co-segregated 
with the low levels of VWF and FVIII.  Briefly, although this family was small, linkage analysis 
showed clear co-segregation of haplotype with VWD. 
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Figure 3.10 Pedigree of family P5F1 showing linkage analysis and mutation results. The 
linkage analysis marker order from top to bottom is: GT(n) promoter dinucleotide repeat (bp), 
TCTA(n)  repeat (bp) (STR III) and TCTA(n) repeat (bp) (STR II). The linkage analysis results 
are shown underneath each family member. Females are indicated by circles and males by 
squares. Filled symbols represent AFM and the black arrow indicates the index case. Mutant 
allele [189]-[151]-[174] associated with p.W2271G and [191]-[159]-[174] associated with 
p.R854Q. 
Table 3.4 Phenotypic data for family P5F1 
Family  
member 
Age* 
(years) 
Status BS VWF:Ag 
IU/dL 
VWF:RCo 
IU/dL 
FVIII:C 
IU/dL 
Multimer 
profile 
ABO 
genotype 
I:2 46 AFM 7 38 37 85 Normal O/A 
II:2 23 AFM -1 37 43 34 Normal O/A 
II:3 21 IC 2 37 32 28 Normal O/A 
II:6 28 UFM -2 73 59 91 Normal O/A 
*At recruitment 
 
 
 
Inferred 
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3.6.1.2. p.W2271G protein prediction and multiple species alignment 
Three different tools were used to predict the effect of amino acid substitutions on protein 
function. These tools included SIFT, PolyPhen2 and Align GVGD (section 2.2.5) (Table 3.5). 
SIFT predicts the effects of amino acid substitutions on protein function based on sequence 
homology and amino acid physical properties. The score ranges from 0 to 1 where 1 is neutral 
and 0 is damaging. The PolyPhen2 tool predicts the potential impact of amino acid replacement 
on the function and structure of human protein using straightforward physical properties such as 
site and type of substitution. The scores range from 0 to 1 where 0.2 is less likely to be 
damaging and high positive scores are damaging and 0 indicates a neutral effect of amino acid 
replacement on human protein function (Paulin and Henikoff, 2006). The Align GVGD tool 
predicts the effect of missense substitutions in a target protein in a spectrum from enriched 
deleterious to enrich neutral. GD measures the biochemical variations such as polarity and 
composition of amino acids between mutant and normal amino acids while GV measures the 
quantity of biochemical variations in the affected position. GD <60 may not affect the structure 
or function of the protein while >60 is probably damaging. The effect of align GVGD is ordered 
from class C0 which indicates less likely to be damaging to most likely class C65 which 
indicates most likely damaging. The amino acid substitution of tryptophan by glycine at 
position 2271 in VWF was analysed by all these methods to be a damaging mutation and 
thereby was predicted to affect the function and structure of VWF. SIFT, PolyPhen2 and Align-
GVGD tools all predicted that the p.W2271G amino acid variant was probably damaging. 
 
Table 3.5 Prediction methods used for amino acid substitution with prediction 
score and range of score for each 
Prediction tool Range of possible scores Prediction score for p.W2271G 
SIFT 0-1 0 (damaging) 
PolyPhen2 0 to positive number 1 (probably damaging) 
Align GVGD C0-C65 Class C65, GD 183.79 (most likely 
damaging) GV 0.00 
 
In addition to the in silico analysis of the protein substitution, evolutionary conservation of the 
tryptophan located at position 2271 was undertaken through alignment with the VWF amino 
acid protein sequence of twelve different species using MULTALIN as described in section 
2.2.8. As a result, the p.W2271 was found to be completely conserved in VWF in all aligned 
species (Figure 3.11). This result indicated that this conserved residue was likely to be 
important in VWF protein structure and/or function. 
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Figure 3.11: Schematic representation of the evolutionary conservation of p.W2271 across 
thirteen VWF orthologues which indicates complete conversation. Residue p.W2271 is 
highlighted by a rectangle (http://mutalin.toulouse.inra.fr/mutalin/).  
3.6.2. Mutation analysis in P9F18 family 
In order to find a candidate missed mutation, the entire VWF coding sequence and exon/intron 
boundaries regions of IC P9F18I:1 were analysed using PCR amplification followed by direct 
sequencing. Analysis of VWF sequences within the IC detected two heterozygous missense 
candidate mutations in addition to 23 previously known heterozygous polymorphisms (Table 
3.6). One novel heterozygous point mutation was identified in the exonic region of exon 26, 
c.3469T>C predicted to result in p.C1157R as shown in figure 3.12, while the other mutation 
was previously known with a single nucleotide deletion located in exon 14 (c.1614del) 
predicted to result in the frameshift mutation p.S539Lfs*38. The novel mutation located in the 
D3 domain was found only in one IC (P9F18I:1). It involved substitution of cysteine which is 
considered an important amino acid required for disulphide bond formation in the VWF protein. 
Subsequently, this candidate mutation was analysed in all family members that included one 
AFM and three UFM. By using bi-directional DNA sequencing, the candidate mutation 
c.3469T>C was sought and detected in AFM I:2, but was absent from all UFM, I:3 II:1 and II:2 
(Figure 3.12). The frameshift mutation c.1614del was detected in all members including IC, 
AFM and UFM, except for I:3. Forward and reverse primers used in the original study to 
amplify VWF exon 26 were checked for the presence of SNP underneath their annealing sites 
using the SNP Check tool (Section 2.2.1). As a result, four SNP were detected, three in the 
forward primer and one in the reverse one detected at the 3' end (Table 3.7).  
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 Figure 3.12 Heterozygous c.3469T>C point mutation in P9F18 family 
 Sequence analysis results of family P9F18 showing the heterozygous change, a T>C at     
 nucleotide position 3469. The nucleotide c.3469T>C is marked by a red arrow. This mutation     
 was found in the IC and the AFM and absent from the UFM. 
 
 Table 3.6: List of 23 known heterozygous SNP in the IC P9F18I:1                                                       
SNP reference 
number 
Nucleotide 
change 
Amino acid 
change 
Effect on protein 
expression 
SNP location 
Exon/Intron 
rs2286608 c.1-64C>T  No Intron 1 
rs3213721 c.997+32G>A  No Intron 8 
rs55907031 c.998-27C>T  No Intron 9 
rs1800375 c.1173A>T p.T391= No Exon 11 
rs1800376 c.1182A>C p.S394= No Exon 11 
rs1800377 c.1411G>A p.V471I No Exon 12 
rs1800378 c.1451A>G p.H484= No Exon 13 
rs1063856 c.2365A>G p.T789A Yes* Exon 18 
rs1063857 c.2385T>C p.Y795= YesƗ Exon 18 
rs216325 c.2546+25C>T  No Intron 19 
rs216321 c.2555A>G p.Q852R No Exon 20 
rs1800380 c.2880G>A p.R960= No Exon 22 
rs34877178 c.2968-53G>A  No Intron 22 
rs3858686 c.2968-125C>T  No Intron 22 
rs56121649 c.3109-90G>C  No Intron 23 
rs73051263 c.3222+31C>T  No Intron 24 
rs177702 c.6799-14C>T  No Intron 38 
rs216867 c.7239T>C p.T2413= No Exon 42 
rs216868 c.7082-7C>T  No Intron 42 
rs2286646 c.8115+66T>C  No Intron 49 
rs7962217 c.8113G>A p.G2705R No Exon49 
rs2270152 c.8116-20A>C  No Intron 50 
rs2362483 c.8253+32T>C  No Intron 51 
*Associated with alteration in VWF levels and in perfect linkage disequilibrium with SNP, Ɨ 
associated with alteration in VWF levels in CHARGE study (Smith et al., 2010). 
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Table 3.7 Identified SNP underlying the primer annealing sites for the VWF exon 26 
primers 
Forward primer (Exon-26) Reverse primer (Exon-26) 
CCCCAACATTATCTCCAGATGGC CCTATCCCATCCCACCAGCCT 
*Nucleotides highlighted in red represent reported SNP 
3.6.2.1. Linkage analysis and mutation study in family P9F18 
This family included five members, two affected (IC+AFM) and three unaffected members 
(Figure 3.13). The IC (I:1) and the AFM (I:2) carried  two mutations on two different alleles 
(compound heterozygous); the newly identified p.C1157R and the previously known 
p.S539Lfs*38 were present with very low levels of VWF:Ag, VWF:RCo and FVIII, increased 
BS (9-10) and abnormal multimers (Table 3.8). The presence of the previously identified 
heterozygous p.S539fs alone did not explain the increased values of BS and a very low levels of 
VWF:Ag in the IC and AFM who carry the additional mutation p.C1157R. Also, the presence 
of p.S539fs alone can explain the mild to moderate reduction of VWF:Ag, VWF:RCo and FVIII 
in the UFM who does not carry the p.C1157R mutation. The phenotypic data of the IC and 
AFM demonstrated undetectable levels of VWF:Ag, VWF:RCo and FVIII:C (<3 IU/dl) for each 
parameter in both with abnormal multimer pattern and the level of VWF:Ag, VWF:RCo and 
FVIII was mildly reduced ranging from 48-60, 45-69 and 41-75 IU/dL respectively in the UFM. 
The IC had O/O blood group genotype while the AFM had O/B (Table 3.8). It has been 
described that the VWF D3 domain is involved in the process of multimerization and FVIII 
binding and the presence of a missense mutation within this domain can potentially affect 
protein folding, multimerization, maturation, secretion and the transport pathway in addition to 
impairing binding to FVIII.  
Linkage analysis results indicated that a shared haplotype [187]-[163]-[174] (GT repeat, STRIII 
and STRII) respectively which is associated with the frameshift mutation c.1614del is present in 
all members including the AFM and two of UFM, while the IC and the AFM shared an 
additional haplotype (black allele) [187]-[159]-[174] which completely co-segregated with the 
low level of VWF and FVIII:C. In summary, this family showed reduced phenotypic levels of 
VWF and FVIII:C, an abnormal multimer pattern and co-segregation of affected haplotypes 
with the disease. The candidate mutation p.C1157R located in D3 domain was classified as type 
2A(IIE) and its presence in compound heterozygosity with p.S539fs was classified as type 3 
VWD. However, the mutant alleles co-segregated with the disease phenotype and were inherited 
in an autosomal recessive manner. 
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Figure 3.13 Pedigree of family P9F18 showing linkage analysis and mutation results. The 
linkage analysis marker order was as previously described and is shown underneath each 
member. Females are indicated by circles and males by squares. Filled symbols represent AFM 
and the black arrow indicates the index case. Both mutant alleles [187]-[159]-[174] associated 
with p.C1157R and [187]-[163]-[174] associated with p.S539fs are shown in the AFM while 
mutant allele [187]-[163]-[174] associated with p.S539fs is shown in UFM. 
Table 3.8 Phenotypic data for family P9F18 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCo 
IU/dL 
FVIII:C 
IU/dL 
VWF:FVIIIB Multimer 
profile 
ABO 
genotype 
I:1 IC 9 <3 <3 <3 NI* Abnormal O/O 
I:2 AFM 10 3 3 3 NI* Abnormal O/B 
I:3 UFM -2 48 45 41 NTƗ Normal O/A2 
II:1 UFM 2 60 69 74 NTƗ Normal A2/B 
II:2 UFM 0 53 50 75 NTƗ Normal O/B 
* Not interpretable       Ɨ Not tested 
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3.6.2.2. p.C1157 protein predictions and multiple species alignment 
Three different in silico tools described in section 2.2.5 (SIFT, PolyPhen2 and Align GVGD 
(Table 3.9) were used to predict the effect of amino acid substitutions on protein function. SIFT 
and PolyPhen2 tools predicted that the p.C1157R amino acid variant was probably damaging 
with 0 and 1 scores respectively. Also the Align-GVGD tool had the same deleterious effect and 
suggested that the p.C1157R variant is most likely damaging. 
Table 3.9 Prediction methods used for amino acid substitution with prediction score and 
range of scores for each tool 
Prediction tool Range of possible scores Prediction score 
SIFT 0-1 0 (damaging) 
PolyPhen2 0 to positive number 1 (Probably damaging) 
Align GVGD  C0-C65 Class C65, GD 179.53 (most likely 
damaging) GV 0.00 
 
Evolutionary conservation of the cysteine located at position 1157 was undertaken through 
alignment with the VWF amino acid protein sequence of twelve different species using 
MULTALIN tool as described in section 2.2.8. As a result, p.C1157 was found to be completely 
conserved in VWF in all aligned species (Figure 3.14). This result indicated that this highly 
conserved residue was potentially important for VWF protein structure and function. 
 
Figure 3.14: Schematic representation of the evolutionary conservation of p.C1157 across 
thirteen orthologues which indicates complete conversation. Residue p.C1157 is highlighted 
by a black rectangle (http://mutalin.toulouse.inra.fr/mutalin/). 
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3.6.3. Mutation analysis in family P10F5 
During analysis and sequencing of VWF exon/intron boundaries in all 18 IC, twenty eight 
variants were detected in IC P10F5II:2. Among all, one known silent change (Hampshire et al., 
2010, Corrales et al., 2012) in addition to 27 previously known heterozygous polymorphisms 
were detected (Table 3.10). This silent heterozygous point mutation c.4146G>T was identified 
in exon 28 in the IC (II:2) which was predicted to result in silent change p.L1382= (Figure 
3.15). This silent mutation located in the A1 domain has been reported previously in 2 patients 
who had two additional mutations in the heterozygous state (Corrales et al., 2012). The 
identified mutation was analysed in all family members including one AFM and two UFM 
using bi-directional DNA sequencing. The c.4146G>T was found in the AFM (I:1) and was 
absent from the UFM I:2 and II:1. No other change was detected in this IC previously. 
Table 3.10: List of 27 known heterozygous SNP in IC P10F5II:2                                                       
SNP reference 
number 
Nucleotide 
change 
Amino acid 
change 
Effect on protein 
expression 
SNP location 
Exon/Intron 
rs2286608 c.1-64C>T  No Intron 1 
rs7980045 c.657+11A>C  No Intron 6 
rs1800378 c.1451A>G p.H484R No Exon 13 
rs7312411 c.1548T>C p.Y516= No Exon 14 
rs216293 c.2282-42C>A  No Intron 17 
rs1063856 c.2365A>G p.T789A Yes* Exon 18 
rs1063857 c.2385T>C p.Y795= YesƗ Exon 18 
rs216325 c.2546+25C>T  No Intron 19 
rs216321 c.2555A>G p.Q852R No Exon 20 
rs1800380 c.2880G>A p.R960= No Exon 22 
rs34877178 c.2968-53G>A  No Intron 22 
rs3858686 c.2968-125C>T  No Intron 22 
rs73051263 c.3222+31C>T  No Intron 24 
rs56121649 c.3109-90G>C  No Intron 23 
rs56068059 c.3109-128G>T  No Intron 23 
rs4008538 c.3414C>T p.N1138= No Exon 26 
rs216312 c.3675-75A>G  No Intron 27 
rs216311 c.4141A>G p.T1381A No Exon 28 
rs216310 c.4641T>C p.T1547= No Exon 28 
rs216305 c.5665-118G>A  No Intron 33 
rs17491334 c.6064-71C>T  No Intron 35 
rs177702 c.6799-14C>T  No Intron 38 
rs10849371 c.6846A>G p.T2282= No Exon 39 
rs55867239 c.6977-22C>T  No Intron 40 
rs216867 c.7239T>C p.T2413= No Exon 42 
rs2270239 c.7549-59A>C  No Intron 44 
rs2270151 c.8155+50C>T  No Intron 50 
*Associated with alteration in VWF levels and in perfect linkage disequilibrium with SNP, Ɨ 
associated with alteration in VWF levels in CHARGE study (Smith et al., 2010). 
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Figure 3.15 Heterozygous c.4146G>T point mutation in P10F5 family 
Sequence analysis results of family P10F5. The nucleotide c.4146G>T is marked by a red 
arrow. This candidate mutation was found in the IC and the AFM and was absent from the 
UFM. 
3.6.3.1. Linkage analysis and mutation study in family P10F5 
This small family had only four members, two affected and two unaffected individuals (Figure 
3.16). The phenotypic data from the IC (II:1) and AFM (I:1) who both carried the c.4146G>T 
mutation indicated a mild increase in BS (4-6), moderate reduction of VWF:Ag in the plasma 
(48 and 54 IU/dl) respectively, moderate reduction of VWF:RCo (41 and 61 IU/dl) and normal 
plasma level of FVIII:C values. All family members had an O/O blood group genotype (Table 
3.11). The linkage study revealed a common haplotype [193]-[155]-[174] (GT repeat, STRIII 
and STRII) respectively to be associated with c.4146G>T which was identified in the IC and the 
AFM (black allele), while absent in the UFM. The mutant allele co-segregated with the low 
level of VWF:Ag and VWF:RCo and was in accordance with an autosomal dominant pattern of 
inheritance. In summary, this family showed reduced VWF levels in analysis of phenotypic data 
and O/O blood group genotype in the IC and AFM. Although this family is small, it showed co-
segregation of affected haplotype with the disease. 
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Figure 3.16 Pedigree of family P10F5 showing linkage analysis and mutation results. The 
linkage analysis marker order was as previously described and is shown underneath each 
member. Females are indicated by circles and males by squares. Filled symbols represent AFM 
and the black arrow indicates the IC. The mutant allele [193]-[155]-[174] was present in the IC 
and AFM. 
Table 3.11 Phenotypic data for family P10F5 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCO 
IU/dL 
FVIII:C 
IU/dL 
Multimer 
pattern 
ABO genotype 
I:1 AFM 6 54 61 87 Normal O/O 
I:2 UFM -1 95 78 144 Normal O/O 
II:1 UFM 3 78 53 90 Normal O/O 
II:2 IC 4 48 41 84 Normal O/O 
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3.6.3.2. In silico splice-site prediction 
In order to predict if there was any possible influence of the c.4146 G>T variant on mRNA 
splicing, four online in silico prediction tools; MaxEntScan: scorsplice (MES), splice site 
prediction by neural network, human splice finder (HSF) and NetGene2 splice prediction were 
used (Section 2.2.6). The results were analysed after comparing the wild-type and mutant 
sequences and predicted no difference between wild-type and mutant and no effect on donor and 
acceptor splice site sequences. Moreover, splicing is known to be regulated by splice enhancer 
and silencer sequences which can occur within both coding and non-coding sequences. In order 
to predict the potential effect of the silent change (c.4146G>T) on splicing enhancer and 
silencer elements, three bioinformatics online in silico prediction tools (ESE, HSF and 
RESCUE-ESE) were used. As a result, these tools showed a significant difference between the 
wild-type and mutant sequences and identified three variations that were predicted to lead to 
disruption of enhancer sequences in addition to creation of three silencer sequence (Table 3.12). 
Therefore, the c.4146G>T change may disrupt the exonic splicing enhancer (ESE) sites and 
alter the splicing mechanism. Also, the graphical codon usage analyser (GCUA) tool which 
compares the frequency of use of two different triplet codons encoding the same amino acid was 
used (http://gcua.schoedl.de/ ) as some codons are recognised more efficiently by transfer RNA 
(tRNA) compare to others which can alter the efficiency and accuracy of translation (Hershberg 
and Petrov, 2008). GCUA compares the frequency usage between the wild-type (CTG) and 
mutant (CTT) codons which both encode leucine. As a result, the mutant codon generates a 68% 
lower frequency than the wild-type. The wild-type codon (CTG) is more frequently used than 
mutant codon (CTT) which may affect the rate of translation and protein folding and therefore 
alter the protein structure and function (Figure 3.17). 
Table 3.12 In silico prediction of effect of c.4146G>T in splice regulatory elements 
 
cDNA position WT motif Enhancer motif value 
(0-100) WT score 
Enhancer motif value (0-100) 
mutant score 
c.4142 ACCCTGCT 34.22 0 (site broken) 
c.4147 GCTCCTGA 27.81 0 (site broken) 
c.4143 CCCTGCTC 39.28 0 (site broken) 
 
cDNA position WT motif Silencer motif WT 
sequence 
Silencer motif mutant 
sequence 
c.4144 CCCTGC  CCTTCT (new site) 
c.4145 CCCTGC  CTTCTC (new site) 
c.4146 CCCTGC  TTCTCC (new site) 
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Figure 3.17 The relative frequency values of normal codon CTG and mutant codon CTT 
that all encode leucine in Homo sapiens. The frequency of CTT mutant codon used by leucine 
is 68% less than wild-type CTG triplet codon (Nakamura et al., 2000). 
3.6.4. Splice mutation c.1432+1G>T and linkage analysis in P10F8 family 
During analysis of the entire VWF coding sequence plus exon/intron boundaries of all 18 IC 
using PCR amplification followed by direct sequencing, twenty four variants were detected in 
P10F8II1 including 22 known heterozygous polymorphisms and two candidate mutations 
(Table 3.13). One novel intronic change was identified at the donor splice site of intron 12 
c.1432+1G>T in the IC P10F8II:1 (Figure 3.18). This change was detected in the IC II:1 who 
previously had a known 2N mutation in exon 19 (c.2446C>T) which is predicted to result in 
p.R816W, while the AFM (II:2) showed only the intronic change c.1432+1G>T and the 
previously identified mutation p.R816W was not observed in the unaffected mother (I:2).  
The phenotypic data in the IC and AFM confirmed a reduced level of VWF:Ag in plasma 49 
and 47 IU/dl respectively (Figure 3.19). BS was increased (10) in the IC who had a reduced 
value of FVIII:C of 14 IU/dl (Table 3.14). However, analysis of the phenotypic and genotypic 
data from the P10F8 family suggested that the samples had potentially been incorrectly labelled 
in the original EU study. By examining the previously described marker data from linkage 
analysis, a non-linkage pattern was present in this family. Although the IC II:1 and the AFM 
II:2 had the same mutation and common haplotype, the maternal allele was absent from both 
children, providing further evidence for a sample error (Figure 3.19). These findings led to the 
exclusion of this family from a previously analysis of linkage of VWF to VWD (Eikenboom et 
al., 2006).  
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Figure 3.18 A) Sequence chromatogram analysis results of family P10F8 showing the 
heterozygous c.1432+1G>T substitution. This mutation was found in the IC and the AFM and 
absent in the UFM. B) Partial sequence of intron 12. The red arrow indicates the sequence 
alteration between the WT and IC showing the G>T change. 
Table 3.13: List of 22 known heterozygous SNP in IC P10F8II:1   
SNP reference 
number 
Nucleotide 
change 
Amino acid 
change 
Effect on protein 
expression 
SNP location 
Exon/Intron 
rs2286608 c.1-64C>T  No Intron 1 
rs1800378 c.1451A>G  No Exon 13 
rs61908661 c.1945+24C>T  No Intron 15 
rs1063856 c.2365A>G p.T789A Yes* Exon 18 
rs1063857 c.2385T>C p.Y795= YesƗ Exon 18 
rs216321 c.2555A>G p.Q852R No Exon 20 
rs1800380 c.2880G>A p.R960= No Exon 22 
rs34877178 c.2968-53G>A  No Intron 22 
rs3858686 c.2968-125C>T  No Intron 22 
rs56121649 c.3109-90G>C  No Intron 23 
rs73051263 c.3222+31C>T  No Intron 24 
rs177702 c.6799-14C>T  No Intron 38 
rs10849371 c.6846A>G p.T2282= No Exon 39 
rs55867239 c.6977-22C>T  No Intron 40 
rs216867 c.7239T>C p.T2413= No Exon 42 
rs216868 c.7082-7C>T  No Intron 42 
rs2286646 c.8115+66T>C  No Intron 49 
rs7962217 c.8113G>A p.G2705R No Exon49 
rs2270152 c.8116-20A>C  No Intron 50 
rs2270151 c.8155+50C>T  No Intron 50 
rs2362483 c.8253+32T>C  No Intron 51 
rs7976955 c.8442+204C>T  No 3' untranslated 
region 
*Associated with alteration in VWF levels and in perfect linkage disequilibrium with SNP, Ɨ 
associated with alteration in VWF levels in CHARGE study (Smith et al., 2010). 
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Figure 3.19 Initial pedigree of family P10F8 showing linkage analysis and mutation 
results. The linkage analysis marker order was as previously described and is shown underneath 
each member. Females are indicated by circles and males by squares. Filled symbols represent 
AFM and the black arrow indicates the index case. No maternal allele was present in either of 
the children II:1 and II:2. 
 Table 3.14 Initial phenotypic data for family P10F8 
Family 
member 
Status BS VWF:Ag 
IU/dl 
VWF:RCo 
IU/dl 
FVIII:C 
IU/dl 
VWF:FVIIIB Multimer 
profile 
Blood 
group 
I:2 UFM 4 145 141 120 Normal Normal O/A2 
II:1 IC 10 49 52 14 2N Normal O/O 
II:2 AFM -1 47 67 113 Normal Normal O/O 
 
Forward and reverse primers used in the original study to amplify VWF exon 12 were checked 
for the presence of SNP underneath their annealing sites using the SNP Check tool. As a result, 
two SNP were detected in the forward primer only, located in the middle and at the 3' end of the 
primer sequence (Table 3.15).  
Table 3.15 Identified SNP underlying the primer annealing site for the VWF exon 12 
primer 
Forward primer (Exon-12) Reverse primer (Exon-12) 
TTGAGGCCTTTCTCTGATTAA GGCCAGGGTTGAGAAGGA 
*Nucleotides highlighted in red represent reported SNP 
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3.6.4.1. Review of linkage analysis and mutation in P10F8 family 
In order to determine the linkage of mutations within this family, 6 SNP markers were assessed 
to establish whether there was likely to have been a sample mix up through comparison of the 
mutations present within the family and also the phenotype of individuals within the family. 
These new SNP markers are listed in table 3.16. However, in an attempt to find the reason of the 
non-linkage pattern in this family, the genotypic and phenotypic data of the mother I:2 (UFM) 
and II:2 (AFM) were swapped. As a result of this exchange, the mother I:2 became the AFM, 
while the healthy son (II:2) became the UFM. After this modification, linkage study results 
demonstrated a common haplotype [CTGTGA] which was associated with the c.1432+1G>T 
change observed in the IC which apparently originated from the mother (I:2) (Figure 3.20). 
Also, the type 2N mutation p.R816W which affects VWF binding to FVIII was found only in 
the IC (daughter) and likely originated in the father who not recruited. The presence of the 
p.R816W mutation in the IC explains the reduction of FVIII:C level in the IC and the normal 
levels in the son and the mother who do not carry the p.R816W variant. 
With the pedigree modifications, the IC who was compound heterozygous for two mutations 
revealed a high bleeding score of 10 in addition to low levels of VWF:Ag, VWF:RCo and 
FVIII:C in plasma, 49, 52 and 14 IU/dl respectively, while the AFM (I:2) who had only the 
intronic change c.1432+1G>T revealed a reduction in VWF:Ag level of 47 IU/dl and normal 
values of VWF:RCo and FVIII:C. Both IC and AFM had an O/O blood group genotype (Table 
3.17).  
In summary, with using the new SNP markers and swapping the genotypic and phenotypic data 
between two family members with taking into account that initial categorisation of BS in AFM 
and UFM was likely correct, more logical results were obtained. The affected members of this 
family showed a moderate reduction of phenotypic data. However, the mutant allele [CTGTGA] 
in the IC and AFM co-segregated with a reduced level of VWF and was accordant with a 
haploinsufficient allele. 
Table 3.16 The new SNP markers used for linkage analysis showing SNP number and its 
location 
Rs No Nucleotide substitution SNP location 
rs216883 c.6799-2826C>T Intron- 38 
rs216856 c.7288-839T>C Intron- 42 
rs11063965 c.7548+170G>A Intron- 44 
rs4764478 c.7729+252T>A Intron- 45 
rs2363309 c.7887+5813G>A Intron- 47 
rs10849363 c.7888-3597A>G Intron- 47 
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Figure 3.20 Revised pedigree of family P10F8 showing linkage analysis and mutation 
results using new SNP markers. The linkage analysis markers are shown underneath each 
member. Females are indicated by circles and males by squares. Filled symbols represent AFM 
and the black arrow indicates the index case. The mutant black allele [AGTGTC] associated 
with c.1432+1G>T was observed in the IC and AFM and mutant red allele [GAAACT] 
associated with p.R816W. 
Table 3.17 Phenotypic data for family P10F8 after modification 
Family 
member 
Status BS VWF:Ag 
IU/dl 
VWF:RCo 
IU/dl 
FVIII:C 
IU/dl 
VWF:FVIIIB Multimer 
pattern 
Blood 
group 
I:2 AFM 4 47 67 113 Normal Normal O/O 
II:1 IC 10 49 52 14 2N Normal O/O 
II:2 UFM -1 145 141 120 Normal Normal O/A2 
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3.6.4.2. In silico splice site prediction 
In order to examine the possible influence of the variant located at VWF sequence c.1432+1G>T 
donor splice site on splicing mechanisms, several in silico online prediction tools were used 
(Section 2.2.6). The results from each prediction tool of wild type and mutant sequences were 
compared with each other. The results indicated that c.1432+1G>T candidate mutation most 
likely resulted in disruption of the splice donor-site of exon 12. Results achieved from the 
neural network, NetGene2 and MES predicted that this splice variant alters the consensus splice 
donor site sequence and likely results in the skipping for exon 12 after comparing the wild-type 
and mutant sequences (Table 3.18). Human Splice Finder suggested that this change may 
abolish the wild type exon 12 donor site but also create a new exon 12 donor site which would 
result in retention of 1bp of intron 12 and result in a frameshift. This splice site change could 
result in skipping of exon 12 which further causes loss of all  139 nucleotides  of exon 12 and 
produces a stop codon 9 amino acids downstream of the mutation (p.C432Vfs*9). However, 
review of these prediction tools suggests that a consensus of at least three tools should be used 
to decide a likely outcome.  
Table 3.18 In silico prediction tools to determine the effects of c.1432+1G>T 
Splice site prediction 
tool 
Donor splice site score 
WT allele c.1432+1G 
Range of 
score 
Donor splice site score 
mutant allele c.1432+1G>T 
Neural network 0.96 0-1 0 (splice site loss) 
NetGene2 0.95 0-1 0 (splice site loss) 
MES 9.55 0-10 1.05 (splice site loss) 
HSF 88.0 0-100 61.23 (possible splice site loss) 
  
3.6.5. Confirmation of the presence of mutations previously identified 
During analysis of DNA samples of all 18 IC, 4 additional nucleotide changes that were 
previously identified were detected in two IC. They included c.7630C>T in exon 45 in PF2II:2 
family, which is predicted to result in p.Q2544*.  
3.6.5.1. Mutation analysis in family P9F14 
The other three changes were all found in IC P9F14III:1 and included one splice change located 
in the donor splice site of intron 13, c.1533+1G>T and two missense changes, c.2771G>A in 
exon 21 and c.5779T>C in exon 34 which are predicted to result in the p.R924Q and p.C1927R 
respectively. The identified mutations in the IC (II:2) were analysed in all family members 
including two AFM and three UFM. The c.1533+1G>T was found in the UFM (I:1) and was 
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absent from the AFM (I:2), (III:1) and from both UFM (II:1) and (II:3). The other two changes 
c.2771G>A and c.5779T>C were detected in the AFM (1:2 and III:1) in addition to the UFM 
(II:3) and absent from UFM (I:1) and (II:1) (Figure 3.21). 
3.6.5.1. Linkage analysis and mutation study in family P9F14 
This family included six members, three AFM and three UFM (Figure 3.21). The IC (II:2) 
carried three mutations; a splice change c.1533+1G>T, on one allele and two other mutations 
p.[R924Q;C1927R], on the other allele and presented with undetectable levels of VWF:Ag and 
VWF:RCo (<3 IU/dL), FVIII (7 IU/dL), a high BS (18), O/A genotype and absent multimers 
(Table 3.19). The splice change originated from the unaffected father and p.[R924Q;C1927R] 
on the same allele originated from the affected mother. The p.[R924Q;C1927R] were found in 
the two AFM (I:2 and III:1). The phenotypic data of the AFM (III:1) who had O/O blood group 
genotype indicated markedly reduced of VWF:Ag (19 IU/dL), VWF:RCo (18 IU/dL), FVIII:C 
(25 IU/dL) and abnormal multimers (smeary pattern) while the levels of VWF:Ag, VWF:RCo 
and FVIII:C in the AFM (I:2) who had A/A blood group genotype was moderately reduced to 
57, 58 and 63 IU/dL respectively in addition to normal multimers. Also, p.[R924Q;C1927R]  
were found in UFM (II:3) who had a similar phenotype to AFM (1:2), abnormal multimer and 
blood group genotype A/B (Table 3.19). Linkage analysis results indicated that a shared 
haplotype (red allele) [191]-[155]-[174] (GT repeat, STRIII and STRII) respectively which was 
associated with the splice mutation c.1533+1G>T was present in the IC and unaffected father, 
while the IC (II:2) AFM (I:2), (III:1) and UFM (II:3) shared an  additional haplotype (black 
allele) [187]-[159]-[182] which incompletely co-segregated with the level of VWF and FVIII.  
In summary, this linkage study revealed a non-linkage pattern and the VWF mutation 
inheritance pattern was not completely certain in this family. Although, the IC, the AFM (I:2 
and III:1) and UFM (II:3) had the same mutations and common haplotype, they presented with 
variable phenotypes and this may due to incomplete penetrance and age variation.  
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Figure 3.21 Pedigree of family P9F14 showing linkage analysis and mutation results. The 
linkage analysis marker order was as previously described and is shown underneath each 
member. Females are indicated by circles and males by squares. Filled symbols represent AFM 
and the black arrow indicates the index case. 
Table 3.19 Phenotypic data for family P9F14 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCo 
IU/dL 
FVIII:C 
IU/dL 
CB/Ag Multimer 
pattern 
ABO 
genotype 
I:1 UFM 0 88 79 82 NT Normal O/O 
I:2 AFM 4 57 58 63 NT Normal A/A 
II:1 UFM 0 150 215 88 NT Normal O/A 
II:2 IC 18 3 3 7 0.33 Abnormal O/A 
II:3 UFM 5 57 80 50 NT Abnormal A/B 
III:1 AFM 1 19 18 25 0.63 Abnormal O/O 
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3.6.5.2. In silico predictions 
In silico tools described in section 2.2.5 (SIFT, PolyPhen2 and Align GVGD) were used to 
predict the effect of p.C1927R on protein function. As a result, SIFT and polyPhen2 tools 
predicted that the p.C1927R amino acid variant was probably damaging with 0 and 1 scores 
respectively. Also the Align-GVGD tool predicted the same deleterious effect and suggested 
that the p.C1927R variant is most likely damaging. Furthermore, the human VWF amino acid 
sequence was aligned to protein sequences of twelve different species using the MULTALIN 
tool as described in section 2.2.8. As a result, p.C1927 was shown to be a highly conserved 
residue and is potentially important for VWF protein structure and function (Figure 3.22). 
 
 
Figure 3.22: Schematic representation of the evolutionary conservation of p.C1927 across 
thirteen orthologues. Residue p.C1927 is highlighted by a black rectangle 
(http://mutalin.toulouse.inra.fr/mutalin/). 
 
 
 
 
 
 
 
104 
  
The study conducted by Hickson et al (2010) predicted no effect of the p.R924Q variant on 
VWF function or on the intron 20 acceptor/intron 21 donor splice sites (Hickson et al., 2010). 
Also, results obtained from the neural network, MES and HSF tools predicted that the splice 
variant c.1533+1G>T alters the consensus splice donor site sequence and a skip of exon 13 is 
very likely after comparing the wild-type and mutant sequences (Table 3.20).  
 
Table 3.20 In silico prediction tools to determine the effects of c.1533+1G>T 
Splice site prediction 
tool 
Donor splice site score 
WT allele c.1432+1G 
Range of 
score 
Donor splice site score 
mutant allele c.1533+1G>T 
Neural network 0.98 0-1 0 (splice site loss) 
MES 10.3 0-10 1.67 (splice site loss) 
HSF 90.7 0-100 63.8 (possible splice site 
loss) 
  
For the remaining 14 IC, no new mutation(s) were identified, but heterozygous SNP were 
detected in each. The least SNP number (11) were present in IC P7F8I:2, while IC P10F5II:1 
showed the highest number of SNP (27) (Appendix Table 13).  
Also, 8 IC out of 18 IC were investigated for the presence of CNV and as a result, none of them 
showed any large deletion or insertion (Appendix Table 14) (Cartwright et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
105 
  
3.7. Discussion 
This study aimed to re-analyse and re-sequence VWF among 18 IC historically diagnosed with 
type 1 VWD, where point mutations were most likely to have been missed during the original 
MCMDM-1VWD study. One of the hypotheses proposed that mutations in VWF may have been 
missed in a proportion of type 1 VWD patients who were analysed in the original study due to 
either lack of sensitivity of the detection methods used or due to presence of SNP underneath 
primer annealing sites (Goodeve et al., 2007). In the original study, several mutation detection 
methods have been used to analyse VWF exonic regions. These methods included SSCP, CSGE, 
DHPLC and direct DNA sequencing (Zhang et al., 1994, Abuzenadeh, 1998, Schneppenheim et 
al., 2000, Goodeve et al., 2003), but these mutation detection methods were not sufficiently 
sensitive to identify all point mutations that may be present in the EU cohort. These methods 
range in their degree of sensitivity between 75%  to 100% based on the DNA size and sequence 
context (Markoof et al., 1998, Whittock et al., 1999, Eng et al., 2001).  
 
3.7.1. Polymorphism screening and mono-allelic amplification 
It was proposed that mutation within the 30% of IC from the MCMDM-1VWD study who 
showed no identified mutation could possibly have been missed due to limitations of sensitivity 
of mutation scanning methods that were previously used, due to presence of mono-allelic 
amplification or due to a large deletion or duplication that would not be detected by the methods 
used.  In addition the presence of SNP within primer sequences especially at the 3' end of the 
primer annealing sites can prevent the effective annealing of the primers to the template DNA 
and thereby lead to reduced or absent amplification of the target fragment. To avoid mono-
allelic amplification, historical PCR primers used in the MCMDM-1VWD cohort were checked 
and screened for the presence of SNP within primer annealing sites. Primers found to have SNP 
within their annealing sites were re-designed. In this study, a significant number of VWF 
primers (20 primer pairs) were redesigned according to the criteria described in section 2.2.1. 
They were re-designed either due to presence of SNP within the primer sequence or other 
reasons such as some primers were too close to the target exon, due to poor amplification or due 
to presence of errors in primers sequences (Appendix 10). However, in the VWFP region, it was 
not always possible to design primers following the required criteria, due to the constraint of the 
small number of possible positions to design primers in this region (Figure 3.2). As a result, the 
last nucleotide of forward primers of exon 30 and 31 and the reverse primer for exon 27 were 
closer to the target exon than 50 nucleotides. The reason for the constraint was that the presence 
of SNP within gene-pseudogene mismatched areas prevented design of primers in these regions 
due to the high sequence homology between the two regions. Also, in order to maximise the 
specificity of VWF amplification, to prevent the amplification of the pseudogene and to de-
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stabilise binding of primer to VWFP, mismatches between VWF and VWFP were introduced to 
forward and reverse sequence of primers of several VWF exon (Section 3.2). 
These newly optimised re-designed primers and previously used primers that showed no SNP 
within their sequences were used to successfully amplify and sequence all 52 VWF coding 
exons and flanking intronic regions in 18 selected IC that showed no genetic alteration in the 
original study (MCMDM-1VWD) or mutation that did not fully explain their VWD. Moreover, 
these newly designed primers were used to confirm that no further point mutation(s) had been 
missed because of mono-allelic amplification. In order to avoid the mono-allelic amplification 
during PCR, primers should regularly be checked for the presence of SNP within their annealing 
sites and re-designed when necessary. 
3.7.2. Hypothesis 1; detection of missed mutation in MCMDM-1VWD study 
Throughout this study, four mutations, three of which were novel, were identified in four 
families. Screening for potential missed mutations in VWF within 18 IC revealed two missense 
mutations in exon 26 and 39, one silent mutation in exon 28 and one splice mutation in intron 
12 plus three previously identified mutations (Table 3.2). No new SNP were identified, but 57 
different known SNP in different intronic and exonic VWF regions were found in all studied 18 
IC (Appendix 13). 
 
One novel heterozygous mutation was identified in the exonic region of exon 39 (c.6811T>G) 
in P5F1 II:3 IC predicted to result in p.W2271G . The French family consisted of four members, 
one IC, two AFM and one UFM. In addition to the index case, the two AFM were heterozygous 
for this mutation whereas the UFM was negative. Also during mutational analysis of this IC, no 
new SNP were identified (Appendix 13).  
The p.W2271G missense mutation which is located in the D4 assembly has not been identified 
previously. This heterozygous mutation was likely to be responsible for the abnormal phenotype 
observed in the IC and AFM. The level of plasma VWF:Ag was markedly decreased in IC and 
AFM ranging from 37 to 38 IU/dL (normal range 48-167 IU/dL) and levels of VWF:RCo 
ranging between 32 to 43 IU/dL (normal range 47-194 IU/dL). Moreover, the levels of FVIII:C 
were significantly reduced in the IC (28 IU/dL) and AFM P5F1II2 (34 IU/dL) although their 
bleeding scores were normal ranging between -1 to 2, while the other AFM P5F1I:2 who had a 
high bleeding score of 7 showed a normal level of FVIII:C (85 IU/dL) (normal range 57-198 
IU/dL). A second mutation c.2561G>A predicted to result in p.R854Q that affects the binding 
of FVIII to VWF was present in the two children, IC II:3 plus AFM II:2, but was absent from 
their mother AFM I:2. The presence of p.R854Q is sufficient to explain reduced FVIII:C levels 
in the children and normal levels in the mother who does not carry this mutation. Moreover, the 
bleeding score is affected by age due to an increased chance of haemostatic challenges 
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especially post-delivery, post dental and surgical procedures which can explain the higher BS in 
the mother and lower BS in children due to reduced exposure to bleeding challenges 
(Montgomery, 2005). These mutations may possibly explain the significantly low levels of 
plasma VWF and FVIII:C in the index case and affected members. VWF level is influenced by 
type of ABO blood group. Souto et al (2000) reported that the mean VWF levels in the normal 
population having blood group with one O allele were 25-30% lower than those having no O 
allele.  Also, the average level of VWF in individuals with one O allele (AO) was 2-5% lower 
than the average level in individuals with no O allele, that is the (AA) genotype (Souto et al., 
2000). All family members were phenotypically blood group A, but presence of one O allele 
(AO) with presence of mutation may contribute to slight reduction of VWF level. The multimer 
analysis of all family members revealed a normal pattern. The p.W2271G mutation was fully 
penetrant and appears sufficient to cause VWD in this family. The linkage study in this family 
showed an autosomal dominant inheritance pattern with a common mutant allele [189]-[151]-
[174] (GT repeat, STRIII and STRII) in the IC and affected members which co-segregated with 
the disease phenotype (Figure 3.10).  
 
To determine whether the p.W2271G substitution could be responsible for the reduction in 
VWF levels and to evaluate the mechanism underlying this mutation, in silico prediction was 
performed. Glycine is a simple amino acid and is the smallest of the 20 amino acids having only 
two hydrogen atoms, while tryptophan is larger and has a complex carbon ring structure. The 
replacement of the largest amino acid tryptophan that has a very large steric hindrance with the 
smallest one glycine that has very less steric hindrance at protein position 2271 is likely to cause 
conformational changes and thereby disturb protein expression and structure. As a result, this 
mutation is predicted to be probably damaging and thereby is likely to affect VWF structure or 
function. In type 1 VWD, mutations have been reported to increase the rate of VWF clearance, 
reduce secretion or slightly increase the susceptibility of VWF to ADAMTS13 and cleavage. 
This candidate mutation located in the D4 assembly is most likely increase the intracellular 
retention and thereby reduce VWF secretion as previously described (Eikenboom et al., 2009). 
Mutations in the D4 assembly may lead to production of mis-folded protein which subsequently 
binds to a chaperone protein in the ER. Chaperones cause accumulation of mis-folded mutant 
protein in the ER and prevent their transport to the Golgi and facilitate protein degradation by 
the proteosome in the cytosol  (Brodsky and McCracken, 1997). The substitution of tryptophan 
to glycine may cause the partial quantitative deficiency of VWF due to accumulation and 
retention of protein subunits within the ER resulting in reduction of VWF secretion. Several 
mutations (p.L2207P, p.C2257S and p.R2287W) located in the D4 assembly were identified in 
patients with type 1 VWD. These patients presented with high BS, moderate reduction in the 
levels of VWF:Ag ranging between 26-47 IU/dL, moderate reduction of VWF:RCo ranging 
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between 19-49 IU/dL and normal multimers (Goodeve et al., 2007, Eikenboom et al., 2009) 
which are similar to phenotypic data observed in AFM with p.W2271G. An in vitro expression 
study of VWF mutations located in the D4 assembly that identified in patients with type 1 VWD 
were shown to impair the VWF secretion due to marked intracellular retention as the pathogenic 
mechanism and a normal multimer pattern (Eikenboom et al., 2009). Also, the expression of 
missense mutations identified in patients diagnosed with type 3 VWD located in the D4 
assembly that involved cysteine changes showed reduced secretion due to intracellular retention 
within the cell (Solimando et al., 2012). Moreover, mutation p.S2179F located in the D4 
assembly can influence VWF survival in plasma and thus increase a rate of clearance indicating 
additional mechanism of mutation in this assembly although this family involved in our study 
showed normal clearance (Haberichter et al., 2006). 
Family P5F1 was originally screened and sequenced for VWF mutations by using manual and 
fluorescent CSGE methods during the EU study. Although the pre-screening method CSGE 
followed by DNA sequencing for mutation detection is a sensitive, rapid and reproducible 
method, direct DNA sequencing remains the gold standard method used for detection of 
mutations. Primers used in the original study to amplify VWF exon 39 were checked for the 
presence of SNP underneath their annealing sites. Although there was no SNP found in the 
forward and reverse primers used, it is assumed that this mutation could have been missed due 
to lack in the degree of sensitivity of the CSGE methods used, which is estimated around 76% 
(Hinks et al., 1999, Eng et al., 2001) or due to technical error.  
Mutation analysis revealed a second novel heterozygous mutation which was missed during EU 
study. This missense mutation was located in exon 26 where c.3469T>C was predicted to result 
in the amino acid change p.C1157R in the IC of P9F18 family. This IC had an additional 
previously known mutation of one nucleotide deletion in exon 14 (c.1614del) predicted to result 
in the frameshift deletion p.S539fs and lead to premature termination codon (PTC). No new 
polymorphisms were identified in the P9F18I1 (IC). 
This family included a total of five individuals, two affected members (IC+AFM) who showed 
undetectable levels of VWF:Ag, VWF:RCo and FVIII:C of 3 IU/dL in both and high bleeding 
scores of 9 and 10 respectively. The remaining members were healthy individuals who 
presented with normal levels of phenotypic parameters and normal bleeding scores. 
To determine whether the p.C1157R substitution could be responsible for the reduction in VWF 
levels and to evaluate the mechanism underlying this mutation, in silico prediction was 
performed (Section 2.2.5). As a result, this mutation in the form of a substitution of cysteine 
which is essential for disulphide bridge formation between cysteine residues to arginine at VWF 
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codon 1157 is predicted to be probably damaging and thereby is likely to affect VWF structure 
or function. 
The nucleotide changes were investigated in all family members which showed that p.C1157R 
was identified in the IC (I:1) and the AFM (I:2) while the frameshift mutation was detected in 
all AFM and in two UFM, II:1 and II:2, and UFM (I:3) did not show any nucleotide change. 
The IC and AFM who had the p.C1157R and p.S539fs variants showed an abnormal pattern of 
multimer structure and reduced HMW multimers, whilst a normal multimer pattern was 
observed in the UFM who had only p.S539fs. The presence of a frameshift mutation alone in 
the IC (I:1) and AFM (I:2) was insufficient to explain the very low level of VWF:Ag, 
VWF:RCo and FVIII:C and abnormal multimer pattern, but may explain the normal level of 
VWF level in UFM who harboured only this variant. The UFM (II:1 and II:2) who carried 
p.S539fs only presented with normal BS and that could be explained due to reduced number of 
haemostatic challenges that is affected by age or may due to a haplosufficiency mechanism 
where a single copy of normal gene is sufficient to contribute to normal function of VWF. The 
most carriers of null allele do not have bleeding symptoms (Nichols et al., 2008a, Bowman et 
al., 2013), but symptomatic patients who are heterozygous for frameshift mutation can be 
classified as type 3 carrier VWD.  The frameshift mutation may contribute to the reduction of 
VWF level due to non-sense mediated decay (NMD) mechanism that degrades mRNA 
containing PTC to prevent the production of a truncated protein. These findings suggest that the 
presence of two mutations on different alleles were likely responsible for the very low plasma 
level of VWF in the affected members of this family and could be classified as type 3 VWD. 
The patient was subsequently classified as having VWD3 and was compound heterozygous for 
p.C1157R with p.S539fs. In the current classification, mutations within D3 assembly that cause 
intracellular retention and disturb multimer assembly are classified as type 2A(IIE) 
(Schneppenheim et al., 2010).  
p.C1157R has not been identified previously, but a mutation at the same codon with a different 
substituted amino acid has been described. Hommais et al (2006) identified a heterozygous 
change c.3470G>T predicted to result in a p.C1157F mutation in a family with unclassified 
VWD. In vitro expression and transfection studies reported that the recombinant heterozygous 
VWF (rVWF-C1157F) was retained within the ER which resulted in a failure to form HMW 
multimers and reduced secretion (Hommais et al., 2006a).  
The p.C1157R missense mutation which is located in the D3 assembly has not been identified 
previously. Cysteine residues in VWF are essential and involved in the formation of covalent 
disulphide bridges between the sulfhydryl (-SH) groups of pairs of cysteines within or between 
VWF polypeptide chains. The D3 assembly is located at the amino-terminal of the pro-VWF 
110 
  
dimer and is known to be essential for multimer production and assembly and the presence of 
cysteine loss mutation p.C1157R in this location could explain the abnormal multimers 
observed in AFM who had p.C1157R and normal multimers found in UFM who had the 
frameshift variant only. Moreover, the D3 assembly is the region responsible for the binding of 
VWF to FVIII and some mutations in this domain may reduce FVIII binding. The substitution 
of cysteine with arginine may impair the multimer formation and lead to the protein being 
retained and degraded within the ER and thereby reduced secretion of VWF. 
Several mutations located in the D3 domain have been identified that may impair VWF 
multimerisation and lead to type 2A VWD. The hallmark of VWF among these patients is the 
reduction of HMW multimers, decreased secretion and decreased platelet function (Sadler et al., 
2006). Most mutations that have been identified in D3 assembly are associated with type 2A 
VWD and found to impair multimerisation leading to a reduction in HMW multimers. These 
mutations include p.C1149Y, p.Y1146C, p.C1130F and p.C1125G, while other mutations, such 
as p.C2739Y and p.C2754W, cause a near absence of HMW multimers and low secretion when 
present in homozygous form (Tjernberg et al., 2004, Schneppenheim et al., 2010). Patients who 
harboured mutations clustered in D3 assembly may present with similar phenotypes that include 
a moderate reduction of VWF:Ag, VWF:RCo and aberrant multimer pattern classified as type 
2A(IIE). The secretion defect may be due to mutations affect multimerization causes 
intracellular retention and results in rapid clearance (Haberichter et al., 2008, Schneppenheim et 
al., 2010). The common feature of VWF oligomers observed in patients with mutations in D3 
assembly was the presence of abnormal triplet structure with lack of outer bands results from 
proteolysis of mutant VWF by ADAMTS13.  
The linkage study in family P9F18 demonstrated an autosomal recessive inheritance pattern and 
shared a common mutant allele [187]-[159]-[174] (GT repeat, STRIII and STRII) respectively 
in the IC and the AFM who had an elevated BS, very low VWF:Ag and abnormal multimer 
associated with p.C1157R mutation and also a common mutant allele [187]-[163]-[174] in the 
IC, AFM (I:2), UFM (II:1 and II:2) which is associated with the frameshift mutation (Figure 
3.13). All these findings co-segregated with the low level of VWF:Ag and disease phenotype.  
Family P9F18 was initially screened and sequenced for VWF mutation by using the DHPLC 
method during the EU study. SNP within the primer sequence could mask a heterozygous 
genetic defect, and this could cause a mutation to be missed (mono-allelic amplification) 
(Eikenboom et al., 1994, Thomas et al., 2006b, Hampshire et al., 2010). However, it is assumed 
that this mutation could have been previously missed in the MCMDM-1VWD study due to 
presence of a SNP found underneath both of the forward and reverse primer annealing sites 
(Table 3.7).  
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In family P10F5, a silent heterozygous mutation was identified during EU study. It was 
identified in exon 28 and could be responsible for the phenotype present. This silent change was 
located in the A1 domain at nucleotide position c.4146G>T, and was predicted to result in the 
silent change p.L1382=. This change had been identified previously during the MCMDM-
1VWD and it was found in the female AFM (I:1) and IC was not analysed due to absence of 
sufficient quantity of DNA sample (Hampshire et al., 2010). However, it was excluded from a 
previous re-analysis of MCMDM-1VWD patients due to unavailability of a sufficient quantity 
of DNA in family members to rule out the co-segregation of the mutation with type 1 VWD 
(Hampshire et al., 2010). 
In the current study, it was identified in the IC (II:2) who did not have any additional pathogenic 
change, but in whom 27 previously known heterozygous polymorphisms were found and also 
identified in the AFM (I:1). It was detected currently because less DNA is now needed using 
direct sequencing. 
In order to confirm whether this change was a SNP, it was screened in 107 healthy individuals 
and was absent from all but 4, with low frequency of 0.996/0.004 within the Caucasian 
population.  
This family consisted of four members, two affected members and two healthy individuals. The 
IC (II:2) and the affected mother (I:1) showed a mild reduction in plasma levels of VWF:Ag, 
VWF:RCo and FVIII:C with bleeding scores of 4 and 6 respectively. The healthy individuals 
presented with normal phenotypic data and normal bleeding scores.  
The identified variant c.4146G>T was examined in all family members and it was found in 
addition to the IC in the AFM (I:1) but was absent from the remaining individuals (Figure 3.16). 
All family members had a normal multimer pattern and had O/O ABO genotype which may 
contribute to the reduction of VWF level in the affected individuals.  
Using the previously described linkage markers, the affected mother and the son (IC) who had 
an elevated BS and abnormal phenotype shared a mutant allele [193]-[155]-[174] (GT repeat, 
STRIII and STRII) respectively (Figure 3.16) which segregated with the silent change. This 
synonymous variant was examined for any potential creation of new splice site and in silico 
analysis predicted that the change would not create a new donor or acceptor splice site but was 
found to have a potential effect on splicing regulatory enhancers and silencers. Also, the wild-
type triplet codon CTG was found more frequently used than mutant codon CTT which may 
influence translation rate and protein folding (Nakamura et al., 2000). 
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Primers used in the original study to amplify VWF exon 28 were checked for the presence of 
SNP underneath their annealing sites. Although there was no SNP found in the forward and 
reverse primers used, this mutation was not missed, but excluded from the MCMDM-1VWD 
study because the IC was not originally screened due to insufficient DNA and only the family 
members were screened first and it was identified in the AFM. 
Unlike regular mutations that impair protein production when one specific amino acid is 
replaced by another, it was previously believed that silent changes that encode the same amino 
acid with different codons cannot lead to a genetic disease. Knobe et al, (2008) studied the 
effect of a silent mutation c.321G>A predicted to result in p.V107= in exon 5 of the F9 gene in 
five Swedish families diagnosed with haemophilia B. The absence of other variants in the 
remaining exons, closely flanking introns and the promoter was confirmed. As a result, it was 
assumed that the silent F9 change reduces the translation rate and thus impairs protein folding. 
No effect on splicing mechanisms was predicted (Knobe et al., 2008).  
It has been suggested that apparently silent change may always not be neutral and may play an 
essential role for translation and gene function of regulatory elements including for messenger 
RNA (mRNA). The silent change may alter kinetics of protein translation and folding via 
different mechanisms. It was found that silent substitutions can be affected by codon frequency 
as some codons are recognised more efficiently by tRNA corresponding to this codon compared 
to others which can alter the efficiency and accuracy of translation (Hershberg and Petrov, 2008, 
Zhang et al., 2010). Following transcription, mRNA moves through ribosome forming rRNA-
protein complex followed by transferring the amino acids by different transfer RNA (tRNA) at 
variable speed to link the amino acid to the growing polypeptide chain. However, the triplet 
code alteration resulting in a silent change may affect the mutant codon translation rate, 
translation efficiency, protein folding and expression due to variable speed of tRNA 
transportation of the replacement mutant codon (Sorensen and Pedersen, 1991, Lavner and 
Kotlar, 2005). Also, the synonymous codon exchange impairs the translation rate which 
subsequently alters ribosome movement on mRNA. The acceleration or delay of nearby 
multiple ribosomes movement affects mutant codon folding and can terminate translation due to 
mis-folding (Komar et al., 1999, Nackley et al., 2006). 
Experimental studies showed that silent mutations can impair mRNA folding, stability of 
secondary structure of mRNA and the rate of translation and thereby impair gene function 
(Sharp et al., 1995, Chamary et al., 2006, Shabalina et al., 2006). As a result of this codon bias, 
silent mutations can change mRNA shape, impair its normal translocation with the ribosome 
and delay its translation rate and protein production.  
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It was believed that mRNA acts as a carrier of genetic code and transmitting of genetic 
information from genes to functional protein only, but recent studies have shown that mRNA 
plays an essential role of controlling and regulating numerous nucleotide signals that are 
required for protein production and function (Sauna and Kimchi-Sarfaty, 2011, Shabalina et al., 
2013).  
The rate of protein expression is influenced by the position of the affected nucleotide within the 
triplet codon. Shah et al (2008) reported a reduction in the rate of expression when the 
nucleotide change is present at the third position of a silent codon which impairs transport of the 
codon by tRNA (Shah et al., 2008). 
Hurust (2011) reported that a silent mutation in IRGM gene encoding (immunity-related 
GTPase family, M) found in patients with Crohn's disease can be highly deleterious. The 
nucleotide change leading to a silent change may form a small section of mRNA which has a 
sequence complementary to micro RNA (miRNA) forming a double stranded RNA which is 
destroyed or prevented from translation (Hurst, 2011).  
Furthermore, it was suggested that the silent mutations may affects mRNA splicing by 
destroying or creating splicing site sequences including exonic splicing enhancer (ESE) or 
exonic splicing silencer (ESS) sites resulting in abnormal splicing mechanism and causes exon 
skipping and NMD which could contribute to VWD pathogenicity  (Blencowe, 2000, Pan et al., 
2008). However, the presence of the silent change in the affected members of the EU family 
may impair splicing mechanism contributing to the reduction of the VWF level due to NMD. 
From these findings, silent mutation alters the translation rate, protein mis-folding or disrupts 
splicing mechanism can be considered as the possible mechanisms in this family. 
Family P10F8 were shown to have a novel heterozygous intronic change at the donor splice site 
of intron 12 c.1432+1G>T in IC II:1 in addition to previously identified p.R816W (type 2N). 
This small family consisted of three members, one IC, one AFM and one UFM. In addition to 
the IC, the AFM was heterozygous for this mutation whereas the UFM was negative for the 
substitution.  
This substitution was located within the donor splice site of intron 12 and had not been 
identified previously. This heterozygous mutation was likely to be responsible for the abnormal 
phenotype observed in the IC (daughter) and AFM (son) who showed a reduction in the level of 
VWF:Ag. Initially, this family was excluded from the original EU study due to absence of a 
maternal allele in the offspring and also this family was non informative for linkage between 
VWF and type 1 VWD. The non-linkage between family members was re-assessed by using 
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new SNP markers and swapping the genotypic and phenotypic data of the mother I:2 and the 
son II:2. As a result of these modifications and according to revised linkage analysis and family 
pedigree, it was suggested that two mutant alleles were inherited by the daughter (IC). They 
include the mutant allele [CTGTGA] that was associated with the c.1432+1G>T change which 
seems to have originated from the mother I:2 and the mutant allele [TCAAAG] which was 
associated with the type 2N (p.R816W) mutation which affects VWF binding to FVIII found 
only in the IC (daughter) and was likely to have originated in the father who was not recruited. 
In this family, the IC (II:1) who was compound heterozygous for c.1432+1G>T and p.R816W 
and had high BS, mild reduction of VWF:Ag (49 IU/dL) and VWF:RCo (52 IU/dL) levels, a 
significant reduction of FVIII:C level (14 IU/dL) resulting from presence of p.R816W that 
affects binding of FVIII to VWF but not multimer profile. The mother (I:2) was heterozygous 
for c.1432+1G>T only and exhibited a normal BS, mild reduction of VWF:Ag (47 IU/dL) and 
normal VWF:RCo and FVIII:C levels. The AFM who had the c.1432+1G>T mutation bleeds 
and this may be due to haploinsufficiency where produced VWF was reduced in all AFM. Both 
mutant alleles were absent from the son (UFM) who exhibited normal phenotypic data. The 
presence of the c.1432+1G>T mutation that leads to a null allele may possibly explain the mild 
reduction of plasma VWF levels in the IC and in the AFM. Moreover, the presence of splice 
donor and the p.R816W mutations in the IC in addition to blood group O (O/O) may explain the 
reduced level of FVIII:C in the IC and the normal levels in the son and mother who did not 
carry this variant. 
The splice donor site mutation was incompletely penetrant and this was explained by mild 
reduction of plasma phenotypes in the IC and this may be more deleterious when second defect 
on the other VWF allele is co-inherited.  
Several splice-site mutations have been identified in VWD patients (James et al., 2004, 
Gadisseur et al., 2007). In vitro study of donor splice-site variant c.3538+1G>A found in VWF 
intron 26 identified in type 2A/IIE VWD patient was found to cause exclusion of exon 26 
(James et al., 2004). Nesbitt et al (1999) reported the presence of a donor splice site mutation in 
intron 25 which results in a null allele in two unrelated patients who had two different type 2N 
mutations; p.R854Q and p.T791M respectively on their second alleles. A third patient was 
found to have type 2N p.T791M co-inherited with a stop codon p.Q1707*. These patients were 
phenotypically diagnosed as type 1 VWD and were found to have a mild reduction of VWF:Ag 
and VWF:RCo levels with very low levels of FVIII:C and absent binding of FVIII to VWF. 
Initially, the presence of type 2N mutations was not enough to explain the observed phenotype 
in the IC especially markedly reduced levels of FVIII. The phenotype was consistent with the 
compound heterozygosity (Nesbitt et al., 1999). Also, type 2N mutation p.G785E was identified 
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in combination with a stop codon variant in a patient diagnosed with type 1 VWD who showed 
mild reduction in VWF:Ag and severe reduction of FVIII:C (Gu et al., 1997). The presence of a 
donor splice site mutation in one allele causes a mild effect in VWF level and this may be due to 
haploinsufficiency.  
The linkage study in this family showed an autosomal dominant inheritance pattern with a 
common mutant allele [CTGTGA] in the IC and affected members associated with 
c.1432+1G>T which co-segregated with the disease phenotype (Figure 3.20). To determine 
whether the c.1432+1G>T substitution could be responsible for the reduction in VWF levels 
and to evaluate the mechanism underlying this mutation, in silico prediction was performed. 
The results achieved from splice prediction tools indicated that the c.1432+1G>T candidate 
mutation was most likely to be deleterious and resulted in disruption of the splice donor-site 
sequence and skipping of exon 12. This may abolish the wild-type exon 12 donor site and would 
result in retention of intron 12 sequence and it is predicted to result in a frameshift 
p.C432Vfs*9. The donor splice site c.1432+1G>T likely causes a null allele and results in 
reduction of VWF level in the AFM due to NMD mechanism that degrades mRNA containing 
PTC. 
SNP within the primer sequence were sought and it was therefore assumed that this mutation 
could have been previously missed in the MCMDM-1VWD study due to presence of SNP 
found underneath the forward primer annealing site (Table 3.15).  
This study was able to confirm the presence and detect mutations that were previously identified 
by the EU study. Three mutations were detected in the study in one IC and also detected in this 
study included c.1533+1G>T; p.[R924Q;C1927R]. The splice prediction tools indicated that the 
c.1533+1G>T candidate mutation was most likely to be deleterious and resulted in disruption of 
the splice donor-site sequence and a skip of exon 13. This may abolish the wild-type exon 13 
donor site and would result in retention of intron 13 sequence, skipping of exon 13 sequence 
and loss of 101 amino acid. It was predicted to result in a frameshift p.G478Cfs*138 which 
creates a stop codon 138 amino acids, downstream of the mutation. It was predicted to produce 
a null allele due to NMD. Also, the p.C1927R was predicted to be damaging to VWF and 
p.R924Q predicted to have no effect on VWF expression. 
The level of plasma VWF is influenced by multiple factors either genetic, environmental or 
both. For the remaining index cases listed in table 3.1 who showed no mutation neither in the 
original study nor in this study despite the reduction of VWF level, may due to presence of a 
large deletions or duplications that could not be detected by the standard sequencing methods 
and require an advanced mutation detection method. Cartwright et al (2013) identified large 
deletions of exon 4-5 in three of these IC in addition to deletions of exon 3, exons 32-34 and 33-
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34 in one IC each (total of 6 large deletions) within this cohort where no VWF mutation had 
been identified in the original EU study (Cartwright et al., 2013). Eight out of 18 IC were 
investigated for the presence of CNV, but none of them showed any large deletions or 
duplications. 
Mutations may also be missed due to deep intronic or transcriptional changes in regions of VWF 
not analysed. Mutations in these regions may alter the normal splice sites or may impair the 
initiation of normal translation process. Mutations in deep intronic regions can impair normal 
splicing due to creation of an aberrant pseudoexon within intronic regions that impair mRNA 
synthesis (Khelifi et al., 2011). Also, it has been found that mutations in deep intronic regions 
can create new cryptic splice site that disrupt mRNA normal synthesis (Corrales et al., 2011, 
Pezeshkpoor et al., 2013). 
Furthermore, mutation may be missed due to the presence of a genetic defect in another gene 
outside of VWF such as STXBP5, STX2, STAB2, CLEC4M and SCARA5 which have been shown 
to correlate with VWF:Ag levels (Smith et al., 2010, Rydz et al., 2013).  
Of the 14 IC with no VWF mutation after further screening, 10 patients had VWF:Ag levels less 
than 50 IU/dL and the remaining 4 less than 62 IU/dL (between 51-61 IU/dL). The bleeding 
score in these IC was significant (>3) ranging between 3 and 19 (Table 3.1). The multimer 
pattern was normal in all remaining IC except one IC (P9F14II:2) who showed abnormal 
multimers. The level of VWF is decreased significantly in the normal population with blood 
group O rather than other blood groups (Gill et al., 1987, Shima et al., 1995). The ABO 
genotype for all 14 IC was O/O except for two IC P8F2II:2 (O/A2) and P8F3I:2 where ABO 
genotype was not determined. These findings may support the effect of different gene loci on 
the level of VWF. None of the remaining 14 IC had large deletion or insertion (Appendix 14). 
In conclusion, this research was able to identify four mutations, three of which were novel in 
exons 26, 39, intron 12 in addition to silent change in exon 28 in four families. These mutations 
were missed in the previous MCMDM-1VWD study due to limitations in the sensitivity of the 
methods used, due to technical error or due to the presence of SNP within PCR primer 
annealing sites leading to mono-allelic amplification. These findings confirmed that direct DNA 
sequencing is a sensitive method for mutation detection and the presence of SNP within primer 
sequences may hide heterozygous mutations. The presence of other genetic alterations in VWF 
such as heterozygous deletions or duplications or the presence of genetic defects elsewhere in 
VWF or in other genes may affect the level of VWF and thus the extent of bleeding. Further 
investigations are required in order to explain the molecular pathogenesis behind 
mucocutaneous bleeding and reduced VWF levels in these cases with a historic diagnosis of 
type 1 VWD. 
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4. In vitro expression of type 1 VWD candidate mutations 
4.1. Introduction  
Type 1 VWD is characterized by a partial quantitative deficiency of plasma VWF, variable 
penetrance and expressivity. VWF is synthesised in endothelial cells and megakaryocytes. Pre-
pro VWF dimerisation and folding take place in ER via formation of disulfide bonds between 
adjacent VWF monomers through their c-terminal regions (Katsumi et al., 2000). VWF that is 
successfully dimerised and folded in the ER moves to the Golgi apparatus where 
multimerisation occurs via disulfide bonds between adjacent D3 assemblies to produce HMW 
multimers (Section 1.4) (Mayadas and Wagner, 1992). VWF that shows improper folding is 
retained in the ER which is rapidly degraded causing reduced secretion (Lodish, 1988, Hurtley 
and Helenius, 1989).  
The European Union study (MCMDM-1VWD) successfully identified candidate mutations 
throughout VWF in approximately 70% of type 1 VWD IC and these are mostly made up of 
missense mutations. The remaining IC showed no candidate mutations (Goodeve et al., 2007, 
Hickson et al., 2010). The current study was able to identify additional novel mutations that 
were missed in the previous analysis (Section 3.6). Eighteen out of 42 IC who showed no 
previously identified mutations or mutations that were identified, but were insufficient to 
explain the patient’s phenotype were screened using direct sequencing for the presence of 
missed mutations. As a result, four mutations were identified in four index cases, two novel 
missense changes; c.3469T>C (p.C1157R) and c.6811T>G (p.W2271G) in exons 26 and 39 
respectively, one silent change; c.4146G>T (p.L1382=) in exon 28 and one novel splice change; 
c.1432+1G>T in intron 12. In silico analysis of the newly identified mutations suggested that 
the two missense mutations were probably damaging, the silent mutation was predicted to 
disrupt several exonic splicing enhancer (ESE) sites and alter the splicing mechanism and the 
splice change was predicted to result in a frameshift due to retention of intron 12. The purpose 
of in vitro expression is to try and determine how each mutation has an effect within the cells 
and to understand the main mechanisms that lead to disease pathogenicity. These mechanisms 
need to be found in order to understand the function of the mutations and to try and replicate the 
phenotype of the patients using in vitro expression. For the particular mutations, in the 
heterozygous form type 1 VWD phenotype is examined and in the homozygous form a potential 
type 3 VWD phenotype is examined. 
Previous studies have investigated the mechanism of several novel mutations that resulted in 
VWD by in vitro expression. Eikenboom et al (2009) performed in vitro expression on 14 
candidate missense mutations identified within the MCMDM-1VWD cohort. Mutant constructs 
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were generated by undertaking site-directed mutagenesis on pcDNA3.1 plasmid containing 
VWF cDNA expressed in COS-7 cells. The expressed mutations were located in a number of 
VWF domains and some involved cysteine residues. As a result, intracellular retention and 
impaired secretion of VWF were recognised as the main mechanisms behind the pathogenicity 
for some of the mutations (Eikenboom et al., 2009). Also, a cluster of mutations in the VWF D3 
assembly identified in patients with type 2A(IIE) VWD were expressed. Most of these 
mutations involved cysteine residues and were expressed using the 293-EBNA cell line 
(Schneppenheim et al., 2010). This study showed that most of these D3 assembly mutations lead 
to intracellular retention as the main mechanism of pathogenicity in addition to abnormal 
multimers. 
Since patients’ blood was not available and hence BOEC cells could not have been prepared, a 
heterologous expression system was used whereby transient transfection of the desired mutant 
plasmid into cell lines to measure an outcome was used. Many expression studies for VWF have 
used various mammalian cell lines including HEK293T, Aat20 and COS-7 (Eikenboom et al., 
2009, Schneppenheim et al., 2010). However, HEK293T cells have a number of advantages 
over COS-7 cells for analysis of VWF mutants. The HEK293T cells were first described in 
1977 (Graham et al., 1977). They are a specific cell line originally obtained from human 
embryonic kidney obtained from a foetus that was legally aborted and the 293 comes from the 
product of his 293
rd
 experiment. These cells are widely used for expression of various genes and 
contain the simian vacuolating virus 40 (SV40) origin of replication that enables transformation 
of many cell types. HEK293T cells contain the SV40 large T-antigen required for plasmid 
replication and result in a high level of transient expression of gene products.  
HEK293T cells were selected particularly to be used for transient transfection for wild-type and 
mutant VWF in this study. HEK293T cells do not express endogenous VWF hence only VWF 
that is transiently transfected will be expressed. Also, these cells make WPB-like organelles for 
storage of VWF. The formation of WPB-like organelles requires VWF to be present. The cell 
line is very easy to culture, to transfect and very hardy, making them a good and readily 
transfectable cell line to use. They are characterized by fast growth reaching 70-90% confluency 
within 48 hr of splitting.  
Transfection using Lipofectamine was undertaken to introduce plasmid DNA containing the full 
length VWF cDNA into HEK293T cells. Lipofectamine LTX transfection reagent was the 
selected method used to mediate and deliver the plasmid containing the full length VWF cDNA 
into HEK293T cells. Compared to other transfection methods, Lipofectamine LTX has low 
toxicity. Also, there is no need to change the media after 4-6 hr unlike other more toxic 
reagents. Moreover, Lipofectamine LTX reagent is highly efficient at transfecting cells and 
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hence a large proportion of cells may be transfected. Lipofectamine was used to transiently 
introduce full length wild-type and mutant plasmid DNA into HEK293T cell lines (Section 
2.2.13.5). 
The presence of a candidate mutation in VWF resulting in a missense change does not 
conclusively confirm that this mutation is the main cause of the VWD phenotype in the patient. 
One of the main aims of this study was to transfect the mutagenized plasmid bearing mutant 
cDNA (recombinant VWF-rVWF) into HEK293T mammalian cells and to perform in vitro 
expression of selected VWF mutations during this study in order to determine the effect of 
candidate mutations on VWF structure and function. Also, this study was aimed to analyse the 
multimer structure of secreted VWF in addition to confocal microscopy to evaluate the effect of 
mutants in VWF storage following transfection. 
In each transfection experiment, the efficiency of transfection was evaluated using Renilla 
plasmid as a control in transfections via measuring the luciferase activity. Renilla was used in 
order to correct for transfection efficiencies and to confirm that the quantities of expressed 
protein detected by ELISA was a true reflection of what was happening in the cells. 
Six mutations detected in the EU study were subjected to further study in order to determine the 
mechanisms by which the mutations identified affect VWF synthesis and secretion. Three 
candidate missense mutations identified in two IC were expressed in this study. First, 
c.6811T>G predicted to result in the p.W2271G mutation located in D4 assembly that was 
identified in family P5F1 with type 1 VWD in addition to a second mutation p.R854Q known to 
impair VWF binding to FVIII (Section 3.6.1). The affected members having this novel mutation 
presented with moderate bleeding symptoms and were found to have reduced levels of 
VWF:Ag, VWF:RCo and a marked reduction in FVIII level in individuals who had both 
mutations (Section 3.6.1.1). Secondly, two missense mutations, c.2771G>A in exon 21 and 
c.5779T>C in exon 34 which were predicted to result in p.R924Q (D3 assembly) and p.C1927R 
(D4 assembly) respectively were identified in family P9F14 on the same allele (Section 3.6.5). 
The affected members harbouring these two changes presented with moderate reductions in 
their phenotypic data.  
Since the p.W2271G and p.C1927R are located in the D4 assembly and appeared to be 
responsible for type 1 VWD, their effect on VWF level and structure were analysed using in 
vitro expression. In vitro expression studies of various mutations located in the same assembly 
showed a secretion defect of VWF due to intracellular retentions in type 1 and type 3 VWD 
patients. The transient transfection using COS-7 cells undertaken on four mutations; p.L2207P, 
p.C2257S and p.R2287W located in the D4 assembly showed a significant reduction of secreted 
VWF accompanied by intracellular retention and abnormal HMW multimers when present in 
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homozygous form (Eikenboom et al., 2009). Also, the expression of p.L2207P and p.C2257S in 
the heterozygous form results in a significant secretion defect due to intracellular retention and 
normal HMW multimers. The other mutations not involve cysteine residues; p.R2287W showed 
a mild secretion defect while p.P2063S revealed normal VWF expression (Eikenboom et al., 
2009, Hampshire and Goodeve, 2013). 
The heterozygous transfection of cysteine loss mutations p.C2184S and p.C2212R located in the 
D4 assembly identified in type 3 VWD showed a moderate reduction of secreted VWF and 
normal multimers while homozygous forms of both mutations illustrated a severe reduction, 
intracellular retention and abnormal multimers (Solimando et al., 2012).  
In an attempt to investigate whether these candidate mutations were the major cause for the 
observed phenotype correlated with type 1 VWD in affected patients, in vitro expression of 
mutant rVWF was carried out using transient transfection. In order to create a specific 
mismatch, QuikChange® lightning site-directed mutagenesis was used. 
The transfection experiments of mutant and wild-type constructs were conducted in triplicate 
and repeated three times and the level of intra and extracellular VWF was measured using the 
ELISA method. The initial set up and optimisation of the ELISA and transfection methods was 
previously performed within the group. 
 
4.2. Results 
4.2.1. Confirmation of wild type VWF cDNA sequence 
The pcDNA3.1/Hygro (-) expression plasmid containing the full-length wild type human VWF 
cDNA was kindly provided by Prof. Reinhard Schneppenheim, Germany. The full length VWF 
cDNA originated from the VWF-PMT2 plasmid which was transferred to a pcDNA3.1/Hygro (-
) expression plasmid. The VWF cDNA was introduced into the plasmid using two restriction 
enzymes, EcoRI and NotI, producing a 14kb pcDNA3.1VWF plasmid.  
The wild-type VWF cDNA3.1 was isolated from E.coli NM554 cells. The entire VWF cDNA 
plasmid was sent for sequencing and the received data was aligned to the VWF reference 
sequence (Gene ID: ENSG00000110799; Accessed May 2011) (Section 2.2.12.5.1). As a result, 
the two sequences aligned except for the presence of five variant sites (Table 4.1). All detected 
variants were reported in the ISTH VWF mutation database and none of them would be 
expected to impair VWF function or structure (www.ragtimedesign.com/vwf/polymorphism, 
Accessed May 2011) (Section 2.2.12.5.1). 
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Table 4.1 List of SNP identified in full length VWF cDNA 
Nucleotide 
change 
Location 
Exon/intron 
Minor allele frequency % 
(1000 genomes) 
Amino acid 
change 
Effect on 
protein 
expression 
c.2555A>G Exon 20 10.3 p.R852Q No effect 
c.4141A>G Exon 28 27 p.T1381A No effect 
c.4414G>C Exon 28 15 p.D1472H No effect 
c.4641T>C Exon 28 30 p.T1547= Silent 
c.7239T>C Exon 42 14.3 p.T2413= Silent 
 
4.2.2. Efficiency of site-directed mutagenesis and transformation  
A series of different quantities of DNA plasmid template of 10, 25, 50 and 100 ng were added 
to separate mutagenesis reactions in order to optimise the number of colony following 
transformation. Mutagenesis was then performed on each template with primers designed to 
introduce the identified mutations into the plasmid VWF cDNA. As a result, the best colony 
number was achieved when using a template quantity of 100 ng.  At this DNA quantity, more 
than 5 colonies grew on transformed agar. The number of colonies was less when using 50ng 
and no colonies were observed when using 10 and 25ng. 
Also, the efficiency of mutagenesis and transformation was evaluated using pWhitescript 4.5 kb 
and pUC18 control plasmids respectively (Section 2.2.12.4). The pWhitescript control plasmid 
contains a TAA stop codon instead of the CAA codon that encodes glutamine at amino acid 
position 9 that appears normally in the ẞ-galactosidase gene. The oligonucleotide control 
primers used for mutagenesis of the control plasmid produce a point mutation on the 
pWhitescript plasmid where T in the stop codon replaced by C enables creation of the glutamine 
found in the wild-type sequence. However, following transformation of control plasmid in 
XL10-Gold ultracompetent cells on agar plates containing IPTG and X-gal, the colonies of 
pWhitescript plasmid that contains a stop codon appear white due to inactivity of ẞ-
galactosidase gene, while the control plasmid that contains the normal sequence of ẞ-
galactosidase gene due to mutagenesis shows blue coloured colonies due to metabolisation of 
glutamine. 
The efficiency of mutagenesis of the pWhitescript control plasmid and of transformation of the 
pUC18 control plasmid were evaluated by calculating the percentage of blue colonies from the 
transformation of pWhitescript and pUC18 control plasmids on agar plates containing IPTG and 
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X-gal. As a result, the mutagenesis and transformation were highly efficient with values of 96.2 
and 98.7% respectively. 
4.2.3. Mutagenesis 
Initially the plasmid DNA was sent for sequencing following mini-prep to confirm the presence 
of the desired mutation only. As a result, the sequencing data successfully showed the presence 
of the desired change in the plasmid DNA for all examined variants listed in appendix 8. The 
T>G transition at nucleotide 6811 for the rVWF-G2271, predicted to result in amino acid 
exchange of tryptophan by glycine, c.2771G>A for the rVWF-Q924 predicted to result in 
exchange of arginine by glutamine and c.5779T>C predicted to result in exchange of cysteine 
by arginine were successfully introduced into the full length VWF recombinant plasmid (Figure 
4.1). Also, both mutations p.[R924Q;C1927R] were successfully introduced into the full length 
rVWF on the same allele to mimic the allelic state. Mutagenesis was undertaken using 
pcDNA3.1 plasmid template in order to express the novel candidate mutations p.W2271G, 
p.R924Q. p.C1927R and p.[R924Q;C1927R] respectively (Figure 4.1). Additional sequencing 
of the entire VWF cDNA for each revealed no further mutations following the maxi-prep. 
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Figure 4.1 Sequence chromatographs to show introduction of novel variants into the cDNA VWF plasmid. A, C and E show the wild type VWF 
cDNA sequence. B) Shows the p.W2271G change (c.6811T>G); D) shows the p.C1927R change (c.5779T>C); F) shows the p.R924Q change 
(c.2771G>A.
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4.2.4. In vitro expression of recombinant VWF containing the candidate mutations 
The rVWF plasmid harbouring each candidate mutation was transiently transfected into 
HEK293T cells in parallel with rVWF-WT plasmid using Lipofectamine to evaluate the effect 
of the candidate mutation on VWF expression. In order to mimic the in vivo state and to 
replicate the phenotypic pattern of patients with each mutation, co-transfection of mutations was 
carried out using three different conditions. The first experiment was conducted to mimic the 
wild-type state using 100% (6µg) wild-type plasmid while in the second condition; the same 
quantity of mutant plasmid was transfected in order to mimic the mutant homozygous state. In 
the third condition, a mixture of 50% wild-type (3µg) and 50% of recombinant mutant plasmid 
(3µg) was transfected making a final quantity of 6 µg in order to mimic the heterozygous state 
of the mutation (Section 2.2.13.5). For each condition, transfection was undertaken in triplicate 
and repeated three times. The tissue culture supernatant and harvested cell lysate were collected 
48 hr post transfection (Section 2.2.13.6). Following co-transfection, the level of VWF:Ag 
secreted from HEK293T cells into the growth medium and that retained within the HEK293T 
cells resulting from expression of transfected plasmids bearing wild-type and mutant sequences 
was analysed using ELISA (Section 2.2.14.2). The expression level of transfection data was 
normalized to correct for transfection efficiency of the cells using Renilla.  
The expression data of wild-type, homozygous and heterozygous plasmids in the medium and 
cell lysates was calculated using the standard curve plotted between the known concentrations 
of each diluted reference plasma against its corresponding optical density (OD) (Figure 4.2). 
The VWF concentration was divided by Renilla expression to give a ratio, from which mutants 
were then compared to wild type expression. Mean values of VWF either homozygous or 
heterozygous mutant were expressed as a percentage with respect to the expressed level of wild-
type. Statistical analysis including mean values, standard deviation (SD), one way test and 
“analysis of variance (ANOVA)” to compare mean values of wild-type, homozygous and 
heterozygous VWF with each other were calculated. 
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Figure 4.2 VWF standard ELISA curve plotted between reference VWF plasma with 
known concentration (x) against its corresponding OD (y). The red dots represent the VWF 
antigen level expressed by transfected HEK293T cells with mutant plasmid after 48 hr. The 
expression data of wild-type, homozygous and heterozygous in the medium and cell lysates was 
calculated against the readings of VWF level in the reference plasma calibrator. 
4.2.5. Quantitative analysis of supernatant and cell lysates following transfection of 
HEK293T cells with rVWF-WT and mutant plasmid (rVWF-G2271) 
Analysed mean values of secreted VWF obtained by expression of wild-type plasmid alone, 
mutant plasmid alone (homozygous) and mutant plasmid co-expressed with WT (heterozygous) 
are shown in table 4.2. The observed mean values of secreted VWF:Ag of mutant heterozygous 
and homozygous rVWF-G2271 into growth medium were significantly decreased to 23% and 
3.5% respectively compared to 100% of rVWF-WT (Figure 4.3). The difference in the secreted 
VWF level for heterozygous and homozygous states compared to wild-type was statistically 
significant with P values of <0.0001 (ANOVA) (Figure 4.3). In the HEK293T cell lysate, data 
showed mildly increased mean values of retained VWF of heterozygous rVWF-G2271 in the 
cells compared with the corresponding values of 100% wild-type with values of 109.5% 
(P>0.05) and intracellular mean values of VWF:Ag of homozygous rVWF-G2271 was 
significantly increased to 130.6% (P<0.05) compared to the wild-type (Table 4.3) (Figure 4.3). 
In summary, the p.W2271G change lead to a significant difference in the level of secreted 
VWF:Ag in both heterozygous (77%) and homozygous (96.5%) states compared to 100% of 
wild-type and these values attained statistical significance indicating that p.W2271G results in 
VWF secretion defect due to intracellular retention. Also, the expression data from HEK293T 
cell lysates indicated an increase in the level of retained VWF within the cells, although this 
increase was not significant in the heterozygous state, but was significant for the homozygous 
mutant. 
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Table 4.2 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-G2271) in HEK293T cells 
VWF (supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 21.0 
WT:Mut (50:50) (heterozygous) 23.0 8.8 
rVWF-W2271G (homozygous) 3.5 2.5 
*SD= standard deviation 
 
Table 4.3 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-G2271) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 20.0 
WT:Mut (50:50) (heterozygous) 109.5 18.5 
rVWF-W2271G (homozygous) 130.6 29.5 
*SD= standard deviation 
 
 
Figure 4.3 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.W2271G 
mutation on VWF expression. Results are expressed as a percentage in comparison with wild-
type. The horizontal black bars represent the extent of difference between mean values of 
VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate the standard 
deviation. Statistical test used was one-way ANOVA. 
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4.2.5.1. Multimer analysis of expressed mutation 
The multimeric composition of VWF secreted from the transfected HEK293T cells into the 
growth medium was evaluated using medium resolution 1.6% sodium dodecyl sulphate (SDS) 
in agarose gel electrophoresis (Section 2.2.16). A full array of multimer bands was observed in 
the normal VWF in plasma composed of high, intermediate and low molecular weights 
multimers. Each multimer band consists of triplet bands that include a central band located 
between two faint satellite proteolytic bands. For each mutation, multimers were analysed for 
transfections of rVWF-wild-type, mutant-rVWF and co-transfection of wild-type with mutant 
(hybrid) secreted from HEK293T cells (media). All obtained multimer analysis results in the 
current study were kindly provided by Prof. Ulrich Budde on medium resolution 1.6% SDS gels 
at 1:3 or 1:5 dilutions (Hamburg, Germany). 
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4.2.5.1.1. Multimer analysis for the p.W2271G VWF protein secreted from 
HEK293T cells 
The secreted rVWF results from transfection of wild-type plasmid, rVWF-G2271 plasmid and 
co-transfection of mutant/wild-type were analysed for multimer pattern using 1.6% medium 
resolution SDS agarose gel. As a result of multimer analysis, a significant defect in 
multimerisation with a complete loss of high-molecular weight VWF (HMW-VWF) multimers 
was observed in the homozygous state. The multimeric composition of rVWF secreted from 
HEK293T cells in the heterozygous state showed the presence of a full set of multimers with 
relative reduction of large multimers in comparison to wild-type multimers (Figure 4.4).  
 
 
Figure 4.4 Multimer analysis of secreted rVWF from HEK293T cells transfected with 
p.W2271G. Multimer pattern of wild-type (lane 1), homozygous rVWF-G2271 (lane 2) and 
heterozygous rVWF (lane 3) mutants electrophoresed on 1.6% medium resolution SDS gel at 
1:5 dilution. VWF multimers of homozygous mutant rVWF-G2271 (lane 2) showed a totally 
absence of HMW-VWF multimers with presence of only dimers in comparison to wild-type 
(lane 1). The multimeric composition of rVWF resulting from the heterozygous state post in 
vitro expression (lane 3) demonstrated a relative reduction of large multimers in comparison to 
wild-type multimers.  
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4.2.5.2. Immunofluorescence staining and confocal microscopy imaging of 
expressed mutations 
Following in vitro expression of mutants in HEK293 cells, transfected cells were stained and 
examined using a confocal microscope in order to determine the intracellular storage. For each 
mutation, confocal microscopy was undertaken in the homozygous and heterozygous forms and 
compared to wild-type. The shape of WPB-like structure, size and frequency of each form was 
compared to those of wild-type. To determine intracellular storage of VWF, cells were stained 
with two markers to visualise VWF and the cell membrane using two pairs of antibodies; anti-
VWF rabbit primary antibody and an anti- rabbit Alexa Fluor 488 green secondary antibody to 
visualise intracellular VWF, the second pair of antibodies was the mouse anti α-tubulin primary 
antibody and an anti-mouse Alexa Fluor 555 red secondary antibody as a cell membrane 
marker.  
The confocal microscopy images of each mutation to determine intracellular storage were 
presented in 3x3 rows, first horizontal row represents VWF (green) for wild-type, homozygous 
and heterozygous forms respectively. The middle horizontal row represents the cell membrane 
marker α-tubulin (red) and the lower horizontal row shows a merge of VWF and α-tubulin 
staining for all forms within HEK293 cell line. 
Also, to determine the localisation of VWF within cells, cells were stained with anti-VWF 
rabbit and mouse anti-ER PDI primary antibodies using transmitted light with phase contrast. 
Alexa Fluor 488 green and Alexa Fluor 555 red secondary antibodies were used respectively. 
The confocal images of each mutation to detect VWF localisation were presented in 4x3 rows, 
first vertical row represents VWF (green) for wild-type, homozygous and heterozygous forms 
respectively. The second vertical row represents the ER-PDI marker (red) and the third vertical 
row represents a merge of VWF and PDI staining for all forms within HEK293 cell line. The 
last vertical row shows images of cells by phase contrast. 
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4.2.5.2.1. Confocal microscopy of p.W2271G 
The effect of p.W2271G on VWF storage within HEK293 heterologous cell lines was evaluated 
using confocal microscopy. In vitro expression of the p.W2271G revealed a secretion defect 
resulting from intracellular retention. In the wild-type form, small rounded punctate WB-like 
vesicles were formed throughout the cells (Figure 4.5 A and C). In the homozygous form of 
p.W2271G mutant, WPB-like vesicles were present, but appeared larger in size and this may be 
due to stacking of WPB-like organelles on top of each other, also WPB were more in number 
and localised VWF diffuse staining patterns were observed in comparison to the wild-type 
(indicated with a white arrow, Figure 4.5 D). Similarly to homozygous, in the heterozygous 
form of p.W2271G mutant, WPB-like organelles were formed, but smaller than those in the 
homozygous state with presence of diffuse staining pattern (indicate with white arrow) (Figure 
4.5 G). The presence of the diffuse staining pattern may be due to VWF WPB-like structures 
accumulated over each other in cross-section analysis caused by intracellular retention. These 
findings suggested that p.W2271G has an influence in WPB storage. Also, confocal microscopy 
confirms in vitro findings of increased intracellular retention. 
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Figure 4.5 Intracellular storage of rWT and rVWF-G2271 mutant in HEK293 cells by 
confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous plasmids respectively into HEK293 cells. White arrows indicate 
regions where there was diffuse staining of VWF within the cell. B, E and H) Represent the cell 
membrane marker α-tubulin (red) after transfection of wild-type, homozygous and heterozygous 
respectively into HEK293 cells. C, F and I) Represent merged images of VWF and α-tubulin 
staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 
cells. Cells of the upper horizontal row (A, D and G) were stained with rabbit anti-VWF 
primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of the middle horizontal 
row (B, E and H) were stained with mouse anti-α-tubulin and anti-mouse Alexa Fluor 555 for 
the cell membrane α-tubulin marker (red). The lower horizontal row (C, F and I) shows a 
merge of VWF and α-tubulin staining.  
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4.2.5.2.2. Confocal microscopy of p.W2271G to determine retention of VWF in the 
ER 
Confocal microscopy showed the formation of small rounded punctate WB-like organelles in 
the wild-type form (Figure 4.6 A and C). As shown by the co-localisation of VWF and PDI 
marker, the homozygous form of p.W2271G showed the presence of rounded punctuate pseudo 
WPB-like organelles and led to significant retention of VWF in the ER compared to wild-type 
(Figure 4.6 E and G). The retention of VWF in ER was observed but appeared reduced when 
p.W2271G expressed in the heterozygous form (Figure 4.6 I and K). These findings postulated 
that p.W2271G led to reduce VWF secretion due to retention of VWF in the ER. 
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Figure 4.6 Intracellular localisation of VWF in rWT and rVWF-G2271 mutant in HEK293 cells. A, E and I) Represent VWF (green) after 
transient transfection of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, F and J) Represent the ER marker PDI 
(red) after transfection of wild-type, homozygous and heterozygous respectively into HEK293 cells. C, G and K) Represent merged images of VWF 
and PDI staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. D, H and L) Represent phase contrast (PC) 
image for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. Cells of the column (A, E and I) were stained with 
rabbit anti-VWF primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of the second column (B, F and J) were stained with mouse 
anti-PDI and anti-mouse Alexa Fluor 555 for the ER marker (red). The Third column (C, G and K) shows a merge of VWF and PDI. 
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4.2.6. In vitro expression of recombinant VWF containing the candidate mutations 
p.R924Q and p.C1927R 
The variants c.2771G>A predicted to result in p.R924Q and c.5779T>C predicted to result in 
p.C1927R were previously identified in one family (P9F14) in IC (III:1) and AFM within the 
EU study. These two variants were found on the same allele (Section 3.6.5). Each mutation was 
successfully introduced alone into the full length VWF recombinant plasmid in order to express 
the candidate mutations p.R924Q and p.C1927R. Also, both mutations were successfully 
introduced into the full length rVWF on the same allele to mimic the allelic state.  
Three separate experimental conditions were performed including; transfection of rVWF-Q924 
alone, transfection of rVWF-R1927 alone and transfection of both mutants rVWF 
[R1927;Q924] on the same allele. Transfection for each mutant was undertaken as previously 
described (Section 2.2.13.5). 
4.2.6.1. Quantitative analysis of supernatant and cell lysates following transfection 
of HEK293T cells with rVWF-WT and mutant plasmid (rVWF-Q924) 
The measured values of VWF in cell supernatant and cell lysates are shown in tables 4.4 and 
4.5. In vitro expression of rVWF-Q924 showed that the rVWF values measured in growth 
medium of mutant heterozygous and homozygous was reduced to 97% and 91.5% respectively 
with no significant change compared to 100% rVWF-WT (Figure 4.7).  
Analysis of the intracellular VWF showed no significant change in mean values of VWF in the 
heterozygous and homozygous state with values of approximately 87% and 88% respectively 
compared to 100% of rVWF-WT (Figure 4.7).  
In summary, in vitro expression of rVWF-Q924 suggested that this candidate mutation 
(p.R924Q) had no effect on VWF secretion and does not lead to intracellular accumulation of 
VWF within cells. The secretion of homozygous p.R924Q was not significantly reduced 
compared to wild-type VWF. 
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Table 4.4 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-Q924) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 16.0 
WT:Mut (50:50) (heterozygous) 97.0 21.7 
rVWF-R924Q (homozygous) 91.5 9.6 
*SD= standard deviation 
 
Table 4.5 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-Q924) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 19.0 
WT:Mut (50:50) (heterozygous) 87.0 17.0 
rVWF-R924Q (homozygous) 88.0 15.0 
*SD= standard deviation 
 
 
Figure 4.7 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.R924Q 
mutation on VWF expression. Results are expressed as a percentage in comparison with wild-
type. The vertical black bars indicate the standard deviation. Statistical test used is one-way 
ANOVA. 
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4.2.6.1.1. Multimer analysis for the p.R924Q VWF protein secreted from 
HEK293T cells 
The multimer analysis of rVWF of p.R924Q mutation collected following in vitro expression 
showed that both the heterozygous and homozygous state produced normal VWF multimers 
containing high, intermediate and low molecular weight bands similar to the multimeric pattern 
observed in the wild-type (Figure 4.8). The obtained results after in vitro expression reflected 
the p.R924Q has no effect on VWF multimer formation although it’s located in D3 domain.  
 
Figure 4.8 Multimer analysis of rVWF p.R924Q secreted from HEK293T cells Multimer 
pattern of wild-type rVWF (lane 1), mutant homozygous rVWF-Q924 (lane 2) and 
heterozygous rVWF (lane 3) electrophoresed on 1.6% medium resolution SDS gel at 1:5 
dilution  are shown. The multimeric composition of rVWF resulting from transfecting cells with 
mutant and hybrid showed normal VWF multimer patterns similar to the multimeric pattern of 
wild-type.  
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4.2.6.1.2. Confocal microscopy of p.R924Q 
In vitro expression of p.R924Q located in D3 assembly showed no significant effect in VWF 
expression or multimerisation. Intracellular imaging of wild-type showed the formation of 
WPB-like structures with presence of punctuated rounded organelles throughout the cell (Figure 
4.9 A and C). Similarly to the wild-type pattern, both homozygous and heterozygous patterns 
showed the presence of WPB-like organelles that appeared similar in shape and size to ones 
observed in wild-type (Figure 4.9 D, F, G and I). Confocal microscopy suggested that p.R924Q 
does not affect VWF synthesis or storage when present alone or in the presence of wild-type.   
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Figure 4.9 Intracellular storage of rWT and rVWF-Q924 mutant in HEK293 cells by 
confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous respectively into HEK293 cells. B, E and H) Represent the cell 
membrane marker α-tubulin (red) after transfection of wild-type, homozygous and heterozygous 
respectively into HEK293 cells. C, F and I) Represent merged images of VWF and α-tubulin 
staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 
cells. Cells were stained as described in figure 4.5. 
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4.2.6.2. Quantitative analysis of supernatant and cell lysates following transfection 
of HEK293T cells with rVWF-WT and mutant plasmid (rVWF-R1927) 
The mean values of secreted VWF obtained by expression of wild-type plasmid alone, mutant 
plasmid alone (homozygous) and mutant plasmid co-expressed with wild-type (heterozygous) 
are shown in table 4.6. In vitro expression indicated that the observed mean values of secreted 
VWF of mutant heterozygous and homozygous rVWF-R1927 into growth medium were 
significantly decreased. In the homozygous form of p.C1927R there was a significant 89% 
reduction in the secreted VWF, while the heterozygous form resulted in a 81% reduction 
compared to 100% of rVWF-wild-type (Figure 4.10). The difference in the secreted VWF:Ag 
level for heterozygous and homozygous states compared to wild-type was statistically 
significant with P values of p<0.0001.  
In the HEK293T cell lysate, data for secreted VWF (Table 4.7) interestingly showed that 
intracellular mean values of VWF:Ag of homozygous rVWF-R1927 was significantly increased 
to 145% (P<0.0001) compared to the wild-type (Figure 4.10) and decreased mean values of 
retained VWF:Ag of heterozygous rVWF-R1927 in the cells compared with the corresponding 
values of 100% wild-type with values of 78% (p<0.05). 
In summary, the p.C1927R leads to a significant reduction in the level of secreted VWF in both 
heterozygous and homozygous states. Also, the expression data from HEK293T cell lysates 
indicated a significant increase in the level of retained VWF within cells in the homozygous 
state that could lead to intracellular retention. 
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Table 4.6 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-R1927) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 15.0 
WT:Mut (50:50) (heterozygous) 19.2 2.5 
rVWF-C1927R (homozygous)  10.8 1.4 
*SD= standard deviation 
 
Table 4.7 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-R1927) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 6.0 
WT:Mut (50:50) (heterozygous) 78.0 14.8 
rVWF-C1927R (homozygous) 145.0   23.0 
*SD= standard deviation 
 
 
Figure 4.10 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.C1927R 
mutation on VWF expression. Results are expressed as a percentage in comparison with wild-
type. The horizontal black bars represent the extent of difference between mean values of 
VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate the standard 
deviation. Statistical test used is one-way ANOVA. 
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4.2.6.3. Quantitative analysis of supernatant and cell lysates following transfection 
of HK293T cells with rVWF-WT and mutant plasmid rVWF [R1927;Q924] 
Mutation p.C1927R in combination with p.R924Q located on the same allele were expressed to 
replicate the allelic mutations found in the patient. The measured values of VWF in cell media 
and cell lysates are shown in tables 4.8 and 4.9. In vitro expression of rVWF [R1927;Q924] 
showed that the rVWF values measured in growth medium of mutant heterozygous and 
homozygous were reduced to 32% and 11% respectively with a significant reduction ( 
p<0.0001) compared to 100% of rVWF-WT (Figure 4.11).  
The VWF level from HEK293T cell lysate of transfected cells obtained from three different 
experiments of homozygous rVWF-R1927+Q924 was significantly increased to 150% 
(P<0.001) compared to the 100% wild-type (Figure 4.11) and decreased mean values of retained 
VWF:Ag of heterozygous rVWF-R1927+Q924 in the cell lysates compared with the 
corresponding values of 100% wild-type with values of 80% (p>0.05). 
In summary, the p.[C1927R;R924Q] lead to a significant reduction in the level of secreted VWF 
in both heterozygous and homozygous states. Also, the expression data from HEK293T cell 
lysates indicated a significant increase in the level of retained VWF within the cells in the 
homozygous state resulted from intracellular retention. Also, comparing the mean values of 
released and retained VWF of mutant plasmid rVWF-R1927 alone to mean values of mutant 
plasmid rVWF [R1927;Q924] showed no significant differences between the two sets of 
experiments which indicated the lack of effect of p.R924Q on VWF expression. However, the 
levels of VWF obtained from in vitro expression of p.[C1927R;R924Q] was comparable to the 
expressed VWF levels of p.C1927R alone. 
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Table 4.8 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-R1927+R924Q) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 6.0 
WT:Mut (50:50) (heterozygous) 32.0 8.0 
rVWF-C1927R+R924Q (homozygous) 11.0 2.7 
*SD= standard deviation 
 
Table 4.9 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-R1927+R924Q) in HEK293T cells 
VWF (cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 7.0 
WT:Mut (50:50) (heterozygous) 80.0 11.5 
rVWF-C1927R+R924Q (homozygous) 150.0 32.0 
*SD= standard deviation 
 
 
Figure 4.11 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of 
p[.C1927R;R924Q] mutation on VWF expression. Results are expressed as a percentage in 
comparison with wild-type. Black line represent the significant difference of mean value of 
VWF:Ag between wild-type and mutant VWF. Upper bar indicated the standard deviation. 
Statistical test used is one-way ANOVA. 
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4.2.6.3.1. Multimer analysis for the rVWF-R1927 and rVWF [R1927;Q924] rVWF 
protein secreted from HEK293T cells 
Multimer analysis of VWF secreted from HEK2293T cells into the growth medium from 
transfection of wild-type plasmid, rVWF-R1927 plasmid and co-transfection of mutant/wild-
type in addition to similar experiments for rVWF-R1927+Q924 was analysed using 1.6% 
medium resolution SDS agarose gel. As a result, the HMW-VWF multimers observed in the 
homozygous form of the p.C1927R alone showed the presence of some HMW and dimers 
indicating that p.R924Q may acts as a modifier of phenotype (Figure 4.12A2). The multimer 
analysis for the p.[C1927R;R924Q] mutations revealed a complete absence of HMW-VWF 
multimers in the homozygous form with presence of only dimers in comparison to wild-type 
multimers (Figure 4.12B2). The analysis of heterozygous form multimer showed normal 
multimers in p.C1927R when expressed alone and a relatively decrease of HMW-VWF in 
comparison to wild-type multimers in p.[C1927R;R924Q] mutant (Figure 4.11 A3&B3).  
 
A               B  
Figure 4.12 Multimer analysis of secreted rVWF from HEK293T cells transfected with 
p.C1927R (A) and p.[C1927R;R924Q] (B) mutants.  Multimer analysis of wild-type (lane 1), 
mutant rVWF (lane 2) and hybrid rVWF (lane 3) electrophoresed on 1.6% medium resolution 
SDS gel at 1:5 dilutions respectively are shown. The multimeric composition of rVWF-R1927 
(A) and rVWF-R1927+Q924 (B) resulting from transfecting cells in the heterozygous forms 
(lanes A3 & B3) showed a reduced proportion of HMW but not loss of HMW multimers in 
comparison to wild-type multimers in p.[C1927R;R924Q] and normal multimers in p.C1927R 
alone. The homozygous form of the p.[C1927R;R924Q] revealed a totally loss of HMW-VWF 
multimers but there are some of HMW-VWF present in p.C1927R alone (lanes A2 & B2). 
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4.2.6.3.2. Confocal microscopy of p.C1927R and p.[C1927R;R924Q] 
In vitro expression of the p.C1927R revealed a secretion defect resulting from intracellular 
retention. In the wild-type form, small rounded punctate WPB-like organelles were present 
(Figure 4.13 A and C). Confocal analysis of the p.C1927R mutant in the homozygous form 
showed the presence of punctuated rounded WPB-like vesicles, but localised VWF diffuse 
staining patterns were also observed in the analysed cross-section (indicated with white arrow, 
Figure 4.13 D) in comparison to the wild-type (Figure 4.13 D and F). This diffuse pattern may 
be explained due to stacking of WPB-like organelles on top of each other. Unlike the 
homozygous form, the heterozygous forms of p.C1927R showed the presence of punctuate 
rounded WPB-like organelles similar to those observed in wild type (Figure 4.13 G and I). 
These findings suggested that p.C1927R does influence in WPB storage. The pattern of 
localised diffuse pattern observed in the homozygous form supports the in vitro findings of 
increased intracellular retention. 
Similarly to p.C1927R, the confocal imaging of p.[C1927R;R924Q] showed the presence of 
WPB-like organelles with presence of diffuse staining patterns similar to WPB and patterns 
shown in p.C1927R in homozygous form. These diffuse patterns represent accumulation of 
VWF over each other (indicate with white arrow, Figure 4.14 D and F). These organelles 
appeared relatively larger in size compare to those present in wild-type. In the heterozygous 
form of p.[C1927R;R924Q], WPB-like organelles are visualised and appeared punctuate and 
round similar to those seen in wild type (Figure 4.14 G and I). Confocal analysis indicated that 
p.[C1927R;R924Q] influences WPB storage. 
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Figure 4.13 Intracellular storage of rWT and rVWF-R1927 mutant in HEK293 cells by 
confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous plasmids respectively into HEK293 cells. White arrows indicate 
regions where there was diffuse staining of VWF within the cell. B, E and H) Represent the cell 
membrane marker α-tubulin (red) after transfection of wild-type, homozygous and heterozygous 
respectively into HEK293 cells. C, F and I) Represent merged images of VWF and α-tubulin 
staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 
cells. Cells were stained as described in figure 4.5. 
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Figure 4.14 Intracellular storage of rWT and rVWF-R1927+Q924 mutant in HEK293 cells 
by confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous plasmids respectively into HEK293 cells. White arrows indicate 
regions where there was diffuse staining of VWF within the cell. B, E and H) Represent the cell 
membrane marker α-tubulin (red) after transfection of wild-type, homozygous and heterozygous 
respectively into HEK293 cells. C, F and I) Represent merged images of VWF and α-tubulin 
staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 
cells. Cells were stained as described in figure 4.5. 
 
.  
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4.2.6.3.3. Confocal microscopy of p.C1927R and p.[C1927R:R924Q] to determine 
retention of VWF in the ER 
Confocal analysis using VWF and PDI markers revealed the formation of rounded punctate 
WB-like organelles in the wild-type as observed in figure 4.15 A and C. In comparison to the 
WPB-like organelles observed in the wild-type images, similar rounded punctuate organelles 
were seen accompanied by accumulation of VWF in the ER when p. C1927R expressed in the 
homozygous form (Figure 4.15 E and G). In the heterozygous form of p.C1927R, similar size of 
pseudo WPB organelles were observed with also presence of VWF significantly retained in the 
ER (Figure 4.15 I and K). These findings indicated that VWF appeared to be retained in the ER. 
The confocal images of p.[C1927R;R924Q] were also analysed using co-staining of VWF and 
PDI-ER markers. The obtained findings were similar to those observed when p.C1927R 
expressed alone. In the homozygous form of p.[C1927R;R924Q], the rounded punctuate pseudo 
WPB organelles were found (Figure 4.16 A and C) and considerable retention of VWF in the 
ER was observed (Figure 4.16 E and G). The retention of VWF in the ER also was observed 
when p.[C1927R;R924Q] was co-transfected with wild-type. The retention was less pronounced 
than that seen in the homozygous form (Figure 4.16 I and K). These results indicated that both 
p.C1927R and p.[C1927R;R924Q] variants caused marked retention of VWF in the ER. 
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Figure 4.15 Intracellular localisation of VWF in rWT and rVWF-R19271 mutant in HEK293 cells. A, E and I) Represent VWF (green) after 
transient transfection of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, F and J) Represent the ER marker PDI 
(red) after transfection of wild-type, homozygous and heterozygous respectively into HEK293 cells. C, G and K) Represent merged changes of VWF 
and PDI staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. D, H and L) Represent phase contrast (PC) 
image for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. Cells were stained as previously described. 
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Figure 4.16 Intracellular localisation of VWF in rWT and rVWF-R1927+Q924 mutant in HEK293 cells. A, E and I) Represent VWF (green) 
after transient transfection of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, F and J) Represent the ER marker 
PDI (red) after transfection of wild-type, homozygous and heterozygous respectively into HEK293 cells. C, G and K) Represent merged changes of 
VWF and PDI staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. D, H and L) Represent phase contrast 
(PC) image for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. Cells were stained as previously described. 
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4.3. Discussion 
In this chapter, in vitro expression studies of 4 candidate missense heterozygous mutations 
identified in patients historically diagnosed with type 1 VWD was performed. These 
experiments have been designed to examine whether the mutations identified might be 
responsible for the disease phenotype and considered as causative for the observed partial 
quantitative deficiency of VWF in the investigated patients. Another aim of these expression 
studies was to define the possible mechanisms associated with each genetic change. The 
expressed missense mutations included; one novel missense mutation found in one family 
p.W2271G (Section 3.6.1), where the other two missense mutations were detected previously 
during the EU study; p.R924Q identified in several families and p.C1927R found in 
combination with p.R924Q (Section 3.6.5) in addition to expression of both mutation 
p.[C1927R;R924Q] that were found on the same allele in one family (Section 3.6.5.1). 
4.3.1. In vitro expression of p.W2271G 
When mutant plasmid rVWF-G2271was transfected in a homozygous form, the obtained levels 
of secreted VWF:Ag showed a significant reduction of VWF:Ag  (p<0.0001). The reduced 
secretion of VWF was accompanied by a significant increase in the retained VWF (p<0.05) 
compared to the corresponding levels of wild type. The homozygous form of rVWF-G2271 
mutant indicated complete loss of HMW-VWF multimers. 
When the mutated plasmid rVWF-G2271 was co-transfected with the recombinant wild type to 
mimic the heterozygous state, the levels of VWF:Ag secreted were significantly lower than 
levels of wild type (p<0.05) with no significant change of retained VWF:Ag in cell lysates  
(p>0.05) compared to wild type. The level of retained VWF:Ag was significantly increased 
when both mutated plasmids were co-transfected compared to co-transfection of mutant plasmid 
with wild-type. However, p.W2271G resulted in a reduction of VWF secretion into the growth 
medium. 
Multimer analysis of secreted mutant VWF produced from transfection of rVWF-G2271 
plasmid in the heterozygous form showed nearly normal multimers with a relative reduction 
which is similar to those observed in patients and AFM plasma. The mild differences between 
normal multimer patterns observed in patient plasma who harbour p.W2271G in the 
heterozygous form and the multimers obtained from in vitro expression can be explained due to 
variation between cell lines used in vitro from in vivo (Figure 4.4).  
Similar to multimerisation, the missense mutation p.W2271G located in D4 assembly has an 
effect in VWF storage. It was able to produce WPB-like granules, but pseudo WPB-organelles 
were stacked over each other and retained in the ER compared to those present in wild-type. 
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Confocal microscopy suggested the occurrence of intracellular retention of VWF in the ER. 
This mutant was able to synthesise VWF although it impairs multimerisation and storage.  
Therefore, the homozygous form of p.W2271G resulted in reduced secretion, abnormal 
multimers and VWF storage but the heterozygous form affected only VWF secretion and 
storage. 
However, the achieved results from transfection studies indicated that p.W2271G resulted in a 
significant reduction (77%) of secreted rVWF from mutant heterozygous compared to wild-type 
indicating a dominant negative nature of this mutation. These findings are similar to VWF level 
in vivo and similar to the phenotypic data found in the affected members (Section 3.6.1.1). The 
affected members who were heterozygous for the mutation p.W2271G presented with mild 
bleeding symptoms (BS: 2-7) and demonstrated a moderate reduction of phenotype data and 
blood group genotype of O/A (Section 3.6.1.1). The levels of VWF:Ag and VWF:RCo in the IC 
who harboured this mutation in the heterozygous state was decreased to 37 and 32 IU/dL 
respectively with normal plasma multimers (Appendix 15).  
Therefore, in vitro expression of the p.W2271G mutation into HEK293T cells indicated that 
secretion of mutated rVWF-G2271 was significantly reduced due to intracellular retention that 
is impaired due to the effect of the mutation on intracellular transport. The significant defect 
resulting from p.W2271G can be possibly explained due to a dominant negative mechanism 
when mutant protein impairs the activity of wild-type usually by dimerizing with it.  
In silico predictions indicated that this mutation is probably damaging and in vitro expression 
confirmed these predictions. 
An essential aim of expression studies is to investigate the disease causing mechanism. The 
presence of a mutation within VWF can alter the VWF processing including assembly, secretion 
and expression and reduced secretion can thus be explained. Some mutated protein is 
characterized by mis-folding and poor assembly in the ER. In mammals, there are proteins 
found in the ER called chaperones that act as a checkpoint for the presence of any mis-folded, 
incompletely assembled proteins. When mis-folded or mutated protein is recognised by 
chaperones in the ER, they bind the mutated protein and rather than pass protein to the Golgi 
apparatus, chaperones support a reversed transport of mutated protein from ER to the cytosol, 
where they are retained and then degraded by the proteasome complex (Brodsky and 
McCracken, 1997). These chaperones include calnexin (CNX) and calreticulin (CRT) (Ellgaard 
et al., 1999). However, the novel p.W2271G mutation appear to cause intracellular retention and 
accumulation of VWF in the ER that may impair the intracellular transport resulting in reduced 
secretion into the growth media when mutant plasmid was transfected in HEK293T cells. These 
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findings suggested that p.W2271G is likely to act through a dominant-negative mechanism as 
the level of secreted VWF in the heterozygous state is less than 50% (23%). A dominant-
negative effect occurs when the mutant allele impairs the activity of the wild-type allele.  
Intracellular retention has been observed previously in different mutations located in D4 
assembly associated with partial quantitative deficiencies of VWF in patients with type 1 and 
type 3 VWD. Eikenboom et al (2009) expressed 14 VWF mutations identified in patients with 
type 1 VWD from the MCMDM-1VWD study. All patients were heterozygous for these 
mutations that were transfected in COS-7 cells. Out of 14, four candidate mutations were 
located in the D4 assembly including; p.L2207P, p.C2257S, p.R2287W and p.P2063S. The 
transient transfection of rVWF-P2207 and rVWF-S2257 in COS-7 cells showed significant 
intracellular retention, highly reduced secretion and formation of HMW multimers with an 
altered anodic band migration the VWF compared with wild type. Moreover, the co-transfection 
of rVWF-P2207 and rVWF-S2257 with rVWF-WT indicated reduced VWF secretion 
accompanied by intracellular retention and normal multimers (Eikenboom et al., 2009). The 
expression of the other two mutations p.[R2287W;P2063S] located on the same allele in the D4 
assembly that do not involve cysteine residues indicated mild reduction of secretion of 
p.R2287W while p.P2063S was considered as a non-pathogenic (Eikenboom et al., 2009, 
Hampshire and Goodeve, 2013). Also, the transfection of two missense mutations located in the 
D4 assembly identified in type 3 patients, p.C2184S and p.C2212R that both involved cysteine 
changes in COS-7 cells indicated a severe  reduction in secretion of 83% and 79% respectively 
due to intracellular retention within the cell and abnormal multimers, while the co-transfection 
performed to confirm the recessive nature of these mutations showed reduced secretion of 45% 
and 11% respectively in comparison to wild-type and normal multimers (Solimando et al., 
2012). However, the cells used in these studies, COS-7 cells do not form WPB-like structures 
and hence are not fully representative of the VWF expression pathway.  
Type 1 VWD is mostly inherited as an autosomal dominant trait and patients usually present 
with mild to moderate reduction in VWF:Ag, VWF:RCo and FVIII:C with normal multimers 
that is characterized by a partial quantitative deficiency of VWF (Keeney and Cumming, 2001). 
The achieved results obtained by expression studies of p.W2271G demonstrated that this 
mutation resulted in reduced secretion due to intracellular retention of VWF which further 
causes partial quantitative deficiency of plasma VWF and suggests the dominant negative nature 
of this variant. On the basis of impaired secretion and intracellular retention, p.W2271G is 
considered as the cause of type 1 VWD phenotype. Therefore, these findings confirmed that this 
mutation is responsible for the patient phenotype and is classified as type 1 VWD. 
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4.3.2. In vitro expression of p.C1927R 
In vitro expression of rVWF-R1927 indicated that this mutation significantly reduced the level 
of secreted VWF:Ag (p<0.0001) in both homozygous and heterozygous states and this reduction 
was accompanied by a significant increase in the retained VWF:Ag (p<0.0001) compared to 
wild type when transfected in a homozygous form only. The multimer analysis of rVWF in the 
homozygous form showed a loss of HMW-VWF, but some HMW-VWF multimers were 
present while a normal HMW multimers were observed in the heterozygous form. These 
findings are similar to the multimers found in the AFM (I:2) plasma who also carries this 
mutation in addition to p.R924Q. 
However, in vitro expression of p.C1927R suggested that this mutation impaired VWF secretion 
from the HEK293T cells into the growth medium due to the intracellular retention in the cell. 
p.C1927R resulted in a significant VWF secretion defect potentially through a dominant 
negative mechanism where the mutant VWF alters the function of wild-type. Although 
p.C1927R impairs VWF secretion, it does not affect VWF synthesis and was able to produce 
WPB organelles, but could impair VWF storage.  
These findings suggested that p.C1927R appeared to reduce VWF secretion, impair 
multimerisation and VWF storage when expressed in the homozygous form, but the 
heterozygous form of p.C1927R appeared to influence VWF secretion and storage significantly. 
Confocal analysis suggested that this variant leads to secretion defect due to retention of VWF 
in the ER. 
In silico predictions using several prediction tools showed that the loss of cysteine in this 
mutation is probably damaging which is consistent with the in vitro expression findings (Section 
3.6.5.2). The substitution of cysteine which is required for interchain disulphide bond formation 
between cysteine amino acids by arginine is likely to impair multimer formation and lead to 
retained and degraded mis-folded mutant protein within the ER thereby reducing secretion of 
VWF. The disulphide bonds between adjacent cysteine are important for proper protein folding, 
packaging and release. The presence of any mutation causing cysteine loss may impair protein 
folding and multimerization, thereby resulting in retention of VWF in ER and reducing 
secretion due to degradation of mutant protein in the ER. p.C1927R is located in the linker 
between the A3 and D4 domains according to the original domain structure (Figure 1.1). This 
region between A3 and D4 domains is rich with cysteine and was re-annotated and named as 
D4N as a part of D4 assembly (Figure 1.1) (Zhou et al., 2012). The D4N region has a large 
number of cysteines (8) and losses of cysteine results in unpaired cysteines which can affect 
protein folding and tertiary structure and thereby is likely to create abnormal multimer 
formation and retention of VWF within cells.  
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The results obtained by expression studies of p.C1927R are consistent with phenotypic data 
found in affected members who have this mutation in combination with p.R924Q as p.R924Q 
had no significant effect on VWF expression. Levels of VWF and FVIII:C were reduced in 
plasma in patients who harboured p.R924Q in combination with other change (Hickson et al., 
2010). The two AFM who had the p.C1927R and p.R924Q only on the same allele presented 
with moderate reductions in the level of VWF:Ag ranging between 19-57 IU/dL and moderate 
reduction in the levels of VWF:RCo ranging between 18-58 IU/dL and this variations may be 
due to variable penetrant pattern and age in the AFM. One AFM had normal multimers and the 
other one had abnormal multimers (Appendix 16). The achieved results from heterozygous 
transfection of rVWF-R1927 and rVWF-Q924 together on the same allele showed a 68% 
reduction of secreted rVWF compared to wild-type. The phenotypic data found in AFM (I:2) 
and UFM (II:3) who harboured both mutations is almost different to the VWF expressed in this 
study and this may due to in-complete penetrance or due to different ages (Appendix 16). Also, 
the IC who has both mutations in addition to an intronic donor splice site mutation 
c.1533+1G>T in intron 13 presented with a high BS (18), severe reduction of VWF:Ag, 
VWF:RCo (3 IU/dL) and FVIII:C (7) in addition to an absence of multimers  (Section 3.6.5.1) 
as the donor splice site variant was likely to contribute to the abnormal phenotype observed in 
the IC due to NMD which prevents protein formation in addition to the effect of other 
mutations. However, the missense p.C1927R mutation can be considered as the major 
contributor to the partial quantitative deficiency of VWF in the two AFM and the UFM who 
harboured these two variant. 
Several mutations involving the loss of cysteine residues located in the D4 assembly have been 
reported. The expression of p.C2257S located in the D4 assembly identified in a type 1 VWD 
patient in COS-7 showed a very similar effect of reduced secretion and intracellular retention 
similar to our findings (Eikenboom et al., 2009). Moreover, the transfection of two missense 
mutations located in the D4 assembly identified in type 3 patients, p.C2184S and p.C2212R into 
COS-7 cells indicated a severe reduction, intracellular retention within the cell and abnormal 
multimers in homozygous form as previously described (Solimando et al., 2012).  
The achieved results obtained from expression studies showed that p.C1927R is responsible for 
the moderate reductions of VWF levels and appears to act through dominant negative 
mechanism and could indicates the dominant negative nature of this variant.  
4.3.3. In vitro expression of p.R924Q 
The p.R924Q mutation appeared to have no significant effect on the level of VWF compared to 
expressed wild type when transfected in both heterozygous and heterozygous states. Although 
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p.R924Q is located within D3 assembly which is essential for the normal multimerization 
process, a full array of normal multimers, normal synthesis and normal storage were observed in 
both homozygous and heterozygous forms. Therefore, in vitro expression studies have indicated 
that p.R924Q does not affect VWF synthesis, storage or multimerisation significantly when 
present either in homozygous or heterozygous form. 
In silico predictions showed that this mutation had no significant effect either on VWF 
expression or on splice sites which is compatible with earlier expression findings using COS7 
cells (Hickson et al., 2010). The level of VWF:Ag and VWF:RCo in AFM who have the 
p.R924Q in combination with p.C1927R show a moderate reduction of VWF:Ag and 
VWF:RCo levels. When reviewing EU cases, the AFM (P8F1I:1) who had only p.R924Q 
presented with high BS (13), normal to a mild reduction of VWF levels and normal multimers, 
while the IC P6F5II:1 who had p.R924Q in combination with p.R1205H that is known to 
increases VWF clearance showed markedly decreased levels of VWF:Ag, VWF:RCo and FVIII 
at 11, 7 and 18 respectively with a high BS at 18, but the UFM (II:3) who had only p.R924Q 
presented with normal BS (-1) and normal phenotypic levels, with all 3 parameters above 50 
IU/dL (Appendix 17). Within the EU study, a number of IC who harbour only p.R1205H 
presented with high BS with mean value of 12 ranging between 6-18, VWF:Ag mean value of 9 
ranging between 3-21 IU/dL), VWF:RCo mean value of 8 ranging between 3-25 IU/dL and 
FVIII:C with mean value of 16 ranging between 3-32 IU/dL indicated the mild effect of 
p.R924Q on VWF level. Also, the P7F3II:1 IC who had p.R924Q co-inherited with p.R854Q 
that impairs binding to FVIII showed a reduction of VWF:Ag, VWF:RCo and FVIII at 25, 38 
and 15 IU/dL respectively, but their AFM (I:2) who had only p.R924Q presented with high BS 
(8) and normal phenotypic data (Goodeve et al., 2007, Hickson et al., 2010). It has been 
observed the presence of high BS in patient with p.R924Q although normal levels of VWF and 
this may be explained due to presence of other factors that cause bleeding without affecting 
VWF levels. 
The MCMDM-1VWD study has reported the presence of p.R924Q mutation in 6 IC, one was 
heterozygous and the remaining five had this mutation in combination with other variants. The 
identified p.R924Q in association with second mutation include: 1) p.[R924Q;R1351L] on the 
same allele; 2) p.[R1205H];[R924Q] in 2 different alleles; 3) c.3675-14G>A + p.R924Q in 2 
different alleles; 4) p.[R854Q];[R924Q] in two different alleles and 5) p.[C1927R;R924Q] on 
the same allele (Goodeve et al., 2007). It was observed that the presence of p.R924Q alone is 
insufficient to influence VWF, but when combined with other mutation may affect disease 
phenotype (Goodeve et al., 2007). Moreover, it was reported that the IC who was heterozygous 
for de novo p.R1205H in combination with p.R924Q that inherited from his mother presented 
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with moderate to severe bleeding symptoms, unlike the mother who showed mild bleeding 
symptoms due to presence of p.R924Q mutation alone and blood group O (Woods et al., 2013).  
This variant was identified in 3.6% of IC diagnosed with type 1 VWD in EU study and was 
found almost in 1.4% of healthy Caucasian alleles (Goodeve et al., 2007, Hickson et al., 2010). 
All three multicentre type 1 VWD cohort studies have reported the presence of the c.2271G>A 
variant in IC. It was documented as the second most frequent variant in the Canadian study and 
was considered as a benign change in the UK study (Cumming et al., 2006, Goodeve et al., 
2007, James et al., 2007). Also, Casais et al (2006) have reported the presence of heterozygous 
c.2771G>A variant in three symptomatic patients who had normal levels of VWF:Ag and 
reduced levels of FVIII (Casais et al., 2006). 
Although many studies had examined p.R924Q, there was inconsistency in the behaviour and 
characteristics of this genetic variant (Table 4.10). The p.R924Q variant was first described as a 
polymorphism in a type 2N VWD patient who was compound heterozygous with p.C1060R on 
the other allele and had moderately reduced FVIII binding capacity. In vitro expression of 
rVWF-Q924 showed normal binding to FVIII (Hilbert et al., 2003). Casais et al (2006) linked 
the presence of this mutation with mild bleeding symptoms and decreased FVIII/VWF:Ag ratios 
while Lester et al (2008) suggested that this variant in some cases may behave as a null allele 
(Lester et al., 2008). Many experimental expression studies have investigated the effect of 
p.R924Q on VWF expression, FVIII and its binding to VWF in order to define the exact effect 
on VWF and the pathogenic significance but none of them had defined the exact mechanism. In 
vitro expression of rVWF-Q924 in COS-7 and AtT-20 cells indicated that p.R924Q has no 
significant effect on VWF expression, synthesis, storage or intracellular trafficking (Berber et 
al., 2009). Also, following immunofluorescence antibody staining the WPB granules from 
patient's BOEC line appeared larger in size WPB and diffuse cytosolic pattern in comparison to 
normal WPB size and type observed in cells from normal individual (Berber et al., 2009). 
Moreover, Berber et al (2009) suggested that not all alleles harbour p.R924Q are identical and 
the probability of the presence of an additional defect on the same allele carries p.R924Q may 
explain the variation of BOEC morphology between patients and healthy individuals. p.R924Q 
was found in a compound heterozygous patient with an additional type 2N mutation (p.R816W), 
low levels of FVIII and reduced FVIII binding capacity (VWF:FVIIIB). Hickson et al (2010) 
demonstrated that rVWF-Q924 had a benign effect on VWF expression, normal levels of 
FVIII:C and VWF, normal multimers, normal binding capacity and normal clearance (Hickson 
et al., 2010). However, these findings suggested that the p.R924Q alone has a minor influence 
on VWF expression unless co-inherited with a second mutation. In some individuals, however 
p.R924Q behaves differently and this may due to the presence of a further un-identified second 
sequence variant on the same allele change. Moreover, Hickson et al (2010) observed that 
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individuals with blood group O in combination with p.R924Q had reduced levels of VWF:Ag 
and FVIII compared to individuals with this variant who had non-O blood groups. The levels of 
VWF:Ag and FVIII:C in heterozygotes for c.2771G>A in combination with blood group O was 
35% lower compared to those with non-O blood groups who were homozygous for c.2771G 
(Hickson et al., 2010). These findings suggested that the presence of p.R924Q alone is 
insufficient to influence VWF, but co-inheritance with a second VWF mutation may contribute 
to disease phenotype (Berber et al., 2009, Hickson et al., 2010). The achieved results in this 
study showed a mild effect of p.R924Q on VWF expression which is compatible with previous 
findings. 
Table 4.10 List of publications relevant to p.R924Q variant 
Author Year Findings 
Hilbert et al 2003 Described as a polymorphism in type 2N VWD patient 
Casais et al 2006 Causes mild bleeding and decreases FVIII:C/VWF:Ag 
ratios 
Lester et al 2008 Behaves as a null allele 
Berber et al  2009 Expression study showed no significant effect on VWF 
expression, synthesis or storage. Low level of FVIII when 
co-inherited with type 2N VWD mutation. Abnormal 
large WPB and diffuse staining pattern were observed in 
patient BOEC line 
Hickson et al  2010 Had no significant effect on VWF expression, normal 
clearance and normal binding to FVIII 
Woods et al  2013 Presence of p.R924Q alone insufficient to influence VWF 
expression unless co-inherited with other variant. 
4.3.4. In vitro expression of p.[R924Q;C1927R] 
Expression studies of recombinant mutant VWF (rVWF-R1927 and rVWF-Q924) showed 
significantly reduced secretion in the levels of VWF:Ag in the heterozygous and homozygous 
state (p<0.0001) compared to rVWF-WT with significantly increased intracellular retention 
when transfected in homozygous form (p<0.05). A relatively reduction of VWF multimers was 
observed in the heterozygous form and a complete loss of HMW-VWF multimers in the 
homozygous form indicating that p.R924Q may acts as a modifier of phenotype. Also, this 
variant appeared to affect storage function in both forms as WPB-like organelles were retained 
in the ER through confocal microscopy. These results appeared to be similar to the expression 
findings of p.C1927R when expressed alone, but mild effect was observed in VWF multimeric 
and synthesis indicating the that p.R924Q acts as a modifier of phenotype. 
These findings were similar to expression data obtained when p.C1927R was transfected alone 
and no significant differences between the two sets of expression data were observed. However, 
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in vitro expression studies confirmed that p.R924Q had no significant effect on VWF 
expression unlike multimerisation. These findings suggested that a significant effect has been 
observed when this variant p.R924Q is co-inherited with a second mutation or with blood group 
O (Berber et al., 2009, Hickson et al., 2010). Therefore, the presence of both mutations 
p.[R924Q;C1927R] on the same allele resulted in a significant secretory defect of VWF due to 
intracellular retention and abnormal multimerisation. These findings are nearly similar to 
phenotypic data observed in patients who had these mutations on the same allele (Section 
3.6.5.1). 
4.3.5. Conclusion 
In conclusion, the transient expression system using HEK293T cells conducted in this study is 
expected to result in better reflection of  in vivo VWF expression level of  rVWF as the cells 
have WPB-like storage structure compared to other cell lines such as COS-7 and Aat20cells that 
do not store VWF. Also, in vitro expression studies demonstrated that mutations located in the 
D4 assembly resulted in reduced VWF secretion due to intracellular retention of VWF as 
previously described for other VWF mutations in this region (Eikenboom et al., 2009).  
Heterozygosity for the p.W2271G and p.C1927R mutations resulted in a VWF secretory defect 
which can result in partial quantitative deficiency of VWF in patient plasma and contributes to 
type 1 VWD and expression findings were similar to phenotypic data obtained in affected 
members. Moreover, p.R924Q seems to have a mild effect on VWF expression and thereby 
causes mild form VWD phenotype as observed in IC, but a more significant effect is observed 
when co-inherited with a second mutation and/or blood group O genotype. p.R924Q is 
considered as a phenotypic modifier of VWF level rather than as a pathogenic variant. 
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5. In vitro expression of non-type 1 VWD 
5.1. Introduction 
Currently, VWD is classified into three main types; quantitative deficiencies which can be 
partial quantitative deficiency (type 1) and complete quantitative deficiency (type 3) and type 2 
which is characterized by abnormal function of VWF due to presence of mutation within VWF. 
Type 3 VWD is inherited as an autosomal recessive trait and patients with homozygous or 
compound heterozygous mutations are usually present with severe bleeding symptoms 
accompanied by undetectable VWF in plasma (Federici, 2004). It has been reported that 20% of 
type 3 VWD mutations are missense located within D1 and D2, D4 and CK domains while null 
allele mutations comprise 80% of all mutation throughout VWF (Baronciani et al., 2003, 
Bowman et al., 2013). 
Type 2 VWD is subdivided into four subtypes: 2A, 2B, 2M and 2N (Section 1.9.2). Type 2A is 
the commonest subtype caused by mutations that affect the normal binding of VWF to platelets 
due to an absence or reduction in HMW-VWF multimers. These mutations can be within the 
CK domain and disrupt dimerization process, within D2 and D3 domains which can impair 
multimerization process and can be within the A1 or A2 domains resulting in degradation of 
VWF due to either poor multimerisation or increased sensitivity to ADAMTS13. Type 2A can 
be further divided into subtypes. Type 2A(IIC) is inherited as autosomal recessive and 
characterised by severely reduced HMW multimers and increased dimers due to presence of 
mutations located in the D2 domain that impair multimerisation and further reaction with 
platelets (Meyer et al., 1997). The type 2A(IID) dominantly inherited subtype is characterised 
by the presence of mutations in the CK domain that impair pro VWF dimerisation and lead to 
secretion of small multimers with an aberrant triplet structure due to chain termination 
(Schneppenheim et al., 1996). The 2A(IIE) subtype is inherited as autosomal dominant and 
characterized by the lack of  HMW VWF multimers and absence of outer bands within the 
triplet structure indicating reduced ADAMTS13 proteolytic cleavage. Type 2A(IIE) occurs due 
to presence of mutations primarily in the D3 domain that can disrupt multimerization and 
multimer assembly (Zimmerman et al., 1986, Schneppenheim et al., 2010) (Section 1.9.2.1). 
Patients with this subtype present with mild to moderate bleeding symptoms and abnormal 
functional assays with decreased VWF:RCo activity due to lack of VWF multimers (Enayat et 
al., 2001, Schneppenheim et al., 2001a, Schneppenheim et al., 2010).  
The pre-pro and mature VWF consist of various domains which are responsible for the major 
functions needed during vascular injury (Figure 1.1A). Also, these domains play an essential 
role in catalysing VWF intramolecular dimerization and multimerization via disulfide bonding. 
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Dimerization is achieved in the ER by forming disulfide bonds between two adjacent monomers 
via their carboxyl termini and multimerization of dimers takes place in the Golgi apparatus by 
forming disulfide bonds between two adjacent D3 assemblies. The D3 assembly of VWF is 
essential for the multimerization process and is also required for VWF binding to FVIII. 
Expression studies of a cluster of mutations in the D3 assembly of VWF in a group of patients 
classified as VWD type 2A(IIE) showed reduced secretion, intracellular retention and lack of 
HMW multimers (Zimmerman et al., 1986, Hommais et al., 2006a, Schneppenheim et al., 
2010). 
During analysis of 18 EU IC who showed no previously identified mutations or had mutations 
that not fully explain disease phenotype, four mutations were identified in four IC, three of 
which were novel (Section 3.6). Out of them, one novel missense heterozygous mutation was 
identified in exon 26, in the D3 domain, c.3469T>C predicted to result in p.C1157R in one IC, 
from family P9F18, who had previously a single nucleotide deletion c.1614del in exon 14 (D2 
domain) predicted to result in the frameshift mutation p.S539Lfs*38.  
Initially, the P9F18 family was part of the EU study and historically diagnosed as type 1 VWD. 
The IC and family members samples were analysed for VWF:Ag, VWF:RCo, FVIII:C and 
multimers. Due to absence of multimers and  undetectable levels of VWF in the IC and AFM, 
this family was considered as type 3 phenotype rather than type 1 and excluded from the main 
study (Goodeve et al., 2007). The frameshift mutation p.S539Lfs*38 was identified in the IC, 
AFM and two of  the UFM (Appendix 18) and its presence alone was not sufficient to explain 
the undetectable level of plasma VWF, abnormal multimers and high BS in the AFM. The 
identification of the newly identified mutation p.C1157R in addition to the previously identified 
frameshift change could explain the very low level of phenotypic data in addition to abnormal 
multimers in the IC and AFM. p.C1157R which is located in the D3 domain may be able to be 
classified as type 2A(IIE) when inherited in the heterozygous form according to previously 
expressed mutations in the same domain (Schneppenheim et al., 2010). In silico prediction of 
the newly identified mutation p.C1157R suggested that this missense change was probably 
damaging, while the frameshift variant p.S539Lfs*38 is likely to impair the secretion of VWF 
due to NMD. 
One of the main aims of this study was to investigate whether these mutations were the major 
cause for the observed phenotype correlated with VWD types in affected patients, to determine 
the effect of these mutations on VWF structure and function and also to understand the mode of 
pathogenicity of mutations identified through in vitro expression. The mutagenized plasmid 
carrying mutant cDNA (rVWF) was transiently transfected into HEK293T cells using the 
Lipofectamine transfection method as previously described in chapter 2.  
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5.2. Results 
5.2.1. Mutagenesis 
The pcDNA3.1/Hygro (-) expression plasmid containing the full-length wild-type human VWF 
cDNA was used to introduce the desired change and for transfection to investigate the effect of 
candidate mutations on the level and structure of VWF. PCR based site-directed mutagenesis 
was performed on the recombinant vector that contained the wild-type human VWF cDNA to 
introduce a specific mismatch for p.C1157R (c.3469T>C) and p.S539Lfs*38 (c.1614del) 
variants to be expressed in HEK293T cells. As a result, the sequencing data successfully 
showed the presence of the desired change in the plasmid DNA examined for variants following 
mini-prep. The sequencing data obtained for rVWF-R1157 and rVWF-L539fs mutations 
containing the desired variant are shown in figure 5.1.  
In order to confirm that the examined plasmid contained only the desired mutation and no 
additional changes were present in the plasmid that could possibly disrupt VWF expression, the 
plasmid DNA was isolated using QIAGEN maxi-prep. The entire VWF cDNA was sent for 
sequencing and the obtained result successfully revealed no further mutations following the 
maxi-prep. 
 
 
Figure 5.1 Sequence chromatographs to show introduction of novel variants into the 
cDNA VWF plasmid. A and C show the wild-type VWF cDNA sequence. B) Shows the 
p.C1157R change (c.3469T>C); D) shows the p.S539Lfs*38 change (c.1614del). 
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5.2.2. In vitro expression of recombinant VWF containing the candidate mutations 
p.C1157R and p.S539Lfs*38 
The variants c.3469T>C predicted to result in p.C1157R and c.1614del predicted to result in 
p.S539Lfs*38 were previously identified in one family (P9F18) within the EU study. The IC 
(I:1) and AFM (1:2) carried both mutations on two different alleles while the UFM II:1 and II:2 
carried only the frameshift variant p.S539fs (Section 3.6.2).  
Three separate experimental conditions were used in order to replicate the phenotypic pattern of 
patients with each mutation including; transfection of rVWF-R1157 alone, transfection of 
rVWF-L539fs alone and co-transfection of both mutants rVWF [R1157];[L539fs] found on two 
different alleles to mimic the compound heterozygous state using 50% of each variant 
p.C1157R and p.S539fs in parallel with rVWF-wild-type.  
The rVWF-R1157 and rVWF-L539fs plasmids were transiently transfected into HEK293T cells 
in parallel with rVWF-wild-type plasmid using Lipofectamine to evaluate the effect of these 
mutations on VWF expression using the protocol described in chapter 2 (Section 2.2.13.5). 
5.2.3. Quantitative analysis of supernatant and cell lysates following transfection of 
HEK293T cells with rVWF-wild-type and mutant plasmid (rVWF-R1157) 
The mean values of secreted VWF obtained by expression of wild-type plasmid alone, mutant 
plasmid alone (homozygous) and mutant plasmid co-expressed with wild-type (heterozygous) 
are shown in table 5.1. In vitro expression indicated that the observed mean values of secreted 
VWF of heterozygous and homozygous rVWF-R1157 into growth medium was decreased to 
45% and 2% respectively compared to 100% of rVWF-wild-type (Figure 5.2). The difference in 
the secreted VWF level for heterozygous and homozygous states compared to wild-type were 
statistically significant with P values of p<0.0001.  
In the HEK293T cell lysate, data for secreted VWF (Table 5.2) interestingly showed that 
intracellular mean values of VWF of both heterozygous and homozygous rVWF-R1157 was 
significantly increased to 147% (p<0.001) and 290% (P<0.0001) respectively compared to the 
corresponding values of 100% wild-type (Figure 5.2). 
In summary, the measured mean values of VWF suggested that this mutation p.C1157R with 
loss of a cysteine residue located in D3 domain lead to a significant reduction in the level of 
secreted VWF in both heterozygous and homozygous states. Also, the expression data from 
HEK293T cell lysates indicated a significant increase in the level of retained VWF within cells 
in the homozygous and heterozygous states that lead to intracellular retention. 
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Table 5.1 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for wild-type and mutant plasmids (rVWF-R1157) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 15.0 
WT:Mut (50:50) (heterozygous) 45.0 10.0 
rVWF-C1157R (homozygous) 1.8 0.5 
*SD= standard deviation 
 
Table 5.2 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for wild-type and mutant plasmids (rVWF-R1157) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 14.0 
WT:Mut (50:50) (heterozygous) 147.0 26.0 
rVWF-C1157R (homozygous) 291.0 50.0 
*SD= standard deviation 
 
 
Figure 5.2 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with wild-type and mutant expression plasmids showing the effect of the 
p.C1157R mutation on VWF expression. Results are expressed as a percentage compared to 
wild-type. The horizontal black bars represent the extent of difference between mean values of 
VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate the standard 
deviation. Statistical test used is one-way ANOVA. 
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5.2.3.1. Multimer analysis for the p.C1157R VWF protein secreted from HEK293T 
cells 
The secreted rVWF results from transfection of wild-type plasmid, rVWF-R1157 plasmid and 
co-transfection of mutant/wild-type were analysed for multimer pattern using a 1.6% medium 
resolution SDS agarose gel. As a result, the multimeric composition of rVWF secreted from 
HEK293T cells showed the presence of a full set of multimers in wild-type and a relative 
reduction of HMW multimers when expressed in heterozygous state. The transfection of the 
p.C1157R multimers showed that in the homozygous state there was a complete absence of 
high-molecular weight VWF (HMW-VWF) multimers with presence of only dimers indicating 
the importance of the D3 domain in VWF multimerisation (Figure 5.3).  
 
 
Figure 5.3 Multimer analysis of secreted rVWF from HEK293T cells transfected with 
p.C1157R in comparison to wild-type. Multimer pattern of wild-type (lane 1), homozygous 
rVWF-R1157 (lane 2) and heterozygous rVWF (lane 3) mutants electrophoresed on 1.6% 
medium resolution SDS gel at 1:5 dilution are shown. VWF multimers of homozygous rVWF-
R1157 mutant (lane 2) showed complete loss of HMW-VWF forms with formation of only 
dimers in comparison to wild-type (lane 1). The multimeric composition of rVWF resulting 
from transfecting cells with heterozygous mutant (lane 3) showed a relative reduction of HMW 
multimers in comparison to wild-type.  
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5.2.3.2. Confocal imaging of p.C1157R 
Confocal microscopy was undertaken to evaluate the effect of p.C1157R on VWF storage 
within the HEK293 heterologous cell line. In vitro expression of the p.C1157R revealed a 
secretion defect resulting from intracellular retention. In the wild-type form, WB-like vesicles 
were present and appeared rounded and punctate (Figure 5.4 A and C). In the homozygous 
form, localised VWF diffuse staining patterns were observed (indicated with a white arrow, 
Figure 5.4 D) in one cross section through the cell (Figure 5.4 D and F). The diffuse pattern may 
be due to VWF WPB-like structures stacking on top of each other in cross-section analysis 
caused by intracellular retention. In the heterozygous form, WPB-like organelles were formed 
with a diffuse staining pattern similar to homozygous but to a lesser degree (indicated with a 
white arrow) (Figure 5.4 G and I). p.C1157R does not appear to affect WPB synthesis, but 
confocal confirms in vitro findings of increased intracellular retention. 
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Figure 5.4 Intracellular storage of rWT and rVWF-R1157 mutant in HEK293 cells by 
confocal microscopy. A) Represents VWF (green) after transfection of wild-type into HEK293 
cells. B)  Represents the cell membrane marker α-tubulin (red) after transfection of wild-type 
into HEK293 cells. C) Represents merged images of VWF and α-tubulin staining for wild-type 
transfected into HEK293 cells. D) VWF (green) after transfection of homozygous p.C1157R 
into HEK293 cells. White arrows indicate regions where there was diffuse staining of VWF 
within the cell.  E) VWF (red) after transfection of homozygous p.C1157R into HEK293 cells. 
F) Merged changes of VWF and α-tubulin staining for homozygous p.C1157R transfected into 
HEK293 cells. G) VWF (green) after transfection of heterozygous p.C1157R into HEK293 
cells. White arrows indicate regions where there was diffuse staining of VWF within the cell. 
H) VWF (red) after transfection of heterozygous p.C1157R into HEK293 cells. I) Merged 
changes of VWF and α-tubulin staining for heterozygous p.C1157R transfected into HEK293 
cells. Cells of the upper horizontal row (A, D and G) were stained with rabbit anti-VWF 
primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of the middle horizontal 
row (B, E and H) were stained with mouse anti-α-tubulin and anti-mouse Alexa Fluor 555 for 
the cell membrane α-tubulin marker (red). The lower horizontal row (C, F and I) shows a 
merge of VWF and α-tubulin staining.  
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5.2.3.2.1. Confocal microscopy of p.C1157R to determine retention of VWF in the 
ER 
In vitro expression of the p.C1157R showed a significant defect in VWF secretion resulting 
from intracellular retention. Confocal microscopy confirmed the retention of VWF within the 
ER using co-staining of VWF and PDI, ER markers. The pseudo-WPB organelles within the 
transfected HEK293 cells appeared rounded and punctuate in the wild-type (Figure 5.5A and 
C). The WPB-like organelles formed by homozygous mutant p.C1157R were also rounded and 
punctuate but appeared smaller in size when compared to wild-type. Confocal imaging 
illustrated that most of the synthesised VWF was retained within the ER when expressed in the 
homozygous form (orange organelles) as observed in figure 5.5 E and G. The retention of 
produced VWF was also observed when cells were co-transfected with wild-type but was less 
pronounced than that seen in the homozygous form (Figure 5.5 I and K). These confocal 
imaging using VWF and ER markers suggested that p.C1157R impaired VWF storage and 
secretion due to retention of VWF within the ER. 
 
 
 
 
 
 
 
 
170 
  
 
Figure 5.5 Intracellular localisation of VWF in rWT and rVWF-R1157 mutant in HEK293 cells. A, E and I) Represent VWF (green) after 
transient transfection of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, F and J) Represent the ER marker PDI 
(red) after transfection of wild-type, homozygous and heterozygous respectively into HEK293 cells. C, G and K) Represent merged changes of VWF 
and PDI staining for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. D, H and L) Represent phase contrast (PC) 
images for wild-type, homozygous and heterozygous respectively transfected into HEK293 cells. Cells of the column (A, E and I) were stained with 
rabbit anti-VWF primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of the second column (B, F and J) were stained with mouse 
anti-PDI and anti-mouse Alexa Fluor 555 for the ER marker (red). The Third column (C, G and K) shows a merge of VWF and PDI.  
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5.2.4. Quantitative analysis of supernatant and cell lysates following transfection of 
HEK293T cells with rVWF-wild-type and mutant plasmid (rVWF-L539fs) 
In an attempt to investigate the effect of c.1614del on the level, structure and function of VWF, 
transient transfection was conducted using HEK293T cells. The analysed values of VWF in cell 
supernatant and cell lysates are shown in tables 5.3 and 5.4. In vitro expression of rVWF-
L539fs showed that the rVWF mean values measured in growth medium of homozygous mutant 
was reduced by 99.6% with a significant change compared to 100% rVWF-wild-type 
(P<0.0001) and the mean values obtained by co-transfecting wild-type and mutant was also 
significantly reduced by 40% compared with the corresponding values of 100% wild- type 
VWF (p<0.0001) (Figure 5.6).  
Also, the mean values of VWF retained within cells of heterozygous and homozygous states 
showed significant reductions with values of approximately 81% (p<0.01) and 5.7% (p<0.0001) 
respectively compared to 100% of rVWF-wild-type (Figure 5.6).  
In summary, these results indicated that the secretion of homozygous and heterozygous rVWF-
L539fs was significantly reduced. In vitro expression of rVWF-L539fs suggested that this 
frameshift mutation (p.S539fs) had impaired VWF secretion resulting from reduced production 
of VWF protein and did not lead to intracellular accumulation of VWF within the cells in both 
states. 
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Table 5.3 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for wild-type and mutant plasmids (rVWF-L539fs) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 14.0 
WT:Mut (50:50) (heterozygous) 60.0 12.0 
rVWF-S539fs (homozygous) 0.4 0.3 
*SD= standard deviation 
 
Table 5.4 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for wild-type and mutant plasmids (rVWF-L539fs) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 14.0 
WT:Mut (50:50) (heterozygous) 81.0 11.4 
rVWF- S539fs (homozygous) 5.7 2.0 
*SD= standard deviation 
 
 
Figure 5.6 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with wild-type and mutant expression plasmids showing the effect of the 
p.S539Lfs*38 mutation on VWF expression. Results are expressed as a percentage in 
comparison with wild-type. The horizontal black bars represent the extent of difference between 
mean values of VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate 
the standard deviation. Statistical test used is one-way ANOVA. 
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Also, in an attempt to investigate whether the low VWF expression for the p.S539fs resulted 
from proteosomal degradation of mutant protein or possibly due to NMD, in vitro expression 
using standard transfection and with proteosome inhibitor was undertaken (Section 2.2.13.5.1). 
Transfected cells were treated with proteosome inhibitor three hours prior to harvesting to 
inhibit proteosome activity. Analysis of secreted VWF between uninhibited (61%) and inhibited 
(50%) cells in the heterozygous state showed no significant change (Figure 5.7 A). Also, no 
significant change was observed between uninhibited (68) and inhibited (51) on analysis of 
lysate VWF in the heterozygous form (Table 5.5). Analysis of secreted and lysate VWF also 
showed no significant differences when comparing uninhibited and inhibited values in the 
homozygous form (Figure 5.7 B). In the homozygous form, very low levels of VWF were 
expressed in both conditions (Table 5.5). Assuming that the low VWF level resulted from 
proteosome degradation, treatment with proteosome inhibitor would lead to an increase in the 
VWF level in the lysate. Therefore, the consistency of results in both experiments and absence 
of significant differences between uninhibited and inhibited experiments suggested that VWF 
protein in the cell was not degraded by a proteosomal mechanism and other mechanism 
potentially resulted in the low protein expression for the p.S539fs mutant. 
 
Table 5.5 The expression mean values of secreted and retained VWF using proteosome 
inhibitor in the heterozygous and homozygous states 
State Uninhibited mean 
(%) 
Inhibited mean (%) 
Heterozygous supernatant 61.0 50.0 
Heterozygous lysate 68.0 51.0 
Homozygous supernatant 2.4 1.6 
Homozygous lysate 3.3 5.0 
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Figure 5.7 In vitro expression of p.S539fs using a proteosome inhibitor. A) Represents the expression of inhibited and uninhibited cells in the 
heterozygous form. B) Represents the expression of inhibited and uninhibited cells in the homozygous form. Both states showed no significant 
differences between VWF levels with and without proteasome inhibitor treatment for supernatant and lysate VWF. Black bars represent cell supernatant 
and white bars represent cell lysate. 
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5.2.4.1. Multimer gel analysis for the p.S539fs VWF protein secreted from 
HEK293T cells 
The secreted rVWF from transfection of wild-type plasmid, rVWF- plasmid and co-transfection 
of mutant/wild-type were analysed for multimer pattern using a 1.6% medium resolution SDS 
agarose gel. As a result, the multimeric composition of rVWF secreted from HEK293T cells 
showed complete absence of HMW-VWF multimers when homozygous multimers were 
analysed. The multimer analysis of the heterozygous p.S539fs mutation was comparable with 
wild-type multimers showing the presence of a full array of multimer bands (Figure 5.8).  
 
 
Figure 5.8 Multimer analysis of secreted rVWF from HEK293T cells transfected with 
p.S539Lfs in comparison to wild-type. Multimer pattern of wild-type (lane 1), homozygous 
rVWF-S539fs (lane 2) and heterozygous rVWF (lane 3) mutants electrophoresed on a 1.6% 
medium resolution SDS gel at 1:5 dilution  are shown. The multimeric composition of rVWF 
resulting from the heterozygous state post in vitro expression (lane 3) showed a full array of 
multimers similar to those observed in wild type. VWF multimers of homozygous mutant 
rVWF-S539fs (lane 2) showed a total absence of HMW-VWF multimers with the presence of 
only the lowest molecular weight forms. 
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5.2.4.2. Confocal imaging of p.S539fs 
The effect of p.S539fs on VWF storage was evaluated using confocal microscopy. In vitro 
expression of the p.S539fs revealed a defect in secretion accompanied by some VWF present in 
cell lysates when the mutant was expressed alone. Confocal imaging confirmed this finding in 
the homozygous form when a very small quantity of VWF were present with only diffuse 
intracellular staining (Figure 5.9 D and F) in comparison to rounded punctate WPB-like 
organelles observed in the wild-type (Figure 5.9 A and C). Unlike the homozygous form, WPB-
like organelles were seen that appeared to be round and punctate but were more in number and 
smaller in size when compared to wild-type (Figure 5.9 G and I). Confocal imaging suggested 
that the p.S539fs when present with wild-type partially rescued storage ability. Also, the small 
amount of VWF retained in cell in the homozygous form could be due to different mRNA 
transcripts being produced, some of which lead to an aberrant protein being made. 
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Figure 5.9 Intracellular storage of rWT and rVWF-L539fs mutant in HEK293 cells by 
confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous plasmids respectively into HEK293 cells. B, E and H) 
Represent the cell membrane marker α-tubulin (red) after transfection of wild-type, 
homozygous and heterozygous respectively into HEK293 cells. C, F and I) Represent merged 
image of VWF and α-tubulin staining for wild-type, homozygous and heterozygous respectively 
transfected into HEK293 cells. Cells of the upper horizontal row (A, D and G) were stained 
with rabbit anti-VWF primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of 
the middle horizontal row (B, E and H) were stained with mouse anti-α-tubulin and anti-mouse 
Alexa Fluor 555 for the cell membrane α-tubulin marker (red). The lower horizontal row (C, F 
and I) shows a merge of VWF and α-tubulin staining.  
 
 
178 
  
5.2.5. Quantitative analysis of supernatant and cell lysates following transfection of 
HEK293T cells with rVWF-wild-type and mutant plasmids rVWF [R1157];[L539fs] 
In order to investigate whether the presence of these two mutations p.[C1157R];[S539Lfs] on 
two different alleles was responsible for the observed phenotype associated with bleeding 
symptoms in patients carrying both variants, in vitro co-expression of both mutations in parallel 
with rVWF-wild-type plasmid was conducted using a transient transfection method. Analysed 
data of secreted and retained VWF obtained by co-transfection are shown in tables 5.6 and 5.7. 
The mean values of secreted and retained VWF were significantly reduced by 99.4%% and 
64.0% respectively in comparison with the corresponding value of 100% wild-type VWF 
(p<0.0001) (Figure 5.10).  
 
In summary, the measured mean values of VWF following co-transfection of rVWF-R1157 and 
rVWF-L539fs on two different alleles suggested a significant reduction of secreted VWF into 
the supernatant and those retained within the cells compared to rVWF-wild-type. These values 
attained statistical significance.  
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Table 5.6 The mean values and standard deviation of secreted VWF:Ag levels post co-
transfection for wild-type and mutant plasmids (rVWF-R1157 and L539fs) in HEK293T 
cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 4.0 
Mut:Mut (50:50) (Compound heterozygous) 0.6 0.3 
*SD= standard deviation 
 
Table 5.7 The mean values and standard deviation of retained VWF:Ag levels harvested 
post co-transfection for both mutant plasmids (rVWF-R1157 and L539fs) in HEK293T 
cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 6.0 
Mut:Mut (50:50) ( Compound heterozygous) 36.0 6.0 
*SD= standard deviation 
 
 
Figure 5.10 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with wild-type and mutant expression plasmids showing the effect of the 
p.[C1157R];[S539Lfs*38] mutations on VWF expression. Results are expressed as a 
percentage in comparison with the corresponding wild-type. The horizontal black bars represent 
the extent of difference between mean values of VWF:Ag between wild-type and mutant VWF. 
The vertical black bars indicate the standard deviation. Statistical test used is one-way ANOVA. 
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5.2.5.1. Multimer analysis for the rVWF [R1157];[L593fs] protein secreted from 
HEK293T cells 
Multimer analysis for the rVWF[R1157];[L593fs] compound heterozygous state secreted from 
HEK293T cells revealed a complete absence of HMW-VWF multimers and only the lowest 
molecular weight forms were visible in comparison to wild-type multimers (Figure 5.11).  
 
 
Figure 5.11 Multimer analysis of secreted rVWF from HEK293T cells co-transfected with 
rVWF-R1157 /rVWF-L539fs in comparison to wild-type. The multimer pattern of wild-type 
(lane 1) and compound heterozygous rVWF-R1157/rVWF-L539fs mutant (lane 2) 
electrophoresed on 1.6% medium resolution SDS gel at 1:5 dilution  are shown. The multimeric 
composition of rVWF resulting from transfecting cells with rVWF-R1157/rVWF-L539fs 
mutants (lane 2) resulted in a complete loss of HMW-VWF forms and only the lowest MW and 
faint tetramers were observed in comparison to wild-type that showed a full set of multimers. 
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5.2.5.2. Confocal imaging of p.[S539fs];[C1157R] 
Confocal microscopy to evaluate the effect of compound heterozygous mutations 
p.[S539fs];[C1157R] on VWF storage within HEK293 cell lines was undertaken. In vitro 
expression of the p.[S539fs];[C1157R] on two different alleles showed that severe secretion 
defect and abnormal intracellular VWF resulting from two independent mechanism that likely 
include NMD and intracellular retention. The confocal imaging of wild-type showed the 
presence of round punctate WPB-like organelles throughout the cell (Figure 5.12 A and C). 
Similarly to the wild-type image, the compound heterozygous mutants p.[S539fs];[C1157R] 
image showed punctate WPB-like organelles throughout the cell but appeared smaller than 
those observed in wild-type (Figure 5.12 D and F). These findings suggest that the allele 
carrying p.C1157R showed a mild effect in WPB storage but was still able to produce WPB-like 
structures retained within transfected cells. The in vitro expression analysis of 
p.[S539fs];[C1157R] mutants showed that 36% of VWF was retained in cell and this was also 
observed when the WPB-like organelles were visualised using confocal analysis. 
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Figure 5.12 Intracellular storage of rWT and rVWF-L539fs + R1157 mutants in HEK293 
cells by confocal microscopy. A and D) Represent VWF (green) after transfection of wild-type 
and compound heterozygous plasmids respectively into HEK293 cells. B and E) Represent the 
cell membrane marker α-tubulin (red) after transfection of wild-type and compound 
heterozygous respectively into HEK293 cells. C and F) Represent merged images of VWF and 
α-tubulin staining for wild-type and compound heterozygous respectively transfected into 
HEK293 cells. Cells of the upper horizontal row (A and D) were stained with rabbit anti-VWF 
primary and anti-rabbit Alexa Fluor 488 for VWF (green), while cells of the middle horizontal 
row (B and E) were stained with mouse anti-α-tubulin and anti-mouse Alexa Fluor 555 for the 
cell membrane α-tubulin marker (red). The lower horizontal row (C and F) shows a merge of 
VWF and α-tubulin staining.  
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5.3. Discussion 
In this chapter, in vitro expression studies of two mutations detected in a family historically 
diagnosed with type 1 VWD was conducted. These mutations included one missense mutation 
p.C1157R and one frameshift variant p.S539Lfs*38 that were found together in affected 
members on two different alleles (Section 3.6.2). The affected members who were compound 
heterozygous for these two mutations had severe bleeding symptoms and demonstrated 
undetectable levels of VWF with absence of multimers (Appendix 18). Initially, due to the 
presence of the frameshift variant only and the AFM presenting with an undetectable level of 
VWF:Ag, abnormal VWF:RCo, absence of multimers and high BS, this family was classified as 
type 3 VWD and excluded from the study (Goodeve et al., 2007). Further identification of the 
novel missense mutation in the D3 domain in addition to the previously identified frameshift 
change could explain the observed undetectable levels of VWF and abnormal multimers in the 
investigated members and led to review the classification for each identified mutation alone and 
when both were present in the same individual. Three separate experimental expression studies 
were designed in order to determine the effect of each mutation on the level and structure of 
VWF. They included; expression of rVWF-R1157 alone, expression of rVWF-L539fs alone and 
co-expression of both mutants (rVWF-L539fs and rVWF-R1157) on two different alleles. The 
purpose of co-expression of both mutations was to mimic the compound heterozygous state and 
to determine whether the presence of both mutations was responsible for the complete 
deficiency of VWF, abnormal multimers and bleeding symptoms in the investigated patients. 
The recombinant plasmids carried full length VWF cDNA and mutated plasmids were 
transiently transfected into HEK293T cells using Lipofectamine method. 
5.3.1. In vitro expression of p.C1157R 
In vitro studies indicated that p.C1157R causes a secretion defect when mutant plasmid was 
transfected in a homozygous form, it showed a significant defect in secretion of VWF (98% 
lower; P<0.0001) compared to the wild-type VWF and higher levels of the mutant VWF by 
(190% higher; P<0.0001) were retained within cells than levels of wild-type. Also, co-
transfection of mutant and wild-type plasmid showed a significant reduction of secreted VWF 
(55%) accompanied by a significant increase in the amount retained in the cells (47% higher; 
P<0.001). These findings suggested that this novel mutation may impair VWF secretion due to 
intracellular retention in the ER and possible degradation of VWF in the ER as previously 
described (Section 4.3.1). 
Furthermore, the analysis of VWF multimers following transient transfection from media 
indicated the complete absence of HMW-VWF multimers in the homozygous form resulting 
from mutant plasmid while the hybrid plasmid in the heterozygous form clearly showed 
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multimers comparable to wild-type although they still showed a relative reduction of HMW 
multimers compared to wild-type. The presence of dimeric VWF with complete loss of HMW-
VWF multimers in the homozygous form indicated the importance of D3 assembly in the VWF 
multimerisation process which is essential for VWF normal function and folding. Unlike 
multimerisation, the cysteine mutation p.C1157R located in D3 assembly had no effect on VWF 
synthesis and was able to form WPB similar to those present in wild-type in both homozygous 
and heterozygous forms, but confocal microscopy confirmed the accumulation of VWF within 
the cell resulting in intracellular retention.  
The D3 assembly of VWF is located at the amino-terminal region of VWF and is known to be 
involved in the multimerization process including multimer assembly via formation of intra-
disulfide and inter-disulfide bonds between adjacent D3 assemblies involving cysteine residues. 
Also, the D3 assembly contributes to binding of VWF to FVIII. The binding of secreted rVWF 
to FVIII (VWF:FVIIIB) was not tested. The location of this mutation in the D3 domain and its 
effect on a cysteine residue suggests the underlying mechanism. The replacement of a cysteine 
residue that is required for disulfide bond synthesis by a basic arginine at the N-terminal will 
affect normal pairing with the other cysteine in the same domain or the formation of disulfide 
bridges between adjacent D3 assemblies and could impair multimerization. The increased 
intracellular accumulation of mutant VWF may be due to protein mis-folding which may cause 
retention of VWF in the ER and prevent it reaching the Golgi apparatus which would result to 
degradation of mutant protein by the proteasome complex and secretion of only a small quantity 
of VWF. Furthermore, the presence of this substitution in the D3 assembly in addition to 
impairing production of VWF appears to explain the observed abnormal multimers found in 
patient’s plasma. One of the major aims of this study was to identify and investigate the disease 
causing mechanism. The results obtained from expression studies showed that p.C1157R in the 
heterozygous form can cause a moderate reduction of VWF secretion and a severe reduction 
when found in the homozygous state due to the intracellular retention observed. Moreover, due 
to the presence of p.C1157R in the D3 assembly involving a cysteine residue that is known to 
play an essential role of VWF disulfide bonding, this mutation affects the VWF multimerisation 
process.  
The affected members who harboured the p.C1157R mutation also co-inherited the frameshift 
variant p.S539Lfs*38 and none of them carried only p.C1157R (Appendix 18). Therefore, it 
was not possible to compare the results from transfection studies to the phenotypic data 
observed in affected p.C1157R heterozygous patients. Expression of p.C1157R alone was 
conducted in order to identify the disease causing mechanism. The affected members who were 
compound heterozygous for p.C1157R and p.S539Lfs*38 presented with severe bleeding 
symptoms, had high BS and had markedly low phenotypic data (Section 3.6.2). The levels of 
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VWF:Ag, VWF:RCo and FVIII:C in the IC and AFM who carried both variants was 
undetectable (< 3 IU/dL) with absence of HMW multimers and O/O and O/B blood group 
genotypes respectively. Moreover, the IC and AFM showed uninterpretable binding of VWF to 
FVIII. From the in vitro expression studies, p.C1157R had a significant effect on VWF 
secretion and impaired multimer assembly similar to the observed phenotype found in the AFM 
as p.S539Lfs*38 had no significant influence on the multimerization process when present in 
the heterozygous form. The observed finding showed that p.C1157R contributes to the absence 
of HMW multimers in the AFM when inherited in the homozygous form or in the compound 
heterozygous form with the second change. In vitro expression showed that p.C1157R can 
influence the level and structure of VWF and these findings are compatible with in silico 
predictions that suggested this mutation was probably damaging.  
Several mutations were identified in the D3 assembly of VWF in patients diagnosed with VWD. 
Schneppenheim et al  expressed 22 mutations correlated with the VWD 2A(IIE) phenotype 
located in the D3 assembly in HEK293T cells (Schneppenheim et al., 2010). Twelve of them 
showed loss of a cysteine, three gain of a cysteine and nine were located in exon 26. The results 
showed that most mutations lead to intracellular retention, reduced secretion and abnormal 
multimers. The hallmark of multimers observed in the expressed VWF protein was the presence 
of abnormal multimers in both homozygous and heterozygous forms. Many mutations in the D3 
assembly involving cysteine residues were investigated previously and were also reported to 
cause intracellular retention, secretion defects and abnormal multimers. The co-transfection of 
p.C1130F and p.C1149R with wild-type VWF indicated reduced secretion accompanied by 
intracellular retention and lack of HMW multimers (Eikenboom et al., 1996, Bodo et al., 2001b, 
Schneppenheim et al., 2010). Also, the expression of mutations p.C1225G and p.C1227R also 
involving cysteine residues indicated the presence of a relative decrease of large multimers in 
addition to abnormal binding to FVIII and defects in secretion (Dong et al., 1994, Allen et al., 
2000a, Schneppenheim et al., 2010). The mutation p.Y1146C that leads to a cysteine gain and 
p.T1156M that does not involve cysteines indicated the same findings as others including 
intracellular retention and impaired multimerization (Lethagen et al., 2002b, Schneppenheim et 
al., 2010). Moreover, Hommais et al (2006) expressed two mutations involving cysteine in 
COS-7 cell, one of them located at the same position p.C1157 but encoding a different amino 
acid p.C1157F. These mutations p.C1157F and p.C1234W were referred as ˝unclassified˝ and 
type 2A respectively. The results obtained by expression studies of p.C1157F and p.C1234W 
illustrated that these variants exhibited reduced secretion due to intracellular retention and had 
abnormal multimers and a defect in binding to FVIII. The retained VWF value of  p.C1157F 
was 300% compared to 100% wild-type and this high value may be explained because there was 
no correction for transfection efficiency in the experiment and also COS-7 cells do not make 
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WPB-like organelles that store VWF (Hommais et al., 2006a). However, the expression of 
p.C1157R showed that this mutation also impaired secretion of VWF associated with 
intracellular retention, lack of HMW multimers but showed normal synthesis and pseudo-WPB 
formation using confocal microscopy. All of these findings highlight similar findings of VWF 
secretion, intracellular retention and abnormal multimers in this study. According to the current 
VWD classification, mutations located in D3 assembly that disturb multimerization can be 
classified as type 2A(IIE) rather than type 1 VWD (Sadler et al., 2006, Schneppenheim et al., 
2010). The missense mutation p.C1157R located in the D3 assembly can be considered as the 
major contributor to the abnormal multimers observed in patients and could contribute to the 
low levels of VWF and be classified as likely to result in VWD type 2A(IIE) when inherited in 
the heterozygous form rather than type 1 or type 3 VWD. 
5.3.2. In vitro expression of c.1614del; p.S539Lfs*38 
In this study, the effect of the previously identified candidate frameshift deletion c.1614del 
located in exon 14, (D2 assembly) on VWF was investigated. Analysis of transfection and co-
transfection experiments indicated a highly reduced level of secreted and retained VWF 
(p<0.0001) when transiently transfected in the homozygous state. The co-transfection of mutant 
plasmid with wild-type to replicate the heterozygous state showed a moderate and significant 
reduction of secreted VWF (40% lower) compared to expressed wild-type (p<0.0001) in 
addition to a significant reduction (p<0.01) of VWF level retained within cells. The effect of 
proteosome degradation on the low VWF level observed was excluded and that was confirmed 
by expression studies that have used proteosome inhibitor which illustrated similar findings to 
standard expression of p.S539fs without using the proteosome inhibitor. However, these 
findings indicated the significant effect of the frameshift mutation p.S539fs in VWF secretion 
likely resulting from NMD mechanism (Shahbazi et al., 2012). 
The VWF multimers secreted into the media following transient transfection showed the 
presence of a full set of multimers including HMW-VWF multimers in the heterozygous form, 
but these was a complete loss of HMW and intermediate MW-VWF multimers resulting from 
mutant plasmid in the homozygous form. These analyses showed that the heterozygous 
frameshift mutation p.S539fs had no effect on VWF multimerisation. Furthermore, the 
homozygous frame-shift mutation p.S539fs that impairs multimerisation significantly altered 
intracellular storage of VWF with a complete absence of punctate pseudo-WPB organelles, 
while the heterozygous form of this mutation illustrated no significant effect on VWF storage as 
pseudo-WPB were formed similar to those present in wild-type. The presence of the wild-type 
allele with the frame-shift deletion explains the normal storage function of VWF and this can 
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occur through a haplosufficiency mechanism. Haplosufficiency occurs when the normal allele is 
sufficient to produce enough protein when the mutant allele is degraded.  
The c.1614del (p.S539Lfs*38) was predicted to create a stop codon, 38 amino acids 
downstream of the mutation of exon 14. In silico prediction showed that this candidate variant 
may result in a null allele and this is likely to be due to a NMD mechanism. The aims of this 
study were to examine the effect of the identified frameshift candidate mutation on VWF 
expression using transient transfection experiments in HEK293T cells and also to determine the 
pathogenesis of this mutation in the affected members of the P9F18 family.  
The results from expression studies and in silico prediction may be able to explain the disease 
mechanism. The single nucleotide deletion in VWF exon 14 interrupts the protein reading frame 
and creates a PTC. The presence of a PTC within the mRNA transcript results in synthesis of a 
shortened protein that is subsequently degraded by NMD. The mRNA surveillance machinery is 
responsible and results in a null allele (Lykke-Andersen et al., 2000, Cartegni et al., 2002). 
NMD is mainly observed in mutated mRNA that includes a PTC and stop codons due to 
insertion, deletion or mutations cause splicing errors. NMD mainly is a pathway that aims to 
diminish the production of potential truncated proteins during expression via removal of 
aberrant mRNA harboring premature termination (nonsense) codons. If translated, these 
mRNAs can produce truncated proteins with dominant-negative or deleterious gain-of-function 
activities. Exon-junction complex (EJC) are formed following mRNA splicing and found 
upstream of normal stop codon which are thus removed by ribosome nuclear protein (RNP) 
before NMD factors UPf1 is recruited. In the presence of premature termination codon, EJC are 
deposited downstream of the PTC which cannot be removed by RNP, allowing EJC to interact 
with NMD factors UPF1 which trigger mRNA decay (Chang et al., 2007). The null allele’s 
disease mechanism can explain the moderate level of secreted VWF following co-transfection 
and near absence of VWF secretion following transfection of the mutant plasmid alone.  
 
Many experimental studies investigated the effect of nonsense, small deletion, small insertion 
and splice site mutations that lead to PTC in open reading frames on VWF. Most mutations 
associated with VWF null alleles were identified in type 3 VWD and several were detected in 
type 1 VWD (Baronciani et al., 2003, Goodeve et al., 2007, Hampshire and Goodeve, 2011, 
Jokela et al., 2013). Also more mutations found in ISTH VWF database 
http://www.vwf.group.shef.ac.uk/ accessed February, 2012. Shahbazi et al (2012) examined the 
effect of the c.7674_7675insC mutation present in type 3 VWD on the expressed VWF mRNA. 
The level of mRNA was measured using real time-PCR and was found to be significantly 
decreased in the patient's platelets with a mean ratio (patient/wild-type) of 0.03 compared to that 
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in normal relatives, but the level of mRNA from a heterozygous carrier was insignificantly 
reduced with a mean ratio of 0.6 compared to wild-type VWF mRNA level (Shahbazi et al., 
2012). These findings suggested degradation of mRNA by NMD-causing null alleles. The study 
conducted by Corrales et al (2011) used RNA isolated from patients’ leucocytes and platelets 
and in silico prediction studies to investigate the effect of several splice site mutations on VWF 
mRNA transcripts. Most of these changes such as c.533-2A>G, c.8155+3G>C, c.7082-2A>G 
resulted in exon skipping, creation of PTC and degradation of VWF mRNA due to NMD and 
compatible effects were predicted using various prediction tools (Corrales et al., 2011). The 
results from these studies in terms of reduced secretion due to NMD were consistent with our 
findings and showed a similar effect of p.S539fs on VWF. 
The P9F18 family had two AFM and three UFM (Appendix 18); the frameshift mutation 
p.S539Lfs*38 was present in both AFM who were compound heterozygous with p.C1157R and 
was present alone in two UFM. The AFM who had the p.C1157R in addition to p.S539fs variant 
showed a very low VWF level and abnormal multimer structure (Section 3.6.2). Therefore, it 
was not possible to compare the expression findings with the phenotype observed in the affected 
members due to presence of two mutations in each affected member. Two UFM were 
heterozygous for only the p.S539fs variant and presented with normal VWF level and normal 
multimer pattern and were asymptomatic and considered as carriers of type 3 VWD. The levels 
of VWF:Ag, VWF:RCo and FVIII were 53-60, 50-69 and 74-75 IU/dL respectively in the UFM 
carrying the p.S539fs only (Table 3.8). VWF:Ag levels from in vitro expression were 
compatible at 60% of wild-type. The presence of p.S539fs alone in UFM with absence of 
bleeding symptoms (BS 0-2) suggested haplosufficiency as the disease mechanism as a single 
copy of wild-type VWF was sufficient to maintain normal function of VWF. 
Also, the obtained results from transfection studies and in silico predictions illustrated that this 
frameshift variant was likely to impair the secretion of VWF due to NMD that leads to null 
alleles which further causes mild quantitative deficiency of plasma VWF observed in VWD 
patients. These findings confirm that p.S539fs was responsible for the mild deficiency of VWF 
observed in UFM who carry this change and it had no effect on multimer structure when present 
in the heterozygous form. Type 3 VWD is mostly inherited as an autosomal recessive trait and 
heterozygous individuals present with a mild to moderate reduction in VWF level and normal 
multimers that may be characterized by a mild deficiency of VWF. According to the current 
classification, the presence of p.S539fsL*38 in the heterozygous form is considered as type 3 
VWD carrier and may be consistent with type 3 VWD when inherited in homozygous form 
(Sadler et al., 2006). These findings indicated that p.S539fs is a recessive mutation and may 
cause bleeding only when inherited in the homozygous state or in the compound heterozygous 
form with an additional variant. The presence of p.S539fs in the heterozygous form in 
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asymptomatic members suggested them to be carriers of type 3 VWD. However, other studies 
have indicated that type 3 VWD carriers can be symptomatic and reported that 15-50% of type 3 
VWD carriers may experience some bleeding symptoms (Nichols et al., 2008b, Bowman et al., 
2013). So, not all mutations are pure recessive changes and some may be inherited as co-
dominant rather than recessive. 
5.3.3. In vitro co-expression of p.[S539fs];[C1157R] 
The purpose of this experiment was to replicate the inheritance pattern found in affected 
members who harbour these mutations on two different alleles and also to define the possible 
pathogenesis leading to complete deficiency of VWF in affected patients. The results obtained 
from co-transfection of both mutations in parallel with wild-type indicated a very low level of 
secreted VWF (0.6%) into the growth medium from HEK293T cells accompanied by a 
significant reduction of VWF (36%) present intracellularly in comparison to wild-type. Also, 
multimer analysis of compound heterozygous rVWF mutants showed complete absence of 
HMW-VWF multimers in addition to a mild effect in VWF storage. However, the expression 
results of the current study showed that the compound heterozygous mutations 
p.[S539fs];[C1157R]  located on two different alleles resulted in  a severe VWF secretion defect 
and complete loss of HMW multimers. The nearly normal storage of compound heterozygous 
mutants may be due to accumulation of VWF throughout cells produced from the allele carrying 
p.C1157R. 
The IC (I:1) and his affected brother (I:2) (Appendix 18) were compound heterozygous for the 
missense mutation p.C1157R in the D3 assembly and frameshift mutation p.S539fs in the D2 
assembly previously reported to be associated with type 3 VWD due to the observed phenotype 
and absence of multimers. The presence of both mutations in affected members resulted in 
severe bleeding symptoms and undetectable levels of documented as VWF:Ag, VWF:RCo and 
FVIII:C 3 IU/dL for each parameter and absence of multimers. The very small amounts of 
mutated rVWF and absence of multimers resulting from co-expression of rVWF L539fs and 
R1157 reflected the situation in patients and was similar to the phenotypic data observed in 
affected members. Also, the obtained results showed a good correlation between genotype and 
phenotype parameters. Based on these findings, we assume that in vivo compound heterozygous 
mutations p.S539fs and p.C1157R together are likely to contribute to the poor synthesis of 
VWF based on two independent mechanisms: firstly, p.C1157R reduced VWF synthesis due to 
intracellular degradation of retained mutated VWF in ER. Also, as this mutation leads to loss of 
cysteine, it causes misfolding of mutant VWF and impairs normal multimerization and produces 
abnormal multimers. The presence of undetectable levels of VWF:Ag in patient plasma cannot 
be explained by intracellular retention of VWF within ER due to missense mutation located in 
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D3 assembly alone. However, the affected members were compound heterozygous for the 
frameshift mutation, p.S539fs that creates a PTC and likely leads to degradation of mRNA 
transcripts by the NMD mechanism and p.C1157R reduces secretion due to intracellular 
retention which can explain the undetectable level of plasma VWF:Ag and abnormal multimers.  
These findings confirmed that compound heterozygous expression of both mutations replicated 
the situation in the IC and AFM via different mechanisms and the affected patients were 
correctly classified as type 3 VWD.  
The expression study of candidate mutation p.T1156M located in the D3 domain showed 
intracellular retention; reduced synthesis and lacking of multimers when expressed in the 
homozygous form, but reduced secretion and normal multimers was observed in the 
heterozygous form. The IC who had p.T1156M mutation had a stop mutation p.Q2470* on the 
other allele and presented with severe bleeding symptoms, a very low VWF level (5-9 IU/dL) 
and lack of HMW multimers (Lethagen et al., 2002a). Also, an ˝unclassified˝ VWD patient who 
had p.C1157F was compound heterozygous for p.K1362T located in exon 28, A1 domain and 
exhibited severe bleeding symptoms, markedly decreased phenotype data and loss of multimers 
(Hommais et al., 2006a). The presence of both mutations p.[C1157F];[K1362T] on two alleles 
contributed to the reduced levels of VWF:Ag to 15 IU/dL, VWF:RCo to 11 IU/dl and FVIII:C 
to 21 IU/dL in addition to impaired multimerisation (Matsushita et al., 2000, Hommais et al., 
2006a). The family who had p.[C1157F];[K1362T] was considered as unclassified rather than 
other types due to the presence of two mutations each acting through a different mechanism. 
Moreover, the co-expression of missense mutations p.D141Y and p.C275S both located in the 
D1 assembly illustrated that both impaired secretion due to intracellular retention and lead to 
presence of dimers only (Baronciani et al., 2008). p.D141Y was found in the compound 
heterozygous form with the null allele c.2016_2019del in one patient and the patient with 
p.C275S was compound heterozygous for nonsense mutation p.W222* (Baronciani et al., 
2003). Both patients were classified as type 3 VWD and presented with severe bleeding 
symptoms and very low levels of VWF, abnormal function of VWF:RCo and abnormal 
multimers. The results from this study indicated that the effect of p.[S539fs];[C1157R] on VWF 
expression was consistent with other findings. 
In conclusion, in vitro expression studies in HEK293T cells confirmed the pathogenic nature of 
p.S539fs and p.C1157R identified in the affected family. Based on expression studies, the 
presence of the single mutation p.C1157R alone located in the D3 assembly causes intracellular 
retention and loss of HMW multimers in patients’ plasma and should be classified as type 
2A(IIE). The presence of p.S539fs alone in the heterozygous state leads tol normal lev of VWF 
and individuals should be classified as carriers of a null VWF allele that could also contribute to 
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to other recessive form of VWD. The presence of both mutations p.[S539fs];[C1157R] in 
affected members is disease related and can explain the low levels of VWF and observed 
phenotypes. The accuracy of classification plays an important role for treatment decision and 
genetic counselling (Sadler et al., 2000, Sadler et al., 2006). Therefore, the presence of both 
changes in compound heterozygous state contributes to the complexity of classification. 
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Chapter 6 
In vitro characterisation of silent mutation 
associated with type 1 VWD 
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6. In vitro characterisation of silent mutation associated with type 1 VWD 
6.1. Introduction 
The EU study (MCMDM-1VWD) successfully detected candidate mutations throughout VWF 
in almost 70% of type 1 VWD IC, but failed to identify mutations in the remaining IC (Goodeve 
et al., 2007). Eighteen IC of 77 that showed no previously identified mutations were re-
sequenced using a sensitive technique and primers free of SNP within primer binding sites. As a 
result, four mutations were identified in four IC (Section 3.6), and one of them was a silent 
heterozygous mutation. This silent mutation was identified in exon 28 in the A1 domain 
(c.4146T>G), located at the third position of codon 1382 and was predicted to result in 
p.L1382= in one IC who showed no other mutation in the previous study. This change was 
found in the IC and AFM who had mild reductions of VWF:Ag levels and normal multimers 
(Appendix 19).  
In silent or synonymous mutations, the nucleotide change alters the triplet codon structure but 
encodes the same amino acid. It was historically believed that apparent silent mutations had no 
effect on gene expression. However, several studies indicated that silent mutations within a gene 
may contribute to disease phenotype through a number of mechanisms (Duan et al., 2003, 
Nielsen et al., 2007). In mammals, silent changes can alter protein synthesis and may contribute 
to disrupting normal mRNA translation rate during gene expression through several 
mechanisms (Table 6.1). They include splice regulation, mRNA translation rate, ribosome 
trafficking and miRNA binding. 
Table 6.1 List of the possible mechanisms that could be involved in silent mutations 
Molecule Level of impact Mode of action 
Splice site Pre-mRNA Introduces new donor or acceptor splice sites leading 
to partial exon skipping (Daidone et al., 2011) 
ESE and ESS Pre-mRNA 
splicing 
(Nucleus) 
Exonic mutation can lead to loss of ESE or gain of 
ESS that causes complete or partial exon skipping 
(Nielsen et al., 2007) 
tRNA mRNA translation Codon usage bias 
Reduces translation rate and can result in misfolded  
protein (Duan et al., 2003) 
Ribosome mRNA translation Impairs movements of multiple ribosomes causing 
collisions that reduce translation rate leading to 
misfolded protein (Mitarai et al., 2008) 
miRNA mRNA translation Leads to formation of small mRNA region 
complementary to miRNA sequence forming dsRNA. 
dsRNA is degraded (Hurst, 2011) 
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6.1.1. Effect of synonymous mutation on normal splicing pathway  
The stored genetic information in DNA is transcribed into pre-mRNA in the nucleus which is 
subsequently translated into protein.  The pre-mRNA contains both protein coding and non-
coding regions and the removal of non-coding pre-mRNA sequences (introns) from the mRNA 
transcript (mRNA splicing) before translation is an important process required for the 
production of mature mRNA and protein synthesis. Several factors that participate in this 
process include exon, intron, donor and acceptor splice-sites, exonic splice enhancer (ESE), 
exonic splice silencer (ESS), intronic splicing enhancer (ISE) and the spliceosome. The donor 
splice-site located at the 5' end of the intron and acceptor splice-site at the 3' end of intron form 
junctions between exons and introns. The splicing process occurs in a number of steps. The 
splicing mechanism is mediated by small protein-RNA complexes including the spliceosome 
complexes, and ESE, ESS and ISE elements. The spliceosome is a protein molecule assembled 
from small ribonuclear proteins (snRNPs) forming the splicing machinery (Hastings and 
Krainer, 2001, Hurst, 2011). ESE, ESS and ISE are short RNA conserved sequences usually 
found in genes with long introns to facilitate handling the splicing tools during splicing found in 
both exons and introns that act as regulators of the splicing mechanism (Fairbrother et al., 
2002). The spliceosome cleaves the pre-mRNA at the junction between exon and intron (splice-
site), beginning at the 5' end of the intron (GU-sequence-donor splice-site) forming a lariat loop 
and then cleaves the 3' end of intron (AG-sequence-acceptor splice-site) releasing the lariat 
loop, joining exons together in order to produce mature mRNA containing exon coding regions 
only (Figure 6.1A). This process is successfully achieved with help of ESE and ESS (Berget, 
1995, Chen and Manley, 2009). 
In silico analysis predicted that the silent change c.4146G>T had no effect on donor and 
acceptor splice site sequences and therefore would not impair mRNA splicing. However, 
additional prediction of ESE and ESS sequences indicated that the silent change had a potential 
effect on both ESE and ESS sequences (Section 3.6.3.2). There are several consensus sequences 
present in the exonic and intronic sites that represent splice enhancer and splice silencer 
sequences essential for normal splicing to occur. Mutations in such sequences may destroy or 
create splice-site regulatory sequences and can be pathogenic leading to either splicing defects 
or complete exon skipping. 
Several experimental studies have demonstrated that silent changes had a pathogenic effect on 
protein synthesis and may contribute to hampering normal mRNA translation rate through 
splicing changes during gene expression (Lorson and Androphy, 2000, Nielsen et al., 2007). 
Some exonic changes have been suggested to alter the pre-mRNA splicing either by leading to 
loss of the main donor/acceptor site sequences or by altering splicing regulatory sequences such  
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Figure 6.1 Schematic representations of normal and defective DNA transcription and translation. A) represents normal DNA transcription, 
splicing and translation. B, C and D) represent possible mechanisms acting on VWF expression associated with c.4146G>T. 
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as ESE and ISE and may contribute to the pathogenicity of type 1 VWD (Figure 6.1B). The 
presence of exonic or intronic silent changes can generate a new donor splice site causing exon 
skipping. The synonymous mutation c.7056C>T; p.G2352= located within VWF exon 41 was 
predicted to create a new donor splice site leading to deletion of 26 exonic nucleotides and the 
entire intron 41. In vitro expression study using a vector lacking nucleotides between 7055 and 
7081 demonstrated the absence of secreted VWF when VWF cDNA lacked 26 nucleotides 
expressed in the homozygous form and 50% of VWF was secreted in heterozygous form 
(Daidone et al., 2011). These findings suggested that this synonymous mutation could cause the 
mutant allele to be missed. Pagliari et al (2013) have also studied the effect of synonymous 
mutation c.3390C>T;p.C1130= located in VWF exon 26 in three type 2A/IIE VWD patients 
through mRNA analysis and in vitro expression using transient transfection in HEK293. These 
patients presented with high BS, moderate reduction of plasma VWF ranging between 13-27 
IU/dL and normal multimers. The analysed mRNA isolated from healthy individuals and patient 
platelets using RT-PCR showed that the wild-type allele is more abundant than the mutant one. 
In silico splicing analysis predicted the effect of c.3390C>T on splicing enhancers and silencers 
that may cause exon 26 exclusion. Transient transfection using a plasmid lacking exon 26 
revealed a 55% reduction of secreted VWF accompanied by a 176% increase of VWF in the cell 
lysate when expressed in the homozygous form and a 32% reduction in the heterozygous form 
accompanied by 132% increase of VWF in cell lysate compared to 100% wild-type (Pagliari et 
al., 2013). 
The impact of exonic silent changes on the splicing pathway is not limited only to complete 
exon exclusion, but it can also lead to partial exclusion causing mild to moderate splicing 
defects (Tournier et al., 2008). Alteration in the conserved nucleotides present in splice-sites or 
ESE in exon can result in abnormal splicing and causes exon skipping and NMD or alters the 
efficiency of splicing (Nielsen et al., 2007, Tournier et al., 2008). Truncated proteins are 
produced when exon skipping disrupts the reading frame producing PTC, but translation will 
continue if the reading frame is restored and produces functional mutant protein. Nielsen et al 
(2007) reported exon skipping of the aberrant mRNA resulting from a silent exonic mutation 
that impairs a putative ESE binding site in the medium-chain acyl-CoA dehydrogenase (MCAD) 
gene. Also, two exonic mutations; c.793C>T and c.794G>A identified in exon 10 of the mutL 
homolog 1 (MLH1) gene were investigated for their effect on splicing regulatory elements using 
a mini-gene assay and found to cause partial exon 10 skipping (Tournier et al., 2008). Not all 
exon skipping leads to NMD as Cartwright (2013) found that expression of type 1 VWD in-
frame heterozygous exon deletions leads to a dominant-negative reduction in VWF secretion 
from transiently transfected HEK293T cells. The  dominant negative mechanism suggests that 
there is no NMD but a shorter functional protein is produced (Cartwright et al., 2013). 
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6.1.2. Effect of synonymous mutation on translation rate and protein folding  
Following splicing, the mature mRNA moves to the cytoplasm across the rough ER outer 
membrane where translation and protein synthesis takes place. Several molecules including 
mature mRNA, ribosomes, tRNA and release factor are used to achieve translation. The mature 
mRNA contains only exon coding regions and has a methylated cap at its 5' end and poly-A tail 
at the 3' end. The small subunit of the ribosome binds to the cap site of mRNA at the 5' end 
initiating the translation process. The tRNA molecule that contains the anti-codon 
complementary to the first mRNA codon binds to the AUG codon encoding methionine, 
followed by binding of the large subunit of ribosome forming the mRNA-ribosome complex. 
The second tRNA which is complementary to the second mRNA codon binds mRNA and joins 
the next amino acid to methionine. The elongation stage in terms of the growing polypeptide 
continues until the stop codon. The stop codon activates release factor that terminates 
translation (Figure 6.1A). Release factor is a protein that recognises the stop codon in an mRNA 
and contributes to termination of translation. At the end, the ribosome subunit dissociates from 
mRNA and the newly formed protein enters the ER to mediate its shape and conformation 
(Chapeville et al., 1962, Karp, 2008). 
It has been found that silent changes can impair the rate of translation and protein folding during 
in vivo and in vitro translation via various mechanisms. Protein folding is a co-translational 
process to which mRNA, ribosome and chaperone proteins contribute. Various experimental 
studies have illustrated that synonymous changes can influence mRNA and protein shape, 
structure, folding and stability (Sharp et al., 1995, Chamary et al., 2006, Shabalina et al., 2006).  
Codon usage frequency has been found to influence translation rate and efficiency, which 
further affects polypeptide folding (Figure 6.1C). Codons that are used more frequently are 
translated faster than rare codons because each codon has a particular tRNA and its relative 
abundance affects translation rate (Mitarai et al., 2008). A reduction in the rate of protein 
translation has been reported when a synonymous nucleotide change is present in the third 
position of the triplet codon. These variants result in disturbing the interaction between mRNA 
codon and the tRNA anti-codon and affect the efficient translation rate and protein folding 
(Shah et al., 2008).  
mRNA is the carrier of genetic code and encodes amino acid sequences using the triplet code. It 
was reported that the less frequent codons are found at the 5' of the mRNA sequence more than 
in the 3' sequence and this may be attributed to either prevent ribosome traffic congestion 
through controlling the high translation rate or due to the need for weak mRNA secondary 
structure in this area to allow translation to start (Kudla et al., 2009, Klumpp et al., 2012).  
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Synonymous codon exchange can impair the translation rate through influencing multiple 
ribosome movements and causing ribosomes collisions. Frequent codons are translated faster 
than rare ones, preventing ribosome collisions and increasing ribosome movements (Mitarai and 
Pedersen, 2013). 
The presence of synonymous mutations in patients with Crohn’s disease results in the formation 
of small regions of mRNA which are complementary to miRNA, forming dsRNA (Figure 
6.1D). The formed aberrant dsRNA is degraded and terminated which leads to formation of null 
allele (Hurst, 2011). 
6.1.3. Hypothesis and aims 
We hypothesised that silent mutations may have a deleterious effect on protein synthesis and 
structure through several mechanisms. It has been reported that silent changes can affect protein 
synthesis via disturbing the translation rate and protein folding which can affect the level of 
protein secreted. The presence of c.4146G>T in the affected family could be responsible for the 
phenotypes observed and could contribute to type 1 VWD. This study aimed to investigate the 
effect of the silent change c.4146G>T plus c.4146G>A and c.4146G>C that alter the same 
codon on VWF level, multimers and storage through in vitro expression and also aimed to 
understand the pathogenicity and disease causing mechanism of this change. The plasmid 
vectors carrying the wild-type and mutant VWF cDNA were transiently transfected into 
HEK293T cells in the heterozygous and homozygous states and VWF in supernatants and 
lysates VWF were quantified using ELISA.  
In addition to effect of the silent change on the mRNA translation rate, it could impair normal 
splicing leading to either exon skipping or reducing splicing efficiency. This study aimed to 
investigate the effect of c.4146G>T silent mutation on splicing efficiency through mini-gene 
analysis.  
 
 
 
 
 
199 
  
6.2. Results 
6.2.1. Graphical codon usage 
Codon usage indicates the differences in codon frequency between several triplet codons that 
each encode the same amino acid. The graphical codon usage analyser (GCUA) (Section 2.2.10) 
was used to compare the frequency of the four triplet codons encoding leucine including the 
wild-type codon CTG, mutant codon CTT and two hypothetical triplet mutant codons CTA and 
CTC that differ only at the third position of the codon. The hypothetical mutant codon CTA was 
predicted to be the least frequently used with a 82% difference compared to the wild-type CTG 
codon. Also, there was a 68% and 51% difference in codon frequency between the wild-type 
codon and the CTT and CTC codons respectively (Figure 6.2). These findings suggested that 
the observed and hypothetical mutant codons are less frequently used than the wild-type codon 
to varying degrees and could impair protein folding and the rate of protein translation. 
Additional codons TTG and TTA that also encode leucine were also analysed and compared to 
wild-type (Figure 6.2). 
 
 
 
Figure 6.2 Frequencies of triplet codon usage that encode leucine at position c.4146 in 
VWF using GCUA analyser in Homo sapiens. CTG represents the wild-type codon at 
nucleotide position c.4146 of VWF, CTT represents the mutant codon while CTA, CTC, TTG 
and TTA represent the other possible codons that encode leucine. The hypothetical mutant 
codon CTA was 82% lower in frequency compared to wild-type, while mutant codons CTT and 
CTC were 68% and 51% lower in frequency respectively (Nakamura et al., 2000). 
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6.2.2. Location of p.L1382= in VWF 
The VWF A1 domain is the site where VWF interacts with platelet GpIbα receptor and the 
presence of mutations within this domain may alter this interaction. The analysed crystal 
structure (Section 2.2.9) showed that the silent mutation p.L1382= is located within a beta sheet 
(Figure 6.3A) and found to be away from the α-helix site of binding with platelets (Figure 6.3B) 
suggesting that this silent variant is unlikely to disturb the interaction of VWF with platelet 
GpIbα receptor. However, whilst this variant is located away from the site of GpIbα interaction, 
if the protein translation rate is affected, this may modify the correct interaction between the 
VWF A1 domain and GpIbα receptor. 
 
 
Figure 6.3 Pymol model of the 3D structural location of p.L1382= in the VWF A1 domain 
and area of interaction between VWF and platelet GpIbα receptor. A) Represents the site 
of the silent change p.L1382 (yellow) within the VWF A1 domain beta sheet (red). B) 
Represents the area of interaction between the VWF A1 domain and platelet GpIbα receptor.           
White two sided arrow represents the interaction between VWF and platelet (A1-GpIb binding 
site). The structure of the VWF A1 domain and platelet GpIbα receptor was obtained from the 
Protein Data Bank (PDB) (Dumas et al., 2004). 
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6.2.3. Mutagenesis 
The expression plasmid pcDNA3.1 Hygro (-) harbouring wild-type VWF cDNA was used to 
insert the desired nucleotide change and was followed by transfection to examine the potential 
effect of c.4146G>T and other hypothetical changes at the same codon on the level and the 
structure of VWF. c.4146G>T was predicted to result in silent change p.L1382=. Also, 
mutagenesis was performed to introduce other possible hypothetical p.L1382= mutants 
c.4146G>A and c.4146G>C at the same codon which still result in leucine. The purpose of 
introducing the other possible mutants was to perform in vitro expression for all mutants and 
compare findings to the predicted rate of codon usage between the four possible nucleotides at 
position c.4146. Following mutagenesis and sequence analysis of the VWF plasmid, c.4146G>T 
and both hypothetical mutants c.4146G>A and c.4146G>C were successfully introduced to the 
VWF cDNA sequence with no additional nucleotide changes observed (Figure 6.4). 
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Figure 6.4 Sequence chromatographs to show introduction of silent variants into the cDNA VWF plasmid. A) shows the wild type VWF cDNA 
sequence. B) shows c.4146G>T; C) shows c.4146G>A; D) shows c.4146G>C. 
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6.2.4. In vitro expression of rVWF harbouring the candidate mutation p.L1382= 
These expression experiments were aimed to evaluate whether the p.L1382= silent change has a 
potential effect on VWF expression. Each of the 4 possible nucleotides at c.4146, rVWF cDNA 
plasmid of wild-type, mutant c.4146G>T and hypothetical mutants c.4146G>A and c.4146G>C 
were expressed in HEK293T cells using the same expression system previously described 
(Section 2.2.13.5) and used in Chapter 4.   
The transfection experiments for the mutant c.4146G>T were performed in triplicate and 
repeated three times for wild-type, mutant homozygous and mutant heterozygous states, while 
the other hypothetical mutants c.4146G>A and c.4146G>C were expressed similarly but 
undertaken in triplicate twice.  
6.2.4.1. Quantitative analysis of the expressed rVWF-WT and mutant plasmid 
(c.4146G>T; rVWF-L1382) transfected into HEK293T cells  
The measured mean values of secreted and intracellular rVWF are shown in tables 6.2 and 6.3. 
In vitro expression of rVWF-L1382 (c.4146G>T) interestingly demonstrated that the secreted 
rVWF heterozygous and homozygous mutant was significantly reduced to 60% and 76% 
respectively (p<0.0001 and <0.001, one way ANOVA) compared to 100% wild-type (Figure 
6.5).  
The level of secreted homozygous mutant VWF was 15% higher than the level of heterozygous 
mutant and the differences between the secreted VWF level of heterozygous and the 
homozygous states attained statistical significance with a p value of <0.05. To confirm these 
findings, a further independent clone of the plasmid harbouring the c.4146G>T change was 
expressed and the obtained results were similar with no significant difference with these 
findings (Figure 6.5). 
The mean values of intracellular rVWF obtained by expression of the heterozygous c.4146G>T 
were significantly decreased to 77% with p values of less than 0.001. In the homozygous form, 
the mean levels of intracellular VWF were 103% with no significant difference when compared 
to 100% wild-type. 
In summary, the measured mean values of VWF suggested that p.L1382= resulted in reduced 
VWF secretion from HEK293T cells following transfection compared to rVWF wild-type. This 
silent change p.L1382= led to a significant reduction in the level of secreted VWF in both 
homozygous and heterozygous states in addition to a significant reduction in the level of 
intracellular VWF when expressed in the heterozygous state. These findings suggest a 
significant effect of p.L1382= on VWF expression.  
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Table 6.2 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-c.4146G>T) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 6.0 
WT:Mut (50:50) (heterozygous) 61.0 14.0 
rVWF-L1382= (homozygous) 76.5 16.0 
*SD= standard deviation 
 
Table 6.3 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-c.4146G>T) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 10.0 
WT:Mut (50:50) (heterozygous) 77.0 15.0 
rVWF-L1382= (homozygous) 103.0 18.0 
*SD= standard deviation 
 
 
Figure 6.5 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.L1382= 
(c.4146G>T) mutation on VWF expression. Results are expressed as a percentage in 
comparison with wild-type. The horizontal black bars represent the extent of difference between 
mean values of VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate 
the standard deviation. Statistical test used is one-way ANOVA. 
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6.2.4.2. Multimer analysis of wild-type and c.4146G>T; p.L1382= VWF secreted 
from HEK293T cells 
The multimeric composition of VWF secreted from the transfected HEK293T cells into the 
growth medium of wild-type plasmid, mutant plasmid and co-transfection of mutant/wild-type 
plasmids was evaluated using medium resolution 1.6% sodium dodecyl sulphate agarose (SDS) 
gel electrophoresis at 1:3 dilution. As a result, the multimeric composition of rVWF secreted 
from HEK293T cells showed a normal multimer pattern in both homozygous and heterozygous 
states compared to wild-type (Figure 6.6). A full array of multimer bands composed of high, 
intermediate and low molecular weight multimers were observed in the wild-type VWF and in 
both homozygous and heterozygous forms. 
 
 
Figure 6.6 Multimer analysis of secreted rVWF c.4146G>T; p.L1382= from HEK293T 
cells. Multimer patterns of wild-type rVWF (lane 1), mutant rVWF-L1382 (lane 2) and hybrid 
rVWF (lane 3) on 1.6% medium resolution gel at 1:3 dilution are shown. The multimeric 
composition of rVWF resulting from transfecting cells with mutant and hybrid showed normal 
VWF multimer patterns with the presence of a full array of multimer bands. 
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6.2.4.3. Confocal microscopy imaging of c.4146 
Following in vitro expression of mutants in HEK293 cells, transfected cells were stained and 
examined using a confocal microscope in order to determine the intracellular storage of VWF. 
For all possible nucleotide changes at c.4146, confocal microscopy was undertaken in the 
homozygous and heterozygous forms and compared to wild-type. The shape of WPB-like 
structures, size and frequency of each form was compared to those of wild-type. Cells were 
stained as previously described in chapter 4 (Section 4.2.5.2). 
6.2.4.3.1. Confocal microscopy of c.4146G>T; p.L1382= 
In vitro expression of the c.4146G>T revealed a significant VWF defect in secretion in both 
homozygous and heterozygous forms. Also, intracellular VWF of the heterozygous form of this 
variant showed a reduction compared to wild-type. Confocal imaging of wild-type showed the 
presence of punctate rounded WPB-like organelles throughout the cell (Figure 6.7 A and C). 
The visualised WPB-like structures in the homozygous form appeared similar in shape and size 
to those present in the wild-type (Figure 6.7 D and F). In the heterozygous form of c.4146G>T; 
p.L1382= silent change, punctate WPB-like structures were seen throughout the cell, but 
appeared relatively fewer in number in comparison to those present in the wild-type (Figure 6.7 
G and I). This variant appears to affect VWF storage when present in the heterozygous form. 
Overall, in this mutant, the heterozygous form of the mutation results in a more severe 
phenotype in vitro than in the homozygous form. This may be due to differences between the 
homozygous and heterozygous mutations during protein synthesis and processing (as discussed 
in section 6.3. 
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Figure 6.7 Intracellular storage of rWT and rVWF-L1382 mutant in HEK293 cells by 
confocal microscopy. A, D and G) Represent VWF (green) after transfection of wild-type, 
homozygous and heterozygous plasmids respectively into HEK293 cells. B, E and H) 
Represent the cell membrane marker α-tubulin (red) after transfection of wild-type, 
homozygous and heterozygous respectively into HEK293 cells. C, F and I) Represent merged 
images of VWF and α-tubulin staining for wild-type, homozygous and heterozygous 
respectively transfected into HEK293 cells. Cells of the upper horizontal row (A, D and G) 
were stained with rabbit anti-VWF primary and anti-rabbit Alexa Fluor 488 for VWF (green), 
while cells of the middle horizontal row (B, E and H) were stained with mouse anti-α-tubulin 
and anti-mouse Alexa Fluor 555 for the cell membrane α-tubulin marker (red). The lower 
horizontal row (C, F and I) shows a merge of VWF and α-tubulin staining.  
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6.2.5. Quantitative analysis of the expressed rVWF-WT and hypothetical mutant 
plasmid (rVWF-c.4146G>A; p.L1382=) transfected into HEK293T cells  
The obtained results revealed a significant reduction in secretion of VWF from both 
heterozygous and homozygous forms of 76% (p<0.0001) and 65% (p<0.001) respectively in 
comparison to 100% wild-type (Table 6.4). Also, the difference between the heterozygous and 
homozygous forms of c.4146G>A; p.L1382= was statistically analysed and found to be 
significant with a p value of <0.01 (Figure 6.8). 
Moreover, analysis of the intracellular VWF within cells showed that in the heterozygous form 
of this silent mutation, a significant 68% (p<0.001) reduction was observed, while a 53% 
(p<0.001) significant reduction was observed when expressed in the homozygous form in 
comparison to 100% wild-type (Table 6.5). The differences between cell lysate VWF levels of 
heterozygous and homozygous forms of this variant was statistically significant (p<0.01, one 
way ANOVA) (Figure 6.8). 
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Table 6.4 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-c.4146G>A) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 7.0 
WT:Mut (50:50) (heterozygous) 24.0 3.0 
rVWF-L1382= (homozygous) 35.0 2.5 
*SD= standard deviation 
 
Table 6.5 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-c.4146G>A) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 10.0 
WT:Mut (50:50) (heterozygous) 32.0 1.5 
rVWF-L1382= (homozygous) 47.0 3.0 
*SD= standard deviation 
 
 
Figure 6.8 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.L1382= 
(c.4146G>A) mutation on VWF expression. Results are expressed as a percentage in 
comparison with wild-type. The horizontal black bars represent the extent of difference between 
mean values of VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate 
the standard deviation. Statistical test used is one-way ANOVA. 
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6.2.5.1. Multimer analysis of wild-type and c.4146G>A; p.L1382= rVWF protein 
secreted from HEK293T cells 
Multimer analysis of the c.4146G>A; p.L1382= revealed the presence of all multimer bands 
including high, intermediate and low molecular weight multimers in both homozygous and 
heterozygous forms similar to multimer patterns observed in the wild-type (Figure 6.9).  
 
 
Figure 6.9 Multimer analysis of secreted rVWF c.4146G>A; p.L1382= from HEK293T 
cells. Multimer patterns of wild-type rVWF (lane 1), mutant rVWF-L1382 (lane 2) and hybrid 
rVWF (lane 3) on 1.6% medium resolution gel at 1:3 dilution are shown. The multimeric 
composition of rVWF resulting from both homozygous and heterozygous forms showed normal 
VWF multimer patterns with the presence of a full array of multimer bands similar to wild-type 
multimers. 
 
 
211 
  
6.2.5.2. Confocal microscopy of c.4146G>A; p.L1382= 
In vitro expression of the c.4146G>A; p.L1382= revealed a significant reduction in supernatant 
and lysate VWF in both homozygous and heterozygous forms compared to wild-type. The 
punctuate round shaped WPB like organelles were visualised throughout the cell in confocal 
imaging of the wild-type (Figure 6.10 A and C). In the homozygous mutant form, the visualised 
WPB-like structures present appeared similar in shape and size to those present in the wild-type 
but less frequent throughout the cell (Figure 6.10 D and F). The punctate WPB-like structures 
found in the heterozygous form of the c.4146G>A variant were formed throughout the cell and 
appeared similar in size and shape to those visualised in the wild-type but with less proportion 
(Figure 6.10 G and I). Confocal imaging suggested that c.4146G>A has an effect on VWF 
storage. 
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Figure 6.10 Intracellular storage of rWT and c.4146G>A;rVWF-L1382 mutant in 
HEK293 cells by confocal microscopy. A, D and G) Represent VWF (green) after transfection 
of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, E and 
H) Represent the cell membrane marker α-tubulin (red) after transfection of wild-type, 
homozygous and heterozygous respectively into HEK293 cells. C, F and I) Represent merged 
images of VWF and α-tubulin staining for wild-type, homozygous and heterozygous 
respectively transfected into HEK293 cells. Cells were stained as described in figure 6.6. 
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6.2.6. Quantitative analysis of the expressed rVWF-WT and mutant plasmid 
(rVWF-c.4146G>C; p.L1382=) transfected into HEK293T cells  
Analysis of secreted VWF level of hypothetical mutant c.4146G>C revealed a significant 
reduction in both heterozygous and homozygous forms (Table 6.6). In the heterozygous form 
c.4146G>C; rVWF-L1382, resulted in a significant reduction of 68% of secreted VWF when 
compared to 100% wild-type (p<0.001). The homozygous form of this mutation also revealed a 
significant reduction of 50% in comparison to wild-type (p<0.001). Furthermore, a significant 
difference between the secreted mean values of both heterozygous and homozygous was 
observed with p value of <0.05 (Figure 6.11).  
Analysis of the mean values of intracellular rVWF obtained by expression of homozygous form 
was significantly increased to 111% with p value of <0.01. Also, in the heterozygous form of 
intracellular VWF a significant reduction of 40% was observed when compared to wild-type 
(p<0.01) (Table 6.7).  
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Table 6.6 The mean values and standard deviation of secreted VWF:Ag levels post-
transfection for WT and mutant plasmids (rVWF-c.4146G>C) in HEK293T cells 
VWF (Supernatant) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 7.0 
WT:Mut (50:50) (heterozygous) 32.0 6.0 
rVWF-L1382= (homozygous) 50.0 1.5 
*SD= standard deviation 
 
Table 6.7 The mean values and standard deviation of retained VWF:Ag levels harvested 
post-transfection for WT and mutant plasmids (rVWF-c.4146G>C) in HEK293T cells 
VWF (Cell lysate) Mean (%) *SD 
rVWF-WT (homozygous) 100.0 10.0 
WT:Mut (50:50) (heterozygous) 60.0 2.5 
rVWF-L1382= (homozygous) 111.0 13.0 
*SD= standard deviation 
 
 
Figure 6.11 Mean levels of VWF:Ag in both supernatant and cell lysates of HEK293T cells 
transfected with WT and mutant expression plasmids showing the effect of the p.L1382= 
(c.4146G>C) mutation on VWF expression. Results are expressed as a percentage in 
comparison with wild-type. The horizontal black bars represent the extent of difference between 
mean values of VWF:Ag between wild-type and mutant VWF. The vertical black bars indicate 
the standard deviation. Statistical test used is one-way ANOVA. 
V
W
F
:A
g
 (
%
 W
T
)
W
T
C
TC
 H
et
C
TC
 H
om
0
50
100
150
Supernatant Lysate
*** = p <0.001
One-way ANOVA
***
**
***
** = p <0.01
**
* * = p <0.05
215 
  
6.2.6.1. Multimer analysis of wild-type and c.4146G>C; p.L1382= rVWF protein 
secreted from HEK293T cells 
Analysis of the p.L1382=; c.4146G>C multimers revealed multimeric composition of rVWF 
secreted from HEK293T cells was normal in both homozygous and heterozygous states 
compared to wild-type multimers (Figure 6.12). A full array of multimer bands composed of 
high, intermediate and low molecular weight multimers was observed in the wild-type VWF 
and in both homozygous and heterozygous forms. However, quantity of VWF in the 
homozygous and heterozygous bands appeared reduced in comparison with wild-type. 
 
 
Figure 6.12 Multimer analysis of secreted rVWF c.4146G>C; p.L1382= from HEK293T 
cells. Multimer patterns of wild-type rVWF (lane 1), mutant rVWF-L1382 (lane 2) and hybrid 
rVWF (lane 3) on 1.6% medium resolution gel at 1:3 dilution are shown. The multimeric 
composition of rVWF resulting from both homozygous and heterozygous forms showed normal 
VWF multimer patterns with presence of a full array of multimer bands similar to wild-type 
multimers. 
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6.2.6.2. Confocal microscopy of c.4146G>C; p.L1382= 
Similarly to the c.4146G>T variant, confocal analysis of the homozygous state showed the 
presence of punctate round WPB-like organelles throughout the cell comparable to those 
visualised in wild-type in shape and size (Figure 6.13 D and F). In the heterozygous form of this 
variant, punctuate round WPB-like structures were visualised throughout the cell and showed 
similar size and shape organelles, but appeared relatively smaller in size compared to those 
present in the wild-type (Figure 6.13 G and I). Confocal imaging indicated that c.4146G>A does 
affect VWF storage. 
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Figure 6.13 Intracellular storage of rWT and c.4146G>C;rVWF-L1382 mutant in 
HEK293 cells by confocal microscopy. A, D and G) Represent VWF (green) after transfection 
of wild-type, homozygous and heterozygous plasmids respectively into HEK293 cells. B, E and 
H) Represent the cell membrane marker α-tubulin (red) after transfection of wild-type, 
homozygous and heterozygous respectively into HEK293 cells. C, F and I) Represent merged 
images of VWF and α-tubulin staining for wild-type, homozygous and heterozygous 
respectively transfected into HEK293 cells. Cells were stained as described in figure 6.6. 
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6.3. Discussion 
Unlike regular pathogenic mutations that are deleterious and cause genetic disease, it was 
historically believed that silent mutations were all benign. Recently, however it has been 
suggested that apparently synonymous sequence changes are not always benign and can impair 
splicing mechanism and disturb mRNA translation and protein folding (Mitarai et al., 2008, 
Daidone et al., 2011). This study aimed to investigate whether c.4146G>T;p.L1382= identified 
in type 1 VWD was responsible for the phenotype observed in the patient through in vitro 
expression. Also, it was aimed to identify the disease causing mechanism associated with this 
silent mutation as well as the two hypothetical silent changes c.4146G>A;p.L1382= and 
c.4146G>C;p.L1382= that encode the same amino acid and to compare findings with codon 
usage analysis. This mutation was identified previously (Corrales et al., 2012) and also 
identified in one IC in the EU study and has not been expressed previously (Goodeve et al., 
2007, Hampshire et al., 2010). 
p.L1382= is located in a β sheet in the A1 domain and was found to be away from the area of 
binding with platelets suggesting that it is unlikely to directly affect the interaction of VWF with 
platelet GpIbα receptor. It has been reported previously that silent mutations may affect protein 
folding which could alter protein conformation (Duan et al., 2003, Mitarai et al., 2008). 
6.3.1. In vitro expression of c.4146G>T;p.L1382= 
Results from in vitro expression indicated that this mutation results in a significant secretion 
defect of VWF in both heterozygous and homozygous states. Expression data from the 
c.4146G>T mutant showed that secreted VWF in the heterozygous and the homozygous states 
was significantly decreased by 39% and 23% respectively compared to wild-type. Interestingly 
unlike the earlier findings, these data indicated that the secreted amount of VWF released from 
the heterozygous mutant was significantly less than VWF released from the homozygous 
mutant. This experiment was repeated using an independent clone of the plasmid harbouring the 
c.4146 variant and similar findings were observed (Figure 6.5). To explain these findings, we 
hypothesised that the presence of normal and mutant alleles with reduced translation rate 
efficiency in the heterozygous state could cause the mutant allele to interfere with the wild-type 
unlike identical mutant alleles in the homozygous form. Also, in vitro expression is an artificial 
system not exactly reflecting the real in vivo expression system. In VWD, the expression of 
VWF silent mutants has never been reported previously. Moreover, the c.4146G>T variant 
resulted in a normal multimer pattern observed in both heterozygous and homozygous forms. 
Furthermore, pseudo WPB vesicles formed in both states indicated that p.L1382= does affect 
VWF formation and storage. 
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6.3.2. In vitro expression of c.4146G>A and c.4146G>C mutants 
Similarly to c.4146G>T expression, expression data from hypothetical mutants; c.4146G>A and 
c.4146G>C also showed a significant reduction of secreted VWF in both mutants in both 
homozygous and heterozygous states. The expression data from c.4146G>A resulted in a 
significant reduction of secreted VWF to 24% and 35% in heterozygous and homozygous states 
respectively compared to 100% wild-type. Also, this variant caused a significant reduction of 
intracellular VWF to 32% and 47% in both heterozygous and homozygous respectively. The 
expression data of c.4146G>C showed also a significant 68% reduction in the heterozygous 
form. However, in the homozygous form of c.4146G>C, a significant 50% defect in VWF 
secretion was accompanied by a significant increase in the VWF level (111%) indicating 
intracellular retention. These experiments also showed that the released amount of VWF from 
the homozygous form was consistently higher than those from heterozygous. Both variants 
resulted in the formation of normal multimer patterns and pseudo-WPB organelles suggested 
that these variants had no effect on VWF multimerisation, but storage appeared to be reduced 
compared to wild-type in the heterozygous form.  
During translation, each codon is recognised efficiently by a specific tRNA corresponding to 
this codon. Although there are 61 codons that encode 20 amino acids, the number of tRNAs is 
fewer at around 31 in humans which reflects the ability of one tRNA to bind with more than one 
codon (Ronneberg et al., 2000). According to the Wobble hypothesis, the interaction between 
mRNA codon and its anticodon is achieved when the first two bases of mRNA are compatible 
with the tRNA anticodon as the anticodon bases inosine (or pseudouridine) in all tRNA at 3
rd
 
position that can pair with any base of mRNA either C, A, G or U (Crick, 1966, Matsuyama et 
al., 1998). Inosine is a nucleotide commonly present in tRNA derived from inosine 
monophosphate that can pair with all natural nucleotides. The Wobble hypothesis showed that 
each nucleotide has two possible anticodons or tRNAs (Table 6.8). 
Table 6.8 Wobble hypothesis 
Anticodon (tRNA) Codon (mRNA) 
C G 
U A,G 
G U,C 
I U,C,A 
C: cysteine, U: uracil, G: guanine, I: inosine 
 It has been found that some amino acids prefer specific codons more than others that encode 
the same amino acid to achieve efficient and accurate translation. So, efficient translation is 
achieved when tRNA with higher abundance complementary to mRNA codon are used (codon 
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usage bias) (Akashi, 1994). Therefore, each codon is recognised efficiently by a specific tRNA 
corresponding to this codon and the presence of a nucleotide change leads to a synonymous 
change that could alter translation rate through codon usage bias. Frequencies of codon usage 
data were compiled from 257,468 gene coding sequences from 8792 different organisms. These 
data were obtained from GenBank DNA sequence database (Nakamura et al., 2000). Codon 
usage analysis can predict the frequency difference between high and low abundance codons 
which can alter mRNA structure, the translation rate and protein folding. The wild-type codon 
CTG showed the highest codon usage frequency and mutant triplet codon CTT showed a 68% 
lower frequency (Nakamura et al., 2000). In vitro expression of silent mutants confirmed the 
deleterious effect of p.L1382= on VWF production. Codon usage data illustrated that CTC is a 
more abundant codon more than CTA and this is compatible with in vitro expression findings. 
This data also, demonstrated that CTC is more frequently used than mutant codon CTT, which 
was not reflected in the in vitro expression data. In vitro expression is an artificial system not 
fully sensitive enough to mimic or represents the in vivo expression system and this could 
explain the differences between expression and codon usage data. Also, there may be 
differences in tRNA abundance between overall codon usage data and HEK293T cells and this 
may explain result variability. 
The mutant VWF produced following transfection displayed a defect in VWF secretion 
confirming the effect of silent change p.L1382= on VWF expression was likely due to codon 
usage. From these findings, we hypothesised that p.L1382= does influence the production of 
VWF and speculate that the mechanism is due to an alteration of the translation rate and 
producing mis-folded protein. However, we demonstrated that the synonymous change 
c.4146G>T contributes to a partial deficiency of VWF leading to bleeding symptoms observed 
in type 1 VWD patients.  
The impact of the silent mutation p.L1382= on VWF expression was documented through in 
vitro expression and codon usage bias. The levels of VWF:Ag measured in plasma of the IC and 
the AFM who harboured c.4146G>T was around 50 IU/dL (Appendix 19) and the in silico 
splicing prediction tools indicated a significant difference between wild-type and mutant 
sequences indicating that the exonic nucleotide change may also affect regulatory splicing 
elements through loss or gain of exonic regulatory elements and impair the splicing mechanism, 
but did not generate new donor or acceptor splice sites. Therefore, we assume that it is also 
possible for the exonic nucleotide change c.4146G>T identified in P10F5 family to impair 
splicing enhancers or silencers causing skipping of exon 28 (Figure 6.1B). The skipping of exon 
28 was predicted to result in a stop codon p.C1225* at the end of exon 27. This skipping of 
exon 28 would then further produce a PTC causing degradation of the mutant allele due to 
NMD, this may affect all or only some of the mRNA produced from the mutant allele. The 
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second hypothesis was derived from the in silico prediction that indicated the possibility of 
c.4146G>T to reduce the efficiency of splicing via disrupting essential ESE and ESS elements. 
These predictions need to be confirmed. Further work may help to confirm the contribution of 
various mechanisms on pathogenicity and to define the exact disease causing mechanism of 
these silent mutations (Future work, section 7.1). 
Previous studies have been undertaken in different conditions to investigate the pathogenicity of 
silent mutations linked to different diseases. In a study of haemophilia B patients who presented 
with mild bleeding symptoms and a moderate reduction of FIX levels (15-20 IU/dL) (Knobe et 
al., 2008), the isolated mRNA from a haemophilia patient who harboured a c.321G>A;p.V107= 
synonymous mutation and from a healthy individual were reverse transcribed and then 
subsequently amplified using PCR to produce cDNA. The analysed cDNA from the patient and 
control individual were similar lengths indicating the absence of exon skipping and intron 
retention. Therefore, the hypothesis of the effect of this silent variant on splicing was excluded 
as a pathological mechanism and other mechanisms could contribute to the phenotype observed 
in the haemophilia B patients. In vitro expression of a plasmid containing the F9 cDNA 
c.321G>A;p.V107= mutation in HEK293T cells showed normal coagulant activity of produced 
FIX protein indicating the subtle effect of this silent change on F9 expression, but it was 
hypothesised that it may alter the translation rate and protein folding in vivo (Knobe et al., 2008, 
Hamasaki-Katagiri et al., 2012). A reduced FIX level following in vitro analysis of mRNA from 
patients with p.V107= was observed when independent study was undertaken and these findings 
were compatible with in silico analysis confirming the adverse impact of p.V107= on F9 mRNA 
stability, codon usage and structure (Kimchi-Sarfaty et al., 2011). Moreover, work on the effect 
of a silent change on translation efficiency by Shah et al (2008) was undertaken in a patient who 
was homozygous for hyperinsulinism. In vitro expression of a vector containing c.570C>T; 
p.A190= in KCNJ11 followed by Western blot analysis showed the absence of bands when 
expressed in the homozygous form in comparison to strong bands observed in wild-type 
indicating the impact of the silent variant on the translation rate and protein production (Shah et 
al., 2008). 
It has been reported that the level of cognate tRNA and strong codon bias is directly 
proportional to frequency of codon usage and the presence of that replacement of a synonymous 
codon may affect the protein shape, structure, efficiency of protein translation and folding 
(Shabalina et al., 2006, Mitarai et al., 2008). In order to investigate the effect of silent changes 
on ribosome movement and protein folding, Komar et al (1999) replaced 16 rare codons present 
in the chloramphenicol acetyltransferase (CAT) gene in E.coli by more frequent ones using in 
vitro mutagenesis and measuring the activity of released wild-type and mutant mRNA. The 
results showed that the replaced mutant codons affected ribosome traffic, ribosome movements 
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and impaired protein translation and folding (Komar et al., 1999). Moreover, Fung et al (2009) 
suggested that the silent nucleotide change and the frequency of codon usage could cause 
ribosome stalling or delaying (Sunohara et al., 2004) that further impairs protein folding and 
leads to abnormal structure and function of MDR1 mRNA that encodes a membrane-bound 
transporter (Fung and Gottesman, 2009). Furthermore, the wild-type and mutant mRNA 
carrying a silent mutation in human dopamine receptor D2 (DRD2) was investigated by Duan et 
al (2003). The results suggested that the synonymous c.957C>T found in DRD2 expressed less 
DRD2 protein than wild-type and this was caused by abnormal mRNA folding that result from 
reduction in the stability of the mRNA and protein translation (Duan et al., 2003). 
Also, many experimental studies have studied the effect of exonic mutations in splicing 
regulatory elements. Analysis of mRNA extracted from patients with spinal muscular atrophy 
revealed that exonic nucleotide changes can create or destroy the ESE or ESS which mediates 
exon skipping and results in a truncated protein (Lorson and Androphy, 2000). Also, similar 
results were obtained by Gaildrat et al (2012) who investigated the effect of mutation located in 
exon 7 of the breast and ovarian cancer gene (BRCA2) on the splicing pathway using a minigene 
assay. The extracted mRNA following transient transfection of mutant and wild-type constructs 
into HeLa cells was reverse transcribed. The cDNA of mutant and wild-type was amplified and 
electrophoresed on an agarose gel. As a result, the shortness of mRNA length in mutant 
compared to wild-type indicated that the exonic mutation disturbed splicing regulatory elements 
which caused skipping of an exon and produced truncated protein. These findings highlight the 
adverse impact of exonic nucleotide changes on splicing mechanism (Gaildrat et al., 2012).  
In conclusion, this study provided experimental evidence using in vitro expression and codon 
usage bias that c.4146G>T is likely to be the major cause of the phenotype observed in the 
affected members who harbour this mutation and was able to highlight the adverse impact of 
this silent variant on protein expression likely through altering mRNA translation rate and 
protein folding. It was suggested that this variant may cause subtle effects on protein folding or 
efficiency of the splicing mechanism. Although we were able to demonstrate that this silent 
mutation c.4146G>T has an effect on protein expression, we were unable to determine exactly 
how the c.4146G>T results in VWD. Moreover, this work has not excluded any effect of 
c.4146G>T on ESE or ESS elements. Therefore, additional experiments are required in order to 
confirm the disease causing mechanisms. This study aimed to investigate the effect of 
c.4146G>T silent mutation on splicing efficiency through analysis of the predicted loss of ESE 
in the splicing pathway through mini-gene analysis but this experiment was discontinued 
(Future work). Ideally this analysis would use either extracted mRNA from a VWD patient 
carrying this silent change, mRNA extracted from transfected cells or mRNA analysis following 
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a splicing minigene assay to assess the splicing regulatory elements of mutant and wild-type 
sequence segments (Future work, section 7.1). 
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7. Discussion 
 
VWD type 1, the most common variant of all VWD types, is characterised by partial 
quantitative deficiency of VWF which results in mild to moderate mucocutaneous bleeding 
symptoms. The previous MCMDM-1VWD study previously investigated the molecular genetic 
basis of type 1VWD and undertook mutation scanning and sequencing of the VWF gene in 150 
IC (Goodeve et al., 2007). Mutations were identified in 70% of IC and most were missense 
mutations while other variants such as splice, transcriptional and nonsense mutations in addition 
to small deletions and insertions were detected in lower proportions. Several mutation detection 
techniques were used for mutational analysis in this cohort study including SSCP, CSGE, 
DHPLC and direct DNA sequencing. These methods have variable degrees of sensitivity 
ranging between 75-100% (Markoof et al., 1998, Whittock et al., 1999, Eng et al., 2001).  
 
Although the EU study provided valuable details about the clinical and molecular basis of type 
1 VWD, it failed to detect mutations in the remaining IC. Reasons for this failure may include 
SNP within primer annealing sites leading to lack of mutant allele amplification or insensitivity 
of mutation analysis methods. Also, a number of patients who were negative for mutations may 
bleed due to other bleeding disorders and may have been falsely positive diagnosed as having 
type 1 VWD. Moreover, mutations were missed in the initial study due to presence of large 
heterozygous deletions which cannot be detected using standard methods (Cartwright et al., 
2013). The presence of large heterozygous deletions could prevent binding of a primer to the 
template when using standard PCR causing only the normal allele to be amplified and 
sequenced. Standard PCR and sequencing would not be able to detect large deletions or 
duplications due to the presence of the wild-type allele. 
 
The aims of this project were to re-analyse all primers used in the initial MCMDM-1VWD 
cohort for the presence of SNP underneath primer binding sites to avoid mono-allelic 
amplification as the primers used in the historical EU study were designed prior to the 
availability of complete VWF sequence with little knowledge of SNP, and to reanalyse all VWF 
exons and closely flanking intronic regions using direct DNA sequencing in IC where the 
clinical phenotype suggested that mutations may have been missed. A further aim was to 
determine the mechanisms by which mutations identified affect VWF synthesis, secretion and 
storage. 
 
The hypothesis that mutations were missed in the previous EU study due to the presence of SNP 
within primer binding sites or lack of sensitivity of mutation scanning methods used was 
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initially investigated. Previously missed mutations were detected in type 1 and type 2 VWD 
patients who were initially negative for mutations following screening of primers for the 
presence of SNP (Thomas et al., 2006b, Hampshire et al., 2010). In silico analysis was 
performed to screen all previously used PCR primers for presence of SNP within primer binding 
sites and when necessary new primers were designed. However, for the current project, all 
newly designed primers and primers free of SNP underneath their binding sites were 
successfully used for amplification and sequencing of VWF exons and closely flanking regions. 
 
Eighteen IC (5 where a previously identified heterozygous mutation did not fully explain 
phenotype and 13 with no mutation identified) having low VWF levels and significant bleeding 
were investigated. Mutations were missed in the historical MCMDM-1VWD study due to 
limitations in sensitivity of previous analyses (p.W2271G) and SNP within primer annealing 
sites (p.C1157R and c.1432+1G>T) while the IC with p.L1382= was excluded from the study 
previously due to an insufficient quantity of DNA sample. As the quantity of DNA used is now 
lower, it was possible to include this individual. 
 
Of the 18 IC analysed for the presence of mutations, heterozygous mutations were identified in 
four families (22%); novel missense mutations p.W2271G (in compound heterozygosity with 
p.R854Q), novel missense p.C1157R (in compound heterozygosity with p.S539Lfs*38), silent 
mutation p.L1382= and the novel splice mutation c.1432+1G>T (in compound heterozygosity 
with p.R816W). p.W2271G and p.C1157R, predicted to be damaging by in silico analysis, 
affect fully conserved residues.  
 
Unlike p.R854Q and p.R816W, p.W2271G and c.1432+1G>T segregated with disease 
phenotype and their presence alone or in compound heterozygosity with p.R854Q (VWF:Ag 37-
38 IU/dL, VWF:RCo 32-43 IU/dL, FVIII:C (p.[W2271G];[R854Q]) 28-34 IU/dL, FVIII:C 
(p.W2271G) 85 IU/dL) and p.R816W (VWF:Ag 47-49 IU/dL, VWF:RCo 52-67 IU/dL, FVIII:C 
(c.1432+1G>T;p.R816W) 14 IU/dL, FVIII:C (c.1432+1G>T) 113 IU/dL) explain phenotype 
differences in the affected families.   
 
The presence of p.W2271G, p.L1382= and c.1432+1G>T appeared to explain the partial 
quantitative deficiency of VWF and bleeding symptoms observed in IC and AFM historically 
diagnosed with type 1 VWD. Also, the presence of p.C1157R along with p.S539fs was the main 
cause for the severe reduction of VWF in the AFM. Therefore, these identified mutations 
contribute to the pathogenesis of VWD in these patients. The detection of missed mutations 
within VWF in the patients who had reductions in their VWF level can explain the disease 
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phenotype observed in the IC who showed no mutation or insufficient mutations in the previous 
study. 
 
In addition to p.W2271G, p.C1157R and p.L1382=, in vitro expression studies of recombinant 
mutant VWF was undertaken for p.C1927R, p.R924Q and p.S539fs. Moreover, expression 
study was conducted for the two hypothetical mutations c.4146G>A and c.4146G>C that both 
resulted to the silent mutation p.L1382=.  
 
Previous in vitro expression investigations of missense mutations indicated that mutations 
located within the D3 and D4 domains can lead to intracellular retention and reduced VWF 
secretion as previously described (Hommais et al., 2006a, Eikenboom et al., 2009). In the 
homozygous state of the previous expressed missense mutation in D3 and D4 assemblies, VWF 
secretion was reduced accompanied by intracellular retention in addition to defects in 
multimerisation, while the heterozygous form resulted in reduced secretion and a relative 
reduction in HMW multimers. Furthermore, some mutations in the D3 assembly of VWF 
affected VWF:FVIIIB and resulted in abnormal binding of VWF to FVIII (Hommais et al., 
2006a). 
 
Expression studies of recombinant mutant VWF (rVWF-G2271, rVWF-R1927 and rVWF-
R1157) showed significantly reduced VWF secretion levels in the homozygous state compared 
to rVWF-wild-type with significantly increased intracellular retention. In the heterozygous state, 
all variants also resulted in significantly reduced secretion while intracellular retention was 
observed only in rVWF-R1157. Furthermore, a complete absence of HMW multimers was 
observed when expressed in the homozygous form, whereas in the heterozygous form, 
multimers ranged between normal and relatively reduced HMW. p.C1157R when inherited 
alone can be classified as type 2A(IIE) due to similarities with a number of mutations in the D3 
assembly that have been classified as type 2A(IIE) (Schneppenheim et al., 2010).  
 
In vitro expression analysis indicated that p.W2271G and p.C1927R resulted in a defect in 
VWF secretion possibly through a dominant negative mechanism. Although p.R924Q is located 
in the D3 assembly, which is important for VWF multimerisation, expression study showed that 
it acts as a modifier of VWF level and appears to have had no significant effect on VWF 
synthesis or secretion. 
 
The historical studies previously undertaken on VWF mutations such as nonsense, small 
deletions or insertions that lead to PTC in the open reading frame in type 1 and type 3 VWD 
found significant VWF reduction in the homozygous and heterozygous forms. The level of 
228 
  
expressed mRNA measured using RT-PCR showed a significant reduction of secreted VWF 
compared to wild-type that indicated mRNA degradation through NMD (Shahbazi et al., 2012). 
The extracted mRNA from VWD patients with splice site changes that lead to the creation of 
PTC was measured and showed significant reduction in comparison to healthy individuals 
(Corrales et al., 2011). The c.1614del mutation located in exon 14 of a single nucleotide 
deletion that leads to PTC creation resulted in a significant reduction in VWF secretion 
probably through NMD when expressed in the homozygous form was accompanied by loss of 
multimers and WPB-like organelles. Only a mild reduction in secreted VWF was observed 
when c.1614del was expressed in the heterozygous form through haplosufficiency mechanism. 
However, c.1614del is a recessive mutation (type 3 VWD) and may cause bleeding only when 
inherited in the homozygous form or in the compound heterozygous with an additional 
mutation. Up to 50% of type 3 carriers symptoms may bleed dependant on their VWF mutation, 
ABO blood group or other genetic factors (Bowman et al., 2013). 
 
Interestingly, the expression analysis highlights the adverse impact of silent mutations p.L1382= 
on VWF expression. It has been reported previously that silent changes may impair protein 
expression through several mechanisms. The presence of exonic silent changes can generate 
new splice sites causing partial exonic deletions that produce either functional protein or 
truncated protein (Daidone et al., 2011). Also, it has been reported that silent change can destroy 
or create splicing regulatory elements which affect splicing efficiency (Nielsen et al., 2007). 
Furthermore, the efficiency of mRNA translation rate and ribosome movements has been 
reported to result from silent mutation (Duan et al., 2003, Mitarai and Pedersen, 2013). 
Additionally, silent change may lead to small mRNA binding with miRNA producing dsRNA 
which is eliminated (Hurst, 2011). It seems likely that p.L1382= contributes to VWF deficiency 
due to its effect on translation rate or on splicing regulatory elements. It would be of interest to 
undertake further investigations to evaluate the effect of p.L1382= on splicing regulatory 
elements and translation rate. 
 
Overall, this research has deciphered further genetic and molecular understanding of type 1 
VWD through identification of additional missense and splice site mutations that were 
previously missed in the original MCMDM-1VWD mutational screening. In vitro expression of 
missense mutations appeared to correlate with affected individuals clinical phenotype. Of 
significance, expression of the p.L1382= silent mutation has shown that this synonymous 
mutation may play a role in type 1 VWD pathogenesis and provides novel insight into VWD 
disease mechanisms. A number of synonymous variants have been reported in the EU study that 
were previously considered to be silent. Therefore, in silico analysis and in vitro expression of 
p.L1382= has provided insight into a new research field and that should encourage further 
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investigations to study the association between these synonymous changes and phenotypes 
observed in type 1 VWD patients. In vitro characterisation of silent variants is not always 
sufficient and may remain inconclusive to identify the disease pathogenicity. This research also 
highlighted that the p.R924Q mutation located in D3 domain, when inherited on its own, does 
not contribute to disease pathogenesis, but a deleterious effect is observed when co-inherited 
with another variant. This research has provided further insight on the effect of heterozygous 
mutations on the pathogenesis of type 1 VWD. 
7.1. Future work 
Among the remaining IC who did not show any mutation neither in the original EU-cohort nor 
in this study, although they had reduced VWF level, the cause of VWD may arise from the 
presence of large heterozygous deletions or duplications of single or multiple exons of VWF that 
were previously unable to be detected by standard sequencing methods. A large exon 4-5 
homozygous deletion was identified in type 3 VWD and exon 4-5 heterozygous deletion was 
identified as the aetiology of type 1 VWD in the UK patients and could likely contributes to 
bleeding symptoms in type 1 VWD patients (Sutherland et al., 2009a). 
 
Recently, 104 of the 150 IC from the historical MCMDM-1VWD cohort were screened for exon 
copy number variation utilising MLPA analysis. In total 6 deletions were identified involving 
the heterozygous deletion of exon 3, exons 32-34 and exons 33-34 with the previously reported 
exons 4-5 deletion being identified in the remaining 3 IC. Heterozygous deletion breakpoints 
were also identified, allowing for the design of a multiplex PCR assay to identify deletions in 
other investigations. However, the study stated that MLPA looked at exons only, does not aid in 
identification of the intronic areas deleted in VWF and hence further investigations of mutation 
negative IC could be undertaken using the next approach array comparative genomic 
hybridisation (aCGH) to identify intronic copy number variations. 
 
Whilst no additional mutations were found in the remaining 14 IC, additional mutations could 
be present in deep intronic and regulatory regions of VWF, which cannot realistically be 
analysed through the methods utilised in this project. The three multi-centre type 1 VWD 
studies conducted in EU, UK and Canada only searched for mutations in exons 2-52 (coding 
region), in small areas around the non-coding regions, approximately 50 bp into each end of 
each intron and in small parts (2kb) of the promoter. The presence of mutations within large 
regions of introns and the VWF promoter in addition to exon 1 may lead to alterations in the 
quantity of VWF. In other genes, it has been reported that mutations within intronic regions 
could disrupt the splicing mechanism and alter mRNA production (Khelifi et al., 2011, 
230 
  
Pezeshkpoor et al., 2013). Analysis of the Duchenne muscular dystrophy gene (DMD) which 
encodes several transcripts has shown that mutations in this gene cause dystrophinopathies. It 
has been reported that the presence of deep intronic deletions lead to pseudoexon (PE) 
activation and may impair the splicing mechanism of the PE and contribute to the pathogenesis 
of muscular dystrophy (Khelifi et al., 2011). PE are sequences similar to exonic sequence 
present within intronic regions created due to intronic alteration flanked by abnormal splice site 
consensus which are not normally seen in wild-type mRNA. Also, it has been reported that one 
or more deep intronic variants can create new cryptic splice sites that result in the insertion of 
intronic sequences into the mRNA and a premature stop codon in haemophilia A patients 
(Bagnall et al., 1999, Pezeshkpoor et al., 2013). Therefore, using aCGH analysis and next 
generation DNA sequencing of VWF to search for non-protein coding region variants in these 
individuals with no mutation identified is suggested as the next step. 
 
aCGH and next generation sequencing can sequence the large VWF intronic regions and 
promoter to search for variants that cannot be detected by the standard DNA sequencing 
method. aCGH is a method of detection of CNV either large deletions or duplications within 
DNA. In this method, the patient DNA is labelled with one coloured dye and control DNA 
samples pooled from a healthy individual including males and females is labelled with a 
different colour. Subsequently, these labelled DNAs are combined and hybridised to a 
microarray which consists of thousands of oligonucleotide probes specific to the investigated 
regions. This approach can be used therefore to analyse the entire VWF for CNV which may 
include large deletions and duplications in exonic, intronic and regulatory regions. This method 
would detect CNV that were missed in the MCMDM-1VWD study due to only investigating 
exonic regions with MLPA. 
 
Also, analysis of mRNA isolated from VWD patients who had VWF levels <35 IU/dL is an 
effective method to identify deep VWF intronic mutations. The isolated RNA is reverse 
transcribed into cDNA using RT-PCR followed by amplification the cDNA which is then 
electrophoresed to measure its size in comparison with that of a healthy individual and also fully 
sequenced to determine its changes. mRNA samples were not available from the historical 
study. 
 
Mutations in the upstream promoter region may lead to the pathogenesis of type 1 VWD. 
Mutations within the promoter region could alter transcription factor binding sites in the 
affected allele, thereby leading to a reduction in RNA transcription. A study reported in 2010, 
identified a 13 bp deletion (c.-1522_-1510del13) within the proximal promoter region that 
impairs binding of the transcription factor protein Ets to the VWF promoter and markedly 
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reduces gene expression thus contributing to type 1 VWD (Othman et al., 2010). Also, the 3 
type 1 VWD studies identified a number of variants located within the 3kb of the proximal 
promoter region, but some of these variants were also found in healthy control individuals and 
were most likely SNP rather than mutations (Cumming et al., 2006, Goodeve et al., 2007, James 
et al., 2007). Moreover, a study conducted by Schwachtgen et al, 1997 showed that a deletion of 
a small section of the VWF promoter reduces transcription because it decreases Ets transcription 
factor binding (Schwachtgen et al., 1997). However, searching for mutations in the deep 
regulatory regions using next generation sequencing or aCGH could contribute to defining the 
pathogenesis of type 1 VWD in the EU-cohort who still showed no mutation although they have 
a bleeding history. 
 
Intronic regions of genes can contain miRNA binding sites and can also encode miRNA 
sequences. The 3'-UTR (un-translated region) and other regions of mRNA may contain binding 
sites for microRNA (miRNA) that regulate mRNA translation. These regulatory elements affect 
mRNA polyadenylation and stability, translation efficiency and codon termination and 
mutations within 3'-UTR region can influence the termination codon, secondary structure or 
polyadenylation signal and can thus cause disease. Also, the presence of mutations in 
polyadenylation signals can impair transcriptional termination, for example α-thalassemia 
(Harteveld et al., 1994, Prior et al., 2007). Therefore, further genetic analysis of these regions 
using LR-PCR and sequencing may enhance our understanding of possible genetic changes that 
may alter VWF in type 1 VWD. 
 
In the IC investigated where no mutations have still been identified, it is possible that there are 
still mutations present that have been missed due to the limitations of the PCR methodology 
undertaken, as discussed previously. However, it is possible in these IC that the historical 
diagnosis of type 1 VWD was incorrect and there was a misdiagnosis of VWD as the causative 
bleeding disorder. This has been shown in the P9F18 family, who were initially categorised as 
having type 1 VWD but were reclassified as having type 3 VWD (which formed the basis of 
chapter 5 in vitro analysis). The EU investigation recruited patients with a historical diagnosis 
of type 1 VWD and even after phenotypic analysis, did not exclude patients who had 'atypical' 
VWD (abnormal multimers). This was to try and minimise the potential for mutations to be 
missed in VWF.  
 
Additionally, the variability of VWF levels within the general population can be explained due 
to both environmental and genetic factors including epigenetic modifications. Epigenetics is 
defined as heritable changes that alter gene expression and activity but do not alter the DNA 
nucleotide sequence (Goldberg et al., 2007). These non-genetic changes that affect chromatin 
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are regulated by two modifications: DNA methylation and histone modification that package the 
genome into the nucleus via binding with histone proteins forming nucleosome complexes 
(Bernstein et al., 2007). Histone modification includes histone acetylation, methylation and 
ubiqutination. Methylation and heterochromatin hide DNA making it inaccessible to 
transcriptional factors and thereby inactivate DNA transcription and activity. In contrast, 
heritable changes alter DNA methylation such as loss of methylation sites (hypomethylation) or 
cause chromatin to be less condensed making DNA more accessible and result in increased 
DNA transcription and activity. It has been shown that levels of VWF increase with increasing 
age which contributes to VWF variability among the normal population (Nossent et al., 2006).  
This variation may be due to decreases in DNA methylation or histone modification that occurs 
with age that make DNA more accessible. Decreased methylation would activate DNA 
transcription and expression (De Smet and Loriot, 2013). It would be of interest to determine 
whether the methylation or histone patterns of the VWF promoter alter with age and could be 
investigated in the MCMDM-1VWD control cohort. These further analyses may enhance our 
understanding and knowledge of type 1 VWD pathogenesis especially in individuals with 
borderline VWF levels. Several approaches have been used to evaluate the DNA methylation 
state but bisulphite modification and sequencing have been considered as the gold standard test. 
This analysis of bisulphite treatment is based on variable sensitivity of cytosine and 
methylcytosine (5-MeC) to bisulphite that causes DNA deamination. Bisulphite treatment 
converts unmethylated cytosine to uracil while methylcytosine remains resistant (Clark et al., 
2006, Darst et al., 2010). DNA amplification and sequencing using specific primers could 
determine the level of DNA methylation. This test could help to explain the effect of epigenetic 
modification on VWF expression among VWD patients and the normal population. Also, next 
generation sequencing can be used to evaluate the level of methylation among VWD patients. 
Also, additional epigenetic mechanisms such as histone acetylation can be investigated to 
evaluate its effect on VWF. 
 
Current in vitro expression is an artificial system not fully representative of in vivo expression. 
The isolation of BOEC from blood of type 1 VWD patients would provide valuable data about 
VWF biosynthesis, secretion and pathophysiology of VWD through culturing these cells in 
suitable media. Using these cells can assist the evaluation of VWF level, production, secretion 
and confocal imaging as they isolated from VWD patients reflecting the in vivo expression 
system. Experimental studies that have used BOEC cell lines isolated from VWD patients 
provided an ideal substrate for ex vivo experimentation. The level of released VWF was found 
to be decreased in types 1 and 2M VWD patients using BOEC isolated from their blood (Starke 
et al., 2013b). Moreover, investigation of derived BOEC from type 1 VWD patients 
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heterozygous for p.S1285P, p.L1307P and p.C2693Y showed VWF retention, reduced secreted 
level of VWF and abnormal morphology of WPB (Wang et al., 2013).  
 
Almost 30% of investigated IC within the EU-cohort and other type 1 VWD cohorts were 
negative for mutations. The absence of identified genetic changes in these individuals in 
addition to variable penetrance and expressivity, and the variability in VWF levels observed in 
normal individuals and VWD patients suggest the contribution of other genetic loci rather than 
VWF could affect VWF levels. Also, among the remaining IC within the EU-cohort who 
remained negative for mutations, a large proportion of cases (77%) were blood group O in 
comparison with 38% of all EU HC. Also, the possibility of presence of mutations in other 
genes rather than ABO that may influence the levels of VWF has been discussed as contributing 
to the aetiology of VWD. Similar to the ABO locus, additional loci outside VWF have been 
reported to influence the level of plasma VWF. Smith et al (2010) detected a number of genetic 
loci outside VWF by genome wide association study (GWAS). These variants have been shown 
to correlate with VWF:Ag levels and include STXBP5, STX2, STAB2, CLEC4M and SCARA5 
(Smith et al., 2010). Therefore, SNP identified in genes from the CHARGE study could help to 
explain disease phenotype in IC with borderline VWF levels and pathogenic mutations in the 
same genes could possibly contribute to VWD phenotype. 
 
The recent study within the MCMDM-1VWD on analysis the effect of CLEC4M on VWF level 
in the general population suggested variants in CLEC4M with a possible association with VWF 
level, although the association was not statistically significant (Mufti et al., 2013, Rydz et al., 
2013).  
 
Additionally, it was suggested that the FUT3 locus may have an influence on VWF level 
through VWF glycosylation by an unknown mechanism (O'Donnell et al., 2002b). Hickson et al 
(2009) reported a 9% reduction of VWF level in individuals with the FUT3 variant 
c.202T>C;p.W68R in individuals with the T reference allele in comparison to those with the C 
non-reference allele (Hickson et al., 2009b). Analysis of this gene for the presence of further 
genetic variants that is associated with abnormal phenotypes more severe than those associated 
with identified common SNP could be undertaken. The presence of these changes could 
contribute to bleeding symptoms in patients diagnosed with type 1 VWD. 
 
One of the important issues relevant to the diagnosis of type 1 VWD is possible misdiagnosis. 
In all three cohort studies, a number of patients with a bleeding history may have been falsely 
diagnosed as having type 1 VWD. This false positive diagnosis could be due to the presence of 
a proportion of the normal population who have mild bleeding symptoms in the EU study being 
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indistinguishable from classical type 1 VWD or due to the wide distribution of the normal range 
of VWF (48-167 IU/dL). The EU study analysed a number of IC who had high BS with normal 
levels of VWF. This suggests the presence of other bleeding disorders rather than type 1 VWD 
that could explain the occurrence of bleeding symptoms observed in IC (Daly et al., 2009). 
Belen et al (2014) reported an overlap and similarities in bleeding symptoms among patients 
with VWD and platelet function disorders (Belen et al., 2014). The addition of platelet function 
tests such as platelet aggregation test using several agonists during the initial investigation of 
the patient could assist the accuracy of diagnosis. Platelet aggregation tests could define which 
platelet receptor, intracellular signalling or secretion pathway is influenced and enable further 
genetic investigation required for the associated genes (Watson et al., 2010).  
 
The silent mutation p.L1382= identified in one IC within the MCMDM-1VWD study showed a 
significant effect of this variant on VWF expression. In silico prediction illustrated that this 
silent variant has no effect on splice donor or acceptor sites but may disrupt ESE sequences that 
may alter the splicing mechanism. However, in order to provide evidence that c.4146G>T could 
result in VWF mRNA alteration due to the exonic change predicted to disrupt an ESE, a 
minigene assay was planned to be established. pcDNA-Dup (SF2/ASF3x) was selected as the 
appropriate vector to investigate the effect of c.4146G>T on ESE. This vector contains three 
exons where the middle one is recognised if a functional ESE motif resides within the exon. 
This assay is based on the insertion of a short DNA segment (30 bp) of wild-type or mutant 
sequence corresponding to the sequence of interest including c.4146G>T and wild-type 
sequence. These constructs of mutant and wild-type sequences would be transiently transfected 
into the HEK293T cell line followed by extraction of mRNA 24 hr post transfection. mRNA is 
reverse transcribed into cDNA, amplified using PCR then RT-PCR products electrophoresed on 
polyacrylamide agarose gel. The size and number of minigene product bands of wild-type and 
mutant are compared to evaluate the effect of silent change on ESE and may also be sequenced 
(Gaildrat et al., 2012).  
 
Within the group, we attempted to investigate the effect of c.4146G>T and other VWF SNP on 
ESE. A short pair of forward and reverse primers each of 30 bp sequences corresponding to the 
VWF region containing wild-type and mutant sequences surrounding c.4146 were designed to 
be inserted into the vector. The restriction and ligation steps to remove the existing middle exon 
from the minigene vector and to insert the desired 30bp oligonucleotides of interest of wild-type 
and mutant construct were unsuccessful after many attempts. With persistent failure using 
several different conditions, the work was discontinued due to limited time. In addition to the 
effect of c.4146G>T on protein expression, other work to determine how any impact on ESE 
could be investigated using either patients and HC RNA samples or using transfected cell line 
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DNA. The MCMDM-1VWD study did not historically collect RNA from IC and hence RNA 
analysis is not available. Collection of RNA samples from individuals harbouring the 
c.4146G>T variant may contribute to identify the disease causing mechanism. Therefore, 
completing these experiments using patients RNA or a minigene assay could confirm or exclude 
whether this silent change affects an ESE and the splicing mechanism and thereby contributes 
through this mechanism to bleeding symptoms observed in the affected members. Moreover, in 
vitro expression using vector lacking the entire exon 28 could be undertaken to evaluate the 
effect of exon 28 skipping resulting from improper splicing in rVWF and  findings compared to 
phenotypes in the affected individuals. 
In conclusion, this project has provided insight into the pathogenicity of type 1 VWD through 
identification and re-design of primers free of SNP in the primer binding regions, applicable to 
future VWF screening approaches utilising standard DNA sequencing. In addition, the 
identification of missed mutations has identified a further 3 IC that were originally mutation 
negative. In vitro analysis of these previously missed mutations has also shown that the type 1 
VWD phenotype in the IC is likely to be a result of the missed mutations and hence has added 
information on the molecular mechanisms of type 1 VWD. Historically, the role of synonymous 
mutations within VWF have been dismissed as ‘silent changes’ unlikely to lead to disease 
phenotype. However, this thesis has provided insight into the pathogenic nature of such 
mutations through in vitro expression. This area of research is vastly under investigated in VWF 
genetics and some IC in the EU study who only have silent mutations in VWF might have 
VWD due to the nature of the silent synonymous changes. Throughout VWF, there have been 
number of synonymous changes reported and most are likely to remain as silent mutations, but 
this thesis has provided insight into a research area for synonymous mutation expression, in 
silico analysis and a potential novel type 1 VWD disease mechanism.  
 
These investigations were an initial step to understand the genetics and molecular mechanisms 
of the disease better. Further investigations as suggested above will help to improve knowledge 
about this complex disease. 
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9. APPENDICES 
 
Appendix 1 Sequences of M13 forward and reverse primers used for tailing PCR 
primers for DNA sequencing 
Primer Sequence Complementary sequence for 
DNA sequencing 
M13 F (5'-3') dTGTAAAACGACGGCCAGT 
   
dACATTTTGCTGCCGGTCA 
M13 R (5'-
3'): 
dCAGGAAACAGCTATGACC 
 
dGTCCTTTGTCGATACTGG 
 
 
 
 
Appendix 2  Reaction mixture for conventional PCR using ReddyMix (Fisher 
Scientific, Loughborough, UK) with various concentration of MgCl2 
30 µl final 
volume 
                                                  [MgCl2] mM 
         1.5                      2                      2.5                       3                       4 
Master mix 27 27 27 27 27 
 
F primer 0.6 0.6 0.6 0.6 0.6 
 
R primer 0.6 0.6 0.6 0.6 0.6 
 
dH2O 1.2 0.9 0.6 0.3 0 
 
50mM 
MgCl2 
0 0.3 0.6 0.9 1.5 
 
 
 
 
 
Appendix 3 PCR program for the amplification of VWF 
Initiation Cycling Final extension 
94 °C for 7 min 35 cycles 72 °C for 7 min 
 94 °C for 1 min  
 n °C for 1 min*  
 72 °C for 1 min  
* See Appendices 4, 6, 11 and 12 for details of temperature used 
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Appendix 4 List of VWF PCR primers used within the EU study which did not 
require re-design                                        
EXON Primer sequence (5' to 3')* Annealing temp 
°C 
MgCl2 conc 
(mM) 
2F GTCCATGTTCAAAGGGGAAA 59 3 
2R GGCAGGAATGAGAAATGGAG   
3F GAGATCACCAGCCCAACCT 60 1.5 
3R CAGCCCTCCCTCTGAAGTC   
4F GGTTACGTAGATAATGATTC 53 1.5 
4R AACATTTGCTTCCATTCTCT   
5F AAGGTGGGAGAGACATCCAG 51 1.5 
5R AGTGAAGGTTTATGAGCAAG   
6F ACCACCAGCAGACCTAGAAT 51 1.5 
6R TGGAAGGATATGAGACTGAG   
7F AGGGAGACACTAACGGAGCA 59 1.5 
7R TGTGGTAAAGCCGCACATAC   
9F ACCCAACCATTGTCCCTG 55 1.5 
9R AGGTCTCCCAGAGCACGC   
10F GAGCTCTAAATCCATTTGC 51 1.5 
10R GGAGACGCCTCCCCGATT   
11F CACCCTGCTTGCATATGCAT 51 1.5 
11R TCTGGAAGAGACCTCCCTCA   
13F CCCAAATACATCTGCCTGCC 60 1.5 
13R TTCTTCTCCCACCACACAAA   
16F AACCACAGTCCTTGCTGTCC 60 1.5 
16R CCCCAGCTCTGCTGTTTTAG   
17F AGAGTGAGTGGGAGGTGAAG 59 1.5 
17R CCATTCCACACGTGAGGAAT   
19F GGCTTTAGATCAGTCACTGTG 59 1.5 
19R GTGCACCCTCACTCCACCCGC   
21F AATCTTCTGGTCTGGTGAGA 60 1.5 
21R CCTCATCCTCTTTAATGGCT   
22F AGAGTGGAGGGAGGATCTGG 59 1.5 
22R TAGAGACCTACGATCAGGGA   
35F GCATCCATCCTCTGCTTCTC 60 1.5 
35R CCTGACATTCTATTGCCTTACCA   
37F CTGGTGAGGATCAAGAATGG 61 1.5 
37R AAGAATCTGGGGCACAGAGA   
38F GTCTGATGATTAACCATGTTGA 55 1.5 
38R GGCCAATCACTGGTGAACAT   
39F GAATTCTGGGCTTCGTACCT 55 1.5 
39R CAGTGTTTGAGTCTGCTCTG   
40F CAAATCCCTCTGAGGCTGTC 59 1.5 
40R AGACACCTTTCAGCACCTTCA   
41F GCATCCCACTCACAGGTAAT 55 1.5 
41R AACAGGAAATGACGTGATCT   
42F GCACCCTATAGCATAGCTGA 55 1.5 
42R ATGGATGGGTGGATAGAAGG   
43F CTTCTGTGTTAGTAGGTGCTAA 51 1.5 
43R TACCCTTCCTAAGATGCCCT   
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Appendix 4 List of VWF PCR primers used within the EU study which did not 
require re-design cont                                                     
EXON Primer sequence (5' to 3')* Annealing temp °C MgCl2 conc (mM) 
44F TCTGCAGCTGATGTAAGACTTCG 62 1.5 
44R AAGGTCAACGCTGGTCCCTGG AGT   
45F CCTGTGGTGGGACTTACATGTTA 63 1.5 
45R TCAGGAGCCAAAAGTGGAAAGAG   
46F AGGAGGAGCCCCAAAGAGAG 60 1.5 
46R CTAGCCTGGGCTCCATGA   
47F GGCTCATGGGAGCTATGG 59 1.5 
47R CAGTTTGGGTGGGTGATTTT   
48F AGCCTACTTACAATTGGGAT 51 1.5 
48R AAAAGGAAGCAAGATGGTGA   
49F ACCCACTCCTCTTTCCTTCC 60 1.5 
49R GAGAAATTATGCCGGAGCTG   
50F TGGTCAGGTAGGGTGGTCA 58 1.5 
50R AGGAGCAAGCTGCAAAGAGC   
51F CCAGCCAGTCCTCAAGTTTC 60 1.5 
51R CCAGCCCTTATTGAAGCAGA   
52F CTACTGTCCTGGGTGCTTC 59 1.5 
52R TGACACTGAGGCTTGCAGA   
* All primers were tailed with the following sequences (M13) to facilitate DNA sequencing: 
   M13 F (5'-3'): dTGTAAAACGACGGCCAGT 
   M13 R (5'-3'): dCAGGAAACAGCTATGACC 
 
 
 
              Appendix 5 Internal primers used to sequence the long rang PCR   
              product for exon 28 
Primer Primer sequence 5'-3' 
28 AF CTTGGATGTGGAATGGTCCA 
28 AR CTTCAGCAAGATCGACCGCC 
28 BF CAGCAGGCTACTGGACCTGG 
28 BR CGAGATCGTTAGCTACCTCTG 
28 CF CAAGCAGATCCGCCTCATCG 
28 CR GAGATCAAGAGGCTGCCTGG 
28 DF 
28 DR 
AACAGGACCAACACTGGGC 
CGACTCGGGTTCTAATCCTG 
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Appendix 6 List of promoter and exon-intron 1 region primers                                                      
EXON Primer sequences (5' to 3')* GC% Tm °C Optimised annealing 
Temp °C/Cycles 
MgCl2 conc 
(mM) 
Product size 
(bp) 
Promoter F dCTGGCTGCTCTTCCATTTTT 45.0 55.0 57/28 1.5 3500 
Promoter R dGGGATCAGTCAGTCCTGCAT 55.0 59.0    
Intron 1F dCTCATTTGCAGGGGAAGGTA 50.0 57.0 58/30 1.5 1427 
Intron 1R dGAGGCAACCAACAGCCTAAG 55.0 59.2    
* All primers were tailed with M13 sequences to facilitate DNA sequencing: 
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A          B  
Appendix.7 A) Hyperladder IV. It includes 9 fragments ranging between 100-1000bp, B) 
Hyperladder I includes 14 fragments ranging between 200-10,000 bp (www.bioline.com). 
 
 
 
 
 
 
 
 
 
HyperLadder I 
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                                Appendix 8 Mutagenic primers used to introduce mutation to the wild-type VWF construct  
Mutation Exon Nucleotide 
change 
Mutagenic primer 
p.S539Lfs*38 14 c.1614del DEL1614:                        ACTTCCTTACCCCTCTGGGCTGGCGG 
DEL1614-ANTISENSE: CCGCCAGCCCAGAGGGGTAAGGAAGT 
p.R924Q 21 c.2771G>A G2771A:                    AGTGAAATGCAAGAAACAGGTCACCATCCTGGTGG 
G2771A_ANTISENSE: CCACCAGGATGGTGACCTGTTTCTTGCATTTCACT 
p.C1157R 26 c.3469T>C T3469C:                        CCTGTCAAGTCACGCGTCAGCACCCTGAG 
T3469C_ANTISENSE: CTCAGGGTGCTGACGCGTGACTTGACAGG 
p.L1382= 28 c.4146G>T G4146T:                           CCGCATCGCCCTTCTCCTGATGGCC 
G4146T_ANTISENSE:   GGCCATCAGGAGAAGGGCGATGCGG 
p.L1382= 28 c.4146G>A G4146T:                           CCGCATCGCCCTACTCCTGATGGCC 
G4146T_ANTISENSE:   GGCCATCAGGAGTAGGGCGATGCGG 
p.L1382= 28 c.4146G>C G4146T:                           CCGCATCGCCCTCCTCCTGATGGCC 
G4146T_ANTISENSE:   GGCCATCAGGAGGAGGGCGATGCGG 
p.C1927R 34 c.5779T>C T5779C:                        GCTGAGGCCTTCGCGCCCTAACAGCCA 
T5779C_ANTISENSE: TGGCTGTTAGGGCGCGAAGGCCTCAGC 
p.W2271G 39 c.6811T>G T6811G:                         TTCCTGGAAGCCGGGGTCCCGGACC 
T6811G_ANTISENSE: GGTCCGGGACCCCGGCTTCCAGGAA 
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Appendix 9 Primers designed for sequencing the full length VWF cDNA 
Primer Primer Sequence (5'-3') 
 
PC1 (F) TAATACGACTCACTATAGGG 
PC2 CGGCAACTTTCAAGTCCTGCTGT 
PC3 CAGTGTGCCCTGCTGGTATG 
PC4 CAGCCTTGTGAAACTGAAGCATGG 
PC5 CGAAAGGCCAGGTGTACCTGCAG 
PC6 CTGGAGTGCATGAGCATGGGCTG 
PC7 CATCATTCTGCTGCTGGGCAAAG 
PC8 CAGAGCTGCGAGGAGAGGAATC 
PC9 CTTTGTGGTGGACATGATGGAGC 
PC10 CATGGCACAAGTCACTGTGGGC 
P11 CTAATGCCAACGTGCAGGAGCTG 
PC12 TCATCCTGGTCACGGACGTCTC 
PC13 CAAGCTGACTGGCAGCTGTTCTT 
PC14 CATCCTGGAGGAGCAGTGTCTTG 
PC15 CACGTGTGGCCTGTGTGAAGTAG 
PC16 CAGAAGCCCTGTGAGGACAGCT 
PC17 CAAGGAAGAAAATAACACAGGTG 
PC18 (R) TAGAAGGCACAGTCGAGG 
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Appendix 10 Primer set previously used in the EU study with SNP or sequence error within primers sequences                                
Primer Primer sequence (5'-3') Allele SNP Ref No Origin Distance from target 
exon 
Reason for re-design 
Exon 8 R TGCTGGCAAGGTCTCTGATCTGT
A 
G/A rs3213721 Ensembl Close (22bp) SNP found 
Close to target exon 
Exon 12 F TTGAGGCCTTTCTCTGATTAA A/T rs 61754008 SNPCheck Acceptable (>50bp) SNP found 
Exon 14 R GCCTTGCGTGACGTGATTA N/A N/A SNPCheck - Sequence error: could 
not be located by 
BLAST 
Exon 15 R CACCGTGGACGGATTTGGG G/A rs73264986 Ensembl Close (38bp) SNP found 
Close to target exon 
Exon 18 R CCTGCCTACAAGAAAACTGAA G/T rs77372340 Ensembl Close (33bp) SNP found 
Close to target exon 
Exon 20 R AGATCCACAGAACCCAACCT G/T rs73263045 Ensembl Acceptable (>50bp) SNP found 
Exon 23 R CCTTCCAGCCCCCATGAC G/T rs56068059 Ensembl Acceptable (>50bp)   SNP found* 
Exon 24 R GCCAAGCCTTGGGACCGT C/T rs73051263 Ensembl Close (30bp) SNP found 
Close to target exon 
Exon 25 F CAGACTAAGAGCCAGAGTTC C/T rs4021577 Ensembl Close (46bp) SNP found 
Close to target exon 
Exon 26 F CAACATTATCTCCAGATGGC del rs140819 Ensembl Acceptable (>50bp) SNP found 
Exon 26 R TTGCAGGTCAGAGATAGGAC T/C rs13054481 Ensembl Acceptable (>50bp) SNP found 
Exon 27 R ATCCAAAACCTAGTCTC TA T/C N/A N/A Acceptable (>50bp) Sequence error 
Exon 29 F TAGGCCTGGTGGCCATTGTC C/A rs11613273 Ensembl Close (43bp) SNP found 
Close to target exon 
*SNP will destabilise PCR product 
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Appendix 10 Primer set previously used in the EU study with presence of SNP or sequence error within their primers sequences 
cont 
Primer Primer sequence (5'-3') Allele SNP Ref No Origin Distance from target 
exon 
Reason for re-design 
Exon 30 R GAGCAAAGTGACTGGCCGA C/T rs72613680 Ensembl Acceptable (>50bp) SNP found 
Exon 31 F ATCCACCGTTAAGACAGGGTGTCG G/C rs57349683 Ensembl Close (46bp) SNP found 
Close to target exon 
Exon 32 TGAACATCTTCCTCATAGGGCTGA 
 
- - - Acceptable (>50bp) No product 
Exon 33R CCCCAAACACATCTCTAACC G/A rs55664929 Ensembl Close (31bp) SNP found 
Close to target exon 
Exon 34 R GAAAAGCAATTCTTCCTTCCA G/A Rs4764479 Ensembl Acceptable (>50bp) SNP found 
Exon 36 F CCTAGGATTCCTCATTGCTA A/G rs71579337 Ensembl Close (33bp) SNP found 
Close to target exon 
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Appendix 11 List of re-designed primers not in the VWF pseudogene region                                                       
EXON Primer sequences (5' to 3') GC% Tm °C Optimised annealing 
Temp °C/Cycles 
MgCl2 conc (mM) Product size 
(bp) 
8F GTCAGAGTGGGCACGAGAG 
 
63.1 59.5 60/35 1.5 300 
8R GTGGCCTTCATCTCACTTCC 
 
55.0 59.6    
12F AGCCTTCTTGCTGCACAACT 
 
50.0 60.2 60/35 1.5 395 
12R GGTTGAGAAGGAGGGTGCTA 
 
55.0 59.2    
14F GTTTCACCCGGGGAACTT 
 
55.5 59.7 60/35 1.5 374 
14R AACGCACTGCACTAATGTGG 
 
50.0 59.7    
15F CAGCACTGGGCTATTTCCAG 
 
55.0 60.7 55/32 1.5 399 
15R GGAAACAACGCAGAGAAAGG 
 
50.0 59.8    
18F TAGGGGACCAAAGGACAGTG 
 
55.0 59.9 60/35 1.5 349 
18R CCGTGTTTAGCCCTTGTTTC 
 
50.0 59.6    
20F CAGGTCCTCAACTTCCTTGG 
 
55.0 59.6 60/35 1.5 389 
20R GACCCCAGAGTTGTTTCTGC 
 
55.0 59.7    
36F TTTGTGGCTGATGTTGCAGT 
 
45.0 60.3 60/35 1.5 396 
36R AAGCATCCAAGAGCCTCAGA 50.0 60.1    
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Appendix 12 List of re-designed primers showing mismatches between VWF and VWFP 
Exon Primer sequences (5' to 3') Introduced 
mismatch 
GC% Tm °C Optimised 
annealing Temp 
°C/Cycles 
MgCl2 
conc (mM) 
Product 
size (bp) 
23F GGGCATGTTGCCTCTCT--GT*  57.9 61.2 60/35 1.5 473 
23R TCCAGCCCCCATGACAAT  55.5 62.3    
24F GTCCCTCTGTCCCCATTGTC  60.0 61.7 60/35 1.5 343 
24R ACTCTGTGTCCATACCACCAG  52.4 57.5    
25F CCTGGACCCCC-TTATCCTTA  55.0 60.1 60/35 1.5 400 
25R GCCATCCAGTCCC-TACTAA*  52.6 55.1    
26F CAGTGACTCATACCTGTAATCC  45.5 58.4 60/32 1.5 865 
26R GCTGTACCATAGGATCGTGAC G>C 52.4 59.8    
27F1 TTAGTTAAAAATGAGGCTTCCTC  34.7 56.1 62/35 2.5 260 
27F2 AGGCTTGGGGAGGTGAGGTAGGG  65.0 62.0 60/35 1.5 427 
27R CCTGGAGAAGCAATAAGATTCA  40.9 58.4    
28F GGCTATGTGTGTGTTTTGATGG T>G 45.5 64.0 67/32 1.5 1673 
28R CTTGGCAGATGCATGTAGCAG G>C 52.3 65.0    
29F GCCTGGTGGCCATTGTCC  66.6 64.9 60/35 1.5 250 
29R TTATTTTGAATCAAGTAGAGCCA  30.4 55.9    
30F GAGGCTCTTTTTGTGGCTCT  50.0 58.6 60/35 1.5 404 
30R CTTAAAAGCTGAATGATTCAGAA  30.4 55.6    
31F GCAGTCAGTACTGACTTGGC  55.0 56.0 60/35 1.5 278 
31R AACATCCAAAAGTAACCCCAGC  45.4 61.4    
32F CATCTTCCTCATAGGGCTGA  50.0 57.8 56/35 1.5 396 
32R CCTGGGGTCTCTTGAATAC  52.6 54.5    
33F CAGGATGACCACCTCAGCCT  60.0 62.6 61/35 2.5 436 
33R GACCCCTAGAATTGAACTCA T>A 45.0 55.0    
34F CCTCCTTTGGTCTTAGTCCAGT  50.0 58.7                60/35 1.5 733 
34R CCACTGCTATACCCTGAATAGAC G>C 47.8 57.7    
 Bold red nucleotides represent mismatches between VWF and VWFP. 
 Bold blue nucleotides represent introduced mismatches. 
      *     Indicates no nucleotides present to introduce mismatches between VWF and VWFP 
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Appendix 13 List of known SNP identified through DNA sequence analysis cont                                                               
SNP 
reference 
number 
Affected 
nucleotide 
SNP location 
Exon/Intron 
SNP identified in IC 
rs2286608 c.1-64C>T Intron 1 P1F2II1,P2F13I3,P4F5I1,P4F7II1,P5F1II3,P6F4II1,P6F9II1,P7F8I2,P8F2II2, 
P8F3I2,P8F5II1,P9F14III1,P9F18I1,P10F5II2,P10F8II1,P10F9II3,P12F5II1 
rs7980045 c.657+11A>C Intron 6 P10F5II2,P12F5II1 
rs3213721 c.997+32G>A Intron 8 P7F8I2,P8F2II2,P8F3I2,P8F5II1,P9F14III1,P9F18I1,P10F8II1, P12F5II1 
rs55907031 c.998-27C>T Intron 9 P4F7II1P8F5II1,P10F9II3,P9F18I1 
rs1800375 c.1173A>T Exon 11 P4F7II1,P8F5II1,P9F18I1,P10F9II3 
rs1800376 c.1182A>C Exon 11 P4F7II1,P8F5II1,P9F18I1,P10F9II3 
rs1800377 c.1411G>A Exon 12 P1F2II1, P4F7II1,P8F3I2,P8F5II1,P9F18I1,P10F9II3 
 
rs1800378 c.1451A>G Exon 13 P1F2II1,P2F13I3,P4F5I1,P4F7II1,P5F1II3,P6F4II1,P6F9II1,P7F8I2,P8F2II2,P8F3I2, 
P8F5II1,P9F14III1,P9F18II,P10F5II2,P10F7II1, P10F8II1,P10F9II3,P12F5II1 
rs7312411 c.1548T>C Exon 14 P10F5II2, P2F13I3, P5F1II3 
 
rs35365059 c.1626G>A Exon 14 P8F5II1 
rs61908661 c.1945+24C>T Intron 15 P8F2II2,P9F14III1,P10F8II1 
rS216293 c.2282-42C>A Intron 17 P1F2II1,P2F13I3,P4F5I1,P10F7II1 
P6F4II1,P6F9II1,P10F5II2,P10F9II3 
rs1063856 c.2365A>G Exon 18 P2F13I3, P5F1II3,P8F5II1,P9F18I1,P10F5II2,P10F8II1,P12F5II1 
 
rs1063857 c.2385T>C Exon 18 P2F13I3,P5F1II3,P8F5II1,P9F18I1,P10F5II2,P10F8II1,P12F5II1  
rs216325 c.2546+25C>T Intron 19 P1F2II1,P2F13I3,P4F5I1,P6F4II1,P6F9II1,P7F8I2,P8F2II2,P8F3I2 
P9F14III1,P9F18I1,P10F5II2,P10F7II1, P10F9II3,P12F5II1 
 
rs216321 c.2555A>G Exon 20 P1F2II1,P2F13I3,P4F5I1,P5F1II3,P6F4II1,P6F9II1,P7F8I2, P8F2II2,P8F3I2, 
P8F5II1,P9F14III1,P9F18I1,P10F5II2,P10F7II1, P10F8II1,P10F9II3,P12F5II1 
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Appendix 13 List of known SNP identified through DNA sequence analysis cont                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP reference 
number 
Affected 
nucleotide 
SNP location 
Exon/Intron 
SNP identified in IC 
rs1800380 c.2880G>A Exon 22 P2F13I3, P5F1II3, P8F5II1,P9F18I1 
P10F5II2,P10F8II1,P12F5II1 
 
rs34877178 c.2968-53G>A Intron 22 P2F13I3, P5F1II3,P8F5II1,P9F18I1, 
P10F5II2,P10F8II1,P12F5II1  
rs3858686 c.2968-125C>T Intron 22 P2F13I3,P5F1II3,P8F5II1,P9F18I1,P10F5II2,P10F8II1,P12F5II1 
 
rs11063993 c.2968-154C>T Intron 22 P6F4II1,P7F8I2 
 
rs73051263 c.3222+31C>T Intron 24 P2F13I3,P9F18I1,P10F5II2,P10F8II1,P12F5II1 
 
rs56121649 c.3109-90G>C Intron 23 P2F13I3, P5F1II3,P9F18I1,P10F5II2,P10F8II1,P12F5II1 
rs56068059 c.3109-128G>T Intron 23 P2F13I3, P5F1II3, P10F5II2 
 
rs4008538 c.3414C>T Exon 26 P6F9II1,P8F2II2,P8F3I2,P9F14III1,P10F5II2 
 
rs216305 c.5665-118G>A Intron 33 P1F2II1,P2F13I3,P4F5I1,P4F7II1,P6F4II1,P6F9II1, 
P10F5II2,P10F7II1, P10F9II3 
 
rs216305 c.5664+175G>A Intron 33 P1F2II1,P4F7II1,P6F4II1,P6F9II1,P10F5II2,P10F7II1, P10F9II3  
 
rs216902 c.5844C>T Exon 35 P4F5I1, P4F7II1, P6F4II1 
 
rs71579337 c.6064-50A>G Intron 35 P1F2II1,P8F3I2 
rs17491334 c.6064-71C>T Intron 35 P2F13I3,P5F1II3, P10F5II2, P10F9II3 
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Appendix 13 List of known SNP identified through DNA sequence analysis cont                                                               
SNP reference 
number 
Affected 
nucleotide 
SNP location 
Exon/Intron 
SNP identified in IC 
rs3741906 c.6063+25G>A Intron 35 P6F4II1,P7F8I2 
 
rs34230288 c.6532G>T Exon 37 P9F14III1 
rs177702 c.6799-14C>T Intron 38 P1F2II1,P2F13I3,P4F5I1,P4F7II1,P5F1II3,P6F4II1,P6F9II1,P7F8I2,P8F2II2,P8F3I2, 
P8F5II1,P9F14III1,P9F18II,P10F5II2,P10F7II1, P10F8II1,P10F9II3,P12F5II1 
rs10849371 c.6846A>G Exon 39 P2F13I3, P5F1II3, P8F5II1,P10F5II2, P10F8II1,P10F9II3 
 
rs2070885 c.6976+59C>T Intron 40 P6F4II1,P7F8I2 
 
rs55867239 c.6977-22C>T Intron 40 P2F13I3, P5F1II3, P8F5II1,P10F5II2,P10F8II1,P10F9II3 
 
rs2286937 c.7287+61C>T Intron 42 P6F4II1 
 
rs216867 c.7239T>C Exon 42 P1F2II1,P2F13I3,P4F5I1,P4F7II1,P5F1II3,P6F4II1,P6F9II1,P7F8I2,P8F2II2,P8F3I2, 
P8F5II1,P9F14III1,P9F18II,P10F5II2,P10F7II1, P10F8II1,P10F9II3,P12F5II1 
 
rs216868 c.7082-7C>T Intron 42 P1F2II1, P4F5I1, P4F7II1, P6F4II1, P7F8I2,P8F2II2,P8F3I2,P8F5II1, 
P9F18I1,P10F8II1, P12F5II1 
rs3819539 c.7288-21C>T Intron 42 P6F4II1 
 
rs3819540 c.7288-19C>T Intron 42 P6F4II1 
 
rs2270239 c.7549-59A>C Intron 44 P2F13I3,P4F5I1,P5F1II3,P7F8I2,P8F2II2,P8F3I2,P8F5II1 
P9F14II1,P10F5II2,P10F9II3,P12F5II1 
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Appendix 13 List of known SNP identified through DNA sequence analysis cont                                                             
SNP reference 
number 
Affected 
nucleotide 
SNP location 
Exon/Intron 
SNP identified in IC 
rs2286938 c.7082-48G>A Intron 41 P6F4II1 
 
rs11063962 c.7771-13C>T Intron 46 P1F2II1, P5F1II3 
 
rs55687637 c.7887+12T>C Intron 47 P12F5II1 
rs2286646 c.8115+66T>C Intron 49 P6F9II1, P8F3I2,P8F5II1, 
P9F14III1,P9F18I1,P10F5II2,P10F8II1, P12F5II1 
rs41276732 c.8079C>T Exon 49 P2F13I3 
 
rs7962217 c.8113G>A Exon49 P8F5II1,P9F18I1,P10F8II1,P12F5II1 
rs2270152 c.8116-20A>C Intron 50 P8F3I2,P8F5II1,P9F14III1,P9F18I1,P10F8II1, P12F5II1 
rs2270151 c.8155+50C>T Intron 50 P6F9II1,P8F3I2,P9F14II1,P10F5II2,P10F8II1 
rs2362483 c.8253+32T>C Intron 51 P7F8I2,P8F2II2,P8F3I2,P8F5II1,P9F14III1,P9F18I1,P10F8II1,P12F5II1 
rs7976955 c.8442+204C>T 3' untranslated 
region 
P1F2II1, P2F13I3, P5F1II3, P6F9II1,P8F3I2, 
P8F5II1,P9F18I1,P10F8II1P12F5II1 
rs216312 c.3675-75A>G Intron 27 PIF2II1, P2F13I3,P4F5I1,P6F4II1,P6F9II1, P10F5II2, 
P10F7II1,P10F9II3 
rs216311 c.4141A>G Exon 28 PIF2II1, P2F13I3, P4F5I1, P6F4II1, P6F9II1, P10F5II2, 
P10F7II1,P10F9II3  
rs216310 c.4641T>C Exon 28 PIF2II1, P2F13I3, P4F5I1, P6F4II1, P6F9II1, P10F5II2, P10F7II1, 
P10F9II3  
rs1800382 c.4196G>A Exon 28 P4F5I1 
 
rs1800383 c.4414G>C Exon 28 P6F4II1 
 
rs6127535 c.5049A>C Exon 28 P5F1II3 
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                                 Appendix 14 List of present identified mutations in the 18 IC 
Index Case Identified mutation Copy number variation (CNV) 
P1F2II:1  NT 
P2F13I:3  No CNV 
P4F5I:1  NT 
P4F7II:1  NT 
P5F1II:3 p.[R854];[W2271G] No CNV 
P6F4II:1  No CNV 
P6F9II:1  No CNV 
P7F8I:2  No CNV 
P8F2II:2 p.Q2544X No CNV 
P8F3I:2  NT 
P8F5II:1  NT 
                 P9F14II:2          p.[R924Q;C1927R] 
c.1533+1G>T 
NT 
P9F18I:1 p.[S539fs];[C1157R] No CNV 
P10F5II:2 p.L1382= NT 
P10F7II:1  No CNV 
P10F8II:1 c.1432+1G>T; p.R816W NT 
P10F9II:3  NT 
P12F5II:1  NT 
                                        NT (not tested) 
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Appendix 15 Pedigree of family P5F1 
      
        Phenotypic data for family P5F1 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCo 
IU/dL 
FVIII:C 
IU/dL 
VWF:CB 
IU/dL 
VWFpp VWF:FVIIIB 
 
Multimer 
profile 
ABO 
genotype 
I:2 AFM 7 38 37 85 NT* 71.3 1.185 
Normal 
Normal O/A 
II:2 AFM -1 37 43 34 NT* 64.7 NT* Normal O/A 
II:3 IC 2 37 32 28 43 66.8 0.313 
(Heterozygous) 
Normal O/A 
II:6 UFM -2 73 59 91 NT* 96.3 NT* Normal O/A 
             * Not tested 
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Appendix 16 Pedigree of family P9F14 
  
                                  Phenotypic data for family P9F14 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCO 
IU/dL 
FVIII:C 
IU/dL 
CB/Ag Multimer 
pattern 
ABO 
genotype 
I:1 UFM 0 88 79 82 NT Normal O/O 
I:2 AFM 4 57 58 63 NT Normal A/A 
II:1 UFM 0 150 215 88 NT Normal O/A 
II:2 IC 18 3 3 7 0.33 Abnormal O/A 
II:3 UFM 5 57 80 50 NT Abnormal A/B 
III:1 AFM 1 19 18 25 0.63 Abnormal O/O 
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Appendix 17 Pedigree of family P6F5 
 
 Phenotypic data for family P6F5 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCO 
IU/dL 
VWF:CB 
IU/dL 
VWFpp VWF:FVIIIB 
 
pp/Ag 
ratio 
FVIII:C 
IU/dL 
Multimer 
profile 
ABO 
genotype 
II:1 IC 18 11 7 6 127.5 1.15 (Normal) 11.6 ↑ 18 Normal O/O 
II:2 UFM 1 95 90 NT 142.8 NT 1.5 112 Normal O/O 
II:3 UFM -1 131 95 NT 115.5 NT 0.9 107 Normal O/A 
III:1 AFM 3 15 17 NT 141.3 1.2 (Normal)  9.4↑ 28 Normal O/O 
            
III:2 AFM 2 16 25 NT 172.6 1.32 (Normal)   10.8↑ 44 Normal O/O 
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Appendix 18 Pedigree of family P9F18 
 
    Phenotypic data for family P9F18 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCO 
IU/dL 
FVIII:C 
IU/dL 
VWF:CB VWFpp VWF:FVIIIB Multimer 
profile 
ABO 
genotype 
I:1 IC 9 3 3 3 0.7 NI* NI* Abnormal O/O 
I:2 AFM 10 3 3 3 NT 3.4 NI* Abnormal      O/B 
I:3 UFM -2 48 45 41 NT 100.7 NTƗ Normal O/A2 
II:1 UFM 2 60 69 74 NT 100.1 NTƗ Normal A2/B 
II:2 UFM 0 53 50 75 NT 94.4 NTƗ Normal O/B 
        *Not interpretable       ƗNot tested 
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Appendix 19 Pedigree of family P10F5 
 
                                             Phenotypic data for family P10F5 
Family  
member 
Status BS VWF:Ag 
IU/dL 
VWF:RCO 
IU/dL 
FVIII:C 
IU/dL 
Multimer 
pattern 
ABO 
genotype 
I:1 AFM 6 54 61 87 Normal O/O 
I:2 UFM -1 95 78 144 Normal O/O 
II:1 UFM 3 78 53 90 Normal O/O 
II:2 IC 4 48 41 84 Normal O/O 
 
